
<html lang="en"     class="pb-page"  data-request-id="98718cfd-5ad5-45be-a5fc-8e81c7951d2c"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2014.57.issue-10;article:article:10.1021/jm401742r"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Synthesis and Evaluation of Phosphorus Containing, Specific CDK9/CycT1 Inhibitors" /></meta><meta name="dc.Creator" content="Gábor  Németh" /></meta><meta name="dc.Creator" content="Zoltán  Greff" /></meta><meta name="dc.Creator" content="Anna  Sipos" /></meta><meta name="dc.Creator" content="Zoltán  Varga" /></meta><meta name="dc.Creator" content="Rita  Székely" /></meta><meta name="dc.Creator" content="Mónika  Sebestyén" /></meta><meta name="dc.Creator" content="Zsuzsa  Jászay" /></meta><meta name="dc.Creator" content="Szabolcs  Béni" /></meta><meta name="dc.Creator" content="Zoltán  Nemes" /></meta><meta name="dc.Creator" content="Jean-Luc  Pirat" /></meta><meta name="dc.Creator" content="Jean-Noël  Volle" /></meta><meta name="dc.Creator" content="David  Virieux" /></meta><meta name="dc.Creator" content="Ágnes  Gyuris" /></meta><meta name="dc.Creator" content="Katalin  Kelemenics" /></meta><meta name="dc.Creator" content="Éva  Áy" /></meta><meta name="dc.Creator" content="Janos  Minarovits" /></meta><meta name="dc.Creator" content="Susan  Szathmary" /></meta><meta name="dc.Creator" content="György  Kéri" /></meta><meta name="dc.Creator" content="László  Őrfi" /></meta><meta name="dc.Description" content="Although there is a significant effort in the design of a selective CDK9/CycT1 inhibitor, no compound has been proven to be a specific inhibitor of this kinase so far. The aim of this research was ..." /></meta><meta name="Description" content="Although there is a significant effort in the design of a selective CDK9/CycT1 inhibitor, no compound has been proven to be a specific inhibitor of this kinase so far. The aim of this research was ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 2, 2014" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm401742r" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm401742r" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm401742r" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm401742r" /></link>
        
    
    

<title>Synthesis and Evaluation of Phosphorus Containing, Specific CDK9/CycT1 Inhibitors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm401742r" /></meta><meta property="og:title" content="Synthesis and Evaluation of Phosphorus Containing, Specific CDK9/CycT1 Inhibitors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0021.jpeg" /></meta><meta property="og:description" content="Although there is a significant effort in the design of a selective CDK9/CycT1 inhibitor, no compound has been proven to be a specific inhibitor of this kinase so far. The aim of this research was to develop novel and selective phosphorus containing CDK9/CycT1 inhibitors. Molecules bearing phosphonamidate, phosphonate, and phosphinate moieties were synthesized. Prepared compounds were evaluated in an enzymatic CDK9/CycT1 assay. The most potent molecules were tested in cell-based toxicity and HIV proliferation assays. Selectivity of shortlisted compounds against CDKs and other kinases was tested. The best compound was shown to be a highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm401742r"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm401742r">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm401742r&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm401742r&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm401742r&amp;href=/doi/10.1021/jm401742r" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 3939-3965</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm401939g" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm5004599" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Synthesis and Evaluation of Phosphorus Containing, Specific CDK9/CycT1 Inhibitors</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=G%C3%A1bor++N%C3%A9meth">Gábor Németh</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zolt%C3%A1n++Greff">Zoltán Greff</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Sipos">Anna Sipos</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zolt%C3%A1n++Varga">Zoltán Varga</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rita++Sz%C3%A9kely">Rita Székely</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=M%C3%B3nika++Sebesty%C3%A9n">Mónika Sebestyén</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zsuzsa++J%C3%A1szay">Zsuzsa Jászay</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Szabolcs++B%C3%A9ni">Szabolcs Béni</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zolt%C3%A1n++Nemes">Zoltán Nemes</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jean-Luc++Pirat">Jean-Luc Pirat</a></span><span class="author-xref-symbol author-aff-symbol"><sup>||</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jean-No%C3%ABl++Volle">Jean-Noël Volle</a></span><span class="author-xref-symbol author-aff-symbol"><sup>||</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David++Virieux">David Virieux</a></span><span class="author-xref-symbol author-aff-symbol"><sup>||</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=%C3%81gnes++Gyuris">Ágnes Gyuris</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Katalin++Kelemenics">Katalin Kelemenics</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=%C3%89va++%C3%81y">Éva Áy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Janos++Minarovits">Janos Minarovits</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∇</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>○</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Susan++Szathmary">Susan Szathmary</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gy%C3%B6rgy++K%C3%A9ri">György Kéri</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>◆</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=L%C3%A1szl%C3%B3++%C5%90rfi">László Őrfi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Vichem Chemie Ltd., Budapest 1022, Hungary</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Department of Organic Chemistry and Technology, Budapest University of Technology and Economics, Budapest 1111, Hungary</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Department of Pharmaceutical Chemistry, Semmelweis University, Budapest 1092, Hungary</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">||</span> <span class="aff-text">Institut Charles Gerhardt UMR5253, AM2N, ENSCM, Montpellier 34296 cedex 5, France</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">⊥</span> <span class="aff-text">RT Europe Research Center, Mosonmagyaróvár 9200, Hungary</span></div><div class="aff-info" id="aff6"><span class="aff-symbol">#</span> <span class="aff-text">GalenBio Ltd., Mosonmagyaróvár 9200, Hungary</span></div><div class="aff-info" id="aff7"><span class="aff-symbol">∇</span> <span class="aff-text">Microbiological Research Group, National Center for Epidemiology, Budapest 1097, Hungary</span></div><div class="aff-info" id="aff8"><span class="aff-symbol">○</span> <span class="aff-text">Faculty of Dentistry, Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged 6720, Hungary</span></div><div class="aff-info" id="aff9"><span class="aff-symbol">◆</span> <span class="aff-text">MTA-SE Pathobichemistry Research Group, Department of Medical Chemistry, Molecular Biology and Pathobiochemistry, Semmelweis University, Budapest 1094, Hungary</span></div><div class="corresp-info"><strong>*</strong>Phone: +36-1-4872080. Fax: +36-1-7999990. E-mail: <a href="/cdn-cgi/l/email-protection#f5929b909890819db5839c969d9098db9d80"><span class="__cf_email__" data-cfemail="bbdcd5ded6decfd3fbcdd2d8d3ded695d3ce">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm401742r&amp;href=/doi/10.1021%2Fjm401742r" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 3939–3965</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">April 17, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>12 November 2013</li><li><span class="item_label"><b>Published</b> online</span>2 May 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 May 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm401742r" title="DOI URL">https://doi.org/10.1021/jm401742r</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3939%26pageCount%3D27%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DG%25C3%25A1bor%2BN%25C3%25A9meth%252C%2BZolt%25C3%25A1n%2BGreff%252C%2BAnna%2BSipos%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D10%26contentID%3Djm401742r%26title%3DSynthesis%2Band%2BEvaluation%2Bof%2BPhosphorus%2BContaining%252C%2BSpecific%2BCDK9%252FCycT1%2BInhibitors%26numPages%3D27%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3965%26publicationDate%3DMay%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm401742r"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3449</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">46</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm401742r" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Synthesis and Evaluation of Phosphorus Containing, Specific CDK9/CycT1 Inhibitors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Gábor&quot;,&quot;last_name&quot;:&quot;Németh&quot;},{&quot;first_name&quot;:&quot;Zoltán&quot;,&quot;last_name&quot;:&quot;Greff&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Sipos&quot;},{&quot;first_name&quot;:&quot;Zoltán&quot;,&quot;last_name&quot;:&quot;Varga&quot;},{&quot;first_name&quot;:&quot;Rita&quot;,&quot;last_name&quot;:&quot;Székely&quot;},{&quot;first_name&quot;:&quot;Mónika&quot;,&quot;last_name&quot;:&quot;Sebestyén&quot;},{&quot;first_name&quot;:&quot;Zsuzsa&quot;,&quot;last_name&quot;:&quot;Jászay&quot;},{&quot;first_name&quot;:&quot;Szabolcs&quot;,&quot;last_name&quot;:&quot;Béni&quot;},{&quot;first_name&quot;:&quot;Zoltán&quot;,&quot;last_name&quot;:&quot;Nemes&quot;},{&quot;first_name&quot;:&quot;Jean-Luc&quot;,&quot;last_name&quot;:&quot;Pirat&quot;},{&quot;first_name&quot;:&quot;Jean-Noël&quot;,&quot;last_name&quot;:&quot;Volle&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;Virieux&quot;},{&quot;first_name&quot;:&quot;Ágnes&quot;,&quot;last_name&quot;:&quot;Gyuris&quot;},{&quot;first_name&quot;:&quot;Katalin&quot;,&quot;last_name&quot;:&quot;Kelemenics&quot;},{&quot;first_name&quot;:&quot;Éva&quot;,&quot;last_name&quot;:&quot;Áy&quot;},{&quot;first_name&quot;:&quot;Janos&quot;,&quot;last_name&quot;:&quot;Minarovits&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;Szathmary&quot;},{&quot;first_name&quot;:&quot;György&quot;,&quot;last_name&quot;:&quot;Kéri&quot;},{&quot;first_name&quot;:&quot;László&quot;,&quot;last_name&quot;:&quot;Őrfi&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;02&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;3939-3965&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm401742r&quot;},&quot;abstract&quot;:&quot;Although there is a significant effort in the design of a selective CDK9/CycT1 inhibitor, no compound has been proven to be a specific inhibitor of this kinase so far. The aim of this research was to develop novel and selective phosphorus containing CDK9/CycT1 inhibitors. Molecules bearing phosphonamidate, phosphonate, and phosphinate moieties were synthesized. Prepared compounds were evaluated in an enzymatic CDK9/CycT1 assay. The most potent molecules were tested in cell-based toxicity and HIV proliferation assays. Selectivity of shortlisted compounds against CDKs and other kinases was tested. The best compound was shown to be a highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401742r&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401742r" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401742r&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401742r" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401742r&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401742r" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm401742r&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401742r&amp;href=/doi/10.1021/jm401742r" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm401742r" /></input><a href="/doi/pdf/10.1021/jm401742r" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm401742r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm401742r%26sid%3Dliteratum%253Aachs%26pmid%3D24742150%26genre%3Darticle%26aulast%3DN%25C3%25A9meth%26date%3D2014%26atitle%3DSynthesis%2Band%2BEvaluation%2Bof%2BPhosphorus%2BContaining%252C%2BSpecific%2BCDK9%252FCycT1%2BInhibitors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D10%26spage%3D3939%26epage%3D3965%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291719" title="Redox reactions">Redox reactions</a>,</li><li><a href="/action/doSearch?ConceptID=291553" title="Granular materials">Granular materials</a>,</li><li><a href="/action/doSearch?ConceptID=291157" title="Organophosphorus compounds">Organophosphorus compounds</a>,</li><li><a href="/action/doSearch?ConceptID=292593" title="Liquid chromatography-mass spectrometry">Liquid chromatography-mass spectrometry</a>,</li><li><a href="/action/doSearch?ConceptID=292317" title="Ethyl groups">Ethyl groups</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jmcmar.2014.57.issue-10/production/jmcmar.2014.57.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Although there is a significant effort in the design of a selective CDK9/CycT1 inhibitor, no compound has been proven to be a specific inhibitor of this kinase so far. The aim of this research was to develop novel and selective phosphorus containing CDK9/CycT1 inhibitors. Molecules bearing phosphonamidate, phosphonate, and phosphinate moieties were synthesized. Prepared compounds were evaluated in an enzymatic CDK9/CycT1 assay. The most potent molecules were tested in cell-based toxicity and HIV proliferation assays. Selectivity of shortlisted compounds against CDKs and other kinases was tested. The best compound was shown to be a highly specific, ATP-competitive inhibitor of CDK9/CycT1 with antiviral activity.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77370" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77370" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The development of kinase inhibitors remains an area of significant interest in drug discovery. To date, the FDA has approved 29 small molecule drugs targeting kinases.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Cyclin dependent kinases (CDKs) are serine/threonine kinases, which belong to a family of 13 protein kinases that share dependence upon the binding of a cyclin subunit for activation.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> These kinases are valid targets for drug development because their role was revealed in many proliferative disorders (e.g., cancer) and inflammatory diseases.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> The cell cycle is controlled by the activation and deactivation of CDKs. Consequently, the different CDKs may be drug targets in a range of malignancies. To our knowledge, only a few molecules have been reported as selective inhibitors of CDKs and most of them inhibit at least two of the CDKs by the same order of magnitude. Therefore, there remains a need for more selective, or specific, inhibitors of the members of the CDK family.<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5-7)</a></div><div class="NLM_p">CDK9 is known to be involved in the molecular pathomechanisms of several diseases; the four most significant maladies are highlighted below.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8, 9)</a> The first indication, which is the most important disease for this study is HIV-1 infection.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The second area with growing indication is cancer, where the use of selective CDK9 inhibitors may provide an appropriate strategy to drive cancer cells into apoptosis.<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11-13)</a> The third area is chronic activation of CDK9 which may cause cardiac hypertrophy and a predisposition to heart failure, therefore the inhibition of CDK9 may constitute a new opportunity for a curative treatment.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Finally, CDK9 also acts on several cytokines involved in the regulation of inflammation, thus, CDK9 is considered as a promising target for the treatment of rheumatoid arthritis and chronic inflammatory diseases such as multiple sclerosis or psoriasis.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><div class="NLM_p">CDK9 and its cyclin partners (cyclin (Cyc) T1, T2a, b, and K) form dimers upon binding. The CDK9/CycT1 is the most common complex and plays a crucial role in HIV-1 replication.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> The most important role of CDK9/CycT1 is in the phosphorylation of the C-terminal domain of RNA polymerase II, which leads to the transcription of the viral genome.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> With the exception of the viral Tat protein, the other associated proteins are members of the transcription machinery of the host cell. The virus hijacks the host cell signaling to turn it to its own benefit. In this context, inhibition of CDK9 could halt or, at least, slow down the HIV propagation.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">CDK9 shows high level of sequence conservation compared with other members of the CDK family, thus the design of selective CDK9 inhibitors is highly challenging.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The first CDK9 inhibitor involved in clinical trial was flavopiridol, and it was discontinued due to its toxic effects.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> In our previous work, we described several molecules showing remarkable CDK9 inhibition and high level of selectivity over other CDKs.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> At that time, they were among the first selective CDK9 inhibitors. Recently, other research groups have published highly potent molecules, however, these compounds have significant effects on other kinases as well.<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> During the course of our work, Albert et al. published a highly selective CDK9 inhibitor also based on the 4-aminophenyl-6-phenylpyrimidine scaffold.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> These facts maintained our interest to synthesize more selective and potent CDK9 inhibitors containing a phosphorus subunit.</div><div class="NLM_p">Resemblance of phosphorus containing moieties (e.g., phosphonamidates, phosphonates, and phosphinates) to sulfonamides and sulfonyl derivatives is obvious. Their similar shape and electron density make these two types of functionalities to ideal structural mimics of each other.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> Although phosphonamidates, phosphonates, and phosphinates provide higher substituent variability than sulfonyl moieties, they are rarely applied in medicinal chemistry to replace sulfur containing grups. Instead, sulfonamides and sulfonyl derivatives are widely used as mimics of natural phosphate groups.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24, 25)</a> Nonetheless, phosphonates and phosphinates were shown to be potent inhibitors of peptidases as stable tetrahedral mimics of the transitional state species of peptides,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> mimics of phosphorus containing biomolecules involved in signal transduction<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and other biomolecules.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p">Using the isosteric relationship between sulfonamides and phosphonamidates, phosphonates, and phosphinates, we anticipated the synthesis of phosphorus containing analogues of previously published sulfonamide CDK9 inhibitors <b>1</b>–<b>5</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). Our objective was to synthesize potent kinase inhibitors in which a phosphorus moiety is essential to their inhibitory effect. We aimed to improve selectivity toward the target kinase by using these rarely applied functional groups and planned to demonstrate in vitro efficacy on an HIV infected cell line.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of some representative sulfonamide CDK9 inhibitors (<b>1</b>–<b>5</b>), the flavopiridol <b>6</b>, and general structures of the presented phosphorus moieties. References: <b>1</b> and <b>3</b>,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a><b>2</b> and <b>4</b>,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a><b>5</b>,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a><b>6</b>.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56685" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56685" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Inspired by the success of our sulfonamide-based CDK9 inhibitors and facing the incomplete selectivity toward the target enzyme, we developed new synthetic approaches of phosphonamidates, phosphonates, and phosphinates targeting CDK9. They were prepared and evaluated against the corresponding known sulfonamides <b>1</b>–<b>5</b> in biochemical assays. In the enzymatic assays, flavopiridol <b>6</b> was used as a reference (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Synthesis of Phosphonamidate Inhibitors (Ar-NH-P(O)ROR′)</h3><div class="NLM_p">The aniline core was prepared according to published methodologies, and subsequently the primary amino group of <b>9</b> was functionalized with the appropriate phosphonochloridates <b>8a</b>–<b>c</b>.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The phosphonochloridates were prepared by a two-step sequence involving the Arbuzov reaction of ethyl or isopropyl bromide with triethyl or triisopropyl phosphite, respectively, followed by the monochlorination of phosphonates <b>7a</b>–<b>c</b> with oxalyl chloride (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). The reaction of the primary amino group of <b>9</b> with phosphonochloridate <b>8a</b>–<b>c</b> in anhydrous pyridine led to the phosphonamidates <b>10</b>–<b>12</b> in 9–18% yields. Because of the pH sensitivity of the P–N bond, phosphonamidates were readily hydrolyzed upon workup.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Phosphonic Acid Chlorides, Preparation of Phosphonamidates <b>10</b>–<b>12</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Synthesis of Phosphonate Inhibitors (Ar-O-P(O)ROR′)</h3><div class="NLM_p">Phenols <b>15</b>–<b>20</b> were readily accessible by the condensation of 4-chloro-6-phenylpyrimidines <b>13a</b>–<b>b</b> with aniline derivatives <b>14a</b>–<b>c</b> (47–76%) in the presence of potassium <i>tert</i>-butoxide. Phosphonates <b>21</b>–<b>29</b> were also synthesized by the reaction with phosphonochloridates <b>8a</b>–<b>c</b> (9–81%) in better yields compared to phosphonamidates (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). The nitro group of phosphonates <b>22</b>, <b>25</b>, and <b>28</b> (Z = NO<sub>2</sub>) was consecutively reduced to the corresponding amines <b>23</b>, <b>26</b>, and <b>29</b> by tin(II) chloride in 21–81% yields. Finally, both phosphonic acid analogues <b>30a</b> and <b>30b</b> were prepared by selective hydrolysis of the corresponding alkyl phosphonates <b>21a</b> and <b>21b</b> using TMSCl and KI in 70% and 79% yields, respectively.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Phenol Derivatives, Phosphorylation, and Hydrolysis<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) IPA, cat. HCl, reflux; (b) <i>t</i>-BuOK, THF, RT; (c) SnCl<sub>2</sub>, EtOH, reflux; (d) Me<sub>3</sub>SiCl, KI, acetone, reflux.</p></p></figure></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Synthesis of Benzylphosphonate Inhibitors (Ar-CH<sub>2</sub>-P(O)(OR)<sub>2</sub>)</h3><div class="NLM_p">To obtain hydrolytically stable phosphonates where the nitrogen or the oxygen atoms were replaced by a carbon, benzyl derivatives were synthesized (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>). The first reaction of the sequence was a Pudovik addition of diethyl phosphite to the 3- or 4-nitro-benzaldehyde with diethyl phosphite in 76% and 60% yields.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> On one hand, the Pudovik adducts <b>31</b> and <b>32</b> were reduced to the corresponding amines <b>33</b> and <b>34</b> by transfer hydrogenation using ammonium formate and Pd/C (<i>y</i> = 72 and 86%). On the other hand, mesylation of <b>31</b> and <b>32</b> (<i>y</i> = 73 and 52%), followed by reduction with hydrazine and Pd/C, gave the benzylphosphonates <b>35</b> and <b>36</b> in 78% and 94% yields (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>). Alternatively, 3-ethylphosphonomethyl-4-methylaniline <b>37</b> was prepared from 2-methyl-5-nitrobenzoic acid in five steps due to the limited availability of 2-methyl-5-nitrobenzaldehyde (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>).</div><figure id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <i>meta</i>- and <i>para</i>-Benzylphosphonate Intermediates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TEA, toluene, RT; (b) HCOOH·NH<sub>3</sub>, Pd/C, MeOH, RT; (c) MeSO<sub>2</sub>Cl, TEA, THF, RT; (d) NH<sub>2</sub>–NH<sub>2</sub>, Pd/C, MeOH, RT; (e) cat. H<sub>2</sub>SO<sub>4</sub>, EtOH, reflux; (f) LiAlH<sub>4</sub>, THF, RT; (g) PBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, RT; (h) P(OEt)<sub>3</sub>, neat, 140 °C; (i) HCOOH·NH<sub>3</sub>, Pd/C, MeOH, RT.</p></p></figure><div class="NLM_p">The acid-catalyzed condensation of 4-chloro-6-phenylpyrimidines <b>13a</b>–<b>b</b> with anilines <b>33</b>–<b>37</b> was readily accomplished in refluxing 2-propanol, furnishing benzylphosphonates <b>38</b>, <b>39</b>, <b>41</b>, <b>42</b>, and <b>44</b> in 6% to almost quantitative yields (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>). Subsequently, the nitro derivatives <b>39a</b>–<b>b</b> and <b>42a</b> were reduced with tin(II) chloride in refluxing ethanol, giving anilines <b>40a</b>–<b>b</b> and <b>43</b> (65–80%), respectively. Hydrolysis of phosphonate esters <b>42a</b> and <b>43</b> was achieved in refluxing 5 M hydrochloric acid, affording <b>45a</b> and <b>45b</b> in 66% and 90% yield. The hydrochloride salts were converted into the free bases by treatment with propylene oxide (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>).</div><figure id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <i>meta</i>- and <i>para</i>-Benzylphosphonates and Phosphonic Acids<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) IPA, cat. HCl, reflux; (b) SnCl<sub>2</sub>, EtOH, reflux; (c) (1) HCl (5 M), reflux, (2) propylene oxide, EtOH, 0 °C.</p></p></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Synthesis of Phosphinates Inhibitors (Ar-CH<sub>2</sub>-P(O)ROR′)</h3><div class="NLM_p">Precursor <b>46</b> was accessible in three steps from a Michaelis–Becker reaction of 3-nitrobenzyl bromide with phenyl-H-phosphinate (Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>), followed by reduction of the nitro group with tin(II) chloride; overall yield was 35%. During the Michaelis–Becker reaction, the cleavage of the ethyl ester was observed, necessitating an additional re-esterification step with triethylorthoformate. Other precursors were prepared by another pathway starting by the Arbuzov reaction between the corresponding nitrobenzyl bromides and phosphonites,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> followed by the reduction of the nitro group with tin(II) chloride, furnishing the desired aniline intermediates <b>47</b>–<b>51</b> in 28–70% overall yield.</div><figure id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <i>meta</i>- and <i>para</i>-Benzylphosphinate Intermediates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) neat, 140 °C; (b) HC(OEt)<sub>3</sub>, RT; (c) SnCl<sub>2</sub>, EtOH, reflux.</p></p></figure><div class="NLM_p">Anilines <b>46</b>–<b>51</b> were reacted with 4-chloro-6-phenylpyrimidines <b>13a</b>–<b>b</b> under acidic conditions to give a series of benzylphosphinates <b>52</b>, <b>53</b>, <b>55</b>, <b>56</b>, <b>58</b>, and <b>59</b> in yields ranging from 29 to 55%. After reduction of the nitro group with tin(II) chloride, the corresponding anilines <b>54</b>, <b>57</b>, and <b>60</b> were obtained in 77–88% yield. Phosphinic acid <b>61</b> was prepared by cleavage of the ester function (<b>52b</b>) with trimethylsilyl chloride in the presence of potassium iodide (Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>).</div><figure id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <i>meta</i>- and <i>para</i>-Benzylphosphinates and Phosphinic Acids<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) IPA, cat. HCl, reflux; (b) SnCl<sub>2</sub>, EtOH, reflux; (c) Me<sub>3</sub>SiCl, KI, CHCl<sub>3</sub>, reflux.</p></p></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Synthesis of Arylphosphinate (Ar-P(O)ROR′) and Arylphosphonate (Ar-P(O)(OR)<sub>2</sub>) Inhibitors</h3><div class="NLM_p">To further explore the SAR of this compound family, it was also planned to directly connect phosphonate and phosphinate moieties to the aromatic ring without NH, O, or methylene spacers. The phosphorus containing group is isosteric with the previously presented scaffolds but closer in proximity to the aromatic ring. Nonetheless, they can provide key information to the structure–activity relationship.</div><div class="NLM_p">Synthesis of arylphosphonate and phosphinate intermediates was accomplished through a palladium catalyzed coupling reaction between 3-iodo-nitro- or 4-bromo-nitrobenzene and four different phosphinate or phosphonate substrates <b>62a</b>–<b>d</b> (<i>y</i> = 14–64%).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Nitro-phenylphosphonates and phosphinates were reduced by tin(II) chloride to afford anilines in 49–90% yields (Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>).</div><figure id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0023.jpeg" id="GRAPHIC-d1187e1101-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Anilinophosphinates and Phosphonates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, Et<sub>3</sub>N, toluene, reflux; (b) SnCl<sub>2</sub>, EtOH, reflux.</p></p></figure><div class="NLM_p">Next, reactions of anilinophosphonates or phosphinates <b>63</b>–<b>64</b> with 4-chloro-6-phenylpyrimidines <b>13a</b>–<b>b</b> led to the <i>N</i>-substituted analogues <b>65</b>–<b>74</b> (20–80% yields, Scheme <a class="ref internalNav" href="#sch8" aria-label="8">8</a>). Reduction of the nitro group by tin(II) chloride provided the corresponding anilines <b>67</b>, <b>70</b>, and <b>75</b> in 59–97% yields. Deprotection of phosphonic acids was accomplished by refluxing in hydrochloric acid followed by neutralization using propylene oxide (<i>y</i> = 22–69%).</div><figure id="sch8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0010.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of <i>meta</i>- and <i>para</i>-Arylphosphinates and Arylphosphinates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) IPA, cat. HCl, reflux; (b) SnCl<sub>2</sub>, EtOH, reflux; (c) (1) HCl (5 M), reflux, (2) propylene oxide, EtOH, 0 °C.</p></p></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Modifications on the 6-Phenyl Ring</h3><div class="NLM_p">Until now, no variation was made on the phenyl ring apart from the methoxy, nitro, and amino substituents. With this in mind, the effect of a wider range of substituents on biological activity was investigated. Targeted compounds <b>80</b>–<b>90</b> were prepared in two steps from previously synthesized precursors (Scheme <a class="ref internalNav" href="#sch9" aria-label="9">9</a>). First of all, 4-chloro-6-phenylpyrimidines <b>13c</b>–<b>m</b> were prepared by the Suzuki coupling of the appropriate boronic acids and 4,6-dichloropyrimidine in yields ranging from 20 to 80%.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Synthesized intermediates <b>13c</b>–<b>m</b> were then reacted with anilinophosphinate <b>48</b>, affording aminopyrimidines <b>80</b>–<b>90</b> in 10–67% yields. This aniline was preferred because its preparation was more convenient than the ethyl counterpart <b>47</b>.</div><figure id="sch9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0011.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of 6-Phenyl Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME, H<sub>2</sub>O, RT, reflux; (b) IPA, cat. HCl, reflux.</p></p></figure><div class="NLM_p">Benzyloxyphenyl-chloropyrimidine <b>13g</b> was coupled with the aniline <b>47</b> (<i>y</i> = 32%). Then the phosphonic esters <b>84</b> and <b>91</b> were hydrolyzed to acids <b>92</b> and <b>93</b> in moderate yield (<i>y</i> = 32 and 19%, respectively), Scheme <a class="ref internalNav" href="#sch10" aria-label="10">10</a>.</div><figure id="sch10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0012.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of the Compounds with the Optimal Substituent Combination<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) IPA, cat. HCl, reflux; (b) Me<sub>3</sub>SiCl, KI, CHCl<sub>3</sub>, reflux.</p></p></figure><div class="NLM_p last">Preparation of phosphorus containing compounds is usually more difficult than the corresponding sulfonamide analogues, which led sometimes to low yields. Although, there were some analogies between the different reactions applied in this work, the yields were strongly affected by the different substitutions. The conditions for the condensation reaction of 4-chloro-6-phenylpyrimidines with anilines were developed as a general method. However, conversions and yields of this reaction highly depended on the nucleophilicity of the aniline, moreover, minor modifications on the phosphorus groups showed a strong influence on the reactivity of anilines.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43755" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43755" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">For a comparison of phosphorus-based inhibitors with sulfonamide derivatives, an in vitro test was conducted in first intention. The kinase inhibitory profiles of the most potent derivatives were determined, and then the efficiency of this small set of compounds was validated on HIV infected cells. Finally, kinetics of kinase inhibition was studied.</div><div class="NLM_p">In vitro enzymatic assays showed that phosphonamidates <b>10</b>–<b>12</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) were significantly weaker inhibitors of CDK9 than the corresponding sulphonamides (compounds <b>1</b>–<b>5</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). Their low stability toward hydrolysis prompted us to focus our attention on the synthesis of phosphonate derivatives.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Activity of Phosphonamidates</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0013.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">R′</th><th class="colsep0 rowsep0" align="center" char=".">CDK9/CycT1 IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">1450</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">3170</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">5240</td></tr></tbody></table></div></div><div class="NLM_p">Potency of phosphonates <b>21a</b>–<b>30b</b> showed to be deeply dependent on the substituents of aromatic rings and on the phosphorus atom (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Not surprisingly, all the nitro-derivatives <b>22a</b>–<b>b</b>, <b>25a</b>–<b>c</b>, and <b>28a</b>–<b>b</b> were not active at all. 2-Methoxy-derivatives (<b>21a</b>–<b>c</b>, <b>24a</b>–<b>c</b>, and <b>27a</b>–<b>b</b>) were shown to be more active than the corresponding 3-aminophenyl analogues (<b>23a</b>–<b>b</b>, <b>26a</b>–<b>b</b>, and <b>29a</b>–<b>b</b>). The position of the phosphonate group did not considerably influence the inhibitory effect, meanwhile the size of phosphorus substituents on CDK9 inhibition followed the order: ethyl > propyl > phenyl. Free phosphonic acids have a negative charge at physiologic pH; the comparison between the alkyl ester <b>21a</b> and the acid <b>30a</b> showed that the charged species is less active than the neutral one. Comparison of ester <b>21b</b> and acid <b>30b</b> showed increasing potency. Overall, three phosphonate inhibitors <b>24a</b>, <b>27a</b>, and <b>27b</b> achieved an IC<sub>50</sub> close to 400 nM.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro Activity Phosphonates and Phosphonic Acids</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0014.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">R′</th><th class="colsep0 rowsep0" align="center">Z</th><th class="colsep0 rowsep0" align="center" char=".">CDK9/CycT1 IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21a</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">813</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21b</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">3057</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21c</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">4137</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22a</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22b</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23a</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">870</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23b</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">5385</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24a</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">400</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24b</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">1180</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24c</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">3100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25a</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25b</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25c</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26a</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">1800</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26b</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">6430</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26c</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">5330</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">360</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">407</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27c</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">2840</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">3840</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left"><i>i</i>-Pr</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">6060</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30a</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">1490</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30b</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">1457</td></tr></tbody></table></div></div><div class="NLM_p">Methylene spacer between the phenyl ring and the phosphonate group improved biological activity. Methoxy- (<b>38</b>, <b>41a</b>−<b>b</b>) and aminophenyl (<b>40a</b>−<b>b</b>, <b>43</b>) compounds were the most potent ones. Nitrophenyl derivatives <b>39a</b>−<b>b</b> and <b>42a</b> were inactive, but a moderate activity was found with <b>42b</b> and <b>45a</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Substitution on the methylene spacer was not beneficial. The phosphorus pattern attached to the <i>meta</i>-position gave a better biological response than their <i>para</i>-counterparts. Benzylphosphonate <b>44</b> with methyl substituent in the <i>para</i>-position (IC<sub>50</sub> = 5220 nM) was only a weak inhibitor of CDK9. In this series, biological activity of phosphonic acid derivatives <b>45a</b> and <b>45b</b> increased in comparison to their ethyl ester counterpart molecule <b>42a</b> and <b>43</b>. The most potent benzylphosphonates <b>38</b> and <b>40a</b> (IC<sub>50</sub> = 333 and 332 nM, respectively) were better than their phosphonate counterparts <b>24a</b> and <b>26a</b> (IC<sub>50</sub> = 400 and 1800 nM, Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>), respectively.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Activity of Benzylphosphonates and Benzylphosphonic Acids</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0015.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">R′</th><th class="colsep0 rowsep0" align="center">Z</th><th class="colsep0 rowsep0" align="center" char=".">CDK9/CycT1 IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">333</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39a</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">9870</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39b</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40a</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">332</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40b</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">1401</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">490</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">510</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">4577</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">3110</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">5220</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">2100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">1130</td></tr></tbody></table></div></div><div class="NLM_p">Replacement of the phosphonate by a phosphinate group resulted in a significant increase in potency (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). The 3-nitro-phenyl derivatives <b>53</b>, <b>56</b>, and <b>59</b> were found to be weak inhibitors, in accordance with previous results reported in both phosphonate series (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>–<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Once again, compounds of the 2-methoxy series possessed the best bioactivities among the 2-methoxy, 3-nitro, and 3-amino derivatives. Ethyl and propyl substitution on the phosphinate did not make a significant difference, whereas the bigger phenyl group conferred lower activity. <i>meta</i>-Phosphinates were shown to be more potent than their <i>para</i>-equivalents. Hydrolysis of the ester <b>52b</b> to <b>61</b> acid slightly decreased the potency. For instance, compound <b>52a</b> exhibited an IC<sub>50</sub> lower than 200 nM, whereas its phosphonate counterpart <b>24a</b> was 2-fold higher (400 nM). Similarly, the methyl substituted analogue <b>58</b> (IC<sub>50</sub> = 366 nM) was 4-fold more potent than the phosphonamidate <b>10</b> (IC<sub>50</sub> = 1 450 nM) and 2-fold more potent than the phosphonate <b>21a</b> (IC<sub>50</sub> = 813 nM). Finally, three molecules <b>52a</b>, <b>52b</b>, and <b>61</b>, showed IC<sub>50</sub> lower than 300 nM, and all of them contained the phosphorus substituent in the <i>meta</i>-position.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro Activity of Benzylphosphinates and Benzylphosphinic Acid</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0016.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">R′</th><th class="colsep0 rowsep0" align="center">Z</th><th class="colsep0 rowsep0" align="center" char=".">CDK9/CycT1 IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52a</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">197</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52b</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">296</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52c</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">517</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53a</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">6432</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53b</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">8056</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53c</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54a</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">327</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54b</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">682</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54c</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">1019</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">743</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">652</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">7774</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">5525</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">7533</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">7474</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">366</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">7022</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>60</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">346</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>61</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">261</td></tr></tbody></table></div></div><div class="NLM_p">When the phosphorus atom was directly bounded to the aniline ring, no improved biological activity was observed both in arylphosphinate and arylphosphonate series (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). The 2-methoxy substituted derivatives were found to be the best inhibitors regardless of the substituent R or the phosphorus position. Compounds bearing a nitro group were once again weak inhibitors, apart from phosphonic acid <b>77</b>, which had a moderate activity (IC<sub>50</sub> = 4 100 nM). Surprisingly, none of the 3-amino analogues exhibited a considerable inhibitory effect on CDK9 activity. In this series, phosphonic acids (<b>76</b>–<b>79</b>) had significantly lower IC<sub>50</sub>s than their ester counterparts (<b>71</b>–<b>73</b>, <b>75</b>). Again, the ethylphosphinate derivative (<b>68a</b>, IC<sub>50</sub> = 418 nM) was shown to be the most potent inhibitor of this series.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vitro Activity of Arylphosphinates and Phosphonates</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0017.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">R′</th><th class="colsep0 rowsep0" align="center">Z</th><th class="colsep0 rowsep0" align="center" char=".">CDK9/CycT1 IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>65</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">842</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>66</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>67</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">9802</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>68a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">418</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>68b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">1149</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>68c</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">523</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>69a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>69b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>69c</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>70a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>70b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>70c</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">6501</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>71</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">EtO</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">1040</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>72</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">EtO</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>73</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">EtO</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">1020</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>74</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">EtO</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>75</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">EtO</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>76</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">429</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>77</b></td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">3-NO<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">4100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>78</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">2-MeO</td><td class="colsep0 rowsep0" align="char" char=".">580</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>79</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">P-group</td><td class="colsep0 rowsep0" align="left">OH</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">3-NH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">3320</td></tr></tbody></table></div></div><div class="NLM_p">Substituent variations on the 6-phenyl ring provided a clear structure–activity relationship. In general, substitutions in position 2 were preferred (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). Kinase inhibition was optimum with inhibitors containing 2-alkoxy substituents and weakly dependent on the nature of the alkyl substituent. Meanwhile, any substituents in other positions caused a significant decrease of biological activity. If these alkoxy groups were replaced by an alkyl substituent (<b>90</b>) or were moved to another position (<b>85</b>, <b>86</b>, <b>89</b>), the activity significantly decreased. This clearly showed that an alkoxy group is essential in the position 2.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In Vitro Activity of Phosphinates with 6-Phenyl Variations</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0018.gif" alt="" id="fx6" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">Z</th><th class="colsep0 rowsep0" align="center" char=".">CDK9/CycT1 IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>80</b></td><td class="colsep0 rowsep0" align="left">2-EtO</td><td class="colsep0 rowsep0" align="char" char=".">254</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>81</b></td><td class="colsep0 rowsep0" align="left">2-<i>n</i>-PrO</td><td class="colsep0 rowsep0" align="char" char=".">248</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>82</b></td><td class="colsep0 rowsep0" align="left">2-<i>i</i>-PrO</td><td class="colsep0 rowsep0" align="char" char=".">210</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>83</b></td><td class="colsep0 rowsep0" align="left">2-PhO</td><td class="colsep0 rowsep0" align="char" char=".">601</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>84</b></td><td class="colsep0 rowsep0" align="left">2-BnO</td><td class="colsep0 rowsep0" align="char" char=".">143</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>85</b></td><td class="colsep0 rowsep0" align="left">3-MeO</td><td class="colsep0 rowsep0" align="char" char=".">6937</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>86</b></td><td class="colsep0 rowsep0" align="left">4-MeO</td><td class="colsep0 rowsep0" align="char" char=".">5414</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>87</b></td><td class="colsep0 rowsep0" align="left">2,3-diMeO</td><td class="colsep0 rowsep0" align="char" char=".">2387</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>88</b></td><td class="colsep0 rowsep0" align="left">2-MeO-4-F</td><td class="colsep0 rowsep0" align="char" char=".">186</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>89</b></td><td class="colsep0 rowsep0" align="left">3-BnO</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>90</b></td><td class="colsep0 rowsep0" align="left">2-Et</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr></tbody></table></div></div><div class="NLM_p">On the basis of the results obtained from this structure–activity study, a fragment-based approach was applied involving identified groups which gave high inhibitory activity.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> On the 4-aminophenyl ring, the optimal substituent was the ethylphosphinate derivative in the <i>meta</i>-position (compound <b>52a</b>, IC<sub>50</sub> = 197 nM). On the terminal 6-phenyl ring, the best biological result was observed with an <i>ortho</i>-benzyloxy substituent (compound <b>84</b>, IC<sub>50</sub> = 143 nM). Combination of these functionalities (compound <b>91</b>) had a slightly weaker activity (IC<sub>50</sub> = 212 nM) compared to its methoxyphenyl counterpart <b>52a</b>. Moreover, it was less active than the propylphosphinate derivative <b>84</b>. After hydrolysis of ester <b>91</b>, its activity increased considerably (compound <b>92</b>; IC<sub>50</sub> = 163 nM). Interestingly, no change in activity was observed after the hydrolysis of ester <b>84</b> to the phosphinic acid <b>93</b> (IC<sub>50</sub> = 143 and 142 nM, respectively; Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. In Vitro Activity of the Phosphinates with the Best Substituent Combinations</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0019.gif" alt="" id="fx7" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">R′</th><th class="colsep0 rowsep0" align="center" char=".">CDK9/CycT1 IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>91</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="char" char=".">212</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>84</b></td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="char" char=".">143</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>92</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">163</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>93</b></td><td class="colsep0 rowsep0" align="left"><i>n</i>-Pr</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">142</td></tr></tbody></table></div></div><div class="NLM_p">The development of a new drug candidate through the fragment-based approach is an iterative process, and some general structure–activity relationships stand out from these results. First, the ethyl substituted phosphonamidate, phosphonates, and phosphinates were the best inhibitors. Second, the smaller the substituent on the phosphorus atom, the higher the biological effect observed. Phosphinates with methylene spacer in the <i>meta</i> position were shown to be the most potent inhibitors. Examination of substituent variations on the 6-phenyl ring indicated that 2-alkoxy substitutions were the most beneficial. The 3-amino moiety was slightly weaker in activity than the 2-alkoxy, while the 3-nitro and 2-alkyl moieties were inactive. Among the 2-alkoxy moieties, the trend was the bigger the substituent, the lower the IC<sub>50</sub>.</div><div class="NLM_p">One of the aims of this project was to construct a potent kinase inhibitor whose phosphorus moiety was crucial to its inhibitory effect, and this goal was achieved. The examination of the chemical stability of the phosphorus moiety provided the evidence that in the case of the phosphonamidates, it is probable that the P–N bond was cleaved at non-neutral pH. In this case, a low IC<sub>50</sub> of aniline would have been expected,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> however, it was not the case. In the case of phosphonates, hydrolysis of the P–O bond may occur, however, good kinase inhibitory effects of phenols were not observed.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> In the case of benzyl and arylphosphinates and phosphonates, the possibility of hydrolysis may be excluded.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Selectivity of Inhibitors</h3><div class="NLM_p">We aimed to synthesize selective CDK9 inhibitors. For this purpose, inhibitory activity of the best compounds was measured in an in vitro activity assay against the CDK2/CycE and the CDK4/CycD1, which are two of the most important regulators of the cell cycle among the CDKs. CDK9 selectivity was improved from phosphonates to phosphinates (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>), and two compounds (<b>52a</b>, <b>52b</b>) showed almost complete CDK9 inhibition with moderate effects on CDK2 and CDK4.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. CDK Selectivity Profile of Selected Compounds<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char=".">CDK2/CycE inhibition (%)</th><th class="colsep0 rowsep0" align="center" char=".">CDK4/CycD1 inhibition (%)</th><th class="colsep0 rowsep0" align="center" char=".">CDK9/CycT1 inhibition (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="char" char=".">99</td><td class="colsep0 rowsep0" align="char" char=".">84</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21a</b></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21b</b></td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">21</td><td class="colsep0 rowsep0" align="char" char=".">83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21c</b></td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">75</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30b</b></td><td class="colsep0 rowsep0" align="char" char=".">34</td><td class="colsep0 rowsep0" align="char" char=".">46</td><td class="colsep0 rowsep0" align="char" char=".">88</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41a</b></td><td class="colsep0 rowsep0" align="char" char=".">77</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="char" char=".">98</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41b</b></td><td class="colsep0 rowsep0" align="char" char=".">94</td><td class="colsep0 rowsep0" align="char" char=".">68</td><td class="colsep0 rowsep0" align="char" char=".">97</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">30</td><td class="colsep0 rowsep0" align="char" char=".">80</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52a</b></td><td class="colsep0 rowsep0" align="char" char=".">36*</td><td class="colsep0 rowsep0" align="char" char=".">24*</td><td class="colsep0 rowsep0" align="char" char=".">98*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52b</b></td><td class="colsep0 rowsep0" align="char" char=".">23*</td><td class="colsep0 rowsep0" align="char" char=".">14*</td><td class="colsep0 rowsep0" align="char" char=".">95*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54a</b></td><td class="colsep0 rowsep0" align="char" char=".">18*</td><td class="colsep0 rowsep0" align="char" char=".">22*</td><td class="colsep0 rowsep0" align="char" char=".">96*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>73</b></td><td class="colsep0 rowsep0" align="char" char=".">69</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="char" char=".">106</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>75</b></td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">35</td><td class="colsep0 rowsep0" align="char" char=".">43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>76</b></td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="char" char=".">40</td><td class="colsep0 rowsep0" align="char" char=".">91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>79</b></td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">67</td><td class="colsep0 rowsep0" align="char" char=".">100</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">Compound concentration was 10 μM, except * 1 μM.</p></div></div></div><div class="NLM_p">As a consequence, lead compounds <b>52a</b> and <b>52b</b> were further investigated on a panel of 30 kinases in in vitro activity assays. Results of this screen suggested outstanding selectivity: only <b>52a</b> shows moderate inhibition on cKit and Ret kinases, 28 and 34% inhibition at 1 μM, respectively (Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a>).</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Kinase Selectivity Profile of Selected Compounds<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char=".">ABL</th><th class="colsep0 rowsep0" align="center" char=".">AKT1</th><th class="colsep0 rowsep0" align="center" char=".">AXL</th><th class="colsep0 rowsep0" align="center" char=".">bRAF</th><th class="colsep0 rowsep0" align="center" char=".">CDK2/CycE</th><th class="colsep0 rowsep0" align="center" char=".">CDK4/CycD1</th><th class="colsep0 rowsep0" align="center" char=".">CDK9/CycT1</th><th class="colsep0 rowsep0" align="center" char=".">CHK1</th><th class="colsep0 rowsep0" align="center" char=".">cKIT</th><th class="colsep0 rowsep0" align="center" char=".">cMET</th><th class="colsep0 rowsep0" align="center" char=".">CSK</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52a</b></td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">21</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">36</td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="char" char=".">98</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="char" char=".">24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52b</b></td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">–1</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">95</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">14</td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char=".">DDR1</th><th class="colsep0 rowsep0" align="center" char=".">ERBB2</th><th class="colsep0 rowsep0" align="center" char=".">FGFR3</th><th class="colsep0 rowsep0" align="center" char=".">FLT3</th><th class="colsep0 rowsep0" align="center" char=".">IKKβ</th><th class="colsep0 rowsep0" align="center" char=".">INSR</th><th class="colsep0 rowsep0" align="center" char=".">IRAK4</th><th class="colsep0 rowsep0" align="center" char=".">JAK3</th><th class="colsep0 rowsep0" align="center" char=".">JNK1</th><th class="colsep0 rowsep0" align="center" char=".">mTOR</th><th class="colsep0 rowsep0" align="center" char=".">PAK1</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52a</b></td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52b</b></td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">0</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">10</td></tr></tbody></table><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char=".">PAK4</th><th class="colsep0 rowsep0" align="center" char=".">PDGFRb</th><th class="colsep0 rowsep0" align="center" char=".">PIM1</th><th class="colsep0 rowsep0" align="center" char=".">PKCa</th><th class="colsep0 rowsep0" align="center" char=".">RET</th><th class="colsep0 rowsep0" align="center" char=".">ROCK2</th><th class="colsep0 rowsep0" align="center" char=".">SRC</th><th class="colsep0 rowsep0" align="center" char=".">SYK</th><th class="colsep0 rowsep0" align="center" char=".">TIE2</th><th class="colsep0 rowsep0" align="center" char=".">TrkA</th><th class="colsep0 rowsep0" align="center" char=".">VEGFR2</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52a</b></td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">34</td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="char" char=".">11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52b</b></td><td class="colsep0 rowsep0" align="char" char=".">19</td><td class="colsep0 rowsep0" align="char" char=".">2</td><td class="colsep0 rowsep0" align="char" char=".">–2</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">16</td><td class="colsep0 rowsep0" align="char" char=".">7</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">–1</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">–1</td><td class="colsep0 rowsep0" align="char" char=".">6</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup>a</sup><p class="last">Inhibition (%) at 1 μM compound concentration.</p></div></div></div><div class="NLM_p">The most potent CDK9 inhibitor, compound <b>93</b>, was subjected to a wider selectivity profiling against 451 kinases in binding assays. A similar kinase profiling experiment has already been published with flavopiridol <b>6</b> on 442 kinases.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> We used these results as a basis for comparison. Compound <b>93</b> showed noticeable affinity toward only IRAK3 (18% of the control at 1 μM concentration), which means that its selectivity score is <i>S</i>(%Ctrl <35) = 0.003 for nonmutant kinases (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Interestingly, this compound does not bind to the inactive form of CDK9,<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> which was used in this assay. It does, however, inhibit the activity of CDK9/CycT1 in the nanomolar range.</div><figure id="fig2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Kinase selectivity profiles of flavopiridol (<i>K</i><sub>d</sub> ≤ 1 μM; CDK9 is highlighted with blue)<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> and compound <b>93</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">According to these results the phosphonic acid <b>93</b> is a highly specific inhibitor of the CDK9/CycT1 complex. Generally, known CDK9 inhibitors inhibit other CDKs in the nanomolar range. The most selective CDK9 inhibitor published so far is LDC000067, which does not inhibit other CDKs, however, its off-targets are GSK3A and HGK/MAP4K4.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Although the structural similarities between our compounds and LDC000067 are obvious (compound <b>5</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), specificity of compound <b>93</b> toward CDK9/CycT1 is higher.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Cell-Based Assays</h3><div class="NLM_p">Cytotoxic effect of selected compounds was tested in vitro on MT4 human T lymphocyte cell line by MTT cell proliferation assay. MT4 cells are ideal model for HIV-1 infection experiments.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> After 7 days incubation with different compound concentrations (2500 and 1250 nM), we identified the proliferative activity of remaining cells. Viability was determined as relative value to the untreated cells (100%). Most of the compounds did not affect cell viability at 1250 nM; moreover compound <b>93</b> seemed to be triggering cell proliferation. The tested phosphonamidate <b>10</b>, phosphonate <b>23a</b>, and phosphonic acid <b>30a</b> showed some toxic effect at 2500 nM concentration (Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a>). According to these results, 1250 nM concentration was chosen for the HIV-1 proliferation assay.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Cell Viability on MT4 Cells after 7 Days Incubation</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char="±">viability (% of the ctrl)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="±">2500 nM</th><th class="colsep0 rowsep0" align="center" char="±">1250 nM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="char" char="±">29 ± 26</td><td class="colsep0 rowsep0" align="char" char="±">96 ± 22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21a</b></td><td class="colsep0 rowsep0" align="char" char="±">108 ± 62</td><td class="colsep0 rowsep0" align="char" char="±">78 ± 16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23a</b></td><td class="colsep0 rowsep0" align="char" char="±">76 ± 22</td><td class="colsep0 rowsep0" align="char" char="±">72 ± 20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30a</b></td><td class="colsep0 rowsep0" align="char" char="±">74 ± 14</td><td class="colsep0 rowsep0" align="char" char="±">78 ± 14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="char" char="±">100 ± 20</td><td class="colsep0 rowsep0" align="char" char="±">91 ± 11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52a</b></td><td class="colsep0 rowsep0" align="char" char="±">94 ± 24</td><td class="colsep0 rowsep0" align="char" char="±">94 ± 18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52b</b></td><td class="colsep0 rowsep0" align="char" char="±">81 ± 9</td><td class="colsep0 rowsep0" align="char" char="±">66 ± 9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>76</b></td><td class="colsep0 rowsep0" align="char" char="±">90 ± 15</td><td class="colsep0 rowsep0" align="char" char="±">90 ± 7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>84</b></td><td class="colsep0 rowsep0" align="char" char="±">93 ± 13</td><td class="colsep0 rowsep0" align="char" char="±">86 ± 23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>91</b></td><td class="colsep0 rowsep0" align="char" char="±">94 ± 27</td><td class="colsep0 rowsep0" align="char" char="±">98 ± 30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>92</b></td><td class="colsep0 rowsep0" align="char" char="±">104 ± 18</td><td class="colsep0 rowsep0" align="char" char="±">110 ± 20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>93</b></td><td class="colsep0 rowsep0" align="char" char="±">141 ± 11</td><td class="colsep0 rowsep0" align="char" char="±">158 ± 11</td></tr></tbody></table></div></div><div class="NLM_p">Given the fact that CDK9/CycT1 is a validated target in HIV-1 infection, the most potent compounds were tested in an HIV-1 proliferation assay. This experiment is a cell proliferation assay (MTT) on HIV-1 infected MT4 cells. Proliferation of virus infected cells decreased compared to noninfected ones. If the tested compound inhibited virus proliferation, higher proliferative activity would be observed compared to the untreated, infected control.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The HIV-1 infected untreated cells were considered to be 100%. The best CDK9 inhibitors from each group were tested. The treatment concentration was 1250 nM; AZT (azidothymidine) was used as the positive control<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> at 25 nM. Phosphonamidate <b>10</b>, phosphonates <b>21a</b>, <b>23a</b>, and <b>40a</b>, and phosphonic acid <b>30a</b> did not show any inhibition of HIV-1 proliferation. However, phosphinates (<b>52a</b>, <b>52b</b>, <b>84</b>, <b>91</b>–<b>93</b>) did protect MT4 cells against viral infection similarly to the positive control AZT. Higher viability correlated with lower CDK9 IC<sub>50</sub>. Compound <b>76</b> did not fit to this trend. It was hypothesized that this molecule, as a phosphonic acid, may bind and inhibit some proteins other than CDK9 which are beneficial for HIV-1 proliferation inhibition (Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a>). This hypothesis is supported by the lower selectivity of phosphonic and phosphinic acids (<b>30b</b>, <b>76</b>, <b>79</b> in Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>).</div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. HIV-1 Proliferation Assay in MT4 Cells</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center" char="±">viability (rel % to infected, untreated cells)</th><th class="colsep0 rowsep0" align="center" char=".">CDK9/CycT1 IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="char" char="±">102 ± 18</td><td class="colsep0 rowsep0" align="char" char=".">1453</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21a</b></td><td class="colsep0 rowsep0" align="char" char="±">95 ± 15</td><td class="colsep0 rowsep0" align="char" char=".">813</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23a</b></td><td class="colsep0 rowsep0" align="char" char="±">99 ± 23</td><td class="colsep0 rowsep0" align="char" char=".">870</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30a</b></td><td class="colsep0 rowsep0" align="char" char="±">96 ± 20</td><td class="colsep0 rowsep0" align="char" char=".">1490</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>AZT</b></td><td class="colsep0 rowsep0" align="char" char="±">158 ± 24</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40a</b></td><td class="colsep0 rowsep0" align="char" char="±">96 ± 36</td><td class="colsep0 rowsep0" align="char" char=".">332</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52a</b></td><td class="colsep0 rowsep0" align="char" char="±">105 ± 23</td><td class="colsep0 rowsep0" align="char" char=".">197</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52b</b></td><td class="colsep0 rowsep0" align="char" char="±">131 ± 21</td><td class="colsep0 rowsep0" align="char" char=".">296</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>76</b></td><td class="colsep0 rowsep0" align="char" char="±">130 ± 31</td><td class="colsep0 rowsep0" align="char" char=".">429</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>AZT</b></td><td class="colsep0 rowsep0" align="char" char="±">132 ± 29</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>84</b></td><td class="colsep0 rowsep0" align="char" char="±">148 ± 12</td><td class="colsep0 rowsep0" align="char" char=".">143</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>91</b></td><td class="colsep0 rowsep0" align="char" char="±">135 ± 16</td><td class="colsep0 rowsep0" align="char" char=".">212</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>92</b></td><td class="colsep0 rowsep0" align="char" char="±">124 ± 21</td><td class="colsep0 rowsep0" align="char" char=".">163</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>93</b></td><td class="colsep0 rowsep0" align="char" char="±">141 ± 25</td><td class="colsep0 rowsep0" align="char" char=".">142</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>AZT</b></td><td class="colsep0 rowsep0" align="char" char="±">135 ± 22</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Kinetics</h3><div class="NLM_p">For further development, it was beneficial to determine the mechanism of kinase inhibition. We hypothesized that these compounds were ATP-competitive inhibitors. To prove this theory, the kinase inhibition was measured at different ATP concentrations.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The inhibitor concentration was kept at a constant 260 nM in each experiment. Five ATP concentrations were applied: the <i>K</i><sub>mATP</sub> (for this enzyme it was 12 mM), two lower (4 and 1.33 mM) and two higher (36 and 108 mM) concentrations. If these compounds were ATP-competitive inhibitors, the value of the <i>K</i><sub>i</sub> would be half of the measured IC<sub>50</sub> according to the Cheng–Prusoff equation,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and the ratio of IC<sub>50</sub>/<i>K</i><sub>i</sub> would be increased at higher ATP concentration. According to the results (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>), our compounds were shown to be ATP-competitive inhibitors.</div><figure id="fig3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Determination of ATP competition of six inhibitors at 260 nM inhibitor concentration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i34">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20664" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20664" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Different phosphinates, phosphonates, and phosphonamides were prepared in a few steps from readily available starting materials through affordable and general methods. They were considered as bioisosteres of sulfonamide-based CDK9 inhibitors. In these series, the most potent inhibitor was the phosphinic acid <b>93</b>, which was proved to be highly specific to CDK9/CycT1 and acts in an ATP-competitive manner. Although its inhibitory activity is slightly lower than the best CDK9 inhibitors in the literature, its high specificity for CKD9/CycT1 is exceptional. These results suggested that <b>93</b> would have the potential to control HIV-1 replication in vivo while having a lower risk of inhibiting other kinases and consequently causing undesired toxicity.</div><div class="NLM_p last">In general, these results demonstrate the bioisosteric utility of the phosphonamidate, phosphonate, and phosphinate moieties in the design of novel kinase inhibitors.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06668" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06668" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Reagents and solvents were purchased from Sigma-Aldrich Co., AlfaAesar Ltd., or Apollo Ltd. and were used without further purification or drying. Melting points were measured on a Buchi B-540 apparatus, and measured data are uncorrected. For column chromatography, Merck silica gel 60 (35–70 μm) was used or Silica gel 60 F254 1 mm preparative thin layer plates were applied from Merck GmbH. NMR spectra were recorded on different apparatus as it is indicated in the assignation:</div><div class="NLM_p">A Bruker AC 300 for <sup>1</sup>H-300 MHz, <sup>31</sup>P-121 MHz, <sup>13</sup>C-75 MHz measurements.</div><div class="NLM_p">A Bruker AC 400 for <sup>1</sup>H-400 MHz, <sup>31</sup>P-162 MHz, <sup>13</sup>C-101 MHz measurements.</div><div class="NLM_p">A Bruker AC 250 for <sup>1</sup>H-250 MHz, <sup>31</sup>P-101 MHz, <sup>13</sup>C-63 MHz measurements.</div><div class="NLM_p">A Varian Unity Inova 600 for <sup>1</sup>H-600 MHz, <sup>31</sup>P-242 MHz measurements.</div><div class="NLM_p">Chemical shifts are given in parts per million (δ) referenced to TMS (δ = 0.00 ppm <sup>1</sup>H-, <sup>13</sup>C NMR) or 85% H<sub>3</sub>PO<sub>4</sub> (δ = 0.00 ppm <sup>31</sup>P NMR). Coupling constants are given in hertz. Electrospray ionization mass spectra were recorded on Waters 2795 HPLC, equipped with Waters 996 photodiode array detector and Micromass ZMD 2000 LC-MS system, which were also used to determine the purity of certain materials. Retention times concern to a Supelco Discovery C18, 5 cm × 4.6 mm, 5 μm column. Eluents were water/0.05% HCOOH and MeCN/0.05% HCOOH in gradient. Flow rate was 2 mL/min. Injected quantity of each sample was 3 μg. MW-reactor: for 0,2–20 mL, a Personal Chemistry, Emrys Creator; for 30–1000 mL, a Milestone Inc., Ethos MicroSYNTH Labstation reactor was used. Purity of prepared compounds was determined by LC-MS, <sup>1</sup>H and <sup>31</sup>P NMR. All compounds tested in biological assay were >95%. Purity of intermediates was >90%, unless otherwise stated.</div><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Chemistry</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Ethyl Ethylphosphonochloridate (<b>8a</b>)</h4><div class="NLM_p last">Ethyl diethylphosphonate (0.84 mL, 5 mmol) and one drop of dry DMF were dissolved in dry CH<sub>2</sub>Cl<sub>2</sub> (5 mL). The mixture was cooled to 0 °C, and oxalyl chloride (1.27 mL, 15 mmol) was added slowly. The mixture was stirred at ambient temperature for 5–6 h then the volatiles were evaporated and additional CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was evaporated two more times to obtain 0.704 g (90%) as a brown oil. Product was used without further purification. <sup>31</sup>P NMR (CDCl<sub>3</sub>, 162 MHz): δ 46.7 ppm. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 4.10–4.30 (m, 2H), 2.00–2.15 (m, 2H), 1.28–1.38 (m, 3H), 1.13–1.27 (m, 3H).</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Isopropyl Propylphosphonochloridate (<b>8b</b>)</h4><div class="NLM_p last">Triisopropyl-phosphite (12.3 mL, 50 mmol) and 1-bromopropane (18.2 mL, 200 mmol) were reacted in Arbuzov reaction at 150 °C for 4 h in a microwave reactor. The product (<b>7b</b>) was purified by vacuum distillation, and a colorless oil was obtained (6.551 g, 63%); bp = 72–76 °C (3.35 mbar). <sup>31</sup>P NMR (CDCl<sub>3</sub>,162 MHz): δ 30.3 ppm. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 250 MHz): δ 4.60–4.70 (m, 2H), 1.55–1.70 (m, 4H), 1.20–1.30 (m, 12H), 0.92–1.00 (m, 3H). The acid chloride was prepared with the method described for the preparation of <b>8a</b>; 0.830 g (90%) of a brown oil was obtained. <sup>31</sup>P NMR (CDCl<sub>3</sub>, 162 MHz): δ 43.2 ppm. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 250 MHz): δ 4.80–4.95 (m, 1H), 1.95–2.13 (m, 2H), 1.55–1.80 (m, 2H), 1.20–1.40 (m, 6H), 0.90–1.05 (m, 3H).</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Ethyl Phenylphosphonochloridoate (<b>8c</b>)</h4><div class="NLM_p last">Compound <b>8c</b> was prepared according to the method used for <b>8a</b>, but the mixture was refluxed for 24 h, giving a brown oil (0.920 g, 90%). Product <b>8c</b> was used without further purification. <sup>31</sup>P NMR (CDCl<sub>3</sub>, 162 MHz): δ 29.3 ppm. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 250 MHz): δ 7.75–7.95 (m, 2H), 7.50–7.6 (m, 1H), 7.35–7.5 (m, 2H), 4.25–4.45 (m, 2H), 1.43 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.1 Hz, 3H).</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>N</i><sup>1</sup>-[6-(2-Methoxyphenyl)pyrimidin-4-yl]-4-methylbenzene-1,3-diamine (<b>9</b>)</h4><div class="NLM_p last">2-Methyl-5-nito aniline (1.52 g, 10 mmol) was dissolved in dry pyridine (50 mL). Isobutyl chloroformate (1.42 mL, 11 mmol) was added in one portion. The reaction mixture was stirred at RT overnight then evaporated to dryness. The crude product was suspended in 1 M HCl and the precipitate was filtered off and the resulting solid was dried in a desiccator over P<sub>2</sub>O<sub>5</sub>, giving a yellow powder (1.915 g, 76%). If necessary, it can be recrystallized from 2-propanol; mp = 118 °C (IPA). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.74 (s, 1H), 7.8 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 8.3 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.3 Hz, 1H), 7.23 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.6 Hz, 1H), 6.45 (s, 1H), 3.94 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 2H), 2.29 (s, 3H), 1.95 (m, 1H), 0.92 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 6H). The (2-methyl-5-nitro-phenyl)-carbamic acid isobutyl ester was dissolved in MeOH (5 mmol in 100 mL), and 10% Pd/C (10% w/w) was added to the solution. The mixture was stirred under atmospheric pressure of H<sub>2</sub>. When the consumption of H<sub>2</sub> was finished, the catalyst was filtered off through a pad of celite and washed with MeOH. The filtrate was evaporated to give (5-amino-2-methyl-phenyl)-carbamic acid isobutyl ester as a pink or brown powder (∼80%); mp = 100–101 °C (MeOH). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 250 MHz): δ 7.34 (s, 1H), 6.94 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 6.38 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.3 Hz, 2H), 3.97 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 2H), 3.05 (br, 2H), 2.17 (s, 3H), 2.00 (m, 1H), 0.99 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 6H). (5-Amino-2-methyl-phenyl)-carbamic acid isobutyl ester (0.222 g, 1 mmol) and 4-chloro-6-(2-methoxy-phenyl)-pyrimidine <b>13a</b> (0.22 g, 1 mmol) were dissolved in 2-propanol (10 mL) then a solution of HCl saturated 2-propanol (2 mL) was added to the mixture. The reaction mixture was refluxed for 3–4 h then it was concentrated under vacuum. The residue was suspended in satd NaHCO<sub>3</sub> and extracted with EtOAc:THF (2:1, 3 × 50 mL). The combined organics were washed with brine and dried with Na<sub>2</sub>SO<sub>4</sub>. After evaporation of solvents under reduced pressure, the crude product was recrystallized from MeCN to give the {5-[6-(2-methoxy-phenyl)-pyrimidin-4-ylamino]-2-methyl-phenyl}-carbamic acid isobutyl ester as a pale-yellow powder (0.304 g, 75%); mp = 155 °C (MeCN). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 9.58 (s, 1H), 8.84 (s, 1H), 8.66 (d, <sup>4</sup><i>J</i><sub>HH</sub> = 1.2 Hz, 1H), 7.95 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.8 Hz, 1H), 7.68 (d, <sup>4</sup><i>J</i><sub>HH</sub> = 2.3 Hz, 1H), 7.47 (m, 2H), 7.43 (d, <sup>4</sup><i>J</i><sub>HH</sub> = 1.2 Hz, 1H), 7.18 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 1H), 7.14 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.8 Hz, 1H), 7.07 (td, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.0 Hz, 1H), 3.9 (s, 3H), 3.86 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 2H), 2.17 (s, 3H), 1.92 (m, 1H), 0.94 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 6H). MS[ES<sup>+</sup>, Q-TOF]: M + H<sup>+</sup> = 407.25 <i>m</i>/<i>z</i>, 2M + H<sup>+</sup> = 813.41 <i>m</i>/<i>z</i>. The {5-[6-(2-methoxy-phenyl)-pyrimidin-4-ylamino]-2-methyl-phenyl}-carbamic acid isobutyl ester and 5 mol equiv of KOH were refluxed overnight in EtOH:water (4:1, 1 mmol in 50 mL). The reaction mixture was concentrated under vacuum, and the residue was suspended in water and 0.5 mL of EtOAc. This mixture was stirred for 15 min, and then it was filtered off. The white powder was washed with Et<sub>2</sub>O (80%). If necessary, it can be recrystallized from MeCN; mp = 168 °C (MeCN). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 9.19 (s, 1H), 8.54 (s, 1H), 7.85 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.8 Hz, 1H), 7.37 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 8.4 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1,8 Hz, 1H), 7.31 (d, <sup>4</sup><i>J</i><sub>HH</sub> = 1.3 Hz, 1H), 7.08 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 1H), 6.99 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 1H), 6.86 (s, 1H), 6.79 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 6.66 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 4.79 (br, 2H), 3.81 (s, 3H), 1.95 (s, 3H). MS[ES<sup>+</sup>, Q-TOF]: M + H<sup>+</sup> = 307,18 <i>m</i>/<i>z</i>.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> General Procedure for the Preparation of Phosphonamidates</h4><div class="NLM_p last">The aniline <b>9</b> (0.061 g, 0.2 mmol) was dissolved in dry pyridine (5 mL) and the appropriate phosphonic acid <b>8a</b>–<b>c</b> (0.4 mmol) was added and the mixture was stirred at 50 °C for 24 h under N<sub>2</sub> atmosphere. The volatiles were evaporated then the residue was suspended in satd NH<sub>4</sub>Cl aqueous solution (10 mL). The product was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 20 mL). The combined organic layers were washed with 1 M aqueous NaOH (2 × 10 mL), with brine (30 mL), and dried with Na<sub>2</sub>SO<sub>4</sub>. After concentration under vacuum, the crude product was further purified by preparative TLC with 100% EtOAc as eluent. For the required purity, two–three elutions were necessary. The desired product was washed with MeOH from silica. If the product contained some traces of phosphonic acid (coming from its hydrolysis on silica), it was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) washed with 1 M aqueous NaOH (20 mL), dried with Na<sub>2</sub>SO<sub>4</sub>, and evaporated. The product was recrystallized from MeCN.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Ethyl <i>P</i>-Ethyl-<i>N</i>-(5-{[6-(2-methoxyphenyl)pyrimidin-4-yl]amino}-2-methylphenyl)phosphonamidate (<b>10</b>)</h4><div class="NLM_p last">Prepared by the reaction of aniline <b>9</b> and phosphonochloridate <b>8a</b>. Cream-colored powder (0.014 g, 17%); mp = ∼RT, amorphous. <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 162 MHz): δ 32.1 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 9.58 (s, 1H), 8.62 (d, <sup>4</sup><i>J</i><sub>HH</sub> = 1.1 Hz, 1H), 7.91 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.8 Hz, 1H), 7.56 (d, <sup>4</sup><i>J</i><sub>HH</sub> = 2.0 Hz, 1H), 7.42–7.48 (m, 1H), 7.41 (d, <sup>4</sup><i>J</i><sub>HH</sub> = 1.1 Hz, 1H), 7.31 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 8.3 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.0 Hz, 1H), 7.17 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, 1H), 7.04–7.10 (m, 2H), 6.48 (d, <sup>2</sup><i>J</i><sub>PH</sub><i>J</i><sub>PH</sub> = 7.3 Hz, 1H), 3.95–4.01 (m, 2H), 3.88 (s, 3H), 2.19 (s, 3H), 1.75–1.90 (m, 2H), 1.25 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 3H), 1.05 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 19.7 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 3H). MS[ES<sup>+</sup>, Q-TOF]: M + H<sup>+</sup> = 427.23 <i>m</i>/<i>z</i>; 2M + H<sup>+</sup> = 853.35 <i>m</i>/<i>z</i>.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Isopropyl <i>N</i>-(5-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}-2-methylphenyl)-<i>P</i>-propylphosphonamidate (<b>11</b>)</h4><div class="NLM_p last">Prepared by the reaction of aniline <b>9</b> and phosphonochloridate <b>8b</b>. Creamy colored powder (0.008 g, 9%); mp = 151 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 162 MHz): δ 29.3 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 9.52 (s, 1H), 8.62 (s, 1H), 7.92 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.1 Hz, 1H), 7.6 (s, 1H), 7.42–7.48 (m, 1H), 7.41 (s, 1H), 7.27 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.1 Hz, 1H), 7.17 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.6 Hz, 1H), 7.04–7.10 (m, 2H), 6.38 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.1 Hz; 1H), 4.57–4.67 (m, 1H), 3.89 (s, 3H), 2.19 (s, 3H), 1.70–1.90 (m, 2H), 1.48–1.60 (m, 2H), 1.24 (dd, <sup>4</sup><i>J</i><sub>PH</sub> = 25.2 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 6.1 Hz, 6H), 1.0 (dt, <sup>4</sup><i>J</i><sub>PH</sub> = 40.6 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 3H). MS[ES<sup>+</sup>, Q-TOF]: M + H<sup>+</sup> = 455.27 <i>m</i>/<i>z</i>.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Ethyl <i>N</i>-(5-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}-2-methylphenyl)-<i>P</i>-phenylphosphonamidate (<b>12</b>)</h4><div class="NLM_p last">Prepared by the reaction of aniline <b>9</b> and phosphonochloridate <b>8c</b>. Creamy colored powder (0.017 g, 18%); mp = 172 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 162 MHz): δ 17.2 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 9.46 (s, 1H), 8.58 (s, 1H), 7.91 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 9.2 Hz, 1H), 7.82 (dd, <sup>3</sup><i>J</i><sub>PH</sub> = 12.8 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 2H), 7.53–7.59 (m, 2H), 7.46–7.53 (m, 2H), 7.45 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.4 Hz, 1H), 7.36 (s, 1H), 7.26 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, 1H), 7.17 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.5 Hz, 1H), 7.08 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 1H), 6.99–7.05 (m, 2H), 4.10 (dq, <sup>3</sup><i>J</i><sub>PH</sub> ≈ <sup>3</sup><i>J</i><sub>HH</sub> ≈ 7.2 Hz, 2H), 3.88 (s, 3H), 2.19 (s, 3H), 1.29 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 3H). MS[ES<sup>+</sup>, Q-TOF]: M + H<sup>+</sup> = 475.21 <i>m</i>/<i>z</i>; 2 M + H<sup>+</sup> = 949.39 <i>m</i>/<i>z</i>.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 4-Chloro-6-(2-methoxyphenyl)pyrimidine (<b>13a</b>) and 4-Chloro-6-(3-nitrophenyl)pyrimidine (<b>13b</b>)</h4><div class="NLM_p last">These compounds were prepared according to ref <a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">5</a>.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 5-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}-2-methylphenol (<b>15</b>)</h4><div class="NLM_p last">5-Amino-2-methyl-phenol <b>14a</b> (0.682 g, 5.5 mmol) and 4-chloro-6-(2-methoxy-phenyl)-pyrimidine <b>13a</b> (1.10 g, 5.0 mmol) were dissolved in 2-propanol (25 mL) then HCl saturated 2-propanol (5 mL) was added to the mixture. The reaction mixture was refluxed for 1 h then it was evaporated. The residue was suspended in satd NaHCO<sub>3</sub> and extracted with EtOAc (3 × 50 mL). The combined organics were washed with brine and dried with Na<sub>2</sub>SO<sub>4</sub>. After evaporation under reduced pressure, the crude product was recrystallized from MeCN to give a pale-yellow, cream-colored powder (0.924 g, 60%); mp = 220–223 °C (MeCN). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 9.42 (s, 1H, exch with D<sub>2</sub>O), 9.32 (s, 1H, exch with D<sub>2</sub>O), 8.65 (d, <sup>4</sup><i>J</i><sub>HH</sub> = 1.2 Hz, 1H), 7.93 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.8 Hz, 1H), 7.45 (td, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.8 Hz, 1H), 7.40 (d, <sup>4</sup><i>J</i><sub>HH</sub> = 1.1 Hz, 1H), 7.27 (s, 1H), 7.17 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 7.08 (td, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.0 Hz, 1H), 6.98 (m, 2H), 3.89 (s, 3H), 2.08 (s, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 100 MHz): δ 160.4 (1C), 159.2 (1C), 157.8 (1C), 157.5 (1C), 155.3 (1C), 138.4 (1C), 131.0 (1C), 130.3 (1C), 130.1 (1C), 125.9 (1C), 120.5 (1C), 118.0 (1C), 112.0 (2C), 110.6 (1C), 106.7 (1C), 55.7 (1C), 15.5 (1C). MS[ES+, Q-TOF]: M + H<sup>+</sup> = 308.13 <i>m</i>/<i>z</i>.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 2-Methyl-5-{[6-(3-nitrophenyl)pyrimidin-4-yl]amino}phenol (<b>16</b>)</h4><div class="NLM_p last"><b>16</b> was prepared according to the procedure used for compound <b>15</b> starting from 5-amino-2-methyl-phenol <b>14a</b> (0.677 g, 5.5 mmol) and 4-chloro-6-(3-nitrophenyl)-pyrimidine <b>13b</b> (1.178 g, 5.0 mmol). <b>16</b> was recrystallized from MeCN to give a yellow powder (0.757 g, 47%); mp = 240–245 °C (MeCN). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.58 (s, 1H), 9.34 (s, 1H), 8.81 (s, 1H), 8.73 (s, 1H), 8.43 (s, 1H), 8.36 (s, 1H), 7.83 (s, 1H), 7.34 (s, 1H), 7.26 (s, 1H), 7.00 (s, 2H), 2.09 (s, 3H). Each peak is a broad singlet. LC-MS: <i>R</i><sub>t</sub> = 3.44 min. (ESI): <i>m</i>/<i>z</i> = 323 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 3-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}phenol (<b>17</b>)</h4><div class="NLM_p last"><b>17</b> was prepared according to the procedure used for compound <b>15</b> starting from 3-amino-phenol <b>14b</b> (0.600 g, 5.5 mmol) and 4-chloro-6-(2-methoxyphenyl)-pyrimidine <b>13a</b> (1.100 g, 5.0 mmol). <b>17</b> was recrystallized from MeCN to give a yellow powder (0.923 g, 63%); mp = 217 °C (MeCN). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.5 (s, 1H), 9.38 (s, 1H), 8.68 (s, 1H), 7.95 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.7 Hz, 1H), 7.40–7.50 (m, 1H), 7.46 (s, 1H), 7.28 (s, 1H), 7.17 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.2 Hz, 1H), 7.05–7.15 (m, 3H), 6.43 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 1H), 3.90 (s, 3H). LC-MS: <i>R</i><sub>t</sub> = 0.47 min; 1.98 min; 2.25 min. (ESI): <i>m</i>/<i>z</i> = 294 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 3-{[6-(3-Nitrophenyl)pyrimidin-4-yl]amino}phenol (<b>18</b>)</h4><div class="NLM_p last"><b>18</b> was prepared according to the procedure used for compound <b>15</b> starting from 3-amino-phenol <b>14b</b> (0.600 g, 5.5 mmol) and 4-chloro-6-(3-nitrophenyl)-pyrimidine <b>13b</b> (1.178 g, 5.0 mmol). <b>18</b> was recrystallized from MeCN to give a yellow powder (1.17 g, 76%); mp = 250–252 °C (MeCN). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.31 (br, 1H), 9.5 (br, 1H), 8.82 (s, 1H), 8.78 (s, 1H), 8.43 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 8.38 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 7.86 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.9 Hz, 1H), 7.58 (s, 1H), 7.33 (s, 1H), 7.08–7.33 (m, 2H), 6.5 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 1H). LC-MS: <i>R</i><sub>t</sub> = 3.20 min. (ESI): <i>m</i>/<i>z</i> = 309 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 4-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}phenol (<b>19</b>)</h4><div class="NLM_p last">It was prepared according to the procedure used for compound <b>15</b> starting from 4-amino-phenol <b>14c</b> (0.600 g, 5.5 mmol) and 4-chloro-6-(2-methoxyphenyl)-pyrimidine <b>13a</b> (1.100 g, 5.0 mmol). <b>19</b> was recrystallized from MeCN to give a brown powder (0.835 g, 57%); mp = 249 °C (MeCN). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.29 (s, 1H), 9.2 (s, 1H), 8.58 (s, 1H), 7.91 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.6 Hz, 1H), 7.38–7.5 (m, 3H), 7.29 (s, 1H), 7.15 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.3 Hz, 1H), 7.06 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 6.75 (d, <i>J</i><sub>AABB</sub><i>J</i><sub>AABB</sub> = 8.7 Hz, 2H), 3.86 (s, 3H). LC-MS: <i>R</i><sub>t</sub><i>R</i><sub>t</sub> = 0.45 min; 1.85 min; 2.27 min. (ESI): <i>m</i>/<i>z</i> = 294 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 4-{[6-(3-Nitrophenyl)pyrimidin-4-yl]amino}phenol (<b>20</b>)</h4><div class="NLM_p last">It was prepared according to the procedure used for compound <b>15</b> starting from 4-amino-phenol <b>14c</b> (0.600 g, 5.5 mmol) and 4-chloro-6-(3-nitrophenyl)-pyrimidine <b>13b</b> (1.178 g, 5.0 mmol). <b>20</b> was filtered from Et<sub>2</sub>O to give a yellow powder (1.263 g, 82%); mp = 242–243 °C (Et<sub>2</sub>O). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.49 (br, 2H), 8.79 (s, 1H), 8.66 (s, 1H), 8.41 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.3 Hz, 1H), 8.34 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 1H), 7.82 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 7.41 (d, <i>J</i><sub>AABB</sub> = 7.0 Hz, 2H), 7.22 (s, 1H), 6.77 (d, <i>J</i><sub>AABB</sub> = 7.5 Hz, 2H). LC-MS: <i>R</i><sub>t</sub> = 2.85 min. (ESI): <i>m</i>/<i>z</i> = 309 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> General Procedure for the Preparation of Phosphonates (Ar-O-P (O)ROR′)</h4><div class="NLM_p last">The appropriate phenol (<b>15</b>–<b>20</b>) (0.5 mmol) was dissolved in anhydrous THF (25 mL) then KOtBu (0.067 g, 0.6 mmol) was added in one portion. The mixture was stirred for 30 min at RT, and then the corresponding phosphonochloridate <b>8a</b>–<b>c</b> (0.75 mmol) was added. The reaction mixture was stirred overnight at RT and concentrated under vacuum. The residue was suspended in 2 M aqueous NaOH (30 mL), and it was extracted with EtOAc (3 × 70 mL). The combined organic phases were washed with brine, dried with MgSO<sub>4</sub>, and evaporated. For further purification and characterization see the individual compounds.</div></div><div id="sec5_1_17_95" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Ethyl 5-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}-2-methylphenyl Ethylphosphonate (<b>21a</b>)</h4><div class="NLM_p last"><b>21a</b> was prepared by the reaction of phenol <b>15</b> and phosphonochloridate <b>8a</b>. It was purified by column chromatography: 100% EtOAc to EtOAc:MeOH (1:1) in gradient. <b>21a</b> was crystallized from MeCN to give a white powder (0.062 g, 29%); mp = 134–135 °C (MeCN). <sup>31</sup>P NMR (162 MHz): DMSO-<i>d</i><sub>6</sub>, δ 30.9 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 9.76 (s, 1H), 8.68 (s, 1H), 7.95 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.7 Hz, 1H), 7.75 (s, 1H), 7.43–7.51 (m, 3H), 7.21 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.19 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz), 7.08 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.9 Hz, 1H), 4.07–4.20 (m, 2H), 3.9 (s, 3H), 2.2 (s, 3H), 1.97 (dq, <sup>2</sup><i>J</i><sub>PH</sub> = 17.8 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 2H), 1.25 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 3H), 1.16 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 20.6 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 100 MHz): δ 160.2 (1C), 159.4 (1C), 157.7 (1C), 157.5 (1C), 148.5 (d, <sup>2</sup><i>J</i><sub>PC</sub> = 9.5 Hz, 1C), 138.8 (d, <sup>4</sup><i>J</i><sub>PC</sub> = 1.5 Hz, 1C), 131.2 (1C), 131.0 (1C), 130.1 (1C), 125.7 (1C), 122.3 (d, <sup>3</sup><i>J</i><sub>PC</sub> = 4.4 Hz, 1C), 120.6 (1C), 115.7 (1C), 112.1 (1C), 111.4 (d, <sup>3</sup><i>J</i><sub>PC</sub> = 2.9 Hz, 1C), 107.2 (1C), 62.1 (d, <sup>2</sup><i>J</i><sub>PC</sub><i>J</i><sub>PC</sub> = 6.6 Hz, 1C), 55.7 (1C), 18.4 (d, <sup>1</sup><i>J</i><sub>PC</sub> = 140.5 Hz, 1C), 16.2 (d, <sup>3</sup><i>J</i><sub>PC</sub> = 5.1 Hz, 1C), 15.5 (1C), 6.5 (1C). MS[ES<sup>+</sup>, Q-TOF]: M + H<sup>+</sup> = 428.12 <i>m</i>/<i>z</i>; 2 M + H<sup>+</sup> = 855.27 <i>m</i>/<i>z</i>.</div></div><div id="sec5_1_17_96" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Isopropyl 5-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}-2-methylphenyl propylphosphonate (<b>21b</b>)</h4><div class="NLM_p last"><b>21b</b> was prepared by the reaction of phenol <b>15</b> and phosphonochloridate <b>8b</b>. It was purified by column chromatography in 100% EtOAc. <b>21b</b> was crystallized from diisopropylether to give a white powder (0.118 g, 52%). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 162 MHz): δ 28.5 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 9.71 (s, 1H), 8.67 (d, <sup>5</sup><i>J</i><sub>HH</sub> = 1.0 Hz, 1H), 7.95 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.8 Hz, 1H), 7.77 (s, 1H), 7.44–7.48 (m, 2H), 7.45 (d, <sup>5</sup><i>J</i><sub>HH</sub> = 1.2 Hz, 1H), 7.21 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 7.18 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 1H), 7.09 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.7 Hz, 1H), 4.65–4.75 (m, 1H), 3.91 (s, 3H), 2.19 (s, 3H), 1.88–1.99 (m, 2H), 1.56–1.71 (m, 2H), 1.28 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.1 Hz, 3H), 1.18 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.1 Hz, 3H), 1.02 (dt, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, <sup>4</sup><i>J</i><sub>PH</sub> = 1.4 Hz, 3H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>, 100 MHz): δ 160.2 (1C), 159.4 (1C), 157.6 (1C), 157.5 (1C), 148.6 (d, <sup>2</sup><i>J</i><sub>PC</sub> = 8.6 Hz, 1C), 138.8 (d, <sup>4</sup><i>J</i><sub>PC</sub> = 1.2 Hz, 1C), 131.2 (1C), 131.0 (1C), 130.1 (1C), 125.7 (1C), 122.3 (d, <sup>3</sup><i>J</i><sub>PC</sub> = 5.5 Hz, 1C), 120.6 (1C), 115.6 (1C), 112.1 (1C), 111.6 (1C), 107.1 (1C), 70.5 (d, <sup>2</sup><i>J</i><sub>PC</sub> = 6.7 Hz, 1C), 55.7 (1C), 27.8 (d, <sup>1</sup><i>J</i><sub>PC</sub> = 139.7 Hz, 1C), 23.7 (d, <sup>3</sup><i>J</i><sub>PC</sub> = 4.3 Hz, 1C), 23.5 (d, <sup>3</sup><i>J</i><sub>PC</sub> = 4.3 Hz, 1C), 15.9 (d, <sup>2</sup><i>J</i><sub>PC</sub> = 5.5 Hz, 1C), 15.6 (1C), 14.9 (d, <sup>3</sup><i>J</i><sub>PC</sub> = 17.2 Hz, 1C). MS[ES<sup>+</sup>, Q-TOF]: M + H<sup>+</sup> = 456.17 <i>m</i>/<i>z</i>; 2 M + H<sup>+</sup> = 911.36 <i>m</i>/<i>z</i>.</div></div><div id="sec5_1_17_97" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> Ethyl 5-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}-2-methylphenyl Phenylphosphonate (<b>21c</b>)</h4><div class="NLM_p last"><b>21c</b> was prepared by the reaction of phenol <b>15</b> and phosphonochloridate <b>8c</b>. It was purified by column chromatography in EtOAc:hexane (9:1). <b>21c</b> was crystallized from MeCN to give a white powder (0.021 g, 9%); mp = 146 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 162 MHz): δ 14.7 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 9.69 (s, 1H), 8.62 (s, 1H), 7.95 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.7 Hz, 1H), 7.83–7.89 (m, 2H), 7.76 (s, 1H), 7.67–7.73 (m, 1H), 7.58–7.63 (m, 2H), 7.44–7.48 (m, 1H), 7.42 (s, 1H), 7.40–7.42 (m, 1H), 7.18 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.6 Hz, 2H), 7.09 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.3 Hz, 1H), 4.21 (m, 2H), 3.90 (s, 3H), 2.15 (s, 3H), 1.29 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 3H). MS[ES<sup>+</sup>, Q-TOF]: M + H<sup>+</sup> = 476.1 <i>m</i>/<i>z</i>; 2 M + H<sup>+</sup> = 951.25 <i>m</i>/<i>z</i>.</div></div><div id="sec5_1_17_98" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> Ethyl 2-Methyl-5-{[6-(3-nitrophenyl)pyrimidin-4-yl]amino}phenyl Ethylphosphonate (<b>22a</b>)</h4><div class="NLM_p last"><b>22a</b> was prepared by the reaction of phenol <b>16</b> and phosphonochloridate <b>8a</b>. <b>22a</b> was recrystallized from MeCN to give a pale-yellow powder (0.177 g, 79%); mp = 194–195 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 243 MHz): δ 29.8 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.9 (s, 1H), 8.83 (s, 1H), 8.76 (s, 1H), 8.46 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 1H), 8.36 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.9 Hz, 1H), 7.84 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.9 Hz, 1H), 7.74 (s, 1H), 7.46 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.9 Hz, 1H), 7.32 (s, 1H), 7.23 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 4.07–4.19 (m, 2H), 2.21 (s, 3H), 1.91–2.07 (m, 2H), 1.25 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 3H), 1.13 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 20.5 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 4.05 min. (ESI): <i>m</i>/<i>z</i> = 443 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_17_99" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> Isopropyl 2-Methyl-5-{[6-(3-nitrophenyl)pyrimidin-4-yl]amino}phenyl Propylphosphonate (<b>22b</b>)</h4><div class="NLM_p last"><b>22b</b> was prepared by the reaction of phenol <b>16</b> and phosphonochloridate <b>8b</b>. <b>22b</b> was recrystallized from MeCN to give a pale-yellow powder (0.111 g, 47%); mp = 164–166 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 243 MHz): δ 27.6 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.85 (s, 1H), 8.82 (s, 1H), 8.74 (s, 1H), 8.45 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 8.35 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.4 Hz, 1H), 7.83 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.74 (s, 1H), 7.44 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 7.36 (s, 1H), 7.21 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.3 Hz, 1H), 4.65–4.72 (m, 1H), 2.19 (s, 3H), 1.86–1.98 (m, 2H), 1.58–1.66 (m, 2H), 1.27 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.1 Hz, 3H), 1.17 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.1 Hz, 3H), 1.01 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.1 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 4.55 min. (ESI): <i>m</i>/<i>z</i> = 271 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 5-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}-2-methylphenyl Ethyl Ethylphosphonate (<b>23a</b>)</h4><div class="NLM_p last">The nitro-compound <b>22a</b> (0.049 g, 0.11 mmol) was dissolved in the mixture of MeOH:CH<sub>2</sub>Cl<sub>2</sub> (20 mL:10 mL). Ammonium formate (0.069 g, 1.1 mmol) and 10% Pd/C (0.005 g, 10% w/w) were added. Reaction mixture was stirred under inert atmosphere overnight at RT. After the reduction was completed, catalyst was filtered off on a celite pad and washed with MeOH (10 mL). Filtrate was concentrated under vacuum. The residue was suspended in satd aqueous Na<sub>2</sub>CO<sub>3</sub> (30 mL) and extracted with EtOAc (3 × 70 mL). The combined organic phases were washed with brine and dried with MgSO<sub>4</sub>. After evaporation, the product <b>23a</b> was crystallized from the mixture of 2-propanol and hexane to obtain an off-white powder (0.031 g, 67%); mp = 148–150 °C (<i>i</i>-PrOH, hexane). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 243 MHz): δ 29.9 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.66 (s, 1H), 8.63 (s, 1H), 7.70 (s, 1H), 7.42 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 1H), 7.28 (s, 1H), 7.19 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.4 Hz, 1H), 7.00–7.20 (m, 3H), 6.60–6.70 (m, 1H), 5.24 (br, 2H), 4.11 (q, <sup>3</sup><i>J</i><sub>HH</sub> = 6.7 Hz, 2H), 2.18 (s, 3H), 1.89–2.19 (m, 2H), 1.23 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.7 Hz, 3H), 1.14 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 20.4 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.69 min. (ESI): <i>m</i>/<i>z</i> = 413 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 5-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}-2-methylphenyl Isopropyl Propylphosphonate (<b>23b</b>)</h4><div class="NLM_p last">The nitro-compound <b>22b</b> (0.094 g, 0.2 mmol) was reduced with the method used for <b>23a</b>. After evaporation of organic phases, the product was dissolved in dry EtOAc (5 mL) and the HCl salt was prepared with 0.5 mL of EtOAc satd with HCl. The precipitate was filtered and washed with Et<sub>2</sub>O, affording a yellow powder (0.060 g, 63%); mp = 165 °C dec (EtOAc). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 243 MHz): δ 27.7 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 11.00 (s, 1H), 8.82 (s, 1H), 7.73 (br, 2H), 7.20–7.60 (m, 7H), 6.00 (br, 2H), 4.65–4.70 (m, 1H), 2.22 (s, 3H), 1.89–2.21 (m, 2H), 1.60–1.65 (m, 2H), 1.27 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.6 Hz, 3H), 1.18 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.6 Hz, 3H) 1.14 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.08 min. (ESI): <i>m</i>/<i>z</i> = 441 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18_94" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> Ethyl 3-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}phenyl Ethylphosphonate (<b>24a</b>)</h4><div class="NLM_p last"><b>24a</b> was prepared by the general method used for phosphonates by the reaction of phenol <b>17</b> (0.060 g; 0.2 mmol) and the phosphonochloridate <b>8a</b> (0.047 g; 0.3 mmol). The product was purified by preparative TLC in 100% EtOAc, giving a light-brown viscous oil (0.049 g, 59%). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 243 MHz): δ 33.0 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.77 (s, 1H), 8.72 (s, 1H), 7.96 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.7 Hz, 1H), 7.73 (s, 1H), 7.53 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.3 Hz, 1H), 7.48 (s, 1H), 7.47 (dt, <sup>3</sup><i>J</i><sub>HH</sub> = 8.4 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.8 Hz, 1H), 7.32 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.3 Hz, 1H), 7.19 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.3 Hz, 1H), 7.08 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 1H), 6.83 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 4.09–4.20 (m, 2H), 3.91 (s, 3H), 1.86–2.00 (m, 2H), 1.26 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 3H), 1.13 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 20.4 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.77 min. (ESI): <i>m</i>/<i>z</i> = 414 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18_95" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> Isopropyl 3-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}phenyl Propylphosphonate (<b>24b</b>)</h4><div class="NLM_p last"><b>24b</b> was prepared by the general method used for phosphonates by the reaction of phenol <b>17</b> (0.060 g; 0.2 mmol) and the phosphonochloridate <b>8b</b> (0.055 g; 0.3 mmol). The product was purified by preparative TLC in 100% EtOAc, affording a light-brown viscous oil (0.058 g, 66%). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 243 MHz): δ 30.3 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.76 (s, 1H), 8.71 (s, 1H), 7.96 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.6 Hz, 1H), 7.73 (s, 1H), 7.43–7.54 (m, 2H), 7.48 (s, 1H), 7.32 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.2 Hz, 1H), 7.19 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.3 Hz, 1H), 7.08 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 1H), 6.83 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 4.65–4.77 (m, 1H), 3.91 (s, 3H), 1.83–1.93 (m, 2H), 1.54–1.67 (m, 2H), 1.28 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.2 Hz, 3H), 1.22 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.2 Hz, 3H), 1.00 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, <sup>4</sup><i>J</i><sub>PH</sub> = 1.0 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.16 min. (ESI): <i>m</i>/<i>z</i> = 442 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18_96" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> Ethyl 3-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}phenyl Phenylphosphonate (<b>24c</b>)</h4><div class="NLM_p last"><b>24c</b> was prepared by the general method used for phosphonates by the reaction of phenol <b>17</b> (0.060 g; 0.2 mmol) and the phosphonochloridate <b>8c</b> (0.061 g; 0.3 mmol). The product was purified by preparative TLC in EtOAc:hexane = 1:1, giving a light-brown viscous oil (0.037 g, 40%). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 243 MHz): δ 17.1 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.75 (s, 1H), 8.68 (s, 1H), 7.95 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.3 Hz, 1H), 7.84 (dd, <sup>3</sup><i>J</i><sub>PH</sub> = 13.5 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz; 2H), 7.75 (s, 1H) ; 7.65–7.71 (m, 1H), 7.55–7.62 (m, 2H), 7.4–7.5 (m, 2H), 7.45 (s, 1H), 7.28 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 7.18 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 7.08 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.3 Hz, 1H), 6.79 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 4.15–4.25 (m, 2H), 3.90 (s, 3H), 1.29 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.14 min. (ESI): <i>m</i>/<i>z</i> = 462 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18_97" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> Ethyl 3-{[6-(3-Nitrophenyl)pyrimidin-4-yl]amino}phenyl Ethylphosphonate (<b>25a</b>)</h4><div class="NLM_p last"><b>25a</b> was prepared by the general method used for phosphonates by the reaction of phenol <b>18</b> (0.090 g; 0.29 mmol) and the phosphonochloridate <b>8a</b> (0.068 g; 0.44 mmol). The product was recrystallized from MeCN to give a yellow powder (0.075 g, 60%); mp = 142–144 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 243 MHz): δ 33.0 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.96 (s, 1H), 8.83 (s, 1H), 8.80 (s, 1H), 8.47 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, 1H), 8.37 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.85 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.75 (s, 1H), 7.53 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7. Hz, 1H), 7.41 (s, 1H), 7.35 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 6.87 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, 1H), 4.08–4.2 (m, 2H), 1.87–2.01 (m, 2H), 1.26 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 3H), 1.13 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 20.5 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.79 min. (ESI): <i>m</i>/<i>z</i> = 429 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18_98" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> Isopropyl 3-{[6-(3-Nitrophenyl)pyrimidin-4-yl]amino}phenyl Propylphosphonate (<b>25b</b>)</h4><div class="NLM_p last"><b>25b</b> was prepared by the general method used for phosphonates by the reaction of phenol <b>18</b> (0.090 g; 0.29 mmol) and the phosphonic acid chloride <b>8b</b> (0.057 g; 0.44 mmol). The product was recrystallized from MeCN to give a yellow powder (0.057 g, 60%); mp = 163–164 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 243 MHz): δ 27.4 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.04 (s, 1H), 8.84 (s, 1H), 8.79 (s, 1H), 8.47 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 8.37 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 7.85 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.76 (s, 1H), 7.53 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H),7.44 (s, 1H), 7.34 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 6.86 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 4.68–4.75 (m, 1H), 1.84–1.96 (m, 2H), 1.57–1.65 (m, 2H), 1.28 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.0 Hz, 3H), 1.22 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.0 Hz, 3H), 1.00 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.1 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 4.28 min. (ESI): <i>m</i>/<i>z</i> = 457 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_18_99" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Ethyl 3-{[6-(3-Nitrophenyl)pyrimidin-4-yl]amino}phenyl Phenylphosphonate (2<b>5c</b>)</h4><div class="NLM_p last"><b>25c</b> was prepared by the general method used for phosphonates by the reaction of phenol <b>18</b> (0.102 g; 0.33 mmol) and the phosphonochloridate <b>8c</b> (0.102 g; 0.54 mmol). The product was recrystallized from MeCN to give a cream-colored powder (0.083 g, 53%); mp = 162–164 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 243 MHz): δ 17.2 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.94 (s, 1H), 8.83 (s, 1H), 8.77 (s, 1H), 8.42 (dd, <sup>3</sup><i>J</i><sub>PH</sub> = 27.2 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.1 Hz, 2H), 7.80–7.90 (m, 3H), 7.76 (s, 1H), 7.65–7.7 (m, 1H), 7.55–7.65 (m, 2H), 7.47 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 1H), 7.38 (s, 1H), 7.31 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 6.82 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 1H), 4.18–4.24 (m, 2H), 1.29 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.2 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 4.28 min. (ESI): <i>m</i>/<i>z</i> = 457 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 3-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}phenyl Ethyl Ethylphosphonate (<b>26a</b>)</h4><div class="NLM_p last">The nitro compound <b>25a</b> (0.055 g, 0.13 mmol) and SnCl<sub>2</sub> (0.099 g; 0.52 mmol) were dissolved in EtOH (10 mL), and the mixture was refluxed for 4 h. After the reaction was completed, volatiles were evaporated then the residue was suspended in 2 M aqueous NaOH (10 mL). The precipitate was filtered and washed with EtOAc. The filtrate was extracted with EtOAc (3 × 20 mL), and the organic phases were washed with brine and dried with MgSO<sub>4</sub>. After evaporation, the pure product was dissolved in the minimal quantity of EtOH, and the HCl salt was prepared by adding 4 M HCl in dioxane. Volatiles were evaporated, and dry toluene (30 mL) was added and distilled from the residue. The hydrochloride salt of the <b>26a</b> was suspended in Et<sub>2</sub>O, filtered, and dried to obtain a yellow powder (0.042 g, 74%); mp = 205–206 °C (EtOH, Et<sub>2</sub>O). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 243 MHz): δ 33.1 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.94 (s, 1H), 8.85 (s, 1H), 7.77 (s, 1H), 7.73 (br, 2H), 7.55–7.62 (m, 2H), 7.36–7.42 (m, 2H), 7.39 (s, 1H), 6.96 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 5.50 (br, 2H), 4.05–4.21 (m, 2H), 1.90–1.99 (m, 2H), 1.26 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 3H), 1.13 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 20.5 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 0.43 min; 2.48 min; 2.57 min. (ESI): <i>m</i>/<i>z</i> = 399 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 3-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}phenyl Isopropyl Propylphosphonate (<b>26b</b>)</h4><div class="NLM_p last">Compound <b>25b</b> (0.133 g, 0.29 mmol) was reduced according to the preparation of <b>26a</b>, giving a green–yellow powder (0.109 g, 81%); mp = 148–150 °C (EtOH, Et<sub>2</sub>O). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 243 MHz): δ 30.4 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.35 (s, 1H), 8.72 (s, 1H), 7.70 (s, 1H), 7.30–7.60 (m, 3H), 7.20–7.30 (m, 3H), 7.06 (br, 1H), 6.84 (br, 1H), 4.67 (br, 1H), 3.70 (br, 2H<sub>2</sub>), 1.75–1.90 (m, 2H), 1.50–1.60 (m, 2H), 1.24 (s, 3H), 1.19 (s, 3H), 0.96 (br, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.00 min. (ESI): <i>m</i>/<i>z</i> = 427 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 3-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}phenyl Ethyl Phenylphosphonate (<b>26c</b>)</h4><div class="NLM_p last">Compound <b>25c</b> (0.065 g, 0.14 mmol) was reduced according to the preparation of <b>26a</b>, giving a yellow powder (0.051 g, 76%); mp = 214–215 °C (EtOH, Et<sub>2</sub>O). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 243 MHz): δ 17.3 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.89 (s, 1H), 8.82 (s, 1H), 7.50–7.90 (m, 10H), 7.30–7.50 (m, 3H), 6.91 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 5.40 (br, 2H), 4.15–4.26 (m, 2H), 1.29 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.96 min. (ESI): <i>m</i>/<i>z</i> = 447 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_21_95" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> Ethyl 4-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}phenyl Ethylphosphonate (<b>27a</b>)</h4><div class="NLM_p last"><b>27a</b> was prepared by the general method used for phosphonates by the reaction of phenol <b>19</b> (0.033 g; 0.11 mmol) and the phosphonochloridate <b>8a</b> (0.060 g; 0.17 mmol). The product was purified by preparative TLC in 100% EtOAc, providing a light-brown viscous oil (0.022 g 48%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.64 (s, 1H), 8.67 (s, 1H), 7. 95 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.5 Hz, 1H), 7.69 (d, <i>J</i><sub>AABB</sub> = 8.8 Hz, 2H), 7.45 (dt, <sup>3</sup><i>J</i><sub>HH</sub> = 8.6 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.5 Hz, 1H), 7.42 (s, 1H), 7.18 (d, <i>J</i><sub>AABB</sub> = 8.3 Hz, 2H), 7.17 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 7.08 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 4.04–4.16 (m, 2H), 3.90 (s, 3H), 1.83–1.98 (m, 2H), 1.24 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 3H), 1.11 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 20.3 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.70 min. (ESI): <i>m</i>/<i>z</i> = 414 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_21_96" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> Isopropyl 4-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}phenyl Isopropylphosphonate (<b>27b</b>)</h4><div class="NLM_p last"><b>27b</b> was prepared by the general method used for phosphonates by the reaction of phenol <b>19</b> (0.100 g; 0.34 mmol) and the phosphonochloridate <b>8b</b> (0.094 g; 0.51 mmol). The product was purified by preparative TLC in 100% EtOAc, yielding a yellow powder (0.020 g, 13%); mp = 119–121 °C (CH<sub>2</sub>Cl<sub>2</sub>). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 243 MHz): δ 30.6 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.63 (s, 1H), 8.67 (s, 1H), 7.95 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 1H), 7.69 (<i>J</i><sub>AABB</sub> = 7.4 Hz, 2H), 7.35–7.50 (m, 2H), 7.15–7.18 (m, 3H), 7.05–7.13 (m, 1H), 4.60–4.70 (m, 1H), 3.9 (s, 3H), 1.81–1.90 (m, 2H), 1.49–1.70 (m, 2H), 1.27 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.1 Hz, 3H), 1.20 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.1 Hz, 3H), 0.99 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.6 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.07 min. (ESI): <i>m</i>/<i>z</i> = 442 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_21_97" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> Ethyl 4-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}phenyl Phenylphosphonate (<b>27c</b>)</h4><div class="NLM_p last"><b>27c</b> was prepared by the general method used for phosphonates by the reaction of phenol <b>19</b> (0.033 g; 0.11 mmol) and the phosphonochloridate <b>8c</b> (0.035 g; 0.17 mmol). The product was purified by preparative TLC in EtOAc:hexane = 1:1, affording a light-brown viscous oil (0.041 g, 81%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.63 (s, 1H), 8.66 (s, 1H), 7.94 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.2 Hz, 1H), 7.82 (dd, <sup>3</sup><i>J</i><sub>PH</sub> = 13.3 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.1 Hz, 2H), 7.60–7.75 (m, 3H), 7.50–7.60 (m, 2H), 7.45 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 7.40 (s, 1H), 7.17 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.3 Hz, 1H), 7.13 (d, <i>J</i><sub>AABB</sub> = 8.5 Hz, 2H), 7.07 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 1H), 4.13–4.22 (m, 2H), 3.88 (s, 3H), 1.27 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.06 min. (ESI): <i>m</i>/<i>z</i> = 462 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_21_98" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> Ethyl 4-{[6-(3-Nitrophenyl)pyrimidin-4-yl]amino}phenyl Ethylphosphonate (<b>28a</b>)</h4><div class="NLM_p last"><b>28a</b> was prepared by the general method used for phosphonates by the reaction of phenol <b>20</b> (0.150 g; 0.49 mmol) and the phosphonochloridate <b>8a</b> (0.115 g; 0.74 mmol). After recrystallization from MeCN, a yellow powder was obtained (0.085 g, 41%); mp = 187 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 243 MHz): δ 33.2 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.81 (s, 1H), 8.86 (s, 1H), 8.75 (s, 1H), 8.45 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 8.36 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 7.84 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.71 (d, <i>J</i><sub>AABB</sub> = 8.8 Hz, 2H), 7.34 (s, 1H), 7.19 (d, <i>J</i><sub>AABB</sub> = 8.5 Hz, 2H), 4.04–4.19 (m, 2H), 1.90 (dq, <sup>3</sup><i>J</i><sub>PH</sub> = 7.6 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 2H), 1.25 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 3H), 1.12 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 20.4 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.63 min. (ESI): <i>m</i>/<i>z</i> = 429 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_21_99" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> Isopropyl 4-{[6-(3-Nitrophenyl)pyrimidin-4-yl]amino}phenyl Propylphosphonate (<b>28b</b>)</h4><div class="NLM_p last"><b>28b</b> was prepared by the general method used for phosphonates by the reaction of phenol <b>20</b> (0.154 g; 0.50 mmol) and the phosphonochloridate <b>8b</b> (0.138 g; 0.75 mmol). After recrystallization from MeCN, a cream-colored powder was obtained (0.012 g, 12%); mp = 187 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 243 MHz): δ 27.6 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.86 (s, 1H), 8.82 (s, 1H), 8.75 (s, 1H), 8.45 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.3 Hz, 1H), 8.36 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 1H), 7.84 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.71 (d, <i>J</i><sub>AABB</sub> = 8.1 Hz, 2H), 7.36 (s, 1H), 7.18 (d, <i>J</i><sub>AABB</sub> = 8.1 Hz, 2H), 4.60–4.70 (m, 1H), 1.81–1.93 (m, 2H), 1.55–1.63 (m, 2H), 1.27 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.8 Hz, 3H), 1.20 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.7 Hz, 3H), 1.00 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.6 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 4.20 min. (ESI): <i>m</i>/<i>z</i> = 457 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 4-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}phenyl Ethyl Ethylphosphonate (<b>29a</b>)</h4><div class="NLM_p last">Compound <b>28a</b> (0.067 g, 0.16 mmol) was reduced according to the preparation of <b>26a</b>, giving a yellow powder (0.043 g, 62%); mp = 207–209 °C (EtOH, Et<sub>2</sub>O). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.63 (s, 1H), 8.64 (s, 1H), 7.68 (d, <i>J</i><sub>AABB</sub> = 8.7 Hz, 2H), 7.28 (s, 1H), 7.09–7.19 (m, 5H), 6.68 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.4 Hz, 1H), 5.26 (br, 2H), 4.40–4.17 (m, 2H), 1.83–1.98 (m, 2H), 1.24 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.05 Hz, 3H), 1.11 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 12.7 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 0.43 min 2.28 min; 2.47 min. (ESI): <i>m</i>/<i>z</i> = 399 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 4-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}phenyl Isopropyl Propylphosphonate (<b>29b</b>)</h4><div class="NLM_p last">Compound <b>28b</b> (0.076 g, 0.17 mmol) was reduced according to the preparation of <b>26a</b>, affording a yellow powder (0.016 g, 21%); mp = 150–160 °C (EtOH, Et<sub>2</sub>O). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 243 MHz): δ 27.6 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.62 (s, 1H), 8.64 (s, 1H), 7.68 (d, <i>J</i><sub>AABB</sub> = 8.9 Hz, 2H), 7.28 (s, 1H), 7.12–7.23 (m, 4H), 7.09 (s, 1H, H12), 6.68 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.6 Hz, 1H), 5.26 (br, 2H), 4.64–4.71 (m, 1H), 1.81–1.9 (m, 2H), 1.58–1.63 (m, 2H), 1.27 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.2 Hz, 3H), 1.20 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.2 Hz, 3H), 1.00 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.3 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.78 min. (ESI): <i>m</i>/<i>z</i> = 427 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 4-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}phenyl Hydrogen Ethylphosphonate (<b>30a</b>)</h4><div class="NLM_p last">Chlorotrimethylsilane (0.21 mL, 1.65 mmol) and potassium iodide (0.274 g; 1.65 mmol) were dissolved in anhydrous acetone (20 mL). The mixture was stirred for 30 min at RT then the solution of phosphonate <b>21a</b> (0.235 g, 0.55 mmol in 30 mL anhydrous acetone) was added. The reaction mixture was refluxed for 20 h, and then it was concentrated under vacuum. The crude product was suspended in satd NH<sub>4</sub>Cl solution and 0.5 mL of EtOAc. The suspension was stirred for 1 h at RT then it was filtered off and washed with Et<sub>2</sub>O, giving <b>30a</b> as a yellow powder was prepared (0.154 g, 70%); mp = 240–242 °C (water). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 243 MHz): δ 26.9 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, at 110 °C, 300 MHz): δ 10.02 (br, 1H), 8.71 (s, 1H), 7.85 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 7.61 (s, 1H), 7.40–7.55 (m, 3H), 7.41 (s, 1H), 7.2 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 1H), 7.11 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 1H), 4.89 (br, 1H), 3.91 (s, 3H), 2.24 (s, 3H), 1.77–1.92 (m, 2H), 1.17 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 19.9 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.43 min; (ESI): <i>m</i>/<i>z</i> = 400 [M + H]<sup>+</sup>. MS[ES<sup>+</sup>, Q-TOF]: M + H<sup>+</sup> = 400.11 <i>m</i>/<i>z</i>; 2 M + H<sup>+</sup> = 799.18 <i>m</i>/<i>z</i>.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 4-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}phenyl Hydrogen Propylphosphonate (<b>30b</b>)</h4><div class="NLM_p last">Deprotection of phosphonate <b>21b</b> (0.050 g; 0.11 mmol) was performed according to the preparation of <b>30a</b>, affording <b>30b</b> as a brown powder (0.036 g, 79%); mp = 170 °C (water). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 162 MHz): δ 26.6 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 400 MHz): δ 10.48 (br, 1H), 8.81 (s, 1H), 7.78 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 1H), 7.57 (s, 1H), 7.56 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 7.49 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.2 Hz, 1H), 7.32 (s, 1H), 7.25 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.4 Hz, 1H), 7.24 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.6 Hz, 1H), 7.14 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 3.50 (s, 1H), 3.90 (s, 3H), 2.21 (s, 3H), 1.77–1.86 (m, 2H), 1.58–1.67 (m, 2H), 1.01 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.1 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.53 min. (ESI): <i>m</i>/<i>z</i> = 414 [M + H]<sup>+</sup>. MS[ES<sup>+</sup>, Q-TOF]: M + H<sup>+</sup> = 414.12 <i>m</i>/<i>z</i>; 2 M + H<sup>+</sup> = 827.22 <i>m</i>/<i>z</i>.</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> Diethyl [Hydroxy(3-nitrophenyl)methyl]phosphonate (<b>31</b>)</h4><div class="NLM_p last">3-Nitrobenzaldehyde (7.55 g, 50 mmol) was dissolved in toluene (50 mL) then diethyl phosphite (7.59 g, 55 mmol) and triethylamine (5.56 g, 55 mmol) were added and stirred at RT overnight. Water (50 mL) was added to the reaction mixture then the organic phase was washed with 1 M aqueous HCl solution (50 mL). Combined aqueous phases were extracted with toluene (30 mL). The organic phases were washed with brine and dried with MgSO<sub>4</sub>. After concentration, <b>31</b> was recrystallized from toluene to give a pale-yellow powder (11.04 g, 76%); mp = 92 °C (toluene). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 19.8 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.28 (d, <sup>4</sup><i>J</i><sub>HH</sub> = 1.6 Hz, 1H), 8.14 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.86 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 7.65 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.9 Hz, 1H), 6.52 (dd, <sup>3</sup><i>J</i><sub>PH</sub> = 14.5 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 5.9 Hz, 1H), 5.2 (dd, <sup>2</sup><i>J</i><sub>PH</sub> = 14.1 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 5.9 Hz, 1H), 3.90–4.04 (m, 4H), 1.16 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 2.83 min. (ESI): <i>m</i>/<i>z</i> = 290 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_198" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> Diethyl [Hydroxy(4-nitrophenyl)methyl]phosphonate (<b>32</b>)</h4><div class="NLM_p last"><b>32</b> was prepared similarly to compound <b>31</b> from 4-nitrobenzaldehyde (7.550 g, 50 mmol). <b>32</b> was prepared as a pale-yellow powder (8.67 g, 60%); mp = 88–90 °C (toluene). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 19.4 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.21 (d, <i>J</i><sub>AABB</sub> = 8.6 Hz, 2H), 7.68 (dd, <i>J</i><sub>AABB</sub> = 8.9 Hz, <i>J</i> = 2.2 Hz 2H), 6.50 (dd, <sup>4</sup><i>J</i><sub>PH</sub> = 14.6 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 5.7 Hz, 1H), 5.18 (dd, <sup>2</sup><i>J</i><sub>PH</sub> = 15.4 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 5.7 Hz), 3.90–4.05 (m, 4H), 1.16 (dt, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, <i>J</i> = 3.0 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 2.84 min. (ESI): <i>m</i>/<i>z</i> = 290 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> Diethyl [(3-Aminophenyl)(hydroxy)methyl]phosphonate (<b>33</b>)</h4><div class="NLM_p last">Diethyl [hydroxy(3-nitrophenyl)methyl]phosphonate <b>31</b> (1.455 g; 5.0 mmol) and ammonium formate (3.150 g, 50.0 mmol) were dissolved in MeOH (100 mL) under un inert atmosphere. Then 10 m/m % Pd/C (0.145 g, 10 w/w%) was added to the mixture and stirred for 24 h at RT. Catalyst was filtered off on a Celite pad and washed with MeOH (20 mL). After concentration of the filtrate, the residue was suspended in satd aqueous Na<sub>2</sub>CO<sub>3</sub> (50 mL) and it was extracted with EtOAc (3 × 50 mL). The combined organics were washed with brine and dried with MgSO<sub>4</sub>. After evaporation of volatiles under reduced pressure, <b>33</b> was obtained as a yellow oil (0.936 g; 72%). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 21.1 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 6.93 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, 1H), 6.65 (d, <sup>4</sup><i>J</i><sub>HH</sub> = 1.5 Hz, 1H), 6.54 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.3 Hz, 1H), 6.44 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 5.92 (dd, <sup>3</sup><i>J</i><sub>PH</sub> = 16.7 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 5.5 Hz, 1H), 5.00 (br, 2H), 4.7 (dd, <sup>2</sup><i>J</i><sub>PH</sub> = 13.1 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 5.5 Hz, 1H), 3.82–3.99 (m, 4H), 1.15 (dt, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, <sup>4</sup><i>J</i><sub>PH</sub> = 10.6 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 0.48 min; 1.49 min; 2.18 min. (ESI): <i>m</i>/<i>z</i> = 260 [M +H]<sup>+</sup>.</div></div><div id="sec5_1_199" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> Diethyl [(4-Aminophenyl)(hydroxy)methyl]phosphonate (<b>34</b>)</h4><div class="NLM_p last"><b>34</b> was synthesized according to the preparation of compound <b>33</b> from diethyl [hydroxy(4-nitrophenyl)methyl]phosphonate <b>32</b> (1.50 g, 5.19 mmol). <b>34</b> was filtered from Et<sub>2</sub>O to give a yellow powder (1.16 g, 86%); mp = 157–158 °C (Et<sub>2</sub>O). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 21.8 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 7.07 (dd, <i>J</i><sub>AABB</sub> = 8.3 Hz, <i>J</i> = 1.7 Hz 2H), 6.50 (d, <i>J</i><sub>AABB</sub> = 8.3 Hz, 2H), 5.80 (br, 1H), 5.03 (br, 2H), 4.66 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 11.7 Hz), 3.90–4.01 (m, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 2H), 3.70–3.90 (m, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 2H), 1.18 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 3H), 1.11 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 3H). LC-MS: decomposition, <i>R</i><sub>t</sub> = 0.45 min. (ESI): <i>m</i>/<i>z</i> = 242 [M – H<sub>2</sub>O + H]<sup>+</sup>.</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> Diethyl (3-Aminobenzyl)phosphonate (<b>35</b>)</h4><div class="NLM_p last">Diethyl [hydroxy(3-nitrophenyl)methyl]phosphonate <b>31</b> (1.455 g; 5.0 mmol) and triethylamine (0.83 mL, 6.0 mmol) were dissolved in dry THF (25 mL) and cooled to 0 °C. Methanesulfonic acid chloride (0.43 mL, 5.5 mmol) was added dropwise, and the resulting mixture was stirred for 2 h at RT. After concentration, the residue was partitioned between water and EtOAc (50–50 mL). Aqueous phase was extracted with EtOAc (2 × 50 mL). The combined organic phases were washed with 1 M aqueous HCl (50 mL), with satd aqueous NaHCO<sub>3</sub> (50 mL) and with brine and dried with MgSO<sub>4</sub>. After concentration, the methanesulfonate intermediate was filtered from Et<sub>2</sub>O to give a white powder (1.343 g, 73%); mp = 81–82 °C (Et<sub>2</sub>O). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 13.2 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.33 (s, 1H), 8.25 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.93 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 1H), 7.75 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 6.35 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 15.9 Hz), 3.96–4.14 (m, 4H), 3.22 (s, 3H), 1.18 (dt, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, <sup>4</sup><i>J</i><sub>PH</sub> = 10.0 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 3.33 min; (ESI): <i>m</i>/<i>z</i> = 368 [M + H]<sup>+</sup>. (Diethoxyphosphoryl)(3-nitrophenyl)methyl methanesulfonate (0.367 g, 1.0 mmol) was dissolved in MeOH (20 mL) under an inert atmosphere. Then 10 m/m % Pd/C (0.037 g, 10 w/w %) and 70% aqueous solution of hydrazine (2 mL) were added carefully under stirring. After 24 h vigorous stirring at RT, the catalyst was filtered off on a celite pad and washed with MeOH (20 mL) then the filtrate was concentrated under vacuum. The residue was suspended in sat aqueous NaHCO<sub>3</sub> (20 mL), and it was extracted with EtOAc (3 × 20 mL). The organic phases were washed with brine and dried with MgSO<sub>4</sub>. After concentration under vacuum, the title compound <b>35</b> was obtained as a yellow oil (0.190 g, 78%). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 25.5 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.20 (br, 2H), 7.17 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, 1H), 6.81–6.88 (m, 3H), 3.93 (dq, <sup>3</sup><i>J</i><sub>PH</sub>≈<sup>3</sup><i>J</i><sub>HH</sub> = 7.1 Hz, 4H), 3.14 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 21.6 Hz, 2H), 1.16 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 0.46 min; 1.89 min. (ESI): <i>m</i>/<i>z</i> = 244 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> Diethyl (4-Aminobenzyl)phosphonate (<b>36</b>)</h4><div class="NLM_p last">Diethyl [hydroxy(4-nitrophenyl)methyl]phosphonate <b>32</b> (1.445 g; 5.0 mmol) was mesylated similarly to the synthesis of <b>35</b>. The methanesulfonate intermediate was isolated as pale-yellow powder (0.954 g, 52%); mp = 79–80 °C (Et<sub>2</sub>O). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 12.9 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.28 (d, <i>J</i><sub>AABB</sub> = 8.7 Hz, 2H), 7.74 (dd, <i>J</i><sub>AABB</sub> = 8.8 Hz, <i>J</i> = 2.0 Hz, 2H), 6.33 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 16.7 Hz, 1H), 3.96–4.12 (m, 4H), 3.23 (s, 3H, H8), 1.18 (dt, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, <i>J</i> = 4.2 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 3.34 min. (ESI): <i>m</i>/<i>z</i> = 368 [M + H]<sup>+</sup>. (Diethoxyphosphoryl)(4-nitrophenyl)methyl methanesulfonate (0.734 g; 2.0 mmol) was hydrogenated according to the preparation of compound <b>35</b>. The title compound <b>36</b> was obtained as a white powder (0.456 g, 94%); mp = 90–91 °C (EtOAc). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 26.7 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 6.90 (dd, <i>J</i><sub>AABB</sub> = 8.3 Hz, <i>J</i> = 2.2 Hz 2H), 6.49 (d, <i>J</i><sub>AABB</sub> = 8.3 Hz, 2H), 4.92 (br, 2H), 3.90 (dq, <sup>3</sup><i>J</i><sub>PH</sub> = 7.3 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 4H), 2.97 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 20.6 Hz, 2H), 1.16 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 0.45 min; 1.69 min. (ESI): <i>m</i>/<i>z</i> = 244 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> Diethyl (5-Amino-2-methylbenzyl)phosphonate (<b>37</b>)</h4><div class="NLM_p last">2-Methyl-5-nitro benzoic acid (5.00 g; 27.6 mmol) was dissolved in abs EtOH (200 mL), and 96% H<sub>2</sub>SO<sub>4</sub> (2 mL) was added to the solution then it was refluxed for 24 h. The reaction mixture was concentrated under vacuum, and the residue was dissolved in EtOAc (200 mL). The organic phase was washed with 1 M NaOH (2 × 50 mL) with brine and dried with MgSO<sub>4</sub>. After concentration, the ethyl benzoate was obtained as a pale-yellow liquid which crystallizes to yellow crystals upon standing (4.978 g, 92%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 8.75 (d, <sup>4</sup><i>J</i><sub>HH</sub> = 2.5 Hz, 1H), 8.23 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 8.3 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.5 Hz, 1H), 7.43 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.4 Hz, 1H), 4.42 (q, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 2H), 2.72 (s, 3H), 1.44 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.1 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 4.11 min. (ESI): <i>m</i>/<i>z</i> = no molecular ion was observed. The ethyl 2-methyl-5-nitrobenzoate (4.967 g; 23.8 mmol) was dissolved in dry THF (100 mL) and cooled to 0 °C. LiAlH<sub>4</sub> (3.612 g, 95.1 mmol) was added in small portions. After the addition, the reaction mixture was stirred for 2.5 h at RT. Then 2-propanol was added drop by drop until the release of hydrogen stopped. After the addition of 2 M aqueous NaOH was added (50 mL), the precipitated white gel was filtered on celite and washed with EtOAc. The filtrate was separated, and the aqueous layer was extracted with EtOAc (3 × 75 mL). The combined organic phases were washed with brine, dried with MgSO<sub>4</sub>, and concentrated. The benzyl alcohol intermediate was titurated and filtered from Et<sub>2</sub>O to give an orange powder (1.97 g, 50%); mp = 159–162 °C (Et<sub>2</sub>O). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 7.87 (s, 1H), 7.71 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.3 Hz, 1H), 7.25 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 4.73 (s, 2H), 2.36 (s, 3H), 1.52 (br, 1H). LC-MS: <i>R</i><sub>t</sub> = 3.43 min. (ESI): <i>m</i>/<i>z</i> = no molecular ion was observed. The (2-methyl-5-nitro-phenyl)-methanol (0.20 g; 1.2 mmol) was dissolved in dry THF (20 mL) and cooled to −10 °C. PBr<sub>3</sub> (0.056 mL, 0.6 mmol) was added in one portion. After 1.5 h stirring at RT, the reaction mixture was concentrated to dryness. The residue was dissolved in EtOAc:THF (2:1, 80 mL), and it was washed with water (2 × 30 mL) and with brine. The organic layer was dried with Na<sub>2</sub>SO<sub>4</sub> than it was concentrated. The crude benzyl bromide was titurated and filtered from Et<sub>2</sub>O to give a yellow to brown powder (0.233 g, 85%); mp = 195–198 °C (Et<sub>2</sub>O). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): δ 7.81 (d, <sup>4</sup><i>J</i><sub>HH</sub> = 2.1 Hz, 1H), 7.72 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.9 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.1 Hz, 1H), 7.25 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.2 Hz, 1H), 4.52 (s, 2H), 2.43 (s, 3H). LCMS: compound was decomposed on LC. 2-(Bromomethyl)-1-methyl-4-nitrobenzene (0.23 g, 1.0 mmol) was suspended in triethyl-phosphite (4 mL, 23.0 mmol) and was stirred in a closed flask in a microwave reactor at 100 °C for 10 min. The mixture was cooled to 0 °C, and 36% aqueous HCl solution (1 mL) was added. After 30 min stirring, the product was extracted with EtOAc:THF (2:1, 3 × 20 mL). The combined organics were washed with satd aqueous NaHCO<sub>3</sub> (20 mL) and with brine and dried with MgSO<sub>4</sub>. After evaporation, the benzyl-phosphonate was crystallized from Et<sub>2</sub>O to give an orange powder (0.11 g, 38%); mp = 117–119 °C (Et<sub>2</sub>O). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 7.77 (s, 1H), 7.67 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.39 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 3.90–4.03 (m, 4H), 3.40 (d, <sup>2</sup><i>J</i><sub>PH</sub> = ∼22.0 Hz, 2H), 2.43 (s, 3H), 1.18 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 4.18 min. (ESI): <i>m</i>/<i>z</i> = no molecular ion was observed. Diethyl (2-methyl-5-nitrobenzyl)phosphonate (0.100 g, 0.36 mmol) was dissolved in MeOH (20 mL), and ammonium formate (0.227 g, 3.60 mmol) was added to the mixture under inert atmosphere followed by the addition of 10 m/m % Pd/C (0.010 g, 10 w/w%). The reaction mixture was stirred at RT for 20 h, and the catalyst was filtered off on a celite pad and washed with MeOH (20 mL) then the filtrate was evaporated to dry. The residue was dissolved in EtOAc (50 mL) and was washed with satd aqueous NaHCO<sub>3</sub> (20 mL) with brine and dried with MgSO<sub>4</sub>. After evaporation of the volatiles under reduced pressure the title compound <b>37</b> was obtained as a yellow oil (0.071 g, 77%), which was used without further purification. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 6.78 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 6.45 (t, <sup>4</sup><i>J</i><sub>HH</sub> = 2.5 Hz, 1H), 6.35 (dt, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.3 Hz, 1H), 4.77 (br, 2H), 3.85–3.98 (m, 4H), 2.98 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 21.6 Hz, 2H), 2.13 (s, 3H), 1.17 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 0.45 min; 2.16 min. (ESI): <i>m</i>/<i>z</i> = 258 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> General Procedure for the Coupling Reaction of 4-Chloro-6-phenyl-pyrimidines (<b>13</b>) and Phosphorus Containing Anilines</h4><div class="NLM_p last">The appropriate aniline was dissolved in the necessary volume of EtOH and a few drops of 4 M HCl in dioxane were added (approximately 0.1 mL). The volatiles were evaporated then dry toluene (30 mL) was distilled from the residue. The 4-chloro-6-phenyl-pyrimidine <b>13</b> was added to the residue then it was refluxed for 3–24 h in anhydrous 2-propanol (35 mL). Reactions were followed by TLC with toluene:MeOH (4:1) as eluent. After the reaction was complete, volatiles were evaporated then the residue was suspended in satd aqueous NaHCO<sub>3</sub> (30 mL). The product was extracted with EtOAc (3 × 70 mL). The combined organic phases were washed with brine and dried with MgSO<sub>4</sub>, and then solvents were evaporated under reduced pressure. For the exact quantity of reagents, for further purifications, yields, and analytical data see the examples.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> Diethyl (3-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}benzyl)phosphonate (<b>38</b>)</h4><div class="NLM_p last">According to the general coupling procedure 4-chloro-6-(2-methoxyphenyl)-pyrimidine <b>13a</b> (0.165 g, 0.75 mmol) and diethyl (3-aminobenzyl)phosphonate·HCl <b>35</b> (0.252 g, 0.9 mmol) were reacted. The crude product was purified by preparative TLC in EtOAc:EtOH (9:1). The product was extracted from the silica with MeOH. After evaporation, the residue was dissolved in EtOAc (100 mL), washed with 1 M aqueous HCl (100 mL) with satd aqueous NaHCO<sub>3</sub> (100 mL) with brine and then dried with MgSO<sub>4</sub>. After concentration, a yellow powder was obtained (0.041 g, 13%); mp = 217–218 °C (EtOAc). <sup>31</sup>P NMR (CDCl<sub>3</sub>, 121 MHz): δ 29.4 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.62 (s, 1H), 8.68 (s, 1H), 7.94 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.5 Hz, 1H), 7.55–7.66 (m, 2H), 7.45 (s, 2H), 7.27 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, 0.1H), 7.18 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.3 Hz, 1H), 7.08 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 6.93 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 1H), 3.80–4.00 (m, 4H), 3.90 (s, 3H), 3.20 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 22.1 Hz, 2H), 1.18 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 2.58 min; 2.73 min. (ESI): <i>m</i>/<i>z</i> = 428 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> Diethyl (3-{[6-(3-Nitrophenyl)pyrimidin-4-yl]amino}benzyl)phosphonate (<b>39a</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(3-nitrophenyl)-pyrimidine <b>13b</b> (0.230 g, 0.98 mmol) and diethyl (3-aminobenzyl)phosphonate·HCl <b>35</b> (0.408 g, 1.46 mmol) were reacted. The crude product was recrystallized from MeCN and washed with Et<sub>2</sub>O to give a yellow powder (0.228 g, 53%); mp = 188–190 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 25.6 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.83 (s, 1H), 8.83 (s, 1H), 8.76 (s, 1H), 8.47 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 1H), 8.36 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.9 Hz, 1H), 7.83 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.9 Hz, 1H), 7.59–7.70 (m, 2H), 7.40 (s, 1H), 7.29 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 6.97 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 1H), 3.92–4.03 (m, 4H), 3.24 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 21.5 Hz, 2H), 1.19 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 3.66 min. (ESI): <i>m</i>/<i>z</i> = 443 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> Diethyl [Hydroxy(3-{[6-(3-nitrophenyl)pyrimidin-4-yl]amino}phenyl)methyl]phosphonate (<b>39b</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(3-nitrophenyl)-pyrimidine <b>13b</b> (0.230 g, 0.98 mmol) and diethyl [(3-aminophenyl)(hydroxy)methyl]phosphonate·HCl <b>33</b> (0.433 g, 1.46 mmol) were reacted. The crude product was recrystallized from MeCN and washed with Et<sub>2</sub>O to give a yellow powder (0.329 g, 73%); mp = 191 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 20.8 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.85 (s, 1H), 8.84 (s, 1H), 8.77 (s, 1H), 8.48 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 8.36 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.5 Hz, 1H), 7.84 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.69–7.78 (m, 2H), 7.41 (s, 1H), 7.33 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 7.12 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 1H), 6.21 (dd, <sup>3</sup><i>J</i><sub>PH</sub> = 16.2 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 5.5 Hz, 1H), 4.95 (dd, <sup>2</sup><i>J</i><sub>PH</sub> = 13.4 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 5.5 Hz, 1H), 3.88–4.06 (m, 4H), 1.18 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 3.26 min. (ESI): <i>m</i>/<i>z</i> = 459 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> Diethyl (3-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}benzyl)phosphonate (<b>40a</b>)</h4><div class="NLM_p last">According to the nitro group reduction described for compound <b>26a</b>: reduction of compound <b>39a</b> (0.100 g, 0.23 mmol) gave a yellow powder (0.075 g, 73%); mp = 186 °C (Et<sub>2</sub>O). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 28.5 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 11.02 (s, 1H), 8.84 (s, 1H), 7.45–7.70 (m, 5H), 7.30–7.40 (m, 3H), 7.05–7.15 (m, 1H), 3.95–4.00 (m, 4H), 3.26 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 21.0 Hz, 2H), 1.19 (s, 6H). LC-MS: <i>R</i><sub>t</sub> = 2.38 min; 2.48 min. (ESI): <i>m</i>/<i>z</i> = 413 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> Diethyl [(3-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}phenyl)(hydroxy)methyl]phosphonate (<b>40b</b>)</h4><div class="NLM_p last">According to the nitro group reduction described for compound <b>26a</b>: reduction of compound <b>39b</b> (0.100 g, 0.22 mmol) afforded a yellow powder (0.082 g, 80%); mp = 265–267 °C (Et<sub>2</sub>O). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 23.6 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 11.14 (s, 1H), 8.86 (s, 1H), 7.10–7.80 (m, 9H), 6.00 (br, 3H), 4.98 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 13.2 Hz, 1H), 3.95–4.00 (m, 4H), 1.17 (s, 6H). LC-MS: <i>R</i><sub>t</sub> = 2.01 min; 2.23 min. (ESI): <i>m</i>/<i>z</i> = 429 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> Diethyl (4-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}benzyl)phosphonate (<b>41a</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(2-methoxyphenyl)-pyrimidine <b>13a</b> (0.221 g, 1.0 mmol) and diethyl (4-aminobenzyl)phosphonate·HCl <b>36</b> (0.419 g, 1.5 mmol) were reacted. The crude product was recrystallized from MeCN to give a yellow powder (0.212 g, 50%); mp = 151 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 25.9 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.57 (s, 1H; 8.66 (s, 1H), 7.93 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 7.62 (d, <i>J</i><sub>AABB</sub> = 8.2 Hz, 2H), 7.43 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.4 Hz, 1H), 7.42 (s, 1H), 7.22 (dd, <i>J</i><sub>AABB</sub> = 8.4 Hz, <sup>4</sup><i>J</i><sub>PH</sub> = 1.8 Hz, 2H), 7.16 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.3 Hz, 1H), 7.06 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 3.90–3.99 (m, 4H), 3.88 (s, 3H, H20), 3.15 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 21.2 Hz, 2H), 1.17 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 2.41 min; 2.56 min. (ESI): <i>m</i>/<i>z</i> = 428 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> Diethyl [Hydroxy(4-{[6-(2-methoxyphenyl)pyrimidin-4-yl]amino}phenyl)methyl]phosphonate (<b>41b</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(2-methoxyphenyl)-pyrimidine <b>13a</b> (0.221 g, 1.0 mmol) and diethyl [(4-aminophenyl)(hydroxy)methyl]phosphonate·HCl <b>34</b> (0.44 g, 1.5 mmol) were reacted. The crude product was recrystallized first from hexane/CH<sub>2</sub>Cl<sub>2</sub> then from MeCN to give a yellow powder (0.140 g, 32%); mp = 195–196 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 21.0 ppm (82%) and 7.4 ppm (18%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.62 (s, 1H), 8.69 (s, 1H), 7.95 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.2 Hz, 1H), 7.55–7.7 (m, 2H), 7.3–7.5 (m, 4H), 7.18 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.4 Hz, 1H), 7.08 (s, 1H), 6.09 (d, <sup>3</sup><i>J</i><sub>PH</sub> = 12.4 Hz, 1H), 4.88 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 11.1 Hz, 1H), 3.9–4.05 (m, 7H), 1.17 (s, 6H). Peaks are broads, some of them split in 3 to 1 ratio on heating. We hypothesize that α-hydroxy protons can form intramolecular H-bonds with the oxygen of phosphorus, and these asymmetric ring formation causes odd spectra. Derivatives without α-hydroxy group never show this phenomenon. LC-MS: <i>R</i><sub>t</sub> = 0.46 min; 2.14 min; 2.32 min. (ESI): <i>m</i>/<i>z</i> = 444 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> Diethyl (4-{[6-(3-Nitrophenyl)pyrimidin-4-yl]amino}benzyl)phosphonate (<b>42a</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(3-nitrophenyl)-pyrimidine <b>13b</b> (0.236 g, 1.0 mmol) and diethyl (4-aminobenzyl)phosphonate·HCl <b>36</b> (0.419 g, 1.5 mmol) were reacted. Purification was different from the general procedure: after the suspension of the crude product in satd NaHCO<sub>3</sub>, EtOAc (0.5 mL) was added and the mixture was stirred at 0 °C for 30 min. The precipitate was filtered and washed with Et<sub>2</sub>O. The desired compound was isolated as a yellow powder (0.44 g, 99%); mp = 204 °C (water, EtOAc). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 25.8 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.81 (s, 1H), 8.81 (s, 1H), 8.75 (s, 1H), 8.43 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, 1H), 8.35 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 7.83 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.9 Hz, 1H), 7.65 (d, <i>J</i><sub>AABB</sub> = 8.1 Hz, 2H), 7.36 (s, 1H), 7.25 (dd, <i>J</i><sub>AABB</sub> = 8.7 Hz, <i>J</i> = 2.1 Hz, 2H), 3.89–4.00 (m, 4H), 3.18 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 21.2 Hz, 2H), 1.17 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 3.62 min. (ESI): <i>m</i>/<i>z</i> = 443 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> Diethyl [Hydroxy(4-{[6-(3-nitrophenyl)pyrimidin-4-yl]amino}phenyl)methyl]phosphonate (<b>42b</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(3-nitrophenyl)-pyrimidine <b>13b</b> (0.220 g, 0.93 mmol) and diethyl [(4-aminophenyl)(hydroxy)methyl]phosphonate·HCl <b>34</b> (0.363 g, 1.4 mmol) were reacted. The crude product was purified by column chromatography in 100% EtOAc. Fractions containing the desired compound were combined and concentrated. The product was isolated after recrystallization from MeCN as a pale-yellow powder (0.024 g, 6%); mp = 205 °C, dec (MeCN). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.81 (s, 1H), 8.82 (s, 1H), 8.78 (s, 1H), 8.45 (s, 1H), 8.37 (s, 1H), 7.84 (s, 1H), 7.69 (s, 2H), 7.4 (br, 3H), 6.11 (d, <sup>3</sup><i>J</i><sub>PH</sub> = 14.7 Hz, 1H), 4.90 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 9.8 Hz, 1H), 3.98 (br, 4H), 1.18 (br, 6H). The spectrum has the similar phenomena as those of compound <b>41b</b>. LC-MS: <i>R</i><sub>t</sub> = 3.22 min. (ESI): <i>m</i>/<i>z</i> = 459 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> Diethyl (4-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}benzyl)phosphonate (<b>43</b>)</h4><div class="NLM_p last">According to the nitro group reduction described for compound <b>26a</b>: reduction of compound <b>42a</b> (0.300 g, 0.68 mmol) afforded a yellow powder (0.182 g, 65%); mp = 62–65 °C (EtOAc), amorph. <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 25.8 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.57 (s, 1H), 8.64 (s, 1H), 7.62 (d, <i>J</i><sub>AABB</sub> = 8.2 Hz, 2H), 7.21–7.27 (m, 3H), 7.09–7.16 (m, 3H), 6.67 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 1H), 5.26 (br, 2H), 3.88–3.99 (m, 4H), 3.15 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 21.2 Hz, 2H), 1.17 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 0.46 min; 2.22 min; 2.44 min. (ESI): <i>m</i>/<i>z</i> = 413 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> Diethyl (5-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}-2-methylbenzyl)phosphonate (<b>44</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(2-methoxyphenyl)-pyrimidine <b>13a</b> (0.165 g, 0.75 mmol) and diethyl (5-amino-2-methylbenzyl)phosphonate·HCl <b>37</b> (0.072 g, 0.25 mmol) were reacted. The crude product was purified by preparative TLC with EtOAc:hexane (8:1). The pure product was extracted from the silica with MeOH. After evaporation of solvents under vacuum, a yellow powder was obtained (0.04 g, 53%); mp = 134–137 °C (MeOH). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 28.9 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.56 (s, 1H), 8.56 (s, 1H), 7.93 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.5 Hz, 1H), 7.41–7.56 (m, 3H), 7.42 (s, 1H), 7.17 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.3 Hz, 1H; 7.13 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 7.07 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 1H), 3.89–4.00 (m, 4H), 3.89 (s, 3H), 3.17 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 21.6 Hz, 2H), 2.29 (s, 3H), 1.18 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 2.92 min. (ESI): <i>m</i>/<i>z</i> = 442 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> (4-{[6-(3-Nitrophenyl)pyrimidin-4-yl]amino}benzyl)phosphonic Acid (<b>45a</b>)</h4><div class="NLM_p last">Diethyl (4-{[6-(3-nitrophenyl)pyrimidin-4-yl]amino}benzyl)phosphonate <b>42a</b> (0.100 g, 0.23 mmol) was refluxed in 5 M aqueous HCl solution (30 mL) for 24 h. Volatiles were evaporated then the residue was dissolved in water (25 mL) and it was washed with DEE (3 × 100 mL). Water was evaporated then dry toluene (20 mL) was distilled from the residue. The dry residue was dissolved in abs EtOH (5 mL) and cooled to −9 °C then propylene-oxide (0.5 mL) was added to the mixture. After 15 min stirring, the precipitate was filtered and washed with Et<sub>2</sub>O. Compound <b>45a</b> was isolated as a yellow powder (0.059g, 66%); mp = 265–270 °C, dec (EtOH). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 20.1 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.48 (s, 1H), 8.79 (s, 1H), 8.77 (s, 1H), 8.39 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 2H), 7.85 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.63 (d, <i>J</i><sub>AABB</sub> = 7.8 Hz, 2H), 7.15 (s, 1H), 7.24 (d, <i>J</i><sub>AABB</sub> = 7.5 Hz, 2H), 5.2 (br, 2H), 2.93 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 21.4 Hz, 2H). LC-MS: <i>R</i><sub>t</sub> = 2.40 min. (ESI): <i>m</i>/<i>z</i> = 387 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> (4-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}benzyl)phosphonic Acid (<b>45b</b>)</h4><div class="NLM_p last">Compound <b>45b</b> was prepared with the method described for compound <b>45a</b> starting from diethyl phosphonate <b>43</b> (0.128 g, 0.31 mmol), yielding a yellow powder (0.11 g, 99%); mp> 300 °C (EtOH). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 20.4 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 11.08 (s, 1H), 8.73 (s, 1H), 7.52 (d, <i>J</i><sub>AABB</sub> = 8.1 Hz, 2H), 7.38–7.48 (m, 3H), 7.24 (d, <i>J</i><sub>AABB</sub> = 8.1 Hz, 2H), 7.12–7.20 (m, 1H), 7.14 (s, 1H), 6.30 (br, 4H), 2.98 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 21.4 Hz, 2H). LC-MS: <i>R</i><sub>t</sub> = 0.46 min; 1.64 min. (ESI): <i>m</i>/<i>z</i> = 357 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> Ethyl (3-Aminobenzyl)phenylphosphinate (<b>46</b>)</h4><div class="NLM_p last">Ethyl phenylphosphinate (1.02 g, 6.0 mmol) was dissolved in anhydrous THF (20 mL) then triethylamine (0.97 mL; 7.0 mmol) and trimethylsilyl chloride (0.89 mL; 7.0 mmol) were added to the solution, respectively. The mixture was stirred for 1 h at RT then the precipitate was filtered off. Filtrate was evaporated under reduced pressure then anhydrous toluene (30 mL) was evaporated from the residue. To the obtained yellow oil, 3-nitrobenzyl bromide (1.08 g; 5.0 mmol) was added and the mixture was heated to 140 °C under argon flow for 4.5 h. When the reaction mixture was cooled to 50–60 °C and diluted with CHCl<sub>3</sub> (5 mL) then it was cooled further to 0 °C and 5 M aqueous HCl solution (2 mL) was added. After 15 min of stirring, the mixture was diluted with water (10 mL) and was extracted with CHCl<sub>3</sub> (3 × 50 mL). Combined organic phases were washed with 2 M aqueous NaOH solution (2 × 50 mL) and with brine then it was dried with Mg SO<sub>4</sub>. After evaporation of the solvent, the phosphinic acid was obtained as a yellow powder (0.645 g, 47%); mp = 127–128 °C (CHCl<sub>3</sub>). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 54.9 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.03 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.4 Hz, 1H), 7.98 (s, 1H), 7.45–7.75 (m, 7H), 3.43 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 17.3 Hz, 2H). LC-MS: <i>R</i><sub>t</sub> = 2.62 min. (ESI): <i>m</i>/<i>z</i> = 278 [M + H]<sup>+</sup>. (3-Nitrobenzyl)phenylphosphinic acid (0.880 g; 3.18 mmol) was dissolved in DMF (10 mL) then triethyl orthoformate (5.28 mL; 31.80 mmol) and one drop trifluoroacetic acid was added. The reaction mixture was stirred for 1 week at 80 °C, and then it was evaporated. The residue was suspended in 2 M aqueous NaOH solution (50 mL), and it was extracted with EtOAc (3 × 75 mL). The combined organic layers were washed with brine and dried with MgSO<sub>4</sub>. After evaporation, the phosphonic ester was obtained as a yellow oil (0.729 g, 75%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.03 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.1 Hz, 1H), 8.00 (s, 1H), 7.60–7.75 (m, 2H), 7.45–7.60 (m, 5H), 3.80–3.97 and 3.60–3.75 (2xm, 2 × 1H), 3.66 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 17.3 Hz, 2H), 1.18 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.45 min. (ESI): <i>m</i>/<i>z</i> = 306 [M + H]<sup>+</sup>. Reduction of ethyl (3-nitrobenzyl)phenylphosphinate (0.72 g, 2.36 mmol) to compound <b>46</b> was carried out according to the nitro group reduction described for compound <b>26a</b> giving a yellow oil (0.586 g, 90%). <sup>31</sup>P NMR (242 MHz): DMSO-<i>d</i><sub>6</sub>, δ 41.5 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.9 (br, 2H), 7.63–7.77 (m, 2H), 7.57 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.9 Hz, 1H), 7.40–7.60 (m, 2H), 7.15 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 1H), 6.80–7.00 (m, 2H), 6.83 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 4.8 Hz, 1H), 3.75–3.85 and 3.85–3.95 (2 × m, 2 × 1H), 3.42 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 17.2 Hz, 2H), 1.16 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.7 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 0.45 and 2.28 min; (ESI): <i>m</i>/<i>z</i> = 276 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> Ethyl (3-Aminobenzyl)ethylphosphinate (<b>47</b>)</h4><div class="NLM_p last">Diethyl ethylphosphonite was prepared from triethyl-phosphite (16.6 g, 100 mmol) and ethyl bromide (16.35 g, 150 mmol) according to the method described by Petnehazy et al.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The ethylphosphonite was isolated as a colorless oil (11.25 g, 50%). <sup>31</sup>P NMR (CDCl<sub>3</sub>, 121 MHz): δ 185.6 ppm. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 3.72–3.97 (m, <i>J</i><sub>PH</sub> = 12.1 Hz, 4H), 1.86 (dt, <i>J</i><sub>HH</sub> = 6.4 Hz, <i>J</i><sub>PH</sub> = 12.8 Hz, 2H), 1.26 (t, <i>J</i><sub>HH</sub> = 7.1 Hz, 6H), 1.05 (dt, <i>J</i><sub>HH</sub> = 6.5 Hz, <i>J</i><sub>PH</sub> = 14.3 Hz, 3H). 3-Nitro-benzylbromide (1.08 g; 5.0 mmol) and diethyl ethylphosphonite (1.125 g; 7.5 mmol) were heated to 140 °C under argon flow for 1 h. When the reaction mixture was cooled to 50–60 °C and diluted with CHCl<sub>3</sub> (5 mL) then it was cooled further to 0 °C and 5 M aqueous HCl solution (2 mL) was added. After 15 min of stirring, the mixture was diluted with water (10 mL) and was extracted with CHCl<sub>3</sub> (3 × 50 mL). Combined organic phases were washed with 2 M aqueous NaOH solution (2 × 50 mL) and with brine then it was dried with Mg SO<sub>4</sub>. After evaporation of the volatiles under reduced pressure, the residue was suspended in MeOH (100 mL) and it was discolored by charcoal. After filtration on a celite pad and concentration, the phosphinate was obtained as a yellow oil (0.846 g, 66%). It was used in the next step without further purification. <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 54.9 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.18 (s, 1H), 8.10 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 1H), 7.73 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 1H), 7.62 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 3.80–4.00 (m, 2H), 3.40 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 16.4 Hz, 2H), 1.60–1.70 (m, 2H), 1.16 (s, 3H), 1.00 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 18.1 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.91 min. (ESI): <i>m</i>/<i>z</i> = 258 [M + H]<sup>+</sup>. Reduction of ethyl ethyl [(3-nitrobenzyl)phosphinate (0.837 g, 3.26 mmol) to compound <b>47</b> was carried out according to the nitro group reduction described for compound <b>26a</b>, giving a yellow oil (0.69 g, 93%). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 56.1 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 6.92 (s, 1H), 6.47 (s, 1H), 6.41 (s, 2H), 5.07 (br, 2H), 3.80–3.90 (m, 2H), 2.97 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 16.5 Hz, 2H), 1.50–1.60 (m, 2H), 1.18 (s, 3H), 0.97 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 17.6 Hz, <sup>3</sup><i>J</i><sub>HH</sub> ∼ 8.7 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 0.45 and 1.73 min. (ESI): <i>m</i>/<i>z</i> = 228 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> Ethyl (3-Aminobenzyl)propylphosphinate (<b>48</b>)</h4><div class="NLM_p last">The diethyl propylphosphonite was prepared from (18.45 g; 150 mmol) propyl bromide and (16.6 g; 100 mmol) triethyl-phosphite according to the method described by Petnehazy et al.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The propylphosphonite was isolated as a colorless oil (17.71 g, 72%). <sup>31</sup>P NMR (CDCl<sub>3</sub>, 121 MHz): δ 184.9 ppm. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 3.70–3.91 (m, 4H), 1.85 (dt, <i>J</i><sub>HH</sub> = 6.6 Hz, <i>J</i><sub>PH</sub> = 12.0 Hz, 2H), 1.42–1.51 (m, 2H), 1.24 (t, <i>J</i><sub>HH</sub> = 7.0 Hz, 6H), 0.99 (t, <i>J</i><sub>HH</sub> = 6.6 Hz, 3H). Diethyl propylphosphonite (2.61 g, 17.4 mmol) was reacted with 3-nitrobenzyl bromide (2.51 g, 11.6 mmol) as it is described for compound <b>47</b>. The propylphosphinate was isolated as a brown oil (2.88 g; 92%) and was used without further purification. <sup>31</sup>P NMR (CDCl<sub>3</sub>, 121 MHz): δ 50.8 ppm. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 8.17 (d, <sup>4</sup><i>J</i><sub>HH</sub> = 1.2 Hz, 1H), 8.11 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 1H), 7.70 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 7.54 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 1H), 3.94–4.16 (m, 2H), 3.27 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 15.6 Hz, 2H), 1.56–1.80 (m, 4H), 1.27 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 3H), 1.02 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 3H). Reduction of ethyl (3-nitrobenzyl)propylphosphinate (0.88 g, 10.6 mmol) to compound <b>48</b> was carried out according to the nitro group reduction described for compound <b>26a</b>, yielding a yellow oil (2.148 g, 84%). <sup>31</sup>P NMR (CDCl<sub>3</sub>, 121 MHz): δ 53.1 ppm. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 7.07 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 6.68 (d, <sup>4</sup><i>J</i><sub>HH</sub> = 1.5 Hz, 1H), 6.63 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.4 Hz, 1H), 6.60 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.4 Hz, 1H), 3.95–4.05 (m, 2H), 3.03 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 16.8 Hz, 2H), 1.50–1.70 (m, 4H), 1.26 (t, <sup>3</sup>J<sub>HH=</sub> 7.2 Hz, 3H), 0.96 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 3H).</div></div><div id="sec5_1_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> Ethyl (4-Aminobenzyl)ethylphosphinate (<b>49</b>)</h4><div class="NLM_p last">The 4-nitrobenzyl bromide (1.296 g 6.0 mmol) and 1.35 g diethyl ethylphosphonite (9.0 mmol) were reacted according to the preparation of <b>47</b>, giving a yellow oil (0.847 g, 55%). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 54.7 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.18 (d, <i>J</i><sub>AABB</sub> = 7.6 Hz, 2H), 7.55 (d, <i>J</i><sub>AABB</sub> = 6.6 Hz, 2H), 3.90–3.93 (m, 2H), 3.39 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 16.8 Hz, 2H), 1.60–1.68 (m, 2H), 1.16 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 3H), 1.00 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 18.1 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.88 min. (ESI): <i>m</i>/<i>z</i> = 258 [M + H]<sup>+</sup>. Reduction of ethyl ethyl (4-nitrobenzyl)phosphinate (0.843 g, 3.28 mmol) was carried out according to the nitro group reduction described for compound <b>26a</b>, providing a brown oil (0.375 g, 50%). LC-MS: <i>R</i><sub>t</sub> = 0.44 min. (ESI): <i>m</i>/<i>z</i> = 228 [M + H]<sup>+</sup>. Compound <b>49</b> was used without further purification and characterization.</div></div><div id="sec5_1_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> Ethyl (4-Aminobenzyl)propylphosphinate (<b>50</b>)</h4><div class="NLM_p last">The 4-nitro-benzyl bromide (1.296 g, 6.0 mmol) and diethyl propylphosphonite (1.476 g; 9.0 mmol) were reacted according to the preparation of <b>47</b>, yielding a brown oil (1.426 g; 88%). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 53.1 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.18 (d, <i>J</i><sub>AABB</sub> = 7.6 Hz, 2H), 7.55 (d, <i>J</i><sub>AABB</sub> = 7.5 Hz, 2H), 3.90–3.95 (m, 2H), 3.39 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 17.0 Hz, 2H), 1.55–1.65 (m, 2H), 1.40–1.50 (m, 2H), 1.13–1.22 (m, 3H), 0.93 (br, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.16 min. (ESI): <i>m</i>/<i>z</i> = 272 [M + H]<sup>+</sup>. Reduction of ethyl (4-nitrobenzyl)propylphosphinate (1.42 g, 5.24 mmol) was carried out according to the nitro group reduction described for compound <b>26a</b>, giving a brown oil (1.005 g; 80%). LC-MS: <i>R</i><sub>t</sub> = 0.44 and 1.89 min. (ESI): <i>m</i>/<i>z</i> = 242 [M – H]<sup>+</sup>. Compound <b>50</b> was used without further purification and characterization.</div></div><div id="sec5_1_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> Ethyl (5-Amino-2-methylbenzyl)ethylphosphinate (<b>51</b>)</h4><div class="NLM_p last">The 2-(bromomethyl)-1-methyl-4-nitrobenzene (1.150 g, 5.0 mmol, issued from the synthesis of <b>37</b>) and diethyl ethylphosphonite (1.294 g; 7.5 mmol) were reacted according to the reaction described for compound <b>47</b>, affording a brown oil (0.918 g, 68%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 7.78 (s, 1H), 7.66 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 1H), 7.38 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 1H), 3.80–4.10 (m, 2H), 3.30 (2H, overlaps with DMSO’s water), 2.44 (s, 3H), 1.65–1.70 (m, 2H), 1.13 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 3H), 1.04 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 17.7 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 3H). Reduction of ethyl ethyl (2-methyl-5-nitrobenzyl)phosphinate (0.90 g, 3.32 mmol) was carried out according to the nitro group reduction described for compound <b>26a</b>, giving a brown oil (0.411 g, 51%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 6.78 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.1 Hz, 1H), 6.45 (s, 1H), 6.34 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.8 Hz, 1H), 4.70 (br, 2H), 3.80–4.00 (m, 2H), 2.97 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 16.7 Hz, 2H), 1.91 (s, 3H), 1.55–1.75 (m, 2H), 1.16 (br, 3H), 1.00 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 3H). According to the <sup>1</sup>H NMR spectra purity of compound <b>51</b> was about 50%. It was used without further purification in the next step. LC-MS: <i>R</i><sub>t</sub> = 0.44 min. (ESI): <i>m</i>/<i>z</i> = 242 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> Ethyl Ethyl (3-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}benzyl)phosphinate (<b>52a</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(2-methoxyphenyl)-pyrimidine <b>13a</b> (0.075 g, 0.34 mmol) and ethyl (3-aminobenzyl)ethylphosphinate·HCl <b>47</b> (0.108 g, 0.41 mmol) were reacted. The crude product was purified by preparative TLC using EtOAc:hexane (8:1) and 1 v/v% AcOH as eluent. The product was extracted from the silica with MeOH. After concentration, <b>52a</b> was dissolved in EtOAc (100 mL) and it was washed with 0.1 M aqueous AcOH solution (3 × 30 mL), with satd aqueous NaHCO<sub>3</sub> solution (100 mL), and with brine (100 mL). The organic phase was dried with MgSO<sub>4</sub> and evaporated under vacuum. <b>52a</b> was obtained as yellow powder (0.045 g, 32%); mp = 30 °C. <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 55.6 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.62 (s, 1H), 8.67 (s, 1H), 7.94 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.2 Hz, 1H), 7.55–7.68 (m, 2H), 7.45 (s, 2H), 7.27 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, 1H), 7.17 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 7.08 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 6.93 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 1H), 3.80–4.00 (m, 2H), 3.90 (s, 3H), 3.17 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 16.5 Hz, 2H), 1.50–1.70 (m, 2H), 1.18 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 3H), 1.00 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 17.6 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.56 min. (ESI): <i>m</i>/<i>z</i> = 412 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> Ethyl (3-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}benzyl)propylphosphinate (<b>52b</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(2-methoxyphenyl)-pyrimidine <b>13a</b> (0.17 g; 0.77 mmol) and ethyl (3-aminobenzyl)propylphosphinate·HCl <b>48</b> (0.229 g; 0.83 mmol) were reacted. The crude product was purified by column chromatography with 100% EtOAc to EtOAc:EtOH (1:1). After concentration, <b>52b</b> was obtained as a yellow oil (0.16 g, 50%). <sup>31</sup>P NMR (CDCl<sub>3</sub>, 121 MHz): δ 52.5 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.67 (s, 1H), 8.68 (s, 1H), 7.94 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.2 Hz, 1H), 7.55–7.68 (m, 2H), 7.45 (s, 2H), 7.28 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.1 Hz, 1H), 7.17 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.09 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 1H), 6.93 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.8 Hz, 1H), 3.89 (s, 5H), 3.16 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 16.5 Hz, 2H), 1.35–1.70 (m, 4H), 1.18 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 3H), 0.92 (br, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.75 min. (ESI): <i>m</i>/<i>z</i> = 426 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> Ethyl (3-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}benzyl)phenylphosphinate (<b>52c</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(2-methoxyphenyl)-pyrimidine <b>13a</b> (0.157 g, 0.71 mmol) and ethyl (3-aminobenzyl)phenylphosphinate·HCl <b>46</b> (0.332 g, 1.07 mmol) were reacted. The crude product was purified by preparative TLC with EtOAc:hexane (8:1) and 1 v/v% AcOH as eluent. The product was extracted with MeOH from the silica. After evaporation, the residue was dissolved in EtOAc (100 mL) and washed with 0.1 M aqueous AcOH solution (3 × 30 mL), with satd aqueous NaHCO<sub>3</sub> solution (100 mL), and with brine (100 mL). The organic phase was dried with MgSO<sub>4</sub> and evaporated under reduced pressure. <b>52c</b> was obtained as yellow powder (0.094 g, 29%); mp = 103–104 °C (EtOAc). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 41.5 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.56 (s, 1H), 8.64 (s, 1H), 7.93 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.2 Hz, 1H), 7.30–7.75 (m, 8H), 7.00–7.20 (m, 4H), 6.73 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 3.9 Hz, 1H), 3.90–4.00 (m, 1H), 3.90 (s, 3H), 3.80–3.88 (m, 1H), 3.42 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 17.3 Hz, 2H), 1.18 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.0 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.92 min. (ESI): <i>m</i>/<i>z</i> = 460 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> Ethyl Ethyl (3-{[6-(3-Nitrophenyl)pyrimidin-4-yl]amino}benzyl)phosphinate (<b>53a</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(3-nitrophenyl)-pyrimidine <b>13b</b> (0.118 g, 0.5 mmol) and ethyl (3-aminobenzyl)ethylphosphinate·HCl <b>47</b> (0.158 g, 0.6 mmol) were reacted. The crude product was recrystallized from MeCN to give a yellow powder (0.118 g, 55%); mp = 189–190 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 55.8 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.81 (s, 1H), 8.84 (s, 1H), 8.76 (s, 1H), 8.48 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 1H), 8.36 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 7.84 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, 1H), 7.55–7.65 (m, 2H), 7.41 (s, 1H), 7.30 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 1H), 6.99 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 4.8 Hz, 1H), 3.90–4.00 (m, 2H), 3.19 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 16.5 Hz, 2H), 1.60–1.70 (m, 2H), 1.19 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.3 Hz, 3H), 1.01 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 17.7 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 8.8 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.41 min. (ESI): <i>m</i>/<i>z</i> = 427 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> Ethyl (3-{[6-(3-Nitrophenyl)pyrimidin-4-yl]amino}benzyl)propylphosphinate (<b>53b</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(3-nitrophenyl)-pyrimidine <b>13b</b> (0.22 g, 0.92 mmol) and ethyl (3-aminobenzyl)propylphosphinate·HCl <b>48</b> (0.25 g, 1.04 mmol) were reacted. After the reaction the crude product was filtered from the NaHCO<sub>3</sub> suspension. The resulting solid was recrystallized from MeCN to give a yellow powder (0.12 g, 29%); mp = 173–176 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 54.3 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.82 (s, 1H), 8.84 (s, 1H), 8.76 (s, 1H), 8.48 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 1H), 8.36 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.2 Hz, 1H), 7.83 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, 1H), 7.55–7.65 (m, 2H), 7.42 (s, 1H), 7.30 (s, 1H), 6.99 (s, 1H), 3.90–4.00 (m, 2H), 3.18 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 16.7 Hz, 2H), 1.50–1.70 (m, 4H), 1.19 (s, 3H), 0.93 (s, 1H). LC-MS: <i>R</i><sub>t</sub> = 3.63 min. (ESI): <i>m</i>/<i>z</i> = 441 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> Ethyl (3-{[6-(3-Nitrophenyl)pyrimidin-4-yl]amino}benzyl)phenylphosphinate (<b>53c</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(3-nitrophenyl)-pyrimidine <b>13b</b> (0.118 g, 0.5 mmol) and ethyl (3-aminobenzyl)phenylphosphinate·HCl <b>46</b> (0.187 g, 0.6 mmol) were reacted. The crude product was recrystallized from MeCN to give a yellow powder (0.101 g, 43%); mp = 188–190 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 41.7 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.76 (s, 1H), 8.84 (s, 1H), 8.73 (s, 1H), 8.48 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.3 Hz, 1H), 8.36 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.1 Hz, 1H), 7.84 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.6 Hz, 1H), 7.65–7.75 (m, 2H), 7.40–7.60 (m, 5H), 7.39 (s, 1H), 7.18 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 1H), 6.79 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.1 Hz, 1H), 3.90–3.95 (m, 1H), 3.80–3.85 (m, 1H), 3.45 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 17.3 Hz, 2H), 1.18 (s, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.83 min. (ESI): <i>m</i>/<i>z</i> = 475 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> Ethyl (3-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}benzyl)ethylphosphinate (<b>54a</b>)</h4><div class="NLM_p last">Reduction of nitro compound <b>53a</b> (0.099 g, 0.23 mmol) was carried out according to the nitro group reduction described for compound <b>26a</b>, yielding a yellow powder (0.079 g, 79%); mp = 208–211 °C (EtOH, Et<sub>2</sub>O). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 55.6 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 11.09 (s, 1H), 8.84 (s, 1H), 7.50–7.80 (m, 5H), 7.30–7.45 (m, 3H), 7.09 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.4 Hz, 1H), 5.30 (br, 2H), 3.80–3.95 (m, 2H), 3.22 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 16.2 Hz, 2H), 1.60–1.67 (m, 2H), 1.18 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.7 Hz, 3H), 1.00 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 17.6 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 0.45 and 2.06 and 2.35 min. (ESI): <i>m</i>/<i>z</i> = 397 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> Ethyl (3-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}benzyl)propylphosphinate (<b>54b</b>)</h4><div class="NLM_p last">Reduction of nitro compound <b>53b</b> (0.10 g, 0.23 mmol) was carried out according to the nitro group reduction described for compound <b>26a</b>, affording a yellow powder (0.079 g, 77%); mp = 206–208 °C (EtOH, Et<sub>2</sub>O). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 11.02 (s, 1H), 8.83 (s, 1H), 7.65–7.75 (m, 2H), 7.50–7.65 (m, 3H), 7.30–7.45 (m, 3H), 7.05–7.15 (m, 1H). 5.47 (br, 2H), 3.85–4.00 (m, 2H), 3.21 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 15.9 Hz, 2H), 1.60–1.70 (m, 2H), 1.45–1.55 (m, 2H), 1.17 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 3H), 0.93 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.3 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 0.43 and 2.37 and 2.55 min. (ESI): <i>m</i>/<i>z</i> = 411 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> Ethyl (3-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}benzyl)phenylphosphinate (<b>54c</b>)</h4><div class="NLM_p last">Reduction of nitro compound <b>53c</b> (0.08 g, 0.17 mmol) was carried out according to the nitro group reduction described for compound <b>26a</b>, giving a yellow powder (0.068 g, 84%); mp = 208–209 °C (EtOH, Et<sub>2</sub>O). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 41.7 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.82 (s, 1H), 8.80 (s, 1H), 7.45–7.75 (m, 10H), 7.20–7.45 (m, 3H), 6.89 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.0 Hz, 1H). 4.25 (br, 2H), 3.90–3.95 (m, 1H), 3.80–3.85 (m, 1H), 3.48 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 17.3 Hz, 2H), 1.18 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 5.4 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.73 min. (ESI): <i>m</i>/<i>z</i> = 445 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> Ethyl Ethyl (4-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}benzyl)phosphinate (<b>55a</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(2-methoxyphenyl)-pyrimidine <b>13a</b> (0.11 g, 0.5 mmol) and ethyl (4-aminobenzyl)ethylphosphinate·HCl <b>49</b> (0.158 g, 0.6 mmol) were reacted. The crude product was purified by preparative TLC, for the first elution 100% EtOAc, for the second one EtOAc:hexane (8:1), were used as eluents. The pure product was extracted with MeOH from the silica. After evaporation, an amorphous solid was obtained (0.028 g, 14%); mp = 30 °C (MeOH), <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 55.6 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.61 (s, 1H), 8.67 (s, 1H), 7.94 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.1 Hz, 1H), 7.63 (d, <i>J</i><sub>AABB</sub> = 7.3 Hz, 2H), 7.40–7.50 (m, 2H), 7.23 (d, <i>J</i><sub>AABB</sub> = 6.6 Hz, 2H), 7.19 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 7.07 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.6 Hz, 1H), 3.85–4.00 (m, 5H), 3.13 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 16.6 Hz, 2H), 1.50–1.65 (m, 2H), 1.18 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.6 Hz, 3H), 0.98 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 17.4 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 8.4 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.5 min. (ESI): <i>m</i>/<i>z</i> = 412 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> Ethyl (4-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}benzyl)propylphosphinate (<b>55b</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(2-methoxyphenyl)-pyrimidine <b>13a</b> (0.11 g, 0.5 mmol) and ethyl (4-aminobenzyl)propylphosphinate·HCl <b>50</b> (0.167 g; 0.6 mmol) were reacted. The crude product was purified by preparative TLC, for the first elution 100% EtOAc, for the second one EtOAc:hexane (8:1), were used as eluents. The pure product was extracted with MeOH from the silica. After evaporation amorphous solid was obtained (0.026 g, 12%); mp = 30 °C (MeOH). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 54.1 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.61 (s, 1H), 8.67 (s, 1H), 7.94 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.2 Hz, 1H), 7.63 (d, <i>J</i><sub>AABB</sub> = 7.2 Hz, 2H), 7.40–7.50 (m, 2H), 7.22 (d, <i>J</i><sub>AABB</sub> = 6.8 Hz, 2H), 7.15–7.20 (m, 1H), 7.07 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.6 Hz, 1H), 3.85–4.00 (m, 5H), 3.12 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 16.3 Hz, 2H), 1.35–1.70 (m, 4H), 1.18 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.6 Hz, 3H), 0.92 (br, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.48 and 2.68 min. (ESI): <i>m</i>/<i>z</i> = 426 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> Ethyl Ethyl (4-{[6-(3-Nitrophenyl)prymidin-4-yl]amino}benzyl)phosphinate (<b>56a</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(3-nitrophenyl)-pyrimidine <b>13b</b> (0.118 g; 0.5 mmol) and ethyl (4-aminobenzyl)ethylphosphinate·HCl <b>49</b> (0.158 g; 0.6 mmol) were reacted. The crude product was recrystallized from MeCN to give a yellow powder (0.104 g, 49%); mp = 226 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 55.6 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.8 (s, 1H), 8.82 (s, 1H), 8.76 (s, 1H), 8.44 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 1H), 8.36 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.3 Hz, 1H), 7.84 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.3 Hz, 1H), 7.65 (d, <i>J</i><sub>AABB</sub> = 6.2 Hz, 2H), 7.35 (s, 1H), 7.25 (d, <i>J</i><sub>AABB</sub> = 5.4 Hz, 2H), 3.90–3.95 (m, 2H), 3.14 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 16.4 Hz, 2H), 1.50–1.70 (m, 2H), 1.18 (br, 3H), 0.99 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 17.4 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 8.7 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.33 min. (ESI): <i>m</i>/<i>z</i> = 427 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> Ethyl (4-{[6-(3-Nitrophenyl)pyrimidin-4-yl]amino}benzyl)propylphosphinate (<b>56b</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(3-nitrophenyl)-pyrimidine <b>13b</b> (0.118 g, 0.5 mmol) and ethyl (4-aminobenzyl)propylphosphinate·HCl <b>50</b> (0.167 g, 0.6 mmol) were reacted. The crude product was recrystallized from MeCN to give a yellow powder (0.085 g, 39%); mp = 219–220 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 54.3 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.80 (s, 1H), 8.82 (s, 1H), 8.76 (s, 1H), 8.44 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.4 Hz, 1H), 8.36 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 1H), 7.84 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.1 Hz, 1H), 7.66 (d, <i>J</i><sub>AABB</sub> = 7.0 Hz, 2H), 7.35 (s, 1H), 7.25 (d, <i>J</i><sub>AABB</sub> = 5.7 Hz, 2H), 3.90–3.95 (m, 2H), 3.13 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 16.2 Hz, 2H), 1.45–1.63 (m, 4H), 1.18 (br, 3H), 0.99 (br, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.58 min. (ESI): <i>m</i>/<i>z</i> = 441 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> Ethyl (4-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}benzyl)ethylphosphinate (<b>57a</b>)</h4><div class="NLM_p last">Reduction of nitro compound <b>56a</b> (0.081 g; 0.19 mmol) was carried out according to the nitro group reduction described for compound <b>26a</b>, giving a yellow powder (0.062 g, 75%); mp = 152–155 °C (EtOH, Et<sub>2</sub>O). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 55.3 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 11.09 (s, 1H), 8.82 (s, 1H), 7.50–7.70 (m, 5H), 7.25–7.50 (m, 4H), 4.50 (br, 2H), 3.90–3.95 (m, 2H), 3.17 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 15.6 Hz, 2H), 1.55–1.65 (m, 2H), 1.18 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 3H), 0.99 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 17.4 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 8.7 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 0.44 min, 2.09 and 2.29 min. (ESI): <i>m</i>/<i>z</i> = 397 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> Ethyl (4-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}benzyl)propylphosphinate (<b>57b</b>)</h4><div class="NLM_p last">Reduction of nitro compound <b>56b</b> (0.063 g, 0.14 mmol) was carried out according to the nitro group reduction described for compound <b>26a</b>, affording a brown powder (0.053 g, 85%); mp = 200 °C (EtOH, Et<sub>2</sub>O). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 54.0 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 11.20 (s, 1H), 8.85 (s, 1H), 7.50–7.70 (m, 5H), 7.25–7.50 (m, 4H), 4.50 (br, 2H), 3.80–4.10 (m, 2H), 3.17 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 16.2 Hz, 2H), 1.55–1.60 (m, 2H), 1.40–1.50 (m, 2H), 1.18 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 3H), 0.92 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 0.42 min, 2.36 and 2.51 min. (ESI): <i>m</i>/<i>z</i> = 411 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> Ethyl Ethyl (5-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}-2-methylbenzyl)phosphinate (<b>58</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(2-methoxyphenyl)-pyrimidine <b>13a</b> (0.117 g, 0.5 mmol) and ethyl (5-amino-2-methylbenzyl)ethylphosphinate·HCl <b>51</b> (0.296 g, 1.07 mmol) were reacted. The crude product was purified by preparative TLC with EtOAc:hexane (8:1) as eluent. The pure product was extracted from the silica with MeOH. After evaporation, a yellow powder was obtained (0.053 g, 24%); mp = 94 °C, (MeOH). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 55.6 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.53 (s, 1H), 8.64 (s, 1H), 7.92 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 1H), 7.40–7.60 (m, 4H), 7.00–7.20 (m, 3H), 3.85–3.90 (m, 5H), 3.13 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 16.3 Hz, 2H), 2.30 (s, 3H), 1.60–1.80 (m, 2H), 1.15 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.3 Hz, 3H), 1.03 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 17.0 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 8.5 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.78 min. (ESI): <i>m</i>/<i>z</i> = 426 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> Ethyl Ethyl (2-Methyl-5-{[6-(3-nitrophenyl)pyrimidin-4-yl]amino}benzyl)phosphinate (<b>59</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(3-nitrophenyl)-pyrimidine <b>13b</b> (0.118 g, 0.5 mmol) and ethyl (5-amino-2-methylbenzyl)ethylphosphinate·HCl <b>51</b> (0.208 g, 0.75 mmol) were reacted. The crude product was recrystallized from MeCN to give a yellow powder (0.033 g, 15%); mp = 200–203 °C (MeCN). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.72 (s, 1H), 8.84 (s, 1H), 8.72 (s, 1H), 8.49 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 1H), 8.35 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.7 Hz, 1H), 7.83 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 7.52 (s, 1H), 7.47 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 1H), 7.38 (s, 1H), 7.15 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 1H), 3.80–4.00 (m, 2H), 3.17 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 15.7 Hz, 2H), 2.31 (s, 3H), 1.60–1.80 (m, 2H), 1.15 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.3 Hz, 3H), 1.05 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 17.9 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 8.9 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.04 min. (ESI): <i>m</i>/<i>z</i> = 441 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> Ethyl (5-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}-2-methylbenzyl)ethylphosphynate (<b>60</b>)</h4><div class="NLM_p last">Reduction of nitro compound <b>59</b> (0.023 g, 0.05 mmol) was carried out according to the nitro group reduction described for compound <b>26a</b>. The free base was prepared as a yellow powder (0.018 g, 81%); mp = 180–181 °C (EtOH). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 55.7 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.93 (s, 1H), 8.81 (s, 1H), 7.40–7.70 (m, 5H), 7.10–7.40 (m, 3H), 4.20 (br, 2H), 3.80–4.00 (m, 2H), 3.19 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 14.7 Hz, 2H), 2.34 (s, 3H), 1.60–1.80 (m, 2H), 1.15 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.3 Hz, 3H), 1.04 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 17.7 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 9.0 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 0.53 and 1.18 min. (ESI): <i>m</i>/<i>z</i> = 411 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> (3-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}benzyl)propylphosphinic Acid (<b>61</b>)</h4><div class="NLM_p last">Chloro (trimethyl)silane (0.076 mL; 0.6 mmol) and potassium iodide (0.02 g; 0.12 mmol) were dissolved in chloroform (20 mL). The mixture was stirred for 30 min at RT then the solution of phosphinate <b>52b</b> (0.05 g, 0.12 mmol in 3 mL CHCl<sub>3</sub>) was added. The reaction mixture was refluxed for 30 h, and then additional chloro (trimethyl)silane (0.076 mL, 0.6 mmol) and potassium iodide (0.04 g; 0.24 mmol) were added. The reaction mixture was refluxed for further 24 h then satd NH<sub>4</sub>Cl (10 mL) was added. After 5 min stirring, volatiles were evaporated under reduced pressure. The crude product was suspended in water (20 mL) and was extracted with CHCl<sub>3</sub> (3 × 30 mL). The combined organic phases were washed with brine and dried with MgSO<sub>4</sub>. After evaporation, the product was further purified by preparative TLC with 100% EtOH as eluent. The pure product was extracted from the silica with MeOH. After evaporation under vacuum, a white powder was obtained (0.017 g, 36%); mp = 122–125 °C (MeOH). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 121 MHz): δ 36.5 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.99 (s, 1H), 8.63 (s, 1H), 7.90–7.93 (m, 1H), 7.70–7.74 (m, 1H), 7.7–7.5 (m, 3H), 7.0–7.2 (m, 3H), 6.83–6.88 (m, 1H), 3.87 (s, 3H), 2.72 (d, <sup>2</sup><i>J</i><sub>PH</sub> = 14.4 Hz, 2H), 1.35–1.50 (m, 2H), 1.15–1.3 (m, 2H), 1.04 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.4 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 0.44 and 2.41 min. (ESI): <i>m</i>/<i>z</i> = 397 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124"> General Method for the Pd-Catalyzed Coupling of H-Phosphinates and Aromatic Halogens</h4><div class="NLM_p last">The appropriate halogeno-nitrobenzene (1 equiv) was dissolved in dry toluene (5 mL/mmol) then the H-phosphinate (1.1 equiv), triethylamine (4 equiv), and tetrakis (triphenylphosphine)palladium (0) (0.02 equiv) were added under inert atmosphere. The reaction mixture was refluxed for 20 h under inert atmosphere. The mixture was cooled to RT then the precipitate was filtered off. The filtrate was evaporated to dryness then the residue was dissolved in EtOAc (25 mL/mmol). This organic layer was washed with 1 M HCl (15 mL/mmol), 2 M NaOH (15 mL/mmol), and with brine (15 mL/mmol), respectively. Organic phase was dried with MgSO<sub>4</sub>, and volatiles were evaporated under reduced pressure. The crude product was purified by chromatography in hexane:EtOAc (1:1) to 100% EtOAc. For the exact quantity of reagents, for further purifications, yields, and analytical data see the exact examples.</div></div><div id="sec5_1_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> Ethyl (3-Aminophenyl)ethylphosphinate (<b>63a</b>)</h4><div class="NLM_p last">According to the general Pd-catalyzed coupling procedure, 3-iodo-nitrobenzene (0.996 g, 4.0 mmol) and ethyl ethylphosphinate <b>62a</b> (0.537 g, 4.4 mmol) were reacted, giving a yellow oil (0.14 g, 14%). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 45.8 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.40–8.50 (m, 2H), 8.14 (t, <sup>3</sup><i>J</i><sub>PH</sub> ∼ <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, 1H), 7.86 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.5 Hz, 1H), 3.95–4.00 (m, 1H), 3.80–3.90 (m, 1H), 1.95–2.25 (m, 2H), 1.22 (s, 3H), 0.96 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 19.1 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 9.0 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.83 min. (ESI): <i>m</i>/<i>z</i> = 244 [M + H]<sup>+</sup>. Reduction of ethyl ethyl (3-nitrophenyl)phosphinate (0.105 g, 0.43 mmol) was carried out according to the nitro group reduction described for compound <b>26a</b>. The free base was prepared as a yellow oil (0.078 g, 85%). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 48.3 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 7.10–7.20 (m, 1H), 6.93 (d, <sup>3</sup><i>J</i><sub>PH</sub> = 12.9 Hz, 1H), 6.70–6.88 (m, 2H), 5.34 (br, 2H), 3.85–3.95 (m, 1H), 3.70–3.80 (m, 1H), 1.75–1.85 (m, 2H), 1.19 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 3H), 0.94 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 18.5 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.03 min. (ESI): <i>m</i>/<i>z</i> = 214 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> Diethyl (3-Aminophenyl)phosphonate (<b>63d</b>)</h4><div class="NLM_p last">According to the general Pd-catalyzed coupling procedure, 3-iodo-nitrobenzene (2.49 g, 10.0 mmol) and diethylphosphite <b>62d</b> (1.518 g, 11.0 mmol) were reacted, giving a yellow oil (0.951 g, 37%). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 13.5 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.47 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.6 Hz, 1H), 8.40 (d, <sup>3</sup><i>J</i><sub>PH</sub> = 14.2 Hz, 1H), 8.14 (dd, <sup>3</sup><i>J</i><sub>PH</sub> = 12.3 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 7.86 (dt, <sup>3</sup><i>J</i><sub>HH</sub> = 8.5 Hz, <sup>4</sup><i>J</i><sub>PH</sub> = 4.1 Hz, 1H), 4.00–4.15 (m, 4H), 1.26 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 3.20 min. (ESI): <i>m</i>/<i>z</i> = 260 [M + H]<sup>+</sup>. Reduction of diethyl (3-nitrophenyl)phosphonate (0.804 g, 3.1 mmol) was carried out according to the nitro group reduction described for compound <b>26a</b>. The free base was prepared as a yellow oil (0.638 g, 90%). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 16.4 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 7.25–7.50 (m, 4H), 5.80 (br, 2H), 3.95–4.05 (m, 4H), 1.24 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.1 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 2.34 min. (ESI): <i>m</i>/<i>z</i> = 230 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> Ethyl (4-Aminophenyl)ethylphosphinate (<b>64a</b>)</h4><div class="NLM_p last">According to the general Pd-catalyzed coupling procedure, 4-bromo-nitrobenzene (2.02 g, 10.0 mmol) and ethyl ethylphosphinate <b>62a</b> (1.342 g, 11.0 mmol) were reacted, yielding a yellow oil (1.312 g, 54%), which upon standing crystallized. <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 45.7 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.36 (d, <i>J</i><sub>AABB</sub> = 6.7 Hz, 2H), 8.02 (dd, <sup>3</sup><i>J</i><sub>PH</sub> ∼ <i>J</i><sub>AABB</sub> = 9.0 Hz, 2H), 3.92–4.0 (m, 1H), 3.8–3.9 (m, 1H), 1.93–2.05 (m, 2H), 1.21 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 3H), 0.95 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 19.2 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.86 min. (ESI): <i>m</i>/<i>z</i> = 244 [M – H]<sup>+</sup>. Reduction of ethyl ethyl (4-nitrophenyl)phosphinate (1.302 g, 5.36 mmol) was carried out according to the nitro group reduction described for compound <b>26a</b>. The free base was prepared as a yellow oil (0.654 g, 49%). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 48.8 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 7.32 (dd, <sup>3</sup><i>J</i><sub>PH</sub>∼<i>J</i><sub>AABB</sub> = 8.4 Hz, 2H), 6.61 (d, <i>J</i><sub>AABB</sub> = 5.7 Hz, 2H), 5.73 (br, 2H), 3.75–3.85 (m, 1H), 3.65–3.75 (m, 1H), 1.72–1.75 (m, 2H), 1.16 (br, 3H), 0.91 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 18.3 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 8.4 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.16 min. (ESI): <i>m</i>/<i>z</i> = 214 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> Ethyl (4-Aminophenyl)propylphosphinate (<b>64b</b>)</h4><div class="NLM_p last">According to the general Pd-catalyzed coupling procedure, 4-bromo-nitrobenzene (2.02 g, 10.0 mmol) and ethyl propylphosphinate <b>62b</b> (1.496 g, 11.0 mmol) were reacted, giving a yellow oil (1.305 g, 54%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.35 (d, <i>J</i><sub>AABB</sub> = 6.8 Hz, 2H), 8.02 (dd, <sup>3</sup><i>J</i><sub>PH</sub> ∼ <i>J</i><sub>AABB</sub> = 9.0 Hz, 2H), 3.97 (q, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 1H), 3.81 (q, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 1H), 1.95–2.05 (m, 2H), 1.30–1.50 (m, 2H), 1.20 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 3H), 0.92 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.5 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.22 min. (ESI): <i>m</i>/<i>z</i> = 258 [M + H]<sup>+</sup>. Reduction of ethyl (4-nitrophenyl)propylphosphinate (1.30 g, 5.06 mmol) was carried out according to the nitro group reduction described for compound <b>26a</b>. The free base was prepared as a yellow oil (0.985 g, 86%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 7.32 (dd, <sup>3</sup><i>J</i><sub>PH</sub> ∼ <i>J</i><sub>AABB</sub> = 9.0 Hz, 2H), 6.60 (d, <i>J</i><sub>AABB</sub> = 5.7 Hz, 2H), 5.70 (br, 2H), 3.80–3.85 (m, 1H), 3.60–3.75 (m, 1H), 1.70–1.80 (m, 2H), 1.25–1.40 (m, 2H), 1.16 (br, 3H), 0.90 (br, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.53 min. (ESI): <i>m</i>/<i>z</i> = 228 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i129" class="anchor-spacer"></div><h4 class="article-section__title" id="_i129"> Ethyl (4-Aminophenyl)phenylphosphinate (<b>64c</b>)</h4><div class="NLM_p last">According to the general Pd-catalyzed coupling procedure, 4-bromo-nitrobenzene (2.02 g, 10.0 mmol) and ethyl phenylphosphinate <b>62c</b> (1.87 g, 11.0 mmol) were reacted, affording a yellow oil (1.849 g, 64%). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 29.7 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.33 (d, <i>J</i><sub>AABB</sub> = 6.1 Hz, 2H), 8.04 (dd, <sup>3</sup><i>J</i><sub>PH</sub> ∼ <i>J</i><sub>AABB</sub> = 9.5 Hz, 2H), 7.81 (dd, <sup>3</sup><i>J</i><sub>PH</sub> ∼ <i>J</i><sub>AABB</sub> = 9.2 Hz, 2H), 7.60–7.65 (m, 1H), 7.50–7.65 (m, 2H), 4.00–4.10 (m, 2H), 1.31 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.7 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.49 min. (ESI): <i>m</i>/<i>z</i> = 292 [M + H]<sup>+</sup>. Reduction of ethyl (4-nitrophenyl)phenylphosphinate (1.809 g, 6.22 mmol) was carried out according to the nitro group reduction described for compound <b>26a</b>. The free base was prepared as a yellow solid (1.435 g, 88%). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 33.6 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 7.68 (dd, <sup>3</sup><i>J</i><sub>PH</sub> ∼ <sup>3</sup><i>J</i><sub>HH</sub> = 9.1 Hz, 2H), 7.40–7.60 (m, 3H), 7.37 (dd, <sup>3</sup><i>J</i><sub>PH</sub> ∼ <i>J</i><sub>AABB</sub> = 9.4 Hz, 2H), 6.60 (d, <i>J</i><sub>AABB</sub> = 5.9 Hz, 2H), 5.79 (br, 2H), 3.85–3.95 (m, 2H), 1.24 (br, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.83 min. (ESI): <i>m</i>/<i>z</i> = 262 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i130" class="anchor-spacer"></div><h4 class="article-section__title" id="_i130"> Diethyl (4-Aminophenyl)phosphonate (<b>64d</b>)</h4><div class="NLM_p last">According to the general Pd-catalyzed coupling procedure, 4-bromo-nitrobenzene (5.05 g, 25.0 mmol) and diethyl phosphite <b>62d</b> (3.795 g, 27.5 mmol) were reacted, giving a yellow oil (3.948 g, 61%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 8.35 (dd, <i>J</i><sub>AABB</sub> = 8.7 Hz, <sup>4</sup><i>J</i><sub>PH</sub> = 3.1 Hz, 2H), 7.99 (dd, <i>J</i><sub>AABB</sub> = 8.7 Hz, <sup>3</sup><i>J</i><sub>PH</sub> = 12.5 Hz, 2H), 4.00–4.10 (m, 4H), 1.25 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 3.25 min. (ESI): <i>m</i>/<i>z</i> = 260 [M + H]<sup>+</sup>. Reduction of diethyl (4-nitrophenyl)phosphonate (3.947 g, 15.2 mmol) was carried out according to the nitro group reduction described at compound <b>26a</b>. The free base was prepared as a yellow solid (1.807 g, 52%). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 20.3 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 7.31 (dd, <sup>3</sup><i>J</i><sub>PH</sub> = 12.5 Hz, <i>J</i><sub>AABB</sub> = 8.5 Hz, 2H), 6.60 (d, <i>J</i><sub>AABB</sub> = 8.5 Hz, <sup>4</sup><i>J</i><sub>PH</sub> = 3.7 Hz, 2H), 5.77 (br, 2H), 3.80–4.00 (m, 4H), 1.18 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 2.48 min. (ESI): <i>m</i>/<i>z</i> = 230 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i131" class="anchor-spacer"></div><h4 class="article-section__title" id="_i131"> Ethyl Ethyl (3-{[6-(3-Methoxyphenyl)pyrimidin-4-yl]amino}phenyl)phosphinate (<b>65</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(2-methoxyphenyl)-pyrimidine <b>13a</b> (0.057 g, 0.26 mmol) and ethyl (3-aminophenyl)ethylphosphinate·HCl <b>63a</b> (0.077 g, 0.31 mmol) were reacted. The crude product was recrystallized from MeCN to give a yellow powder (0.035 g, 34%); mp = 155 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 47.7 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.85 (s, 1H), 8.72 (s, 1H), 7.85–8.10 (m, 3H), 7.40–7.55 (m, 3H), 7.28–7.40 (m, 1H), 7.14–7.25 (m, 1H), 7.02–7.12 (m, 1H), 3.91 (s, 3H), 3.80–4.00 (m, 2H), 1.80–1.95 (m, 2H), 1.23 (br, 3H), 0.97 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 17.3 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 6.4 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.56 min. (ESI): <i>m</i>/<i>z</i> = 398 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i132" class="anchor-spacer"></div><h4 class="article-section__title" id="_i132"> Ethyl Ethyl (3-{[6-(4-Nitrophenyl)pyrimidin-4-yl]amino}phenyl)phosphinate (<b>66</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(3-nitrophenyl)-pyrimidine <b>13b</b> (0.073 g, 0.31 mmol) and diethyl (3-aminophenyl)phosphonate·HCl <b>63d</b> (0.091 g, 0.37 mmol) were reacted. The crude product was recrystallized from MeCN to give a yellow powder (0.066 g, 52%); mp = 211 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 47.5 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.07 (s, 1H), 8.83 (s, 1H), 8.81 (s, 1H), 8.47 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.6 Hz, 1H), 8.37 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 1H), 8.00–8.10 (m, 2H), 7.85 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 1H), 7.45–7.55 (m, 1H), 7.30–7.45 (m, 2H), 3.90–4.00 (m, 1H), 3.80–3.90 (m, 1H), 1.80–2.00 (m, 2H), 1.23 (br, 3H), 0.99 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 18.3 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 8.7 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.55 min. (ESI): <i>m</i>/<i>z</i> = 413 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i133" class="anchor-spacer"></div><h4 class="article-section__title" id="_i133"> Ethyl (3-{[6-(4-Aminophenyl)pyrimidin-4-yl]amino}phenyl)ethylphosphinate (<b>67</b>)</h4><div class="NLM_p last">Reduction of the nitro compound <b>66</b> (0.048 g, 0.12 mmol) was carried out according to the nitro group reduction described for compound <b>26a</b>, giving a yellow powder (0.04 g, 80%); mp = 213-214 °C (EtOH, Et<sub>2</sub>O). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 47.2 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 11.06 (s, 1H), 8.87 (s, 1H), 8.00–8.15 (m, 2H), 7.75–7.85 (m, 2H), 7.55–7.62 (m, 2H), 7.38–7.50 (m, 3H), 5.30 (br, 2H), 3.95–4.00 (m, 1H), 3.80–3.85 (m, 1H), 1.88–1.93 (m, 2H), 1.23 (br, 3H), 0.98 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 18.7 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.37 min. (ESI): <i>m</i>/<i>z</i> = 383 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i134" class="anchor-spacer"></div><h4 class="article-section__title" id="_i134"> Ethyl Ethyl (4-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}phenyl)phosphinate (<b>68a</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(2-methoxyphenyl)-pyrimidine <b>13a</b> (0.11 g, 0.5 mmol) and ethyl (4-aminophenyl)ethylphosphinate·HCl <b>64a</b> (0.15 g, 0.6 mmol) were reacted. The crude product was purified by preparative TLC with 100% EtOAc and 1 v/v% AcOH as eluent. The pure product was extracted with MeOH from the silica. After evaporation, <b>68a</b> was obtained as a yellow powder (0.075 g, 38%); mp = 151–153 °C (MeOH). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 47.3 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz): δ 9.95 (s, 1H), 8.74 (s, 1H), 7.94 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 2.0 Hz, 1H), 7.88 (dd, <i>J</i><sub>AABB</sub> = 8.4 Hz, <sup>4</sup><i>J</i><sub>PH</sub> = 2.4 Hz, 2H), 7.65 (dd, <i>J</i><sub>AABB</sub> = 8.4 Hz, <sup>3</sup><i>J</i><sub>PH</sub> = 10.8 Hz, 2H), 7.51 (s, 1H), 7.44 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 1H), 7.17 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.4 Hz, 1H), 7.06 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 1H), 3.88 (s, 3H), 3.85–3.92 (m, 1H), 3.70–3.78 (m, 1H), 1.77–1.90 (m, 2H), 1.17 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 3H), 0.93 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 18.6 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.60 min. (ESI): <i>m</i>/<i>z</i> = 398 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135"> Ethyl (4-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}phenyl)propylphosphinate (<b>68b</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(2-methoxyphenyl)-pyrimidine <b>13a</b> (0.11 g, 0.5 mmol) and ethyl (4-aminophenyl)propylphosphinate·HCl <b>64b</b> (0.132 g, 0.6 mmol) were reacted. The crude product was purified by preparative TLC with 100% EtOAc as eluent. The product was extracted with MeOH from the silica. After evaporation, <b>68b</b> was isolated as a yellow powder (0.041 g, 20%); mp = 85 °C (MeOH). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 45.7 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 600 MHz): δ 9.94 (s, 1H), 8.74 (s, 1H), 7.94 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.2 Hz, 1H), 7.88 (dd, <i>J</i><sub>AABB</sub> = 8.4 Hz, <sup>4</sup><i>J</i><sub>PH</sub> = 2.4 Hz, 2H), 7.65 (dd, <i>J</i><sub>AABB</sub> = 9.0 Hz, <sup>3</sup><i>J</i><sub>PH</sub> = 10.8 Hz, 2H), 7.51 (s, 1H), 7.44 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 7.17 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.4 Hz, 1H), 7.06 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 3.88 (s, 3H), 3.84–3.90 (m, 1H), 3.68–3.76 (m, 1H), 1.76–1.88 (m, 2H), 1.30–1.48 (m, 2H), 1.17 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 3H), 0.89 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.82 min. (ESI): <i>m</i>/<i>z</i> = 412 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i136" class="anchor-spacer"></div><h4 class="article-section__title" id="_i136"> Ethyl (4-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}phenyl)phenylphosphinate (<b>68c</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(2-methoxyphenyl)-pyrimidine <b>13a</b> (0.11 g, 0.5 mmol) and ethyl (4-aminophenyl)phenylphosphinate·HCl <b>64c</b> (0.179 g, 0.6 mmol) were reacted. The crude product was recrystallized from MeCN, providing a pale-yellow powder (0.129 g, 58%); mp = 197–198 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 32.0 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.97 (s, 1H), 8.77 (s, 1H), 7.96 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 1H), 7.85–7.95 (m, 2H), 7.70–7.80 (m, 4H), 7.40–7.60 (m, 5H), 7.19 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, 1H), 7.09 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 1H), 3.90–3.80 (m, 2H), 3.90 (s, 3H), 1.29 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.06 min. (ESI): <i>m</i>/<i>z</i> = 446 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i137" class="anchor-spacer"></div><h4 class="article-section__title" id="_i137"> Ethyl Ethyl (4-{[6-(3-Nitrophenyl)pyrimidin-4-yl]amino}phenyl)phosphinate (<b>69a</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(3-nitrophenyl)-pyrimidine <b>13b</b> (0.118 g, 0.5 mmol) and ethyl (4-aminophenyl)ethylphosphinate·HCl <b>64a</b> (0.15 g, 0.6 mmol) were reacted. The crude product was recrystallized from MeCN, providing a yellow powder (0.135 g, 66%); mp = 241–242 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 47.4 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.20 (s, 1H), 8.85 (s, 2H), 8.48 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.3 Hz, 1H), 8.37 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.7 Hz, 1H), 7.30–7.70 (m, 3H), 7.60–7.70 (m, 2H),7.40–7.50 (m, 1H), 3.90–3.93 (m, 1H), 3.76–3.79 (m, 1H), 1.83–1.87 (m, 2H), 1.20 (br, 3H), 0.96 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 18.3 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 9.3 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.57 min. (ESI): <i>m</i>/<i>z</i> = 413 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i138" class="anchor-spacer"></div><h4 class="article-section__title" id="_i138"> Ethyl (4-{[6-(3-Nitrophenyl)pyrimidin-4-yl]amino}phenyl)propylphosphinate (<b>69b</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6- 3-nitrophenyl)-pyrimidine <b>13b</b> (0.118 g, 0.5 mmol) and ethyl (4-aminophenyl)propylphosphinate·HCl <b>64b</b> (0.167 g, 0.6 mmol) were reacted. The crude product was recrystallized from MeCN, providing a yellow powder (0.059 g, 28%); mp = 207–209 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 45.9 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.20 (s, 1H), 8.85 (s, 2H), 8.48 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.5 Hz, 1H), 8.37 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.3 Hz, 1H), 7.75–7.95 (m, 3H), 7.65–7.75 (m, 2H), 7.48 (s, 1H), 3.90–3.95 (m, 1H), 3.75–3.80 (m, 1H), 1.83–1.89 (m, 2H), 1.40–1.45 (m, 2H), 1.20 (br, 3H), 0.92 (br, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.87 min. (ESI): <i>m</i>/<i>z</i> = 427 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i139" class="anchor-spacer"></div><h4 class="article-section__title" id="_i139"> Ethyl (4-{[6-(3-Nitrophenyl)pyrimidin-4-yl]amino}phenyl)phenylphosphinate (<b>69c</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(3-nitrophenyl)-pyrimidine <b>13b</b> (0.118 g, 0.5 mmol) and ethyl (4-aminophenyl)phenylphosphinate·HCl <b>64c</b> (0.179 g, 0.6 mmol) were reacted. The crude product was recrystallized from MeCN, providing a pale-yellow powder (0.149 g, 65%); mp = 243 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 32.1 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.37 (s, 1H), 8.84 (s, 2H), 8.47 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.7 Hz, 1H), 8.36 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.3 Hz, 1H), 7.90–8.00 (m, 2H), 7.60–7.90 (m, 5H), 7.40–7.60 (m, 4H), 3.80–4.05 (m, 2H), 1.30 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 4.02 min. (ESI): <i>m</i>/<i>z</i> = 461 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i140" class="anchor-spacer"></div><h4 class="article-section__title" id="_i140"> Ethyl (4-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}phenyl)ethylphosphinate (<b>70a</b>)</h4><div class="NLM_p last">Reduction of the nitro compound <b>69a</b> (0.108 g, 0.26 mmol) was carried out according to the nitro group reduction described for compound <b>26a</b>, giving a yellow powder (0.084 g, 77%); mp = 136–138 °C (EtOH, Et<sub>2</sub>O). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 47.7 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.88 (s, 1H), 8.87 (s, 1H), 7.92–7.96 (m, 2H), 7.83–7.87 (m, 2H), 7.70–7.75 (m, 2H), 7.59–7.62 (m, 1H), 7.42–7.47 (m, 2H), 4.00 (br, 2H), 3.90–4.00 (m, 1H), 3.80–3.90 (m, 1H), 1.85–1.89 (m, 2H), 1.21 (br, 3H), 0.96 (dt, <sup>3</sup><i>J</i><sub>PH</sub> = 18.5 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.23 and 2.39 min. (ESI): <i>m</i>/<i>z</i> = 383 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_87" class="NLM_sec NLM_sec_level_3"><div id="ac_i141" class="anchor-spacer"></div><h4 class="article-section__title" id="_i141"> Ethyl (4-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}phenyl)propylphosphinate (<b>70b</b>)</h4><div class="NLM_p last">Reduction of the nitro compound <b>69b</b> (0.039 g, 0.09 mmol) was carried out according to the nitro group reduction described for compound <b>26a</b>, affording a yellow powder (0.035 g, 90%); mp = 140–142 °C (EtOH, DEE). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 45.7 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.75 (s, 1H), 8.87 (s, 1H), 7.90–7.93 (m, 2H), 7.69–7.82 (m, 4H), 7.55–7.60 (m, 1H), 7.35–7.44 (m, 2H), 3.68 (br, 4H), 1.83–1.87 (m, 2H), 1.40–1.44 (m, 2H), 1.21 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 3H), 0.92 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.61 min. (ESI): <i>m</i>/<i>z</i> = 397 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_88" class="NLM_sec NLM_sec_level_3"><div id="ac_i142" class="anchor-spacer"></div><h4 class="article-section__title" id="_i142"> Ethyl (4-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}phenyl)phenylphosphinate (<b>70c</b>)</h4><div class="NLM_p last">Reduction of the nitro compound <b>69c</b> (0.132 g, 0.29 mmol) was carried out according to the nitro group reduction described for compound <b>26a</b>, giving a yellow powder (0.073 g, 59%); mp = 131–134 °C (EtOH, Et<sub>2</sub>O). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 33.0 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.98 (s, 1H), 8.73 (s, 1H), 7.99 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.4 Hz, 1H), 7.71–7.76 (m, 5H), 7.55–7.60 (m, 3H), 7.10–7.35 (m, 4H), 6.70–6.75 (m, 1H), 5.29 (br, 2H), 3.97–4.01 (m, 2H), 1.29 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.7 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.81 min. (ESI): <i>m</i>/<i>z</i> = 431 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_89" class="NLM_sec NLM_sec_level_3"><div id="ac_i143" class="anchor-spacer"></div><h4 class="article-section__title" id="_i143"> Diethyl (3-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}phenyl)phosphonate (<b>71</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(2-methoxyphenyl)-pyrimidine <b>13a</b> (0.121 g, 0.55 mmol) and diethyl (3-aminophenyl)phosphonate·HCl <b>63d</b> (0.218 g, 0.82 mmol) were reacted. The crude product was suspended in diisoprpylether, and filtration gave a pale-yellow powder (0.132 g, 58%); mp = 122–123 °C (DIPE). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 17.0 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.87 (s, 1H), 8.74 (s, 1H), 8.10 (d, <sup>3</sup><i>J</i><sub>PH</sub> = 15.4 Hz, 1H), 8.06 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.4 Hz, 1H), 7.97 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 7.44–7.55 (m, 3H), 7.32 (dd, <sup>3</sup><i>J</i><sub>PH</sub> = 12.6 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 1H), 7.19 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.3 Hz, 1H), 7.09 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 1H), 3.98–4.09 (m, 4H), 3.91 (s, 3H), 1.26 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 2.70 min. (ESI): <i>m</i>/<i>z</i> = 414 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_90" class="NLM_sec NLM_sec_level_3"><div id="ac_i144" class="anchor-spacer"></div><h4 class="article-section__title" id="_i144"> Diethyl (3-{[6-(3-Nitrophenyl)pyrimidin-4-yl]amino}phenyl)phosphonate (<b>72</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(3-nitrophenyl)-pyrimidine <b>13b</b> (0.249 g, 1.06 mmol) and diethyl (3-aminophenyl)phosphonate·HCl <b>63d</b> (0.421 g, 1.59 mmol) were reacted. The crude product was suspended in DIPE, and filtration gave a yellow powder (0.364 g, 80%); mp = 206–208 °C (DIPE). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 16.9 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.04 (s, 1H), 8.84 (s, 1H), 8.82 (s, 1H), 8.47 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 8.37 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 1H), 8.13 (d, <sup>3</sup><i>J</i><sub>PH</sub> = 14.7 Hz, 1H), 8.04 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 7.86 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 7.53 (dt, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, <sup>4</sup><i>J</i><sub>PH</sub> = 5.2 Hz, 1H), 7.40 (s, 1H), 7.19 (dd, <sup>3</sup><i>J</i><sub>PH</sub> = 12.9 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 1H), 4.00–4.10 (m, 4H), 1.26 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 3.85 min. (ESI): <i>m</i>/<i>z</i> = 429 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_91" class="NLM_sec NLM_sec_level_3"><div id="ac_i145" class="anchor-spacer"></div><h4 class="article-section__title" id="_i145"> Diethyl (4-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}phenyl)phosphonate (<b>73</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6- (2-methoxyphenyl)-pyrimidine <b>13a</b> (0.097 g, 0.44 mmol) and diethyl (4-aminophenyl)phosphonate·HCl <b>64d</b> (0.174 g, 0.66 mmol) were reacted. The crude product was suspended in DIPE, and filtration gave a yellow powder (0.106 g, 58%); mp = 151 °C (DIPE). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 17.9 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.97 (s, 1H), 8.78 (s, 1H), 7.98 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, <sup>4</sup><i>J</i><sub>HH</sub> = 1.5 Hz, 1H), 7.92 (dd, <i>J</i><sub>AABB</sub> = 8.5 Hz, <sup>4</sup><i>J</i><sub>PH</sub> = 3.5 Hz, 2H), 7.67 (dd, <sup>3</sup><i>J</i><sub>PH</sub> = 12.6 Hz, <i>J</i><sub>AABB</sub> = 8.5 Hz, 2H), 7.55 (s, 1H), 7.47 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 1H), 7.19 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.3 Hz, 1H), 7.09 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 1H), 3.94–4.05 (m, 4H), 3.92 (s, 3H), 1.24 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 2.82 min. (ESI): <i>m</i>/<i>z</i> = 414 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_92" class="NLM_sec NLM_sec_level_3"><div id="ac_i146" class="anchor-spacer"></div><h4 class="article-section__title" id="_i146"> Diethyl (4-{[6-(3-Nitrophenyl)pyrimidin-4-yl]amino}phenyl)phosphonate (<b>74</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(3-nitrophenyl)-pyrimidine <b>13b</b> (0.25 g, 1.06 mmol) and diethyl (4-aminophenyl)phosphonate·HCl <b>64d</b> (0.422 g, 1.59 mmol) were reacted. The crude product was suspended in Et<sub>2</sub>O, and precipitate was filtered. Recrystallization from MeCN gave a yellow powder (0.209 g, 46%); mp = 219 °C (MeCN). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 17.7 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.30 (s, 1H), 8.85 (s, 2H), 8.48 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, 1H), 8.37 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.9 Hz, 1H), 7.94 (dd, <i>J</i><sub>AABB</sub> = 8.2 Hz, <sup>4</sup><i>J</i><sub>PH</sub> = 3.1 Hz, 2H), 7.85 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.68 (dd, <sup>3</sup><i>J</i><sub>PH</sub> = 12.5 Hz, <i>J</i><sub>AABB</sub> = 8.4 Hz, 2H), 7.51 (s, 1H), 3.94–4.05 (m, 4H), 1.24 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 3.87 min. (ESI): <i>m</i>/<i>z</i> = 429 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_93" class="NLM_sec NLM_sec_level_3"><div id="ac_i147" class="anchor-spacer"></div><h4 class="article-section__title" id="_i147"> Diethyl (4-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}phenyl)phosphonate (<b>75</b>)</h4><div class="NLM_p last">Reduction of the nitro compound <b>74</b> (0.14 g, 0.33 mmol) was carried out according to the nitro group reduction described for compound <b>26a</b>. The free base was prepared as a yellow powder (0.127 g, 97%); mp = 174–175 °C (EtOH). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 17.8 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.99 (s, 1H), 8.75 (s, 1H), 7.91 (dd, <i>J</i><sub>AABB</sub> = 8.5 Hz, <sup>4</sup><i>J</i><sub>PH</sub> = 3.5 Hz, 2H), 7.67 (dd, <sup>3</sup><i>J</i><sub>PH</sub> = 12.5 Hz, <i>J</i><sub>AABB</sub> = 8.5 Hz, 2H), 7.31 (s, 1H), 7.23 (s, 1H), 7.10–7.20 (m, 2H), 6.65–6.71 (m, 1H), 5.30 (br, 2H; 3.94–4.04 (m, 4H), 1.23 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 2.56 min. (ESI): <i>m</i>/<i>z</i> = 399 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_93_96" class="NLM_sec NLM_sec_level_3"><div id="ac_i148" class="anchor-spacer"></div><h4 class="article-section__title" id="_i148"> (3-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}phenyl)phosphonic Acid (<b>76</b>)</h4><div class="NLM_p last"><b>76</b> was prepared with the method described for compound <b>45a</b> starting from diethyl phosphonate <b>71</b> (0.05 g, 0.12 mmol). The reaction yielded a yellow powder (0.03 g, 69%); mp = 250–253 °C (dec, EtOH). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 10.9 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 11.41 (s, 1H), 8.91 (s, 1H), 8.00 (d, <sup>3</sup><i>J</i><sub>PH</sub> = 14.0 Hz, 1H), 7.91 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 4.9 Hz, 1H), 7.77 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 1H), 7.61 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.6 Hz, 1H), 7.40–7.55 (m, 2H), 7.45 (s, 1H), 7.27 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.2 Hz, 1H), 7.17 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.4 Hz, 1H), 5.75 (br, 2H), 3.91 (s, 3H). LC-MS: <i>R</i><sub>t</sub> = 0.47 and 1.92 min. (ESI): <i>m</i>/<i>z</i> = 358 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_93_97" class="NLM_sec NLM_sec_level_3"><div id="ac_i149" class="anchor-spacer"></div><h4 class="article-section__title" id="_i149"> (3-{[6-(3-Nitrophenyl)pyrimidin-4-yl]amino}phenyl)phosphonic Acid (<b>77</b>)</h4><div class="NLM_p last"><b>77</b> was prepared with the method described for compound <b>45a</b> starting from diethyl phosphonate <b>72</b> (0.15 g, 0.35 mmol). The reaction yielded a yellow powder (0.039 g, 30%); mp> 350 °C (EtOH). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 11.6 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.16 (s, 1H), 8.82 (s, 2H), 8.43 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.7 Hz, 1H), 8.38 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 8.00 (d, <sup>3</sup><i>J</i><sub>PH</sub> = 14.7 Hz, 1H), 7.94 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 7.86 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.33–7.49 (m, 3H), 5.27 (br, 2H). LC-MS: <i>R</i><sub>t</sub> = 2.50 min. (ESI): <i>m</i>/<i>z</i> = 373 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_93_98" class="NLM_sec NLM_sec_level_3"><div id="ac_i150" class="anchor-spacer"></div><h4 class="article-section__title" id="_i150"> (4-{[6-(2-Methoxyphenyl)pyrimidin-4-yl]amino}phenyl)phosphonic Acid (<b>78</b>)</h4><div class="NLM_p last"><b>78</b> was prepared with the method described for compound <b>45a</b> starting from diethyl phosphonate <b>73</b> (0.077 g, 0.19 mmol). The reaction yielded a yellow powder (0.015 g, 22%); mp> 350 °C (EtOH). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 10.7 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.85 (s, 1H), 8.74 (s, 1H), 7.90 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.5 Hz, 1H), 7.52–7.80 (m, 4H), 7.40–7.50 (m, 2H), 7.19 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.09 (dd, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, <sup>3</sup><i>J</i><sub>HH</sub> = 6.6 Hz, 1H), 4.60 (br, 2H), 3.91 (s, 3H). LC-MS: <i>R</i><sub>t</sub> = 0.46 and 1.83 min. (ESI): <i>m</i>/<i>z</i> = 358 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_93_99" class="NLM_sec NLM_sec_level_3"><div id="ac_i151" class="anchor-spacer"></div><h4 class="article-section__title" id="_i151"> (4-{[6-(3-Aminophenyl)pyrimidin-4-yl]amino}phenyl)phosphonic Acid (<b>79</b>)</h4><div class="NLM_p last"><b>79</b> was prepared with the method described at compound <b>45a</b> starting from diethyl phosphonate <b>75</b> (0.086 g, 0.22 mmol). The reaction yielded a yellow powder (0.046 g, 61%); mp > 350 °C (EtOH). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 242 MHz): δ 12.0 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.63 (s, 1H), 8.83 (s, 1H), 7.83 (dd, <i>J</i><sub>AABB</sub> = 8.4 Hz, <sup>4</sup><i>J</i><sub>PH</sub> = 2.7 Hz, 2H), 7.64–7.72 (m, 4H), 7.51 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.9 Hz, 1H), 7.37 (s, 1H), 7.26 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 5.70 (br, 4H). LC-MS: <i>R</i><sub>t</sub> = 0.45 and 1.07 min. (ESI): <i>m</i>/<i>z</i> = 343 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_94" class="NLM_sec NLM_sec_level_3"><div id="ac_i152" class="anchor-spacer"></div><h4 class="article-section__title" id="_i152"> General Method for the Suzuki Coupling</h4><div class="NLM_p last">To the solution of 4,6-dichloropyridine (0.373 g; 2.5 mmol) in dimethoxyethane (40 mL) tetrakis (triphenylphosphine)palladium (0) (0.145 g; 0.13 mmol; 0.05 equiv) was added under inert atmosphere. The mixture was stirred at RT for 1.5 h then the boronic acid or the boronic acid pinacolate ester (2.5 mmol; 1 equiv), Na<sub>2</sub>CO<sub>3</sub> (0.53 g; 5.0 mmol; 2 equiv), and 0.5 mL of degassed water were added. The reaction mixture was refluxed for 20 h under inert atmosphere. Volatiles were evaporated under reduced pressure then the residue was suspended in 1 M NaH<sub>2</sub>PO<sub>4</sub>. The suspension was extracted 3 times with EtOAc, combined organics were washed with satd Na<sub>2</sub>CO<sub>3</sub> and with brine and dried with MgSO<sub>4</sub>. After evaporation of the volatiles under reduced pressure, the crude product was purified by column chromatography in hexane:EtOAc (4:1). For further purifications, yields, and analytical data see the exact examples.</div></div><div id="sec5_1_95" class="NLM_sec NLM_sec_level_3"><div id="ac_i153" class="anchor-spacer"></div><h4 class="article-section__title" id="_i153"> 4-Chloro-6-(2-ethoxyphenyl)pyrimidine (<b>13c</b>)</h4><div class="NLM_p last">Yellow crystals (0.267 g, 46%); mp = 75–76 °C (EtOAc, hexane). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 7.5–7.7 (m, 4H), 7.3–7.4 (m, 1H), 6.9–7.0 (m, 1H), 4.09 (q, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 2H), 1.36 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.7 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 4.31 min. (ESI): <i>m</i>/<i>z</i> = 234 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_95_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i154" class="anchor-spacer"></div><h4 class="article-section__title" id="_i154"> 4-Chloro-6-(2-propoxyphenyl)pyrimidine (<b>13d</b>)</h4><div class="NLM_p last">White crystals (0.159 g, 26%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.1 (s, 1H), 8.19 (s, 1H), 8.01 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 5.8 Hz, 1H), 7.53 (s, 1H), 7.21 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.6 Hz, 1H), 7.12 (s, 1H), 4.1 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 2H), 1.73–1.8 (m, 2H), 1.02 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.3 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 4.68 min. (ESI): <i>m</i>/<i>z</i> = 248 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_96" class="NLM_sec NLM_sec_level_3"><div id="ac_i155" class="anchor-spacer"></div><h4 class="article-section__title" id="_i155"> 4-Chloro-6-(2-isopropoxyphenyl)pyrimidine (<b>13e</b>)</h4><div class="NLM_p last">Colorless liquid (0.258 g, 42%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.09 (s, 1H), 8.17 (s, 1H), 8.01 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.1 Hz, 1H), 7.52 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.0 Hz, 1H), 7.23 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.2 Hz, 1H), 7.1 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 7.1 Hz, 1H), 3.42–3.51 (m, 1H), 1.32 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.9 Hz, 6H). LC-MS: <i>R</i><sub>t</sub> = 4.55 min. (ESI): <i>m</i>/<i>z</i> = 248 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_97" class="NLM_sec NLM_sec_level_3"><div id="ac_i156" class="anchor-spacer"></div><h4 class="article-section__title" id="_i156"> 4-Chloro-6-(2-phenoxyphenyl)pyrimidine (<b>13f</b>)</h4><div class="NLM_p last">White crystals (0.44 g, 63%); mp = 73 °C (EtOAc, hexane), <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.12 (s, 1H), 8.08 (s, 1H), 8.03 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 7.3 Hz, 1H), 7.54 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 1H), 7.3–7.5 (m, 3H), 7.16 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 6.7 Hz, 1H), 7.0–7.1 (m, 3H). LC-MS: <i>R</i><sub>t</sub> = 4.73 min. (ESI): <i>m</i>/<i>z</i> = 282 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_98" class="NLM_sec NLM_sec_level_3"><div id="ac_i157" class="anchor-spacer"></div><h4 class="article-section__title" id="_i157"> 4-[2-(Benzyloxy)phenyl]-6-chloropyrimidine (<b>13g</b>)</h4><div class="NLM_p last">White crystals (0.388 g, 52%); mp = 87–88 °C (EtOAc, hexane), <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.1 (s, 1H), 8.19 (s, 1H), 8.01 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 6.8 Hz, 1H), 7.3–7.6 (m, 7H), 7.15 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 5.6 Hz, 1H), 5.27 (s, 2H). LC-MS: <i>R</i><sub>t</sub> = 4.74 min. (ESI): <i>m</i>/<i>z</i> = 296 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_99" class="NLM_sec NLM_sec_level_3"><div id="ac_i158" class="anchor-spacer"></div><h4 class="article-section__title" id="_i158"> 4-Chloro-6-(3-methoxyphenyl)pyrimidine (<b>13h</b>)</h4><div class="NLM_p last">White crystals (0.34 g, 62%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 9.02 (s, 1H), 7.23 (s, 1H), 7.65 (s, 1H), 7.61 (d, <sup>3</sup><i>J</i><sub>HH</sub> = 8 Hz, 1H), 7.42 (t, <sup>3</sup><i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.08 (d, <i>J</i><sub>HH</sub> = 6.5 Hz, 1H), 3.90 (s, 3H).</div></div><div id="sec5_1_100" class="NLM_sec NLM_sec_level_3"><div id="ac_i159" class="anchor-spacer"></div><h4 class="article-section__title" id="_i159"> 4-Chloro-6-(4-methoxyphenyl)pyrimidine (<b>13i</b>)</h4><div class="NLM_p last">White crystals (0.21 g, 38%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.96 (s, 1H), 8.06 (d, <i>J</i><sub>HH</sub> = 8.5 Hz, 2H), 7.67 (s, 1H), 7.02 (d, <i>J</i><sub>HH</sub> = 8.5 Hz, 2H<sub>AR</sub>), 3.89 (s, 3H).</div></div><div id="sec5_1_101" class="NLM_sec NLM_sec_level_3"><div id="ac_i160" class="anchor-spacer"></div><h4 class="article-section__title" id="_i160"> 4-Chloro-6-(2,3-dimethoxyphenyl)pyrimidine (<b>13j</b>)</h4><div class="NLM_p last">White crystals (0.24 g, 38%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 9.05 (s, 1H), 8.02 (s, 1H), 7.52 (d, <i>J</i><sub>HH</sub> = 6.5 Hz, 1H), 7.19 (t, <i>J</i><sub>HH</sub> = 8 Hz, 1H), 7.07 (d, <i>J</i><sub>HH</sub> = 8 Hz, 1H), 3.93 (s, 3H), 3.80 (s, 3H).</div></div><div id="sec5_1_102" class="NLM_sec NLM_sec_level_3"><div id="ac_i161" class="anchor-spacer"></div><h4 class="article-section__title" id="_i161"> 4-Chloro-6-(4-fluoro-2-methoxyphenyl)pyrimidine (<b>13k</b>)</h4><div class="NLM_p last">White crystals (0.12 g, 20%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 9.00 (s, 1H), 8.13 (t, <i>J</i><sub>HH</sub> = 7 Hz, 1H), 8.05 (s, 1H), 6.82 (t, <i>J</i><sub>HH</sub> = 8 Hz, 1H), 6.75 (d, <i>J</i><sub>HH</sub> = 8.5 Hz, 1H), 3.94 (s, 3H).</div></div><div id="sec5_1_103" class="NLM_sec NLM_sec_level_3"><div id="ac_i162" class="anchor-spacer"></div><h4 class="article-section__title" id="_i162"> 4-[3-(Benzyloxy)phenyl]-6-chloropyrimidine (<b>13l</b>)</h4><div class="NLM_p last">Yellow oil (0.592 g, 80%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 9.09 (s, 1H), 8.36 (s, 1H), 7.8–7.92 (m, 2H), 7.27.7.55 (m, 6H), 7.24 (d, <i>J</i><sub>HH</sub> = 7.2 Hz, 1H), 5.22 (s, 2H). LC-MS: <i>R</i><sub>t</sub> = 4.79 min. (ESI): <i>m</i>/<i>z</i> = 296 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_104" class="NLM_sec NLM_sec_level_3"><div id="ac_i163" class="anchor-spacer"></div><h4 class="article-section__title" id="_i163"> 4-Chloro-6-(2-ethylphenyl)pyrimidine (<b>13m</b>)</h4><div class="NLM_p last">White crystals were prepared (0.058 g, 11%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 9.12 (s, 1H), 7.24–7.49 (m, 5H), 2.68–2.78 (m, 2H), 1.08 (t, <i>J</i><sub>HH</sub> = 7.5 Hz, 3H).</div></div><div id="sec5_1_105" class="NLM_sec NLM_sec_level_3"><div id="ac_i164" class="anchor-spacer"></div><h4 class="article-section__title" id="_i164"> Ethyl (3-{[6-(2-Ethoxyphenyl)pyrimidin-4-yl]amino}benzyl)propylphosphinate (<b>80</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(2-ethoxyphenyl)-pyrimidine <b>13c</b> (0.262 g, 1.12 mmol) and ethyl (3-aminophenyl)propylphosphinate·HCl <b>48</b> (0.326 g, 1.23 mmol) were reacted. The crude product was purified by chromathography in hexane:EtOAc (9:1). Evaporation of the fractions under reduced pressure provided a pale-yellow oil (0.05 g, 10%). <sup>31</sup>P NMR (CDCl<sub>3</sub>, 121 MHz): δ 54.2 ppm. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.76 (s, 1H), 7.98 (q, <i>J</i><sub>HH</sub> = 4 Hz, 1H), 7.41–7.46 (m, 3H), 7.27–7.38 (m, 3H), 7.06 (t, <i>J</i><sub>HH</sub> = 7 Hz, 2H), 6.95 (d, <i>J</i><sub>HH</sub> = 8.5 Hz, 1H), 4.01–4.06 (m, 2H), 3.94–4.01 (m, 2H), 3.12 (d, <i>J</i><sub>PH</sub> = 16.5 Hz, 2H), 1.59–1.63 (m, 4H), 1.33 (t, <i>J</i><sub>HH</sub> = 7.0 Hz, 3H), 1.24 (t, <i>J</i><sub>HH</sub> = 7.0 Hz, 3H), 0.96 (t, <i>J</i><sub>HH</sub> = 7 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz): δ 162.0 (s, 1C), 161.0 (s, 1C), 158.5 (s, 1C), 157.2 (s, 1C), 139.2 (d, <i>J</i><sub>PC</sub> = 2.6 Hz, 1C), 133.6 (d, <i>J</i><sub>PC</sub> = 7.1 Hz, 1C), 131.3 (s, 1C), 131.0 (s, 1C), 129.7 (d, <i>J</i><sub>PC</sub> = 2.6 Hz, 1C), 126.8 (s, 1C), 125.8 (d, <i>J</i><sub>PC</sub> = 5.5 Hz, 1C), 123.5 (d, <i>J</i><sub>PC</sub> = 5.5 Hz, 1C),15.0 (s, 1C), 121.0 (s, 1C), 120.4 (d, <i>J</i><sub>PC</sub> = 9.3 Hz, 1C), 112.6 (s, 1C), 105.4 (s, 1C), 64.3 (s, 1C), 60.8 (d, <i>J</i><sub>PC</sub> = 6.7 Hz, 1C), 36.6 (d, <i>J</i><sub>PC</sub> = 83.0 Hz, 1C), 29.9 (d, <i>J</i><sub>PC</sub> = 92.0 Hz, 1C), 16.8 (d, <i>J</i><sub>PC</sub> = 5.6 Hz, 1C), 15.6 (s, 1C), 15.5 (s, 1C). LC-MS: <i>R</i><sub>t</sub> = 2.91 min. (ESI): <i>m</i>/<i>z</i> = 440 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_106" class="NLM_sec NLM_sec_level_3"><div id="ac_i165" class="anchor-spacer"></div><h4 class="article-section__title" id="_i165"> Ethyl (3-{[6-(2-Propoxyphenyl)pyrimidin-4-yl]amino}benzyl)propylphosphinate (<b>81</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(2-propoxyphenyl)-pyrimidine <b>13d</b> (0.15 g, 0.6 mmol) and ethyl (3-aminophenyl)propylphosphinate·HCl <b>48</b> (0.175 g, 0.66 mmol) were reacted. The crude product was purified by chromathography in hexane:EtOAc (9:1). Evaporation of the fractions under reduced pressure provided a pale-yellow oil (0.1 g, 37%). <sup>31</sup>P NMR (CDCl<sub>3</sub>, 121 MHz): δ 52.5 ppm. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.74 (s, 1H), 7.90–7.95 (m, 2H), 7.41 (s, 1H), 7.27–7.39 (m, 4H), 7.02 (t, <i>J</i><sub>HH</sub> = 8 Hz, 2H), 6.92 (d, <i>J</i><sub>HH</sub> = 8.5 Hz, 1H), 3.91–4.18 (m, 4H), 3.11 (d, <i>J</i><sub>PH</sub> = 16.5 Hz, 2H), 1.45–1.79 (m, 6H), 1.21 (t, <i>J</i><sub>HH</sub> = 7.0 Hz, 3H), 0.93 (t, <i>J</i><sub>HH</sub> = 7.5 Hz, 3H), 0.87 (t, <i>J</i><sub>HH</sub> = 7.0 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz): δ 162.0 (s, 1C), 161.0 (s, 1C), 158.4 (s, 1C), 157.2 (s, 1C), 139.3 (d, <i>J</i><sub>PC</sub> = 2.6 Hz, 1C), 133.5 (d, <i>J</i><sub>PC</sub> = 7.1 Hz, 1C), 131.1 (s, 1C), 130.9 (s, 1C), 129.6 (d, <i>J</i><sub>PC</sub> = 2.6 Hz, 1C), 126.9 (s, 1C), 125.7 (d, <i>J</i><sub>PC</sub> = 5.5 Hz, 1C), 123.5 (d, <i>J</i><sub>PC</sub> = 5.5 Hz, 1C), 121.0 (s, 1C), 120.5 (d, <i>J</i><sub>PC</sub> = 3.0 Hz, 1C), 112.6 (s, 1C), 105.3 (s, 1C), 70.3 (s, 1C), 60.7 (d, <i>J</i><sub>PC</sub> = 6.7 Hz, 1C), 36.5 (d, <i>J</i><sub>PC</sub> = 83.5 Hz, 1C), 29.8 (d, <i>J</i><sub>PC</sub> = 92.6 Hz, 1C), 22.7 (s, 1C), 16.8 (d, <i>J</i><sub>PC</sub> = 5.6 Hz, 1C), 15.7 (d, <i>J</i><sub>PC</sub> = 5.7 Hz, 1C), 15.5 (d, <i>J</i><sub>PC</sub> = 5.6 Hz, 1C), 10.7 (s, 1C). LC-MS: <i>R</i><sub>t</sub> = 3.09 min. (ESI): <i>m</i>/<i>z</i> = 454 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_107" class="NLM_sec NLM_sec_level_3"><div id="ac_i166" class="anchor-spacer"></div><h4 class="article-section__title" id="_i166"> Ethyl (3-{[6-(2-Isopropoxyphenyl)pyrimidin-4-yl]amino}benzyl)propylphosphinate (<b>82</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(2-isopropoxyphenyl)-pyrimidine <b>13e</b> (0.243 g, 0.98 mmol) and ethyl (3-aminophenyl)propylphosphinate·HCl <b>48</b> (0.286 g, 1.08 mmol) were reacted. The crude product was purified by chromathography in hexane:EtOAc (9:1). After evaporation of the fractions under reduced pressure, the product was crystallized from hexane:<i>i</i>-PrOH (9:1), affording white crystals (0.17 g, 38%). <sup>31</sup>P NMR (CDCl<sub>3</sub>, 121 MHz): δ 52.4 ppm. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.77 (s, 1H), 7.43–7.46 (m, 2H), 7.33–7.37 (m, 2H), 7.27–7.29 (m, 2H), 7.04–7.09 (m, 3H), 6.97 (d, <i>J</i> = 8.0 Hz, 1H), 4.54–4.63 (m, 1H), 3.95–4.07 (m, 2H), 3.13 (d, <i>J</i><sub>PH</sub> = 16.5 Hz, 2H), 1.61–1.64 (m, 4H), 1.26 (t, <i>J</i><sub>HH</sub> = 6.0 Hz, 9H), 0.97 (t, <i>J</i><sub>HH</sub> = 7.5 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz): δ 162.0 (s, 1C), 160.7 (s, 1C), 158.4 (s, 1C), 155.9 (s, 1C), 139.0 (d, <i>J</i><sub>PC</sub> = 2.7 Hz, 1C), 133.6 (d, <i>J</i><sub>PC</sub> = 7.1 Hz, 1C), 131.0 (d, <i>J</i><sub>PC</sub> = 8.2 Hz, 2C), 129.5 (d, <i>J</i><sub>PC</sub> = 2.6 Hz, 1C), 127.6 (s, 1C), 125.7 (d, <i>J</i><sub>PC</sub> = 5.6 Hz, 1C), 123.4 (d, <i>J</i><sub>PC</sub> = 5.5 Hz, 1C), 121.0 (s, 1C), 120.4 (d, <i>J</i><sub>PC</sub> = 3.0 Hz, 1C), 114.3 (s, 1C), 105.1 (s, 1C), 70.9 (s, 1C), 60.6 (d, <i>J</i><sub>PC</sub> = 6.6 Hz, 1C), 36.4 (d, <i>J</i><sub>PC</sub> = 82.9 Hz, 1C), 29.2 (s, 1C), 22.1 (s, 1C), 16.6 (d, <i>J</i><sub>PC</sub> = 5.5 Hz, 1C), 15.5 (d, <i>J</i><sub>PC</sub> = 5.8 Hz, 1C), 15.4 (d, <i>J</i><sub>PC</sub> = 5.5 Hz, 1C). LC-MS: <i>R</i><sub>t</sub> = 3.05 min; (ESI): <i>m</i>/<i>z</i> = 454 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_108" class="NLM_sec NLM_sec_level_3"><div id="ac_i167" class="anchor-spacer"></div><h4 class="article-section__title" id="_i167"> Ethyl (3-{[6-(2-Phenoxyphenyl)pyrimidin-4-yl]amino}benzyl)propylphosphinate (<b>83</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(2-phenoxyphenyl)-pyrimidine <b>13f</b> (0.23 g, 0.81 mmol) and ethyl (3-aminophenyl)propylphosphinate·HCl <b>48</b> (0.236 g, 0.89 mmol) were reacted. The crude product was purified by chromathography in hexane:EtOAc (9:1). After evaporation of the fractions under reduced pressure, the product was crystallized from MeCN to give white crystals (0.12 g, 30%). <sup>31</sup>P NMR (CDCl<sub>3</sub>, 121 MHz): δ 53.3 ppm. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.73 (s, 1H), 8.25 (s, 1H), 8.03 (d, <i>J</i><sub>HH</sub> = 6.5 Hz, 1H), 7.40 (s, 1H), 7.21–7.35 (m, 6H), 7.14 (t, <i>J</i><sub>HH</sub> = 9.0 Hz, 1H), 7.06 (t, <i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 6.97 (d, <i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 6.92 (d, <i>J</i><sub>HH</sub> = 8.0 Hz, 3H), 3.94–4.08 (m, 2H), 3.01 (d, <i>J</i><sub>PH</sub> = 16.5 Hz, 2H), 1.59–1.65 (m, 4H), 1.22 (t, <i>J</i><sub>HH</sub> = 7.3 Hz, 3H), 0.94 (t, <i>J</i><sub>HH</sub> = 7.0 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz): δ 160.9 (s, 1C), 160.8 (s, 1C), 158.5 (s, 1C), 156.9 (s, 1C), 154.9 (s, 1C), 139.2 (d, <i>J</i><sub>PC</sub> = 2.7 Hz, 1C), 133.2 (d, <i>J</i><sub>PC</sub> = 7.1 Hz, 1C), 131.1 (d, <i>J</i><sub>PC</sub> = 3.6 Hz, 1C), 129.9 (s, 1C), 129.7 (s, 1C), 129.5 (s, 1C), 129.4 (s, 1C), 125.3 (d, <i>J</i><sub>PC</sub> = 5.4 Hz, 1C), 124.1 (s, 1C), 123.5 (s, 1C), 122.8 (d, <i>J</i><sub>PC</sub> = 5.6 Hz, 2C), 120.0 (d, <i>J</i><sub>PC</sub> = 2.9 Hz, 2C), 119.6 (s, 1C), 118.6 (s, 1C), 105.4 (s, 1C), 60.7 (d, <i>J</i><sub>PC</sub> = 6.7 Hz, 1C), 36.4 (d, <i>J</i><sub>PC</sub> = 83.0 Hz, 1C), 29.8 (d, <i>J</i><sub>PC</sub> = 92.0 Hz, 1C), 16.7 (d, <i>J</i><sub>PC</sub> = 5.6 Hz, 1C), 15.6 (d, <i>J</i><sub>PC</sub> = 8.6 Hz, 1C), 15.5 (d, <i>J</i><sub>PC</sub> = 2.7 Hz, 1C). LC-MS: <i>R</i><sub>t</sub> = 3.48 min. (ESI): <i>m</i>/<i>z</i> = 488 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_109" class="NLM_sec NLM_sec_level_3"><div id="ac_i168" class="anchor-spacer"></div><h4 class="article-section__title" id="_i168"> Ethyl [3-({6-[2-(Benzyloxy)phenyl]pyrimidin-4-yl}amino)benzyl]propylphosphinate (<b>84</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-[2-(benzyloxy)phenyl]-6-chloropyrimidine <b>13g</b> (0.369 g, 1.25 mmol) and ethyl (3-aminophenyl)propylphosphinate·HCl <b>48</b> (0.363 g, 1.37 mmol) were reacted. The crude product was purified by chromathography in hexane:EtOAc (9:1). After evaporation of the fractions under reduced pressure, the product was crystallized from Et<sub>2</sub>O to give white crystals (0.23 g, 37%). <sup>31</sup>P NMR (CDCl<sub>3</sub>, 121 MHz): δ 52.5 ppm. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.74 (s, 1H), 8.24 (d, <i>J</i><sub>HH</sub> = 4.5 Hz, 1H), 7.87 (d, <i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 7.37 (s, 1H), 7.19–7.33 (m, 8H), 7.09 (t, <i>J</i> = 8.0 Hz, 1H), 7.02 (t, <i>J</i> = 7.5 Hz, 1H), 6.92–6.97 (m, 2H), 5.05 (s, 2H), 3.89–4.01 (m, 2H), 3.00 (d, <i>J</i><sub>PH</sub> = 16.5 Hz, 2H), 1.42–1.59 (m, 4H), 1.17 (t, <i>J</i><sub>HH</sub> = 7.5 Hz, 3H), 0.89 (t, <i>J</i><sub>HH</sub> = 6.5 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz): δ 161.6 (s, 1C), 160.7 (s, 1C), 158.3 (s, 1C), 156.6 (s, 1C), 139.3 (d, <i>J</i><sub>PC</sub> = 2.6 Hz, 1C), 136.7 (s, 1C), 133.2 (d, <i>J</i><sub>PC</sub> = 7.1 Hz, 1C), 130.9 (d, <i>J</i><sub>PC</sub> = 5.4 Hz, 1C), 129.4 (d, <i>J</i><sub>PC</sub> = 2.5 Hz, 1C), 128.6 (s, 1C), 127.9 (s, 2C), 127.6 (s, 1C), 127.1 (s, 1C), 125.1 (d, <i>J</i><sub>PC</sub> = 5.4 Hz, 2C), 122.6 (d, <i>J</i><sub>PC</sub> = 5.6 Hz, 1C), 121.4 (s, 1C), 119.8 (s, 1C), 119.77 (s, 1C), 113.3 (s, 1C), 105.8 (s, 1C), 70.8 (s, 1C), 60.6 (d, <i>J</i><sub>PC</sub> = 6.8 Hz, 1C), 36.3 (d, <i>J</i><sub>PC</sub> = 83.0 Hz, 1C), 29.6 (d, <i>J</i><sub>PC</sub> = 92.0 Hz, 1C), 16.6 (d, <i>J</i><sub>PC</sub> = 5.6 Hz, 1C), 15.5 (d, <i>J</i><sub>PC</sub> = 7.9 Hz, 1C), 15.4 (d, <i>J</i><sub>PC</sub> = 3.5 Hz, 1C). LC-MS: <i>R</i><sub>t</sub> = 3.28 min. (ESI): <i>m</i>/<i>z</i> = 502 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_110" class="NLM_sec NLM_sec_level_3"><div id="ac_i169" class="anchor-spacer"></div><h4 class="article-section__title" id="_i169"> Ethyl (3-{[6-(3-Methoxyphenyl)pyrimidin-4-yl]amino}benzyl)propylphosphinate (<b>85</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(3-methoxyphenyl)-pyrimidine <b>13h</b> (0.33 g, 1.5 mmol) and ethyl (3-aminophenyl)propylphosphinate·HCl <b>48</b> (0.437 g, 1.65 mmol) were reacted. The crude product was purified by chromathography in hexane:EtOAc (9:1). Evaporation of the fractions under reduced pressure provided a pale-yellow oil (0.18 g, 28%). <sup>31</sup>P NMR (CDCl<sub>3</sub>, 121 MHz): δ 53.2 ppm. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.81 (s, 1H), 8.70 (s, 1H), 7.59 (s, 1H), 7.55 (s, 1H), 7.46 (d, <i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.35 (d, <i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.3 (t, <i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.23 (t, <i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.07 (s, 1H), 6.95 (t, <i>J</i><sub>HH</sub> = 8.0 Hz, 2H), 3.9–4.1 (m, 2H), 3.82 (s, 3H), 3.13 (d, <i>J</i><sub>PH</sub> = 16.0 Hz, 2H), 1.59–1.63 (m, 4H), 1.24 (t, 7.0 Hz, 3H), 0.97 (t, <i>J</i><sub>HH</sub> = 7.0 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz): δ 162.7 (s, 1C), 161.4 (s, 1C), 159.9 (s, 1C), 158.4 (s, 1C), 139.6 (d, <i>J</i><sub>PC</sub> = 2.7 Hz, 1C), 132.9 (d, <i>J</i><sub>PC</sub> = 7.3 Hz, 1C), 129.7 (s, 1C), 129.3 (d, <i>J</i><sub>PC</sub> = 2.4 Hz, 1C), 124.8 (d, <i>J</i><sub>PC</sub> = 5.6 Hz, 1C), 122.4 (d, <i>J</i><sub>PC</sub> = 5.3 Hz, 1C), 119.6 (d, <i>J</i><sub>PC</sub> = 2.8 Hz, 1C), 119.2 (s, 1C), 116.1 (s, 1C), 112.2 (s, 1C), 105.7 (s, 1C), 101.7 (s, 1C), 60.7 (d, <i>J</i><sub>PC</sub> = 6.7 Hz, 1C), 55.3 (s, 1C), 36.4 (d, <i>J</i><sub>PC</sub> = 82.5 Hz, 1C), 29.8 (d, <i>J</i><sub>PC</sub> = 92.5 Hz, 1C), 16.7 (d, <i>J</i><sub>PC</sub> = 5.6 Hz, 1C), 15.7 (d, <i>J</i><sub>PC</sub> = 6.9 Hz, 1C), 15.5 (d, <i>J</i><sub>PC</sub> = 8.9 Hz, 1C). LC-MS: <i>R</i><sub>t</sub> = 3.06 min. (ESI): <i>m</i>/<i>z</i> = 426 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_111" class="NLM_sec NLM_sec_level_3"><div id="ac_i170" class="anchor-spacer"></div><h4 class="article-section__title" id="_i170"> Ethyl (3-{[6-(4-Methoxyphenyl)pyrimidin-4-yl]amino}benzyl)propylphosphinate (<b>86</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(4-methoxyphenyl)-pyrimidine <b>13i</b> (0.21 g, 0.95 mmol) and ethyl (3-aminophenyl)propylphosphinate·HCl <b>48</b> (0.278 g, 1.05 mmol) were reacted. The crude product was purified by chromathography in hexane:EtOAc (9:1). Evaporation of the fractions under reduced pressure provided a pale-yellow oil (0.27 g, 67%). <sup>31</sup>P NMR (CDCl<sub>3</sub>, 121 MHz): δ 52.8 ppm. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.69 (s, 1H), 8.19 (s, 1H), 7.93 (d, <i>J</i><sub>HH</sub> = 9.0 Hz, 2H), 7.48 (s, 1H), 7.34 (d, <i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.28 (t, <i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 7.02 (t, <i>J</i><sub>HH</sub> = 8.5 Hz, 2H), 6.94 (d, <i>J</i><sub>HH</sub> = 9.0 Hz, 2H), 4.05 (m, 2H), 3.83 (s, 3H), 3.14 (d, <i>J</i><sub>PH</sub> = 16.5 Hz, 2H), 1.59–1.62 (m, 4H), 1.25 (t, <i>J</i><sub>HH</sub> = 7.0 Hz, 3H), 0.98 (t, <i>J</i><sub>HH</sub> = 7.3 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz): δ 163.0 (s, 1C), 161.5 (d, <i>J</i><sub>PC</sub> = 9.5 Hz, 1C), 158.7 (s, 1C), 139.5 (d, <i>J</i><sub>PC</sub> = 2.8 Hz, 1C), 133.3 (d, <i>J</i><sub>PC</sub> = 7.2 Hz, 1C), 130.0 (s, 1C), 129.6 (d, <i>J</i><sub>PC</sub> = 2.5 Hz, 1C), 128.5 (s, 1C), 125.3 (d, <i>J</i><sub>PC</sub> = 5.6 Hz, 2C), 122.9 (d, <i>J</i><sub>PC</sub> = 5.4 Hz, 2C), 120.1 (d, <i>J</i><sub>PC</sub> = 2.9 Hz, 2C), 114.2 (s, 1C), 99.9 (s, 1C), 60.8 (d, <i>J</i><sub>PC</sub> = 6.7 Hz, 1C), 55.5 (s, 1C), 36.6 (d, <i>J</i><sub>PC</sub> = 82.9 Hz, 1C), 29.9 (d, <i>J</i><sub>PC</sub> = 91.8 Hz, 1C), 16.8 (d, <i>J</i><sub>PC</sub> = 5.6 Hz, 1C), 15.7 (d, <i>J</i><sub>PC</sub> = 4.4 Hz, 1C), 15.6 (d, <i>J</i><sub>PC</sub> = 6.9 Hz, 1C). LC-MS: <i>R</i><sub>t</sub> = 2.90 min. (ESI): <i>m</i>/<i>z</i> = 426 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_112" class="NLM_sec NLM_sec_level_3"><div id="ac_i171" class="anchor-spacer"></div><h4 class="article-section__title" id="_i171"> Ethyl (3-{[6-(2,3-Dimethoxyphenyl)pyrimidin-4-yl]amino}benzyl)propylphosphinate (<b>87</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(2,3-dimethoxyphenyl)-pyrimidine <b>13j</b> (0.24 g, 0.96 mmol) and ethyl (3-aminophenyl)propylphosphinate·HCl <b>48</b> (0.278 g, 1.05 mmol) were reacted. The crude product was purified by chromathography in hexane:EtOAc (9:1). After evaporation of the fractions under reduced pressure, the product was crystallized from Et<sub>2</sub>O to give white crystals (0.16 g, 37%). <sup>31</sup>P NMR (CDCl<sub>3</sub>, 121 MHz): δ 53.9 ppm. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.66 (s, 1H), 8.49 (s, 1H), 7.41 (s, 1H), 7.33 (d, <i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 7.27 (dd, <i>J</i><sub>HH</sub> = 8.0 Hz, 2H), 7.15 (t, <i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 7.03 (t, <i>J</i><sub>HH</sub> = 8.0 Hz, 1H), 6.89 (dd, <i>J</i><sub>HH</sub> = 9.5 Hz, 2H), 3.95 (m, 2H), 3.77 (s, 3H), 3.62 (s, 3H), 3.04 (d, <i>J</i><sub>PH</sub> = 16.5 Hz, 2H), 1.52–1.59 (m, 4H), 1.45 (t, <i>J</i><sub>HH</sub> = 7.0 Hz, 3H), 0.86 (t, <i>J</i><sub>HH</sub> = 7.5 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz): δ 161.4 (s, 1C), 161.0 (s, 1C), 158.3 (s, 1C), 153.0 (s, 1C), 147.6 (s, 1C), 139.5 (d, <i>J</i><sub>PC</sub> = 2.7 Hz, 1C), 133.1 (d, <i>J</i><sub>PC</sub> = 7.1 Hz, 1C), 132.4 (s, 1C), 129.3 (d, <i>J</i><sub>PC</sub> = 2.5 Hz, 1C), 124.9 (d, <i>J</i><sub>PC</sub> = 5.3 Hz, 1C), 124.3 (s, 1C), 122.4 (d, <i>J</i><sub>PC</sub> = 5.5 Hz, 1C), 122.1 (s, 1C), 119.6 (d, <i>J</i><sub>PC</sub> = 2.8 Hz, 1C), 113.6 (s, 1C), 105.9 (s, 1C), 60.9 (s, 1C), 60.6 (d, <i>J</i><sub>PC</sub> = 6.7 Hz, 1C), 55.9 (s, 1C), 36.5 (d, <i>J</i><sub>PC</sub> = 83.0 Hz, 1C), 29.6 (d, <i>J</i><sub>PC</sub> = 91.9 Hz, 1C), 16.6 (d, <i>J</i><sub>PC</sub> = 5.7 Hz, 1C), 15.5 (d, <i>J</i><sub>PC</sub> = 5.9 Hz, 1C), 15.3 (d, <i>J</i><sub>PC</sub> = 6.1 Hz, 1C). LC-MS: <i>R</i><sub>t</sub> = 2.83 min. (ESI): <i>m</i>/<i>z</i> = 456 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_113" class="NLM_sec NLM_sec_level_3"><div id="ac_i172" class="anchor-spacer"></div><h4 class="article-section__title" id="_i172"> Ethyl (3-{[6-(4-Fluoro-2-methoxyphenyl)pyrimidin-4-yl]amino}benzyl)propylphosphinate (<b>88</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(4-fluoro-2-methoxyphenyl)-pyrimidine <b>13k</b> (0.12 g, 0.5 mmol) and ethyl (3-aminophenyl)propylphosphinate·HCl <b>48</b> (0.146 g, 0.55 mmol) were reacted. The crude product was purified by chromathography in hexane:EtOAc (9:1). Evaporation of the fractions under reduced pressure provided a pale-yellow oil (0.05 g, 23%). <sup>31</sup>P NMR (CDCl<sub>3</sub>, 121 MHz): δ 52.6 ppm. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.76 (s, 1H), 7.98 (t, <i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 7.78 (s, 1H), 7.44 (s, 2H), 7.04–7.35 (m, 2H), 6.81 (d, <i>J</i><sub>HH</sub> = 7.5 Hz, 1H), 6.83 (t, <i>J</i><sub>HH</sub> = 8.5 Hz, 1H), 6.71 (d, <i>J</i><sub>HH</sub> = 8.5 Hz, 1H), 3.9–4.1 (m, 2H), 3.87 (s, 3H), 3.15 (d, <i>J</i><sub>PH</sub> = 16.0 Hz, 2H), 1.59–1.64 (m, 4H), 1.3 (t, <i>J</i><sub>HH</sub> = 7.0 Hz, 3H), 1.0 (t, <i>J</i><sub>HH</sub> = 7.5 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz): δ 164.7 (d, J<sub>FC</sub> = 249.7 Hz, 1C), 160.8 (d, <i>J</i><sub>PC</sub> = 8.4 Hz, 1C), 159.1 (d, <i>J</i><sub>PC</sub> = 10.0 Hz, 1C), 158.4 (s, 1C), 139.4 (d, <i>J</i><sub>PC</sub> = 2.7 Hz, 1C), 133.4 (d, <i>J</i><sub>PC</sub> = 7.2 Hz, 1C), 132.4 (d, <i>J</i><sub>PC</sub> = 10.3 Hz, 1C), 129.5 (d, <i>J</i><sub>PC</sub> = 2.6 Hz, 1C), 125.3 (d, <i>J</i><sub>PC</sub> = 2.6 Hz, 1C), 122.9 (d, <i>J</i><sub>PC</sub> = 3.3 Hz, 1C), 122.7 (s, 1C), 122.6 (s, 1C), 119.8 (d, J<sub>FC</sub> = 3.1 Hz, 1C), 107.8 (d, J<sub>FC</sub> = 21.2 Hz, 1C), 105.7 (s, 1C), 99.7 (d, <i>J</i><sub>PC</sub> = 25.8 Hz, 1C), 60.8 (d, <i>J</i><sub>PC</sub> = 6.8 Hz, 1C), 56.1 (s, 1C), 36.6 (d, <i>J</i><sub>PC</sub> = 83.6 Hz, 1C), 29.8 (d, <i>J</i><sub>PC</sub> = 92.5 Hz, 1C), 16.8 (d, <i>J</i><sub>PC</sub> = 5.6 Hz, 1C), 15.7 (d, <i>J</i><sub>PC</sub> = 5.6 Hz, 1C), 15.6 (d, <i>J</i><sub>PC</sub> = 5.6 Hz, 1C). LC-MS: <i>R</i><sub>t</sub> = 2.89 min. (ESI): <i>m</i>/<i>z</i> = 444 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_114" class="NLM_sec NLM_sec_level_3"><div id="ac_i173" class="anchor-spacer"></div><h4 class="article-section__title" id="_i173"> Ethyl [3-({6-[3-(Benzyloxy)phenyl]pyrimidin-4-yl}amino)benzyl]propylphosphinate (<b>89</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-[3-(benzyloxy)phenyl]-6-chloropyrimidine <b>13l</b> (0.241 g, 0.81 mmol) and ethyl (3-aminophenyl)propylphosphinate·HCl <b>48</b> (0.235 g, 0.89 mmol) were reacted. The crude product was purified by chromathography in hexane:EtOAc (9:1). Evaporation of the fractions under reduced pressure provided a pale-yellow oil (0.08 g, 20%). <sup>31</sup>P NMR (CDCl<sub>3</sub>, 121 MHz): δ 52.4 ppm. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz): δ 8.73 (s, 1H), 8.04 (s, 1H), 7.67 (s, 1H), 7.43–7.52 (m, 4H), 7.26–7.39 (m, 6H), 7.01–7.07 (m, 3H), 5.11 (s, 2H), 4.0 (m, 2H), 3.13 (d, <i>J</i><sub>PH</sub> = 16.0 Hz, 2H), 1.59–1.62 (m, 4H), 1.25 (t, <i>J</i><sub>HH</sub> = 8.0 Hz, 3H), 0.97 (t, <i>J</i><sub>HH</sub> = 7.5 Hz, 3H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 75 MHz): δ 163.2 (s, 1C), 161.6 (s, 1C), 159.4 (s, 1C), 158.8 (s, 1C), 139.3 (s, 1C), 139.2 (s, 1C), 139.1 (s, 1C), 136.9 (s, 1C), 133.4 (d, <i>J</i><sub>PC</sub> = 7.3 Hz, 1C), 129.9 (s, 1C), 129.7 (s, 1C), 129.7 (s, 1C), 128.7 (s, 2C), 128.2 (s, 1C), 127.7 (s, 2C), 125.5 (d, <i>J</i><sub>PC</sub> = 5.6 Hz, 1C), 122.9 (d, <i>J</i><sub>PC</sub> = 5.3 Hz, 1C), 120.2 (d, <i>J</i><sub>PC</sub> = 2.9 Hz, 1C), 119.7 (s, 1C), 117.1 (s, 1C), 113.4 (s, 1C), 101.2 (s, 1C), 70.3 (s, 1C), 60.8 (d, <i>J</i><sub>PC</sub> = 6.8 Hz, 1C), 36.6 (d, <i>J</i><sub>PC</sub> = 83.0 Hz, 1C), 30.4 (d, <i>J</i><sub>PC</sub> = 91.8 Hz, 1C), 16.8 (d, <i>J</i><sub>PC</sub> = 5.6 Hz, 1C), 15.8 (d, <i>J</i><sub>PC</sub> = 2.7 Hz, 1C), 15.6 (d, <i>J</i><sub>PC</sub> = 8.6 Hz, 1C). LC-MS: <i>R</i><sub>t</sub> = 3.58 min. (ESI): <i>m</i>/<i>z</i> = 502 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_115" class="NLM_sec NLM_sec_level_3"><div id="ac_i174" class="anchor-spacer"></div><h4 class="article-section__title" id="_i174"> Ethyl (3-{[6-(2-Ethylphenyl)pyrimidin-4-yl]amino}benzyl)propylphosphinate (<b>90</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-chloro-6-(2-ethylphenyl)pyrimidine <b>13m</b> (0.053 g, 0.24 mmol) and ethyl (3-aminophenyl)propylphosphinate·HCl <b>48</b> (0.067 g, 0.24 mmol) were reacted. The crude product was purified by preparative TLC with two elutions (100% EtOAc then EtOAc:EtOH (8:1)). The pure product was extracted from the silica with MeOH. After evaporation of the volatiles under reduced pressure, a white powder was obtained (0.016 g, 16%). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 121 MHz): δ 56.7 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.65 (s, 1H), 8.67 (s, 1H), 7.5–7.7 (m, 2H), 7.2–7.45 (m, 5H), 6.94 (d, <i>J</i><sub>HH</sub> = 7.2 Hz, 1H), 6.83 (s, 1H), 3.85–4.00 (m, 2H), 3.16 (d, <i>J</i><sub>PH</sub> = 16.8 Hz, 2H), 2.73 (q, <i>J</i><sub>HH</sub> = 7.2 Hz, 2H), 1.35–1.70 (m, 4H), 1.17 (t, <i>J</i><sub>HH</sub> = 6.9 Hz, 3H), 1.1 (t, <i>J</i><sub>HH</sub> = 7.5 Hz, 3H), 0.92 (t, <i>J</i><sub>HH</sub> = 6.9 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.05 min. (ESI): <i>m</i>/<i>z</i> = 423 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_116" class="NLM_sec NLM_sec_level_3"><div id="ac_i175" class="anchor-spacer"></div><h4 class="article-section__title" id="_i175"> Ethyl [3-({6-[2-(Benzyloxy)phenyl]pyrimidin-4-yl}amino)benzyl]ethylphosphinate (<b>91</b>)</h4><div class="NLM_p last">According to the general coupling procedure, 4-[2-(benzyloxy)phenyl]-6-chloropyrimidine <b>13g</b> (0.593 g, 2.0 mmol) and ethyl (3-aminophenyl)ethylphosphinate·HCl <b>47</b> (0.553 g, 2.1 mmol) were reacted. The crude product was purified by flash chromathography in 100% EtOAc. After evaporation of the fractions under reduced pressure, the desired compound was isolated as white crystals (0.312 g, 32%); mp = 61–62 °C (EtOAc). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 121 MHz): δ 53.9 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.6 (s, 1H), 8.69 (s, 1H), 7.84 (d, <i>J</i><sub>HH</sub> = 6.9 Hz, 1H), 7.5–7.6 (m, 2H), 7.15–7.5 (m, 9H), 7.08 (t, <i>J</i><sub>HH</sub> = 7.2 Hz, 1H), 6.94 (d, <i>J</i><sub>HH</sub> = 7.2 Hz, 1H), 5.26 (s, 2H), 3.85–4.0 (m, 2H), 3.15 (d, <i>J</i><sub>PH</sub> = 16.5 Hz, 2H), 1.55–1.7 (m, 2H), 1.17 (t, <i>J</i><sub>HH</sub> = 7.2 Hz, 3H), 0.99 (dt, <i>J</i><sub>PH</sub> = 17.7 Hz, <i>J</i><sub>HH</sub> = 7.7 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 3.11 min. (ESI): <i>m</i>/<i>z</i> = 487 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_117" class="NLM_sec NLM_sec_level_3"><div id="ac_i176" class="anchor-spacer"></div><h4 class="article-section__title" id="_i176"> [3-({6-[2-(Benzyloxy)phenyl]pyrimidin-4-yl}amino)benzyl]ethylphosphinic Acid (<b>92</b>)</h4><div class="NLM_p last">Hydrolysis of the ester <b>91</b> (0.136 g, 0.28 mmol) was carried out according to the method described for compound <b>61</b>, providing a yellow oil (0.025 g, 19%). <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 121 MHz): δ 29.8 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 9.99 (s, 1H), 8.63 (s, 1H), 7.79 (d, <i>J</i><sub>HH</sub> = 6.9 Hz, 1H), 7.59 (d, <i>J</i><sub>HH</sub> = 7.2 Hz, 1H), 7.2–7.5 (m, 8H), 7.16 (d, <i>J</i><sub>HH</sub> = 8.4 Hz, 1H), 7.0–7.1 (m, 2H), 6.85 (d, <i>J</i><sub>HH</sub> = 6.9 Hz, 1H), 5.24 (s, 2H), 2.62 (d, <i>J</i><sub>PH</sub> = 16.2 Hz, 2H), 1.0–1.15 (m, 2H), 0.88 (dt, <i>J</i><sub>PH</sub> = 15.3 Hz, <i>J</i><sub>HH</sub> = 6.9 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 0.44 and 2.79 min. (ESI): <i>m</i>/<i>z</i> = 459 [M + H]<sup>+</sup>.</div></div><div id="sec5_1_118" class="NLM_sec NLM_sec_level_3"><div id="ac_i177" class="anchor-spacer"></div><h4 class="article-section__title" id="_i177"> [3-({6-[2-(Benzyloxy)phenyl]pyrimidin-4-yl}amino)benzyl]propylphosphinic Acid (<b>93</b>)</h4><div class="NLM_p last">Hydrolysis of the ester <b>84</b> (0.14 g, 0.28 mmol) was carried out according to the method described for compound <b>61</b>, yielding a yellow oil (0.06 g, 45%). It crystallizes upon standing; mp = 238–240 °C. <sup>31</sup>P NMR (DMSO-<i>d</i><sub>6</sub>, 121 MHz): DMSO, δ 32.3 ppm. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 10.08 (s, 1H), 8.63 (s, 1H), 7.78 (d, <i>J</i><sub>HH</sub> = 7.8 Hz, 1H), 7.61 (d, <i>J</i><sub>HH</sub> = 6.9 Hz, 1H), 7.2–7.6 (m, 8H), 7.17 (d, <i>J</i><sub>HH</sub> = 8.1 Hz, 1H), 7.0–7.1 (m, 2H), 6.84 (d, <i>J</i><sub>HH</sub> = 7.2 Hz, 1H), 5.24 (s, 2H), 2.64 (d, <i>J</i><sub>PH</sub> = 15.6 Hz, 2H), 1.3–1.5 (m, 2H), 1.0–1.2 (m, 2H), 0.8 (t, <i>J</i><sub>HH</sub> = 6.6 Hz, 3H). LC-MS: <i>R</i><sub>t</sub> = 2.90 min. (ESI): <i>m</i>/<i>z</i> = 473 [M + H]<sup>+</sup>.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i178" class="anchor-spacer"></div><h3 class="article-section__title" id="_i178"> Biology</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i179" class="anchor-spacer"></div><h4 class="article-section__title" id="_i179"> Protocol for CDK9/Cyclin T1 Kinase Assay</h4><div class="NLM_p last">CDK9/CycT1 kinase assays were performed in low protein binding 384-well plates (Corning 3676). Test compounds were diluted in 100% DMSO to 5 mM stock concentration, and then further dilutions were made in H<sub>2</sub>O or 100% DMSO to desirable concentrations. Each reaction consisted of 5 nM enzyme: CDK9/CyclinT1 (Proqinase catalogue no. 0371-0345-1), 400 nM TAMRA-Rbtide (synthetic 15-mer peptide derived from human retinoblastoma tumor suppressor protein labeled with TAMRA dye, Genecust Europe), 12 μM ATP (= Kmapp, Sigma-Aldrich) and kinase buffer: 20 mM MOPS pH 7 (Sigma-Aldrich), 1 mM DTT (Sigma-Aldrich), 10 mM MgCl<sub>2</sub> (Sigma-Aldrich), 0.01% Tween 20 (Sigma-Aldrich). For each reaction, 4 or 6 μL containing TAMRA-Rbtide, ATP, and kianse buffer were combined with 2 μL of diluted compound in H<sub>2</sub>O or 0.028 μL of compound in 100% DMSO. The kinase reaction was started by the addition of 2 μL of diluted enzyme. The reaction was allowed to run for 1 h at room temperature. The reaction was stopped by adding 15 μL of IMAP beads (1:400 beads in progressive (100% buffer A) 1× buffer). After an additional 1 h, fluorescent polarization (Ex, 550–10 nm; Em, 590–10 nm; Dich, 561 nm) was measured using an Analyst GT (Molecular devices). IC<sub>50</sub> curves were fitted with XLfit curve fitting software.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i180" class="anchor-spacer"></div><h4 class="article-section__title" id="_i180"> Protocol for CDK2/Cyclin E and CDK4/Cyclin D1 Kinase Assays</h4><div class="NLM_p last">The percentage of inhibition for CDK2/CycE; CDK4/CycD1 were determined by our partners under contract work. These CDK/cyclin protein kinase complexes were assayed using IMAP FAM FP assay method. Assays were performed in low protein binding 384-well plates (Corning 3676). Test compounds were diluted in 100% DMSO to 10 mM stock concentration, and then further dilutions were made in 100% DMSO to desirable concentrations in 384-well polypropylene plate (Falcon, 3995). Kinase specific FAM labeled peptide substrate was used in 400 nM. Optimal kinase buffer conditions were determined for each CDK kinase. ATP concentration was used at the KmATP, app. Kinase concentration used to yield 50% substrate turnover as determined in titration experiment. Optimal kinase incubation time was determined for each kinase: 6 μL of specific FAM-substrate + ATP in reaction buffer were added to each well. Then 10.8 nL of test compound in 100% DMSO was added to wells using Pintool. Then 2 μL of reaction buffer was added to C-wells, and 2 μL of kinase in reaction buffer were added to wells except C-wells. After kinase incubation period, 15 μL of IMAP binding solution were added to each well. After IMAP incubation period, fluorescence polarization (Ex, 485–20 nm; Em, 530–25 nm; Dich, 505 nm) was measured on Analyst GT (Molecular Devices)</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i181" class="anchor-spacer"></div><h4 class="article-section__title" id="_i181"> Protocol for Viability of MT4 Cell Lines Assay (MTT Assay)</h4><div class="NLM_p last">The cytotoxic effect of selected compounds was measured by means of the colorimetric assay (MTT). Briefly, 2–3 × 10<sup>4</sup> MT4 cells per well were cultured in 96-well plates containing RPMI1640 medium supplemented with 10% FCS and antibiotics (100 IU/mL penicillin (SIGMA), 100 μg/mL streptomycin (SIGMA)), and two concentrations of the compounds to be tested (2500 and 1250 nM). After 7 days of incubation (37 °C, 5% CO<sub>2</sub> atmosphere), 20 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; 5 mg/mL dissolved in PBS) was added to each well. After incubation for 4 h, the cell supernatant was removed and (according our modification) 100 μL of DMSO was added, and the contents were mixed thoroughly. The absorbance was measured at 540 nm.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i182" class="anchor-spacer"></div><h4 class="article-section__title" id="_i182"> Determination of the Viability of HIV-1 Infected MT4 cells</h4><div class="NLM_p last">To assess the anti-HIV-1 effects of selected compounds, MT4 cells were cultivated as described above, treated with test compounds (1250 nM), and infected with HIV-1 (strain HTLV-IIIB; 3400 TCID<sub>50</sub>/mL HIV-1/well was used). The TCID<sub>50</sub> (50% tissue culture infectious dose) of HIV-1 was determined by a virus yield assay. The effects of HIV-1 on the viability of infected MT4 cells were measured by MTT assay in the presence or absence of test compounds.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i183"><a href="/doi/suppl/10.1021/jm401742r">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77160" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77160" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Predicted and measured ADME-T properties of selected compounds. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm401742r/suppl_file/jm401742r_si_001.pdf">jm401742r_si_001.pdf (150.67 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm401742r" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06404" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06404" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gábor Németh</span> - <span class="hlFld-Affiliation affiliation">Vichem
Chemie Ltd., Budapest 1022, Hungary</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#b2d5dcd7dfd7c6daf2c4dbd1dad7df9cdac7"><span class="__cf_email__" data-cfemail="8bece5eee6eeffe3cbfde2e8e3eee6a5e3fe">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zoltán Greff</span> - <span class="hlFld-Affiliation affiliation">Vichem
Chemie Ltd., Budapest 1022, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Sipos</span> - <span class="hlFld-Affiliation affiliation">Vichem
Chemie Ltd., Budapest 1022, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zoltán Varga</span> - <span class="hlFld-Affiliation affiliation">Vichem
Chemie Ltd., Budapest 1022, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rita Székely</span> - <span class="hlFld-Affiliation affiliation">Vichem
Chemie Ltd., Budapest 1022, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mónika Sebestyén</span> - <span class="hlFld-Affiliation affiliation">Department
of Organic Chemistry and Technology, Budapest
University of Technology and Economics, Budapest 1111, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zsuzsa Jászay</span> - <span class="hlFld-Affiliation affiliation">Department
of Organic Chemistry and Technology, Budapest
University of Technology and Economics, Budapest 1111, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Szabolcs Béni</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Chemistry, Semmelweis
University, Budapest 1092, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zoltán Nemes</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Chemistry, Semmelweis
University, Budapest 1092, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jean-Luc Pirat</span> - <span class="hlFld-Affiliation affiliation">Institut
Charles Gerhardt UMR5253, AM2N, ENSCM, Montpellier 34296  cedex
5, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jean-Noël Volle</span> - <span class="hlFld-Affiliation affiliation">Institut
Charles Gerhardt UMR5253, AM2N, ENSCM, Montpellier 34296  cedex
5, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David Virieux</span> - <span class="hlFld-Affiliation affiliation">Institut
Charles Gerhardt UMR5253, AM2N, ENSCM, Montpellier 34296  cedex
5, France</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ágnes Gyuris</span> - <span class="hlFld-Affiliation affiliation">RT
Europe Research Center, Mosonmagyaróvár 9200, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katalin Kelemenics</span> - <span class="hlFld-Affiliation affiliation">GalenBio
Ltd., Mosonmagyaróvár 9200, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Éva Áy</span> - <span class="hlFld-Affiliation affiliation">Microbiological
Research Group, National Center for Epidemiology, Budapest 1097, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Janos Minarovits</span> - <span class="hlFld-Affiliation affiliation">Microbiological
Research Group, National Center for Epidemiology, Budapest 1097, Hungary</span>; 
    <span class="hlFld-Affiliation affiliation">Faculty
of Dentistry, Department of Oral Biology and Experimental Dental Research, University of Szeged, Szeged 6720, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan Szathmary</span> - <span class="hlFld-Affiliation affiliation">GalenBio
Ltd., Mosonmagyaróvár 9200, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">György Kéri</span> - <span class="hlFld-Affiliation affiliation">Vichem
Chemie Ltd., Budapest 1022, Hungary</span>; 
    <span class="hlFld-Affiliation affiliation">MTA-SE
Pathobichemistry Research Group, Department of Medical Chemistry,
Molecular Biology and Pathobiochemistry, Semmelweis University, Budapest 1094, Hungary</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">László Őrfi</span> - <span class="hlFld-Affiliation affiliation">Vichem
Chemie Ltd., Budapest 1022, Hungary</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pharmaceutical Chemistry, Semmelweis
University, Budapest 1092, Hungary</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d1187e19411-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i184">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50104" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50104" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This project was supported in part by a National Innovation Office grant (TECH_08_A2-STEMKILL). G.N. thanks the French Government Grant for financing his stay at ENSCM and Dr. Leo Leung for his useful suggestions in the manuscript preparation. Sz. B. thanks the Hungarian Academy of Sciences for the financial support under the János Bolyai Research Scholarship and OTKA PD 109373. We thank Ferenc Baska for Schrödinger predictions.</p></div><div class="postAsapNotesSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="postAsapNotesSection">Note Added After ASAP Publication</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38517" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38517" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="first last">This paper was published ASAP on May 2, 2014. The spelling of an author’s name was corrected and the revised version was reposted on May 6, 2014. A change was made to Scheme 10 and the revised version was reposted on May 22, 2014.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i185" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i185"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i186" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i186"> Abbreviations Used</h2><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">AZT</td><td class="NLM_def"><p class="first last">azidothymidine</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin dependent kinase</p></td></tr><tr><td class="NLM_term">Ctrl</td><td class="NLM_def"><p class="first last">control</p></td></tr><tr><td class="NLM_term">Cyc</td><td class="NLM_def"><p class="first last">cyclin</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">U.S. Food and Drug Administration</p></td></tr><tr><td class="NLM_term">HIV</td><td class="NLM_def"><p class="first last">human immunodeficiency virus</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term">KI</td><td class="NLM_def"><p class="first last">potassium iodide</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>i</sub></td><td class="NLM_def"><p class="first last">binding affinity</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>mATP</sub></td><td class="NLM_def"><p class="first last">dissociation constant of the kinase and the ATP</p></td></tr><tr><td class="NLM_term">Pd/C</td><td class="NLM_def"><p class="first last">palladium on charcoal</p></td></tr><tr><td class="NLM_term">RNA</td><td class="NLM_def"><p class="first last">ribonucleic acid</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">TMSCl</td><td class="NLM_def"><p class="first last">trimethylsilyl chloride</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i187">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15271" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15271" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 43 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alessi, D. R.</span><span> </span><span class="NLM_article-title">Kinase drug discovery—what’s next in the field?</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span></span><div class="citationLinks">[<a href="/doi/10.1021/cb300610s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=96-104&author=P.+Cohenauthor=D.+R.+Alessi&title=Kinase+drug+discovery%E2%80%94what%E2%80%99s+next+in+the+field%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fcb300610s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300610s%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26atitle%3DKinase%2520drug%2520discovery%25E2%2580%2594what%25E2%2580%2599s%2520next%2520in%2520the%2520field%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D96%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="7b3f090e1c083b3d3f3a">[email protected]</a>: FDA Approved Drug Products; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>; <a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm" class="extLink">http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm</a>, accessed on November 12, 2013.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Drugs%40FDA%3A+FDA+Approved+Drug+Products%3B+U.S.+Food+and+Drug+Administration%3A+Silver+Spring%2C+MD%3B+http%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcder%2Fdrugsatfda%2Findex.cfm%2C+accessed+on+November+12%2C+2013."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%2540FDA%253A%2520FDA%2520Approved%2520Drug%2520Products%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Fisher, R. P.</span><span> </span><span class="NLM_article-title">The CDK Network: Linking Cycles of Cell Division and Gene Expression</span> <span class="citation_source-journal">Genes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">731</span><span class="NLM_x">–</span> <span class="NLM_lpage">738</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1177%2F1947601912473308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=23634260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A280%3ADC%252BC3srpvV2itA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=731-738&author=R.+P.+Fisher&title=The+CDK+Network%3A+Linking+Cycles+of+Cell+Division+and+Gene+Expression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The CDK Network: Linking Cycles of Cell Division and Gene Expression</span></div><div class="casAuthors">Fisher Robert P</div><div class="citationInfo"><span class="NLM_cas:title">Genes & cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11-12</span>),
    <span class="NLM_cas:pages">731-8</span>
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) play essential roles in cell proliferation and gene expression.  Although distinct sets of CDKs work in cell division and transcription by RNA polymerase II (Pol II), they share a CDK-activating kinase (CAK), which is itself a CDK-Cdk7-in metazoans.  Thus a unitary CDK network controls and may coordinate cycles of cell division and gene expression.  Recent work reveals decisive roles for Cdk7 in both pathways.  The CAK function of Cdk7 helps determine timing of activation and cyclin-binding preferences of different CDKs during the cell cycle.  In the transcription cycle, Cdk7 is both an effector kinase, which phosphorylates Pol II and other proteins and helps establish promoter-proximal pausing; and a CAK for Cdk9 (P-TEFb), which releases Pol II from the pause.  By governing the transition from initiation to elongation, Cdk7, Cdk9 and their substrates influence expression of genes important for developmental and cell-cycle decisions, and ensure co-transcriptional maturation of Pol II transcripts.  Cdk7 engaged in transcription also appears to be regulated by phosphorylation within its own activation (T) loop.  Here I review recent studies of CDK regulation in cell division and gene expression, and propose a model whereby mitogenic signals trigger a cascade of CDK T-loop phosphorylation that drives cells past the restriction (R) point, when continued cell-cycle progression becomes growth factor-independent.  Because R-point control is frequently deregulated in cancer, the CAK-CDK pathway is an attractive target for chemical inhibition aimed at impeding the inappropriate commitment to cell division.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS_ZrSWKg0eO3y-c-E1v-fmfW6udTcc2eZEGWcHznzIt7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srpvV2itA%253D%253D&md5=24c36366f64a3d308b3453ceeb453243</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1177%2F1947601912473308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601912473308%26sid%3Dliteratum%253Aachs%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DThe%2520CDK%2520Network%253A%2520Linking%2520Cycles%2520of%2520Cell%2520Division%2520and%2520Gene%2520Expression%26jtitle%3DGenes%2520Cancer%26date%3D2012%26volume%3D3%26spage%3D731%26epage%3D738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Cicenas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valius, M.</span><span> </span><span class="NLM_article-title">The CDK inhibitors in cancer research and therapy</span> <span class="citation_source-journal">J. Cancer Res. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">1409</span><span class="NLM_x">–</span> <span class="NLM_lpage">1418</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1007%2Fs00432-011-1039-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=21877198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFynt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2011&pages=1409-1418&author=J.+Cicenasauthor=M.+Valius&title=The+CDK+inhibitors+in+cancer+research+and+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The CDK inhibitors in cancer research and therapy</span></div><div class="casAuthors">Cicenas, Jonas; Valius, Mindaugas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer Research and Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1409-1418</span>CODEN:
                <span class="NLM_cas:coden">JCROD7</span>;
        ISSN:<span class="NLM_cas:issn">0171-5216</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Chem. compds. that interfere with an enzymic function of kinases are useful for gaining insight into the complicated biochem. processes in mammalian cells.  Cyclin-dependent kinases (CDK) play an essential role in the control of the cell cycle and/or proliferation.  These kinases as well as their regulators are frequently deregulated in different human tumors.  Aberrations in CDK activity have also been obsd. in viral infections, Alzheimer's, Parkinson's diseases, ischemia and some proliferative disorders.  This led to an intensive search for small-mol. CDK inhibitors not only for research purposes, but also for therapeutic applications.  Here, we discuss seventeen CDK inhibitors and their use in cancer research or therapy.  This review should help researchers to decide which inhibitor is best suited for the specific purpose of their research.  For this purpose, the targets, com. availability and IC50 values are provided for each inhibitor.  The review will also provide an overview of the clin. studies performed with some of these inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEjNnnzkVahrVg90H21EOLACvtfcHk0lhu3ozAQwMWkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFynt7rK&md5=85500301e1d113148cf7854125e542ab</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2Fs00432-011-1039-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00432-011-1039-4%26sid%3Dliteratum%253Aachs%26aulast%3DCicenas%26aufirst%3DJ.%26aulast%3DValius%26aufirst%3DM.%26atitle%3DThe%2520CDK%2520inhibitors%2520in%2520cancer%2520research%2520and%2520therapy%26jtitle%3DJ.%2520Cancer%2520Res.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D137%26spage%3D1409%26epage%3D1418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Németh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varga, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greff, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bencze, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sipos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szántai-Kis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baska, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gyuris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelemenics, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szathmáry, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minárovits, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kéri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orfi, L.</span><span> </span><span class="NLM_article-title">Novel, Selective CDK9 Inhibitors for the Treatment of HIV Infection</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">358</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.2174%2F092986711794839188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=21143121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslahtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=342-358&author=G.+N%C3%A9methauthor=Z.+Vargaauthor=Z.+Greffauthor=G.+Benczeauthor=A.+Siposauthor=C.+Sz%C3%A1ntai-Kisauthor=F.+Baskaauthor=A.+Gyurisauthor=K.+Kelemenicsauthor=Z.+Szathm%C3%A1ryauthor=J.+Min%C3%A1rovitsauthor=G.+K%C3%A9riauthor=L.+Orfi&title=Novel%2C+Selective+CDK9+Inhibitors+for+the+Treatment+of+HIV+Infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Novel, selective CDK9 inhibitors for the treatment of HIV infection</span></div><div class="casAuthors">Nemeth, G.; Varga, Z.; Greff, Z.; Bencze, G.; Sipos, A.; Szantai-Kis, C.; Baska, F.; Gyuris, A.; Kelemenics, K.; Szathmary, Z.; Minarovits, J.; Keri, G.; Orfi, L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">342-358</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cyclin Dependent Kinases (CDKs) are important regulators of cell cycle and gene expression.  Since an up-to-date review about the pharmacol. inhibitors of CDK family (CDK1-10) is not available; therefore in the present paper we briefly summarize the most relevant inhibitors and point out the low no. of selective inhibitors.  Among CDKs, CDK9 is a validated pathol. target in HIV infection, inflammation and cardiac hypertrophy; however selective CDK9 inhibitors are still not available.  We present a selective inhibitor family of CDK9 based on the 4-phenylamino-6-phenylpyrimidine nucleus.  We show a convenient synthetic method to prep. a useful intermediate and its derivatisation resulting in novel compds.  The CDK9 inhibitory activity of the derivs. was measured in specific kinase assay and the CDK inhibitory profile of the best ones (IC50 < 100nM) was detd.  The most selective compds. had high selectivity over CDK1, 2, 3, 5, 6, 7 and showed at least one order of magnitude higher inhibitory activity over CDK4 inhibition.  The most selective mols. were examd. in cytotoxicity assays and their ability to inhibit HIV-1 replication was detd. in cellular assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-AaopHRq0S7Vg90H21EOLACvtfcHk0liZjI2pbZz8Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslahtr4%253D&md5=2777a90d212ded68b2399beb97d48531</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2174%2F092986711794839188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711794839188%26sid%3Dliteratum%253Aachs%26aulast%3DN%25C3%25A9meth%26aufirst%3DG.%26aulast%3DVarga%26aufirst%3DZ.%26aulast%3DGreff%26aufirst%3DZ.%26aulast%3DBencze%26aufirst%3DG.%26aulast%3DSipos%26aufirst%3DA.%26aulast%3DSz%25C3%25A1ntai-Kis%26aufirst%3DC.%26aulast%3DBaska%26aufirst%3DF.%26aulast%3DGyuris%26aufirst%3DA.%26aulast%3DKelemenics%26aufirst%3DK.%26aulast%3DSzathm%25C3%25A1ry%26aufirst%3DZ.%26aulast%3DMin%25C3%25A1rovits%26aufirst%3DJ.%26aulast%3DK%25C3%25A9ri%26aufirst%3DG.%26aulast%3DOrfi%26aufirst%3DL.%26atitle%3DNovel%252C%2520Selective%2520CDK9%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520HIV%2520Infection%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D342%26epage%3D358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Guha, M.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase inhibitors move into Phase III</span> <span class="citation_source-journal">Nature Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">892</span><span class="NLM_x">–</span> <span class="NLM_lpage">894</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=892-894&author=M.+Guha&title=Cyclin-dependent+kinase+inhibitors+move+into+Phase+III"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuha%26aufirst%3DM.%26atitle%3DCyclin-dependent%2520kinase%2520inhibitors%2520move%2520into%2520Phase%2520III%26jtitle%3DNature%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D892%26epage%3D894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Canduri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caceres, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Azevedo, W. F.,  Jr.</span><span> </span><span class="NLM_article-title">CDK9 a potential target for drug development</span> <span class="citation_source-journal">Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.2174%2F157340608784325205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=18473913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtFamtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=210-218&author=F.+Canduriauthor=P.+C.+Perezauthor=R.+A.+Caceresauthor=W.+F.+de+Azevedo&title=CDK9+a+potential+target+for+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">CDK9 a potential target for drug development</span></div><div class="casAuthors">Canduri, Fernanda; Perez, Patricia Cardoso; Caceres, Rafael Andrade; Filgueira de Azevedo, Walter, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">210-218</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The family of cyclin-dependent kinases (CDKs) can be subdivided into 2 major functional groups based on their roles in cell cycle and/or transcriptional control.  CDK9 is the catalytic subunit of pos. transcription elongation factor b (P-TEFb).  CDK9 is the kinase of the TAK complex (Tat-assocd. kinase complex), and binds to Tat protein of HIV virus, suggesting a possible role for CDK9 in AIDS progression.  CDK9 complexed with its regulatory partner, cyclin T1, serves as a cellular mediator of the transactivation function of the HIV virus Tat protein.  P-TEFb is responsible for the phosphorylation of the C-terminal domain of RNA polymerase II, resulting in stimulation of transcription.  Furthermore, the complexes contg. CDK9 induce differentiation in distinct tissues.  The CDK9/cyclin T1 complex is expressed at higher levels in more differentiated primary neuroectodermal and neuroblastoma tumors, showing a correlation between kinase expression and tumor differentiation grade.  This may have clin. and therapeutical implications for these tumor types.  Among CDK inhibitors, 2 have been shown to be effective against CDK9; these are rescovitine and flavopiridol.  These 2 inhibitors have prevented the replication of HIV-1 virus by blocking Tat transactivation of the HIV-1 promoter.  These compds. inhibit CDKs by binding to the catalytic domain in place of ATP, preventing transfer of a phosphate group to the substrate.  More sensitive therapeutic agents of CDK9 can be designed, and structural studies can add information for the further understanding of this kinase.  Major features related to CDK9 inhibition are reviewed by the authors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpROfAvp0vSGbVg90H21EOLACvtfcHk0liZjI2pbZz8Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtFamtro%253D&md5=390603a893aead917c500a56e2367bb1</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F157340608784325205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157340608784325205%26sid%3Dliteratum%253Aachs%26aulast%3DCanduri%26aufirst%3DF.%26aulast%3DPerez%26aufirst%3DP.%2BC.%26aulast%3DCaceres%26aufirst%3DR.%2BA.%26aulast%3Dde%2BAzevedo%26aufirst%3DW.%2BF.%26atitle%3DCDK9%2520a%2520potential%2520target%2520for%2520drug%2520development%26jtitle%3DMed.%2520Chem.%26date%3D2008%26volume%3D4%26spage%3D210%26epage%3D218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">302</span><span class="NLM_x">–</span> <span class="NLM_lpage">313</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=302-313&author=S.+Wangauthor=P.+M.+Fischer&title=Cyclin-dependent+kinase+9%3A+a+key+transcriptional+regulator+and+potential+drug+target+in+oncology%2C+virology+and+cardiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3DCyclin-dependent%2520kinase%25209%253A%2520a%2520key%2520transcriptional%2520regulator%2520and%2520potential%2520drug%2520target%2520in%2520oncology%252C%2520virology%2520and%2520cardiology%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2008%26volume%3D29%26spage%3D302%26epage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Romano1, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, A.</span><span> </span><span class="NLM_article-title">Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">3664</span><span class="NLM_x">–</span> <span class="NLM_lpage">3668</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=3664-3668&author=G.+Romano1author=A.+Giordano&title=Role+of+the+cyclin-dependent+kinase+9-related+pathway+in+mammalian+gene+expression+and+human+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRomano1%26aufirst%3DG.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DRole%2520of%2520the%2520cyclin-dependent%2520kinase%25209-related%2520pathway%2520in%2520mammalian%2520gene%2520expression%2520and%2520human%2520diseases%26jtitle%3DCell%2520Cycle%26date%3D2008%26volume%3D7%26spage%3D3664%26epage%3D3668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Price, D. H.</span><span> </span><span class="NLM_article-title">P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2629</span><span class="NLM_x">–</span> <span class="NLM_lpage">2634</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1128%2FMCB.20.8.2629-2634.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=10733565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BD3cXit1ymur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=2629-2634&author=D.+H.+Price&title=P-TEFb%2C+a+cyclin-dependent+kinase+controlling+elongation+by+RNA+polymerase+II"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II</span></div><div class="casAuthors">Price, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2629-2634</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review with 85 refs.  The topics discussed include identification of P-TEFb, cyclin dependence of P-TEFb, involvement of P-TEFb in HIV TAT transactivation, and mechanism of P-TEFb action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ1NqxL4k-67Vg90H21EOLACvtfcHk0liyg1gHh0vuBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXit1ymur0%253D&md5=3a1cfd6f46d2fa10d873497614bc99e3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1128%2FMCB.20.8.2629-2634.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.20.8.2629-2634.2000%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DD.%2BH.%26atitle%3DP-TEFb%252C%2520a%2520cyclin-dependent%2520kinase%2520controlling%2520elongation%2520by%2520RNA%2520polymerase%2520II%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2000%26volume%3D20%26spage%3D2629%26epage%3D2634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">1216</span><span class="NLM_x">–</span> <span class="NLM_lpage">1226</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1002%2Fijc.26127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=21484792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Cgu7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2012&pages=1216-1226&author=X.+Liuauthor=S.+Shiauthor=F.+Lamauthor=C.+Pepperauthor=P.+M.+Fischerauthor=S.+Wang&title=CDKI-71%2C+a+novel+CDK9+inhibitor%2C+is+preferentially+cytotoxic+to+cancer+cells+compared+to+flavopiridol"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol</span></div><div class="casAuthors">Liu, Xiangrui; Shi, Shenhua; Lam, Frankie; Pepper, Chris; Fischer, Peter M.; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1216-1226</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Cancer cells appear to depend heavily on antiapoptotic proteins for survival and so targeted inhibition of these proteins has therapeutic potential.  One innovative strategy is to inhibit the cyclin-dependent kinases (CDKs) responsible for the regulation of RNA polymerase II (RNAPII).  In our study, we investigated the detailed cellular mechanism of a novel small-mol. CDK inhibitor (CDKI-71) in cancer cell lines, primary leukemia cells, normal B - & T- cells, and embryonic lung fibroblasts and compared the cellular and mol. responses to the clin. CDK inhibitor, flavopiridol.  Like flavopiridol, CDKI-71 displayed potent cytotoxicity and caspase-dependent apoptosis induction that were closely assocd. with the inhibition of RNAPII phosphorylation at serine-2.  This was caused by effective targeting of cyclinT-CDK9 and resulted in the downstream inhibition of Mcl-1.  No correlation between apoptosis and inhibition of cell-cycle CDKs 1 and 2 was obsd.  CDKI-71 showed a 10-fold increase in potency in tumor cell lines when compared to MRC-5 human fibroblast cells.  Significantly, CDKI-71 also demonstrated potent anti-chronic lymphocytic leukemia activity with minimal toxicity in normal B- and T-cells.  In contrast, flavopiridol showed little selectivity between cancer and normal cells.  Here, we provide the first cell-based evidence that flavopiridol induces DNA double-strand breaks: a fact which may explain why flavopiridol has such a narrow therapeutic window in preclin. and clin. settings.  Taken together, our data provide a rationale for the development of selective CDK inhibitors as therapeutic agents and CDKI-71 represents a promising lead in this context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4fhWaal47LrVg90H21EOLACvtfcHk0liyg1gHh0vuBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Cgu7vP&md5=61b9dd817cb49855a436af69638a28f6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fijc.26127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.26127%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DLam%26aufirst%3DF.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DCDKI-71%252C%2520a%2520novel%2520CDK9%2520inhibitor%252C%2520is%2520preferentially%2520cytotoxic%2520to%2520cancer%2520cells%2520compared%2520to%2520flavopiridol%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2012%26volume%3D130%26spage%3D1216%26epage%3D1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Hussain, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheney, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span> </span><span class="NLM_article-title">Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2144</span><span class="NLM_x">–</span> <span class="NLM_lpage">2150</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1158%2F1078-0432.CCR-06-2294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=17404098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs12rt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=2144-2150&author=S.+R.+Hussainauthor=C.+M.+Cheneyauthor=A.+J.+Johnsonauthor=T.+S.+Linauthor=M.+R.+Greverauthor=M.+A.+Caligiuriauthor=D.+M.+Lucasauthor=J.+C.+Byrd&title=Mcl-1+is+a+relevant+therapeutic+target+in+acute+and+chronic+lymphoid+malignancies%3A+down-regulation+enhances+rituximab-mediated+apoptosis+and+complement-dependent+cytotoxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity</span></div><div class="casAuthors">Hussain, Syed-Rehan A.; Cheney, Carolyn M.; Johnson, Amy J.; Lin, Thomas S.; Grever, Michael R.; Caligiuri, Michael A.; Lucas, David M.; Byrd, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2144-2150</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The antiapoptotic Bcl-2 family member protein Mcl-1 is dynamically regulated in transformed B-cells, has a short mRNA and protein half-life, and is rapidly processed during apoptosis.  Multiple therapies cause down-regulation of Mcl-1 in chronic and acute lymphoid leukemia (CLL and ALL) cells.  Mcl-1 has also been reported to mediate resistance to rituximab in CLL.  We therefore investigated whether direct redn. of Mcl-1 was sufficient to induce apoptosis and increase sensitivity to rituximab.  Exptl. Design: We used Mcl-1-specific small interfering RNA in ALL cell lines and tumor cells from CLL patients to block transcription of Mcl-1.  RESULTS: We show that Mcl-1 down-regulation alone is sufficient to promote mitochondrial membrane depolarization and apoptosis in ALL and CLL cells.  Given the importance of rituximab in B-cell malignancies, we next assessed the influence of Mcl-1 down-regulation on antibody-mediated killing.  Mcl-1 down-regulation by small interfering RNA increased sensitivity to rituximab-mediated killing both by direct apoptosis and complement-dependent cytotoxicity, but did not enhance antibody-dependent cellular cytotoxicity.  CONCLUSIONS: These results show that Mcl-1 is a relevant therapeutic target for ALL and CLL, and its down-regulation has the potential to enhance the therapeutic effect of rituximab in CD20-bearing lymphoid cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF8amg4BQHg7Vg90H21EOLACvtfcHk0liyg1gHh0vuBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs12rt7c%253D&md5=23c6d82b7bfb48083888967329fdc1c9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-2294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-2294%26sid%3Dliteratum%253Aachs%26aulast%3DHussain%26aufirst%3DS.%2BR.%26aulast%3DCheney%26aufirst%3DC.%2BM.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DLin%26aufirst%3DT.%2BS.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DLucas%26aufirst%3DD.%2BM.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26atitle%3DMcl-1%2520is%2520a%2520relevant%2520therapeutic%2520target%2520in%2520acute%2520and%2520chronic%2520lymphoid%2520malignancies%253A%2520down-regulation%2520enhances%2520rituximab-mediated%2520apoptosis%2520and%2520complement-dependent%2520cytotoxicity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D2144%26epage%3D2150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Natoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murillo, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kliszczak, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catherwood, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montagnoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samali, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santocanale, C.</span><span> </span><span class="NLM_article-title">Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1624</span><span class="NLM_x">–</span> <span class="NLM_lpage">1634</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1158%2F1535-7163.MCT-10-1119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=21768328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCjurjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=1624-1634&author=A.+Natoniauthor=L.+S.+Murilloauthor=A.+E.+Kliszczakauthor=M.+A.+Catherwoodauthor=A.+Montagnoliauthor=A.+Samaliauthor=M.+O%E2%80%99Dwyerauthor=C.+Santocanale&title=Mechanisms+of+action+of+a+dual+Cdc7%2FCdk9+kinase+inhibitor+against+quiescent+and+proliferating+CLL+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Action of a Dual Cdc7/Cdk9 Kinase Inhibitor against Quiescent and Proliferating CLL Cells</span></div><div class="casAuthors">Natoni, Alessandro; Murillo, Laura S.; Kliszczak, Anna E.; Catherwood, Mark A.; Montagnoli, Alessia; Samali, Afshin; O'Dwyer, Michael; Santocanale, Corrado</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1624-1634</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In chronic lymphocytic leukemia (CLL) the proliferation rate and resistance to drug-induced apoptosis are recognized as important factors in the outcome of treatment.  In this study, we assess the activity and the mechanism of action of the prototype cell division cycle kinase 7 (Cdc7) inhibitor, PHA-767491, which inhibits the initiation of DNA replication but also has cyclin-dependent kinase 9 (Cdk9) inhibitory activity.  We have studied the effects of this dual Cdc7/Cdk9 inhibitor in both quiescent CLL cells and CLL cells that have been induced to proliferate using a cellular coculture system that mimics the lymph node microenvironment.  We find that this compd., originally developed as a DNA replication inhibitor, is particularly active in promoting mitochondrial dependent apoptosis in quiescent CLL cells purified from peripheral blood of patients regardless of recognized risk factors.  In this setting, apoptosis is preceded by a decrease in the levels of Mcl-1 protein and transcript possibly due to inhibition of Cdk9.  Following stimulation by CD154 and interleukin-4, CLL cells become highly chemoresistant, reenter into the cell cycle, reexpress Cdc7 kinase, a key mol. switch for the initiation of DNA replication, replicate their DNA, and undergo cell division.  In this context, treatment with PHA-767491 abolished DNA synthesis by inhibiting Cdc7 but is less effective in triggering cell death, although Mcl-1 protein is no longer detectable.  Thus, dual Cdc7/Cdk9 inhibition has the potential to target both the quiescent and actively proliferating CLL populations through two distinct mechanisms and may be a new therapeutic strategy in CLL.  Mol Cancer Ther; 10(9); 1624-34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ3SCRs3F_mbVg90H21EOLACvtfcHk0lgcWYwuM0sVeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCjurjF&md5=a06bf6334282dd3054812e69488c5040</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-1119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-1119%26sid%3Dliteratum%253Aachs%26aulast%3DNatoni%26aufirst%3DA.%26aulast%3DMurillo%26aufirst%3DL.%2BS.%26aulast%3DKliszczak%26aufirst%3DA.%2BE.%26aulast%3DCatherwood%26aufirst%3DM.%2BA.%26aulast%3DMontagnoli%26aufirst%3DA.%26aulast%3DSamali%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DM.%26aulast%3DSantocanale%26aufirst%3DC.%26atitle%3DMechanisms%2520of%2520action%2520of%2520a%2520dual%2520Cdc7%252FCdk9%2520kinase%2520inhibitor%2520against%2520quiescent%2520and%2520proliferating%2520CLL%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D1624%26epage%3D1634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Krystof, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chamrád, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jorda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohoutek, J.</span><span> </span><span class="NLM_article-title">Pharmacological targeting of CDK9 in cardiac hypertrophy</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">646</span><span class="NLM_x">–</span> <span class="NLM_lpage">666</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=19757441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Snurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=646-666&author=V.+Krystofauthor=I.+Chamr%C3%A1dauthor=R.+Jordaauthor=J.+Kohoutek&title=Pharmacological+targeting+of+CDK9+in+cardiac+hypertrophy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological targeting of CDK9 in cardiac hypertrophy</span></div><div class="casAuthors">Krystof, Vladimir; Chamrad, Ivo; Jorda, Radek; Kohoutek, Jiri</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">646-666</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Cardiac hypertrophy allows the heart to adapt to workload, but persistent or unphysiol. stimulus can result in pump failure.  Cardiac hypertrophy is characterized by an increase in the size of differentiated cardiac myocytes.  At the mol. level, growth of cells is linked to intensive transcription and translation.  Several cyclin-dependent kinases (CDKs) have been identified as principal regulators of transcription, and among these CDK9 is directly assocd. with cardiac hypertrophy.  CDK9 phosphorylates the C-terminal domain of RNA polymerase II and thus stimulates the elongation phase of transcription.  Chronic activation of CDK9 causes not only cardiac myocyte enlargement but also confers predisposition to heart failure.  Due to the long interest of mol. oncologists and medicinal chemists in CDKs as potential targets of anticancer drugs, a portfolio of small-mol. inhibitors of CDK9 is available.  Recent detn. of CDK9's crystal structure now allows the development of selective inhibitors and their further optimization in terms of biochem. potency and selectivity.  CDK9 may therefore constitute a novel target for drugs against cardiac hypertrophy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_kVWpP2zntLVg90H21EOLACvtfcHk0lgcWYwuM0sVeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Snurw%253D&md5=bc8a42d21dbd1653e550e00ddf1f3f91</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrystof%26aufirst%3DV.%26aulast%3DChamr%25C3%25A1d%26aufirst%3DI.%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DKohoutek%26aufirst%3DJ.%26atitle%3DPharmacological%2520targeting%2520of%2520CDK9%2520in%2520cardiac%2520hypertrophy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2010%26volume%3D30%26spage%3D646%26epage%3D666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Schmerwitz, U. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sass, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khandoga, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joore, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berberich, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totzke, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krombach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiegs, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vollmar, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fürst, R.</span><span> </span><span class="NLM_article-title">Flavopiridol protects against inflammation by attenuating leukocyte–endothelial interaction via inhibition of cyclin-dependent kinase 9</span> <span class="citation_source-journal">Arterioscler. Thromb. Vasc. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">280</span><span class="NLM_x">–</span> <span class="NLM_lpage">288</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1161%2FATVBAHA.110.213934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=21088252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvVSqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=280-288&author=U.+K.+Schmerwitzauthor=G.+Sassauthor=A.+G.+Khandogaauthor=J.+Jooreauthor=B.+A.+Mayerauthor=N.+Berberichauthor=F.+Totzkeauthor=F.+Krombachauthor=G.+Tiegsauthor=S.+Zahlerauthor=A.+M.+Vollmarauthor=R.+F%C3%BCrst&title=Flavopiridol+protects+against+inflammation+by+attenuating+leukocyte%E2%80%93endothelial+interaction+via+inhibition+of+cyclin-dependent+kinase+9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9</span></div><div class="casAuthors">Schmerwitz, Ulrike K.; Sass, Gabriele; Khandoga, Alexander G.; Joore, Jos; Mayer, Bettina A.; Berberich, Nina; Totzke, Frank; Krombach, Fritz; Tiegs, Gisa; Zahler, Stefan; Vollmar, Angelika M.; Fuerst, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Arteriosclerosis, Thrombosis, and Vascular Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">280-288</span>CODEN:
                <span class="NLM_cas:coden">ATVBFA</span>;
        ISSN:<span class="NLM_cas:issn">1079-5642</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">OBJECTIVE-: The cyclin-dependent kinase (CDK) inhibitor flavopiridol is currently being tested in clin. trials as anticancer drug.  Beyond its cell death-inducing action, we hypothesized that flavopiridol affects inflammatory processes.  Therefore, we elucidated the action of flavopiridol on leukocyte-endothelial cell interaction and endothelial activation in vivo and in vitro and studied the underlying mol. mechanisms.  METHODS AND RESULTS-: Flavopiridol suppressed Con A-induced hepatitis and neutrophil infiltration into liver tissue.  Flavopiridol also inhibited tumor necrosis factor-α-induced leukocyte-endothelial cell interaction in the mouse cremaster muscle.  Endothelial cells were found to be the major target of flavopiridol, which blocked the expression of endothelial cell adhesion mols. (intercellular adhesion mol.-1, vascular cell adhesion mol.-1, and E-selectin), as well as NF-κB-dependent transcription.  Flavopiridol did not affect inhibitor of κB (IκB) kinase, the degrdn. and phosphorylation of IκBα, nuclear translocation of p65, or nuclear factor-κB (NF-κB) DNA-binding activity.  By performing a cellular kinome array and a kinase activity panel, we found LIM domain kinase-1 (LIMK1), casein kinase 2, c-Jun N-terminal kinase (JNK), protein kinase Cθ (PKCθ), CDK4, CDK6, CDK8, and CDK9 to be influenced by flavopiridol.  Using specific inhibitors, as well as RNA interference (RNAi), we revealed that only CDK9 is responsible for the action of flavopiridol.  CONCLUSION-: Our study highlights flavopiridol as a promising antiinflammatory compd. and inhibition of CDK9 as a novel approach for the treatment of inflammation-assocd. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoacqgBRYYzeLVg90H21EOLACvtfcHk0lgcWYwuM0sVeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvVSqtQ%253D%253D&md5=1f502dec3988e3ef290a6a4469f0e50c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1161%2FATVBAHA.110.213934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FATVBAHA.110.213934%26sid%3Dliteratum%253Aachs%26aulast%3DSchmerwitz%26aufirst%3DU.%2BK.%26aulast%3DSass%26aufirst%3DG.%26aulast%3DKhandoga%26aufirst%3DA.%2BG.%26aulast%3DJoore%26aufirst%3DJ.%26aulast%3DMayer%26aufirst%3DB.%2BA.%26aulast%3DBerberich%26aufirst%3DN.%26aulast%3DTotzke%26aufirst%3DF.%26aulast%3DKrombach%26aufirst%3DF.%26aulast%3DTiegs%26aufirst%3DG.%26aulast%3DZahler%26aufirst%3DS.%26aulast%3DVollmar%26aufirst%3DA.%2BM.%26aulast%3DF%25C3%25BCrst%26aufirst%3DR.%26atitle%3DFlavopiridol%2520protects%2520against%2520inflammation%2520by%2520attenuating%2520leukocyte%25E2%2580%2593endothelial%2520interaction%2520via%2520inhibition%2520of%2520cyclin-dependent%2520kinase%25209%26jtitle%3DArterioscler.%2520Thromb.%2520Vasc.%2520Biol.%26date%3D2011%26volume%3D31%26spage%3D280%26epage%3D288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Tahirov, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babayeva, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varzavand, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sedore, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. H.</span><span> </span><span class="NLM_article-title">Crystal structure of HIV-1 Tat complexed with human P-TEFb</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">465</span><span class="NLM_x">, </span> <span class="NLM_fpage">747</span><span class="NLM_x">–</span> <span class="NLM_lpage">751</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2010&pages=747-751&author=T.+H.+Tahirovauthor=N.+D.+Babayevaauthor=K.+Varzavandauthor=J.+J.+Cooperauthor=S.+C.+Sedoreauthor=D.+H.+Price&title=Crystal+structure+of+HIV-1+Tat+complexed+with+human+P-TEFb"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTahirov%26aufirst%3DT.%2BH.%26aulast%3DBabayeva%26aufirst%3DN.%2BD.%26aulast%3DVarzavand%26aufirst%3DK.%26aulast%3DCooper%26aufirst%3DJ.%2BJ.%26aulast%3DSedore%26aufirst%3DS.%2BC.%26aulast%3DPrice%26aufirst%3DD.%2BH.%26atitle%3DCrystal%2520structure%2520of%2520HIV-1%2520Tat%2520complexed%2520with%2520human%2520P-TEFb%26jtitle%3DNature%26date%3D2010%26volume%3D465%26spage%3D747%26epage%3D751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Salerno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasham, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garriga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsygankov, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graña, X.</span><span> </span><span class="NLM_article-title">Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes</span> <span class="citation_source-journal">Gene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">405</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=405&publication_year=2007&pages=65-78&author=D.+Salernoauthor=M.+G.+Hashamauthor=R.+Marshallauthor=J.+Garrigaauthor=A.+Y.+Tsygankovauthor=X.+Gra%C3%B1a&title=Direct+inhibition+of+CDK9+blocks+HIV-1+replication+without+preventing+T-cell+activation+in+primary+human+peripheral+blood+lymphocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSalerno%26aufirst%3DD.%26aulast%3DHasham%26aufirst%3DM.%2BG.%26aulast%3DMarshall%26aufirst%3DR.%26aulast%3DGarriga%26aufirst%3DJ.%26aulast%3DTsygankov%26aufirst%3DA.%2BY.%26aulast%3DGra%25C3%25B1a%26aufirst%3DX.%26atitle%3DDirect%2520inhibition%2520of%2520CDK9%2520blocks%2520HIV-1%2520replication%2520without%2520preventing%2520T-cell%2520activation%2520in%2520primary%2520human%2520peripheral%2520blood%2520lymphocytes%26jtitle%3DGene%26date%3D2007%26volume%3D405%26spage%3D65%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Klebl, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choidas, A.</span><span> </span><span class="NLM_article-title">CDK9/cyclin T1: a host cell target for antiretroviral therapy</span> <span class="citation_source-journal">Future Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">330</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.2217%2F17460794.1.3.317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvVyhsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=317-330&author=B.+M.+Kleblauthor=A.+Choidas&title=CDK9%2Fcyclin+T1%3A+a+host+cell+target+for+antiretroviral+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">CDK9/cyclin T1: a host cell target for antiretroviral therapy</span></div><div class="casAuthors">Klebl, Bert M.; Choidas, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Future Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">317-330</span>CODEN:
                <span class="NLM_cas:coden">FVUIAM</span>;
        ISSN:<span class="NLM_cas:issn">1746-0794</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Hijacking of the host cell's signal transduction machinery has been increasingly regarded as an important strategy for facilitating virus propagation.  The pos.-transcription elongation factor (P-TEFb) complex, cyclin-dependent kinase (CDK)9/cyclin T1, is an example of such an attack by HIV.  Upon infection of cells, the HIV protein transactivator of transcription (Tat) forms a highly specific complex with the two host cell proteins CDK9 and cyclin T1.  This complex ensures phosphorylation of the native CDK9 substrate, RNA polymerase II, leading to productive elongation of viral RNA in the host cell.  Although challenging, inhibition of CDK9 activity with small mols. is a therapeutically valid strategy to inhibit HIV replication.  Other than direct antiviral agents, that inhibit HIV replication through a direct interaction with viral proteins, CDK9 inhibitors might not suffer from the emergence of resistant virus strains.  This review outlines the advantages and prospects of selective CDK9 inhibitors in the management of HIV infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW77hTG1dJSrVg90H21EOLACvtfcHk0lgbbr7u-sl3Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvVyhsbY%253D&md5=b397165e7103194e1cc7b33ce2f8bcbe</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2217%2F17460794.1.3.317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252F17460794.1.3.317%26sid%3Dliteratum%253Aachs%26aulast%3DKlebl%26aufirst%3DB.%2BM.%26aulast%3DChoidas%26aufirst%3DA.%26atitle%3DCDK9%252Fcyclin%2520T1%253A%2520a%2520host%2520cell%2520target%2520for%2520antiretroviral%2520therapy%26jtitle%3DFuture%2520Virol.%26date%3D2006%26volume%3D1%26spage%3D317%26epage%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Shao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hole, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbas, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endicott, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure–activity relationship, and anticancer activities</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">640</span><span class="NLM_x">–</span> <span class="NLM_lpage">659</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301475f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=640-659&author=H.+Shaoauthor=S.+Shiauthor=S.+Huangauthor=A.+J.+Holeauthor=A.+Y.+Abbasauthor=S.+Baumliauthor=X.+Liuauthor=F.+Lamauthor=D.+W.+Foleyauthor=P.+M.+Fischerauthor=M.+Nobleauthor=J.+A.+Endicottauthor=C.+Pepperauthor=S.+Wang&title=Substituted+4-%28thiazol-5-yl%29-2-%28phenylamino%29pyrimidines+are+highly+active+CDK9+inhibitors%3A+synthesis%2C+X-ray+crystal+structures%2C+structure%E2%80%93activity+relationship%2C+and+anticancer+activities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm301475f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301475f%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DAbbas%26aufirst%3DA.%2BY.%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLam%26aufirst%3DF.%26aulast%3DFoley%26aufirst%3DD.%2BW.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DNoble%26aufirst%3DM.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DSubstituted%25204-%2528thiazol-5-yl%2529-2-%2528phenylamino%2529pyrimidines%2520are%2520highly%2520active%2520CDK9%2520inhibitors%253A%2520synthesis%252C%2520X-ray%2520crystal%2520structures%252C%2520structure%25E2%2580%2593activity%2520relationship%252C%2520and%2520anticancer%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D640%26epage%3D659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Capranico, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marinello, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baranello, L.</span><span> </span><span class="NLM_article-title">Dissecting the transcriptional functions of human DNA topoisomerase I by selective inhibitors: implications for physiological and therapeutic modulation of enzyme activity</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1806</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">250</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1806&publication_year=2010&pages=240-250&author=G.+Capranicoauthor=J.+Marinelloauthor=L.+Baranello&title=Dissecting+the+transcriptional+functions+of+human+DNA+topoisomerase+I+by+selective+inhibitors%3A+implications+for+physiological+and+therapeutic+modulation+of+enzyme+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCapranico%26aufirst%3DG.%26aulast%3DMarinello%26aufirst%3DJ.%26aulast%3DBaranello%26aufirst%3DL.%26atitle%3DDissecting%2520the%2520transcriptional%2520functions%2520of%2520human%2520DNA%2520topoisomerase%2520I%2520by%2520selective%2520inhibitors%253A%2520implications%2520for%2520physiological%2520and%2520therapeutic%2520modulation%2520of%2520enzyme%2520activity%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2010%26volume%3D1806%26spage%3D240%26epage%3D250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Albert, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigault, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eickhoff, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgart, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittler, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meisterernst, M.</span><span> </span><span class="NLM_article-title">Characterisation of molecular and cellular CDK9 functions using a novel specific inhibitor</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">171</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1111%2Fbph.12408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=24102143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2mtLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2014&pages=55-68&author=T.+K.+Albertauthor=C.+Rigaultauthor=J.+Eickhoffauthor=K.+Baumgartauthor=C.+Antrechtauthor=B.+Kleblauthor=G.+Mittlerauthor=M.+Meisterernst&title=Characterisation+of+molecular+and+cellular+CDK9+functions+using+a+novel+specific+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor</span></div><div class="casAuthors">Albert, T. K.; Rigault, C.; Eickhoff, J.; Baumgart, K.; Antrecht, C.; Klebl, B.; Mittler, G.; Meisterernst, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-68</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : The cyclin-dependent kinase CDK9 is an important therapeutic target but currently available inhibitors exhibit low specificity and/or narrow therapeutic windows.  Here we have used a new highly specific CDK9 inhibitor, LDC000067 to interrogate gene control mechanisms mediated by CDK9.  Exptl. Approach : The selectivity of LDC000067 was established in functional kinase assays.  Functions of CDK9 in gene expression were assessed with in vitro transcription expts., single gene analyses and genome-wide expression profiling.  Cultures of mouse embryonic stem cells, HeLa cells, several cancer cell lines, along with cells from patients with acute myelogenous leukemia were also used to investigate cellular responses to LDC000067.  Key Results : The selectivity of LDC000067 for CDK9 over other CDKs exceeded that of the known inhibitors flavopiridol and DRB.  LDC000067 inhibited in vitro transcription in an ATP-competitive and dose-dependent manner.  Gene expression profiling of cells treated with LDC000067 demonstrated a selective redn. of short-lived mRNAs, including important regulators of proliferation and apoptosis.  Anal. of de novo RNA synthesis suggested a wide ranging pos. role of CDK9.  At the mol. and cellular level, LDC000067 reproduced effects characteristic of CDK9 inhibition such as enhanced pausing of RNA polymerase II on genes and, most importantly, induction of apoptosis in cancer cells.  Conclusions and Implications : Our study provides a framework for the mechanistic understanding of cellular responses to CDK9 inhibition.  LDC000067 represents a promising lead for the development of clin. useful, highly specific CDK9 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphlq2wB8J8BbVg90H21EOLACvtfcHk0lgbbr7u-sl3Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2mtLbF&md5=61dccacb940578e746fb5f3962ccd87e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fbph.12408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12408%26sid%3Dliteratum%253Aachs%26aulast%3DAlbert%26aufirst%3DT.%2BK.%26aulast%3DRigault%26aufirst%3DC.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DBaumgart%26aufirst%3DK.%26aulast%3DAntrecht%26aufirst%3DC.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DMittler%26aufirst%3DG.%26aulast%3DMeisterernst%26aufirst%3DM.%26atitle%3DCharacterisation%2520of%2520molecular%2520and%2520cellular%2520CDK9%2520functions%2520using%2520a%2520novel%2520specific%2520inhibitor%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D171%26spage%3D55%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2529</span><span class="NLM_x">–</span> <span class="NLM_lpage">2591</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+A.+Meanwell&title=Synopsis+of+Some+Recent+Tactical+Application+of+Bioisosteres+in+Drug+Design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0liCBcKHTZia_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520Some%2520Recent%2520Tactical%2520Application%2520of%2520Bioisosteres%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Moree, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Marel, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Boom, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liskamp, R. M. J.</span><span> </span><span class="NLM_article-title">Peptides containing the novel methylphosphinamide transition-state isostere</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">11055</span><span class="NLM_x">–</span> <span class="NLM_lpage">11064</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1993&pages=11055-11064&author=W.+J.+Moreeauthor=G.+A.+van+der+Marelauthor=J.+H.+van+Boomauthor=R.+M.+J.+Liskamp&title=Peptides+containing+the+novel+methylphosphinamide+transition-state+isostere"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoree%26aufirst%3DW.%2BJ.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%2BA.%26aulast%3Dvan%2BBoom%26aufirst%3DJ.%2BH.%26aulast%3DLiskamp%26aufirst%3DR.%2BM.%2BJ.%26atitle%3DPeptides%2520containing%2520the%2520novel%2520methylphosphinamide%2520transition-state%2520isostere%26jtitle%3DTetrahedron%26date%3D1993%26volume%3D49%26spage%3D11055%26epage%3D11064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Elliot, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slowey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, S. J.</span><span> </span><span class="NLM_article-title">The use of phosphate bioisosteres in medicinal chemistry and chemical biology</span> <span class="citation_source-journal">Med. Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">735</span><span class="NLM_x">–</span> <span class="NLM_lpage">751</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1039%2Fc2md20079a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=735-751&author=T.+S.+Elliotauthor=A.+Sloweyauthor=Y.+Yeauthor=S.+J.+Conway&title=The+use+of+phosphate+bioisosteres+in+medicinal+chemistry+and+chemical+biology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1039%2Fc2md20079a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20079a%26sid%3Dliteratum%253Aachs%26aulast%3DElliot%26aufirst%3DT.%2BS.%26aulast%3DSlowey%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DConway%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520use%2520of%2520phosphate%2520bioisosteres%2520in%2520medicinal%2520chemistry%2520and%2520chemical%2520biology%26jtitle%3DMed.%2520Chem.%2520Commun.%26date%3D2012%26volume%3D3%26spage%3D735%26epage%3D751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Wardle, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigh, S. W. A.</span><span> </span><span class="NLM_article-title"><i>O</i>-Phosphotyrosine Analogues: Synthesis and Therapeutic Role in Modulation of Signal Transduction</span> <span class="citation_source-journal">Curr. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">426</span><span class="NLM_x">–</span> <span class="NLM_lpage">446</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.2174%2F138527210790601189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFGjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=426-446&author=N.+J.+Wardleauthor=H.+R.+Hudsonauthor=S.+W.+A.+Bigh&title=O-Phosphotyrosine+Analogues%3A+Synthesis+and+Therapeutic+Role+in+Modulation+of+Signal+Transduction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">O-phosphotyrosine analogues: synthesis and therapeutic role in modulation of signal transduction</span></div><div class="casAuthors">Wardle, Nick J.; Hudson, Harry R.; Bligh, S. W. Annie</div><div class="citationInfo"><span class="NLM_cas:title">Current Organic Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">426-446</span>CODEN:
                <span class="NLM_cas:coden">CORCFE</span>;
        ISSN:<span class="NLM_cas:issn">1385-2728</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of O-phosphotyrosine (pTyr) analogs is reviewed, along with their application in peptidomimetic ligands to proteins implicated in disease-states arising from dysfunctional intracellular signal transduction pathways.  Salient features of chem. syntheses are critiqued, including those of established mimetics such as 4'-(phosphonomethyl)phenylalanine (Pmp), 4'-(phosphono)phenylalanine (Ppp) and 4'-(phosphonodifluoromethyl)phenylalanine (F2Pmp), their resp. (α-methyl)phenylalanine analogs and "preorganised" side-chain cyclized pTyr mimetics.  Syntheses of 4'-(phosphinomethyl)phenylalanines are also described, as are "bone-directing" residues such as 4'-(diphosphonomethyl)phenylalanine (dpmF), 3',4'-(diphosphono)phenylalanine and 4'-carboxymethyloxy-3'-(phosphono)phenylalanine (CPP), capable of eliciting addnl. interactions with pTyr-binding subsites of specified proteins.  The utility of [(4'-phosphonomethyl)phenyl]propenoic acid in current developments is also discussed as a route to a range of α- and β-substituted pTyr mimetics, and to pTyr mimetics bearing the requisite β-vinyl functionality to facilitate macrocyclization via olefin metathesis of interest in the development of structures exhibiting global conformational constraint.  Finally, developments in prodrug presentation of pTyr mimetics are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoarPHjnlUSArVg90H21EOLACvtfcHk0liCBcKHTZia_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFGjtLk%253D&md5=d11b3b0b6e728ddda9296a302c46abd4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2174%2F138527210790601189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138527210790601189%26sid%3Dliteratum%253Aachs%26aulast%3DWardle%26aufirst%3DN.%2BJ.%26aulast%3DHudson%26aufirst%3DH.%2BR.%26aulast%3DBigh%26aufirst%3DS.%2BW.%2BA.%26atitle%3DO-Phosphotyrosine%2520Analogues%253A%2520Synthesis%2520and%2520Therapeutic%2520Role%2520in%2520Modulation%2520of%2520Signal%2520Transduction%26jtitle%3DCurr.%2520Org.%2520Chem.%26date%3D2010%26volume%3D14%26spage%3D426%26epage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Bartlett, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marlowe, C. K.</span><span> </span><span class="NLM_article-title">Phosphonamidates as transition-state analogue inhibitors of thermolysin</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4618</span><span class="NLM_x">–</span> <span class="NLM_lpage">4624</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi00289a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1983&pages=4618-4624&author=P.+A.+Bartlettauthor=C.+K.+Marlowe&title=Phosphonamidates+as+transition-state+analogue+inhibitors+of+thermolysin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fbi00289a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00289a002%26sid%3Dliteratum%253Aachs%26aulast%3DBartlett%26aufirst%3DP.%2BA.%26aulast%3DMarlowe%26aufirst%3DC.%2BK.%26atitle%3DPhosphonamidates%2520as%2520transition-state%2520analogue%2520inhibitors%2520of%2520thermolysin%26jtitle%3DBiochemistry%26date%3D1983%26volume%3D22%26spage%3D4618%26epage%3D4624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Wardle, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigh, S. W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson, H. R.</span><span> </span><span class="NLM_article-title">Organophosphorus Compounds: Intervention in Mechanisms of Signal Transduction Relevant to Proliferative, Immunological and Circulatory Disorders</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2230</span><span class="NLM_x">–</span> <span class="NLM_lpage">2257</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.2174%2F092986708785747517" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=18781946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFCksbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=2230-2257&author=N.+J.+Wardleauthor=S.+W.+A.+Bighauthor=H.+R.+Hudson&title=Organophosphorus+Compounds%3A+Intervention+in+Mechanisms+of+Signal+Transduction+Relevant+to+Proliferative%2C+Immunological+and+Circulatory+Disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Organophosphorus compounds: intervention in mechanisms of signal transduction relevant to proliferative, immunological and circulatory disorders</span></div><div class="casAuthors">Wardle, Nick J.; Bligh, S. W. Annie; Hudson, Harry R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2230-2257</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Literature publications reporting the development of organophosphorus compds., targeting aspects of signal transduction to the titled therapeutic ends, are reviewed.  With respect to extracellular targets, the development of ligands to purinergic (P2), and endothelial differentiation-gene receptors (of S1P- and LPA-receptor subtypes) is charted, along with inhibitors of the prodn. and release of tumor necrosis factor-α (TNF-α).  Reported also are inhibitors of the ectoenzymes aminopeptidase N, aminopeptidase A and dipeptidyl peptidase IV, the proteolytic enzyme thrombin, ligands to "apoptosis-receptors" and γδ T-cell activators.  In addn., disruption of intracellular signaling chains mediated through reversible coupling of proteins via phosphorylation of Tyr residues and docking of pTyr residues in SH2-binding domains is covered.  In particular, the development of ligands to SH2-binding domains in tyrosine kinases Src and lck, adaptor protein Grb2, and also ZAP70 protein are reported along with inhibitors to relevant phosphatases.  SAR studies of ligands to Ins(1,4,5)-P3- and ryanodine-type receptors of intracellular Ca2+-storage organelles are described including analogs to secondary messengers cyclic-ADP-ribose (cADPR) and myo-inositol-1,4,5-triphosphate.  Inhibitors of phosphatidyl inositol 3-kinase (PI3K) and sphingomyelinase are also reported, as are inhibitors of farnesyl transferase, the enzyme involved in protein-prenylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozB_--f2IKW7Vg90H21EOLACvtfcHk0liCBcKHTZia_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFCksbY%253D&md5=5c16a218ec4457ad5c35d0f25d089949</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F092986708785747517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708785747517%26sid%3Dliteratum%253Aachs%26aulast%3DWardle%26aufirst%3DN.%2BJ.%26aulast%3DBigh%26aufirst%3DS.%2BW.%2BA.%26aulast%3DHudson%26aufirst%3DH.%2BR.%26atitle%3DOrganophosphorus%2520Compounds%253A%2520Intervention%2520in%2520Mechanisms%2520of%2520Signal%2520Transduction%2520Relevant%2520to%2520Proliferative%252C%2520Immunological%2520and%2520Circulatory%2520Disorders%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D2230%26epage%3D2257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Mucha, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kafarski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berlicki, L.</span><span> </span><span class="NLM_article-title">Remarkable Potential of the α-Aminophosphonate/Phosphinate Structural Motif in Medicinal Chemistry</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">5955</span><span class="NLM_x">–</span> <span class="NLM_lpage">5980</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200587f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvVWlsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5955-5980&author=A.+Muchaauthor=P.+Kafarskiauthor=L.+Berlicki&title=Remarkable+Potential+of+the+%CE%B1-Aminophosphonate%2FPhosphinate+Structural+Motif+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Remarkable Potential of the α-Aminophosphonate/Phosphinate Structural Motif in Medicinal Chemistry</span></div><div class="casAuthors">Mucha, Artur; Kafarski, Pawel; Berlicki, Lukasz</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5955-5980</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Potential of the α-aminophosphonate/phosphinate structural motif in medicinal chem. is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPPeUBOTalirVg90H21EOLACvtfcHk0ljYzB08KpqZ3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvVWlsrs%253D&md5=0683f7f9ff6269b7d93ee27e623c21c5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm200587f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200587f%26sid%3Dliteratum%253Aachs%26aulast%3DMucha%26aufirst%3DA.%26aulast%3DKafarski%26aufirst%3DP.%26aulast%3DBerlicki%26aufirst%3DL.%26atitle%3DRemarkable%2520Potential%2520of%2520the%2520%25CE%25B1-Aminophosphonate%252FPhosphinate%2520Structural%2520Motif%2520in%2520Medicinal%2520Chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D5955%26epage%3D5980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Choidas, A.; Backes, A.; Cotten, M.; Engkvist, O.; Felber, B.; Freisleben, A.; Gold, K.; Greff, Z.; Habenberger, P.; Hafenbradl, D.; Hartung, C.; Herget, T.; Hoppe, E.; Klebl, B.; Missio, A.; Müller, G.; Schwab, W.; Zech, B.; Bravo, J.; Harris, J.; Le, J.; Macritchie, J.</span><span> </span><span class="NLM_article-title">Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases</span>. PCT Int. Appl. WO 2005026129,<span class="NLM_x"> </span><span class="NLM_year">2005</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=A.+Choidas&author=A.+Backes&author=M.+Cotten&author=O.+Engkvist&author=B.+Felber&author=A.+Freisleben&author=K.+Gold&author=Z.+Greff&author=P.+Habenberger&author=D.+Hafenbradl&author=C.+Hartung&author=T.+Herget&author=E.+Hoppe&author=B.+Klebl&author=A.+Missio&author=G.+M%C3%BCller&author=W.+Schwab&author=B.+Zech&author=J.+Bravo&author=J.+Harris&author=J.+Le&author=J.+Macritchie&title=Pharmaceutically+active+4%2C6-disubstituted+aminopyrimidine+derivatives+as+modulators+of+protein+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChoidas%26aufirst%3DA.%26atitle%3DPharmaceutically%2520active%25204%252C6-disubstituted%2520aminopyrimidine%2520derivatives%2520as%2520modulators%2520of%2520protein%2520kinases%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="ref29_2"><span> <span class="citation_source-journal">Chem. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">142</span><span class="NLM_x">, </span> <span class="NLM_fpage">336376</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Chem.+Abstr.+2005%2C+142%2C+336376"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref29_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26jtitle%3DChem.%2520Abstr.%26date%3D2005%26volume%3D142%26spage%3D336376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Mucha, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grembecka, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cierpicki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kafarski, P.</span><span> </span><span class="NLM_article-title">Hydrolysis of the Phosphonamidate Bond in Phosphono Dipeptide Analogues—The Influence of the Nature of the N-Terminal Functional Group</span> <span class="citation_source-journal">Eur. J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4797</span><span class="NLM_x">–</span> <span class="NLM_lpage">4803</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2003&pages=4797-4803&author=A.+Muchaauthor=J.+Grembeckaauthor=T.+Cierpickiauthor=P.+Kafarski&title=Hydrolysis+of+the+Phosphonamidate+Bond+in+Phosphono+Dipeptide+Analogues%E2%80%94The+Influence+of+the+Nature+of+the+N-Terminal+Functional+Group"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMucha%26aufirst%3DA.%26aulast%3DGrembecka%26aufirst%3DJ.%26aulast%3DCierpicki%26aufirst%3DT.%26aulast%3DKafarski%26aufirst%3DP.%26atitle%3DHydrolysis%2520of%2520the%2520Phosphonamidate%2520Bond%2520in%2520Phosphono%2520Dipeptide%2520Analogues%25E2%2580%2594The%2520Influence%2520of%2520the%2520Nature%2520of%2520the%2520N-Terminal%2520Functional%2520Group%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2003%26volume%3D24%26spage%3D4797%26epage%3D4803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Pudovik, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arbuzov, B. A.</span><span> </span><span class="NLM_article-title">Addition of dialkyl phosphites to unsaturated ketones, nitriles and esters</span> <span class="citation_source-journal">Dokl. Akad. Nauk SSSR</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1950</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1950&pages=327&author=A.+N.+Pudovikauthor=B.+A.+Arbuzov&title=Addition+of+dialkyl+phosphites+to+unsaturated+ketones%2C+nitriles+and+esters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPudovik%26aufirst%3DA.%2BN.%26aulast%3DArbuzov%26aufirst%3DB.%2BA.%26atitle%3DAddition%2520of%2520dialkyl%2520phosphites%2520to%2520unsaturated%2520ketones%252C%2520nitriles%2520and%2520esters%26jtitle%3DDokl.%2520Akad.%2520Nauk%2520SSSR%26date%3D1950%26volume%3D73%26spage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Petneházy, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jászay, Z. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabó, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everaert, K.</span><span> </span><span class="NLM_article-title">Convenient One-Pot Synthesis of Phosphonites and H-Phosphinates</span> <span class="citation_source-journal">Synth. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1665</span><span class="NLM_x">–</span> <span class="NLM_lpage">1674</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1081%2FSCC-120018928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktFKhsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2003&pages=1665-1674&author=I.+Petneh%C3%A1zyauthor=Z.+M.+J%C3%A1szayauthor=A.+Szab%C3%B3author=K.+Everaert&title=Convenient+One-Pot+Synthesis+of+Phosphonites+and+H-Phosphinates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Convenient one pot synthesis of phosphonites and H-phosphinates</span></div><div class="casAuthors">Petnehazy, Imre; Jaszay, Zsuzsa M.; Szabo, Andrea; Everaert, Kinga</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1665-1674</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    
            (<span class="NLM_cas:orgname">Marcel Dekker, Inc.</span>)
        </div><div class="casAbstract">A convenient and simple one-pot method is described for the synthesis of phosphonites [RP(OEt)2] and H-phosphinates [HP(O)R(OEt)] from tri-Et phosphite and appropriate Grignard reagents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ2vCJYXX497Vg90H21EOLACvtfcHk0ljYzB08KpqZ3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktFKhsLw%253D&md5=895a7d480b73574726aa52ea43892fe4</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1081%2FSCC-120018928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1081%252FSCC-120018928%26sid%3Dliteratum%253Aachs%26aulast%3DPetneh%25C3%25A1zy%26aufirst%3DI.%26aulast%3DJ%25C3%25A1szay%26aufirst%3DZ.%2BM.%26aulast%3DSzab%25C3%25B3%26aufirst%3DA.%26aulast%3DEveraert%26aufirst%3DK.%26atitle%3DConvenient%2520One-Pot%2520Synthesis%2520of%2520Phosphonites%2520and%2520H-Phosphinates%26jtitle%3DSynth.%2520Commun.%26date%3D2003%26volume%3D33%26spage%3D1665%26epage%3D1674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Cristau, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirat, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virieux, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monbrun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciptadi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bekro, Y. A.</span><span> </span><span class="NLM_article-title">Synthesis, reactivity and stereochemistry of new phosphorus heterocycles with 5- or 6-membered rings</span> <span class="citation_source-journal">J. Organomet. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">690</span><span class="NLM_x">, </span> <span class="NLM_fpage">2472</span><span class="NLM_x">–</span> <span class="NLM_lpage">2481</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1016%2Fj.jorganchem.2004.11.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVCru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=690&publication_year=2005&pages=2472-2481&author=H.+J.+Cristauauthor=J.+L.+Piratauthor=D.+Virieuxauthor=J.+Monbrunauthor=C.+Ciptadiauthor=Y.+A.+Bekro&title=Synthesis%2C+reactivity+and+stereochemistry+of+new+phosphorus+heterocycles+with+5-+or+6-membered+rings"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, reactivity and stereochemistry of new phosphorus heterocycles with 5- or 6-membered rings</span></div><div class="casAuthors">Cristau, Henri-Jean; Pirat, Jean-Luc; Virieux, David; Monbrun, Jerome; Ciptadi, Ciptadi; Bekro, Yves-Alain</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organometallic Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">690</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2472-2481</span>CODEN:
                <span class="NLM_cas:coden">JORCAI</span>;
        ISSN:<span class="NLM_cas:issn">0022-328X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review in conference proceedings.  Syntheses of novel phosphorus heterocycles contg. α-amino or α-hydroxyphosphonic or phosphinic acids motifs are developed.  2,3-Dihydro-1,3-oxaphospholes (1) and 1,4,2-oxazaphosphinanes (2) exhibit a reactive part, resp. the enol ether moiety and the P-H bond, which allows various structural modifications: (i) for 1a, by introduction of amino substituents, (ii) for 2a, by hydroxy- or aminoalkylation, by Michael addn. or by P-arylation.  These reactions present generally a good or even an excellent kinetic diastereoselectivity which can often be predicted by mol. models of the transition states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX7-BQ1tlu1rVg90H21EOLACvtfcHk0lgB37mTjUA5jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVCru7s%253D&md5=12adb5db3a09920897c42d32d0a14a52</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.jorganchem.2004.11.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jorganchem.2004.11.035%26sid%3Dliteratum%253Aachs%26aulast%3DCristau%26aufirst%3DH.%2BJ.%26aulast%3DPirat%26aufirst%3DJ.%2BL.%26aulast%3DVirieux%26aufirst%3DD.%26aulast%3DMonbrun%26aufirst%3DJ.%26aulast%3DCiptadi%26aufirst%3DC.%26aulast%3DBekro%26aufirst%3DY.%2BA.%26atitle%3DSynthesis%252C%2520reactivity%2520and%2520stereochemistry%2520of%2520new%2520phosphorus%2520heterocycles%2520with%25205-%2520or%25206-membered%2520rings%26jtitle%3DJ.%2520Organomet.%2520Chem.%26date%3D2005%26volume%3D690%26spage%3D2472%26epage%3D2481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Hartung, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backes, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Missio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philipp, A.</span><span> </span><span class="NLM_article-title">Efficient microwave-assisted synthesis of highly functionalized pyrimidine derivatives</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">10055</span><span class="NLM_x">–</span> <span class="NLM_lpage">10064</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=10055-10064&author=C.+G.+Hartungauthor=A.+C.+Backesauthor=B.+Felberauthor=A.+Missioauthor=A.+Philipp&title=Efficient+microwave-assisted+synthesis+of+highly+functionalized+pyrimidine+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHartung%26aufirst%3DC.%2BG.%26aulast%3DBackes%26aufirst%3DA.%2BC.%26aulast%3DFelber%26aufirst%3DB.%26aulast%3DMissio%26aufirst%3DA.%26aulast%3DPhilipp%26aufirst%3DA.%26atitle%3DEfficient%2520microwave-assisted%2520synthesis%2520of%2520highly%2520functionalized%2520pyrimidine%2520derivatives%26jtitle%3DTetrahedron%26date%3D2006%26volume%3D62%26spage%3D10055%26epage%3D10064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, R.</span><span> </span><span class="NLM_article-title">Fragment-based lead discovery</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">660</span><span class="NLM_x">–</span> <span class="NLM_lpage">672</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=660-672&author=D.+C.+Reesauthor=M.+Congreveauthor=C.+W.+Murrayauthor=R.+Carr&title=Fragment-based+lead+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DCarr%26aufirst%3DR.%26atitle%3DFragment-based%2520lead%2520discovery%26jtitle%3DNature%26date%3D2004%26volume%3D3%26spage%3D660%26epage%3D672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nature Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1051</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0lgB37mTjUA5jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNature%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="note"><p class="first last">CDK9 protein was used without its cyclinT1 counterpart.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span>Downloaded from TREEspot Compound Profile Visualization Tool; <span class="NLM_publisher-name">DiscoveRx Corporation</span>: <span class="NLM_publisher-loc">Fremont, CA</span>; <a href="http://treespot.discoverx.com" class="extLink">http://treespot.discoverx.com</a>, accessed on September 3, 2013.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Downloaded+from+TREEspot+Compound+Profile+Visualization+Tool%3B+DiscoveRx+Corporation%3A+Fremont%2C+CA%3B+http%3A%2F%2Ftreespot.discoverx.com%2C+accessed+on+September+3%2C+2013."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DTREEspot%2520Compound%2520Profile%2520Visualization%2520Tool%26pub%3DDiscoveRx%2520Corporation" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Gyuris, Á.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vajda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Földes, I.</span><span> </span><span class="NLM_article-title">Establishment of an MT4 cell line persistently producing infective HIV-1 particles</span> <span class="citation_source-journal">Acta Microbiol. Hung.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">279</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A280%3ADyaK2c7mtVKrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1992&pages=271-279&author=%C3%81.+Gyurisauthor=G.+Vajdaauthor=I.+F%C3%B6ldes&title=Establishment+of+an+MT4+cell+line+persistently+producing+infective+HIV-1+particles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Establishment of an MT4 cell line persistently producing infective HIV-1 particles</span></div><div class="casAuthors">Gyuris A; Vajda G; Foldes I</div><div class="citationInfo"><span class="NLM_cas:title">Acta microbiologica Hungarica</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">271-9</span>
        ISSN:<span class="NLM_cas:issn">0231-4622</span>.
    </div><div class="casAbstract">Human T cell Lymphotropic Virus-I (HTLV-I) carrying human T cell line MT4 is highly sensitive to Human Immunodeficiency Virus-1 (HIV-1).  After HIV-1 infection cell clusters characteristic of intact MT4 rapidly disintegrate, syncytia appear and the cells die.  Surviving MT4 cells were subcultured following HIV-1 infection of high multiplicity.  We succeeded to establish an MT4 cell line continuously producing infective HIV (MT4/HIV-1).  The original and the HIV-1 infected MT4 cells were morphologically similar.  The MT4/HIV-1 cells proved to be nearly 100% positive in indirect immunofluorescence assay using the serum of an HIV-1 antibody positive individual.  OKT4 surface antigen could not be demonstrated on MT4/HIV-1 cells.  On electron microscopic pictures typical and atypical virus particles could be seen near the surface of the cell membrane.  The persistently produced virus particles were infective for H9 and MT4 cells.  The antigenic structure of the virus produced by MT4 cells was similar to that produced by H9 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRas9ugBpmLmUEgZCMqtRBifW6udTcc2eaV6Fl2a5lf27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c7mtVKrsQ%253D%253D&md5=ec87e45c1d16800d7dd36fce7a9f1e15</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGyuris%26aufirst%3D%25C3%2581.%26aulast%3DVajda%26aufirst%3DG.%26aulast%3DF%25C3%25B6ldes%26aufirst%3DI.%26atitle%3DEstablishment%2520of%2520an%2520MT4%2520cell%2520line%2520persistently%2520producing%2520infective%2520HIV-1%2520particles%26jtitle%3DActa%2520Microbiol.%2520Hung.%26date%3D1992%26volume%3D39%26spage%3D271%26epage%3D279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Gyuris, Á.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szlávik, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minárovits, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molnár, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohmann, J.</span><span> </span><span class="NLM_article-title">Activities of extracts of <i>Euphorbia hirta</i> L. against HIV-1, HIV-2 and SIV<sub>mac251</sub></span> <span class="citation_source-journal">In Vivo</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">432</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=429-432&author=%C3%81.+Gyurisauthor=L.+Szl%C3%A1vikauthor=J.+Min%C3%A1rovitsauthor=A.+Vasasauthor=J.+Moln%C3%A1rauthor=J.+Hohmann&title=Activities+of+extracts+of+Euphorbia+hirta+L.+against+HIV-1%2C+HIV-2+and+SIVmac251"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGyuris%26aufirst%3D%25C3%2581.%26aulast%3DSzl%25C3%25A1vik%26aufirst%3DL.%26aulast%3DMin%25C3%25A1rovits%26aufirst%3DJ.%26aulast%3DVasas%26aufirst%3DA.%26aulast%3DMoln%25C3%25A1r%26aufirst%3DJ.%26aulast%3DHohmann%26aufirst%3DJ.%26atitle%3DActivities%2520of%2520extracts%2520of%2520Euphorbia%2520hirta%2520L.%2520against%2520HIV-1%252C%2520HIV-2%2520and%2520SIVmac251%26jtitle%3DIn%2520Vivo%26date%3D2009%26volume%3D23%26spage%3D429%26epage%3D432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Teixeira, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomes, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbault, F.</span><span> </span><span class="NLM_article-title">Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">979</span><span class="NLM_x">–</span> <span class="NLM_lpage">992</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1016%2Fj.ejmech.2011.01.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=21345545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFWgsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=979-992&author=C.+Teixeiraauthor=J.+R.+Gomesauthor=P.+Gomesauthor=F.+Maurelauthor=F.+Barbault&title=Viral+surface+glycoproteins%2C+gp120+and+gp41%2C+as+potential+drug+targets+against+HIV-1%3A+brief+overview+one+quarter+of+a+century+past+the+approval+of+zidovudine%2C+the+first+anti-retroviral+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: Brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug</span></div><div class="casAuthors">Teixeira, Catia; Gomes, Jose R. B.; Gomes, Paula; Maurel, Francois</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">979-992</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The first anti-HIV drug, zidovudine (AZT), was approved by the FDA a quarter of a century ago, in 1985.  Currently, anti-HIV drug-combination therapies only target HIV-1 protease and reverse transcriptase.  Unfortunately, most of these mols. present numerous shortcomings such as viral resistances and adverse effects.  In addn., these drugs are involved in later stages of infection.  Thus, it is necessary to develop new drugs that are able to block the first steps of viral life cycle.  Entry of HIV-1 is mediated by its two envelope glycoproteins: gp120 and gp41.  Upon gp120 binding to cellular receptors, gp41 undergoes a series of conformational changes from a non-fusogenic to a fusogenic conformation.  The fusogenic core of gp41 is a trimer-of-hairpins structure in which three C-terminal helixes pack against a central trimeric-coiled coil formed by three N-terminal helixes.  The formation of this fusogenic structure brings the viral and cellular membranes close together, a necessary condition for membrane fusion to occur.  As gp120 and gp41 are attractive targets, the development of entry inhibitors represents an important avenue of anti-HIV drug therapy.  The present review will focus on some general considerations about HIV, the main characteristics of gp120, gp41 and their inhibitors, with special emphasis on the advances of computational approaches employed in the development of bioactive compds. against HIV-1 entry process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodbE31viIEoLVg90H21EOLACvtfcHk0lgJvhoF9Ocw-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFWgsbk%253D&md5=ee617a973417efe3e4f5c4d7fc4213c3</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.01.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.01.046%26sid%3Dliteratum%253Aachs%26aulast%3DTeixeira%26aufirst%3DC.%26aulast%3DGomes%26aufirst%3DJ.%2BR.%26aulast%3DGomes%26aufirst%3DP.%26aulast%3DMaurel%26aufirst%3DF.%26aulast%3DBarbault%26aufirst%3DF.%26atitle%3DViral%2520surface%2520glycoproteins%252C%2520gp120%2520and%2520gp41%252C%2520as%2520potential%2520drug%2520targets%2520against%2520HIV-1%253A%2520brief%2520overview%2520one%2520quarter%2520of%2520a%2520century%2520past%2520the%2520approval%2520of%2520zidovudine%252C%2520the%2520first%2520anti-retroviral%2520drug%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D979%26epage%3D992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Copeland, R. A.</span> <span class="citation_source-book">Evaluation of Enzyme Inhibitors in Drug Discovery</span>; <span class="NLM_publisher-name">John Wiley & Sons</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=48-81&author=R.+A.+Copeland&title=Evaluation+of+Enzyme+Inhibitors+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26btitle%3DEvaluation%2520of%2520Enzyme%2520Inhibitors%2520in%2520Drug%2520Discovery%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D2005%26spage%3D48%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Cheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prusoff, W. H.</span><span> </span><span class="NLM_article-title">Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3099</span><span class="NLM_x">–</span> <span class="NLM_lpage">3108</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=Y.+Chengauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28K1%29+and+the+concentration+of+inhibitor+which+causes+50%25+inhibition+%28IC50%29+of+an+enzymatic+reaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528K1%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2525%2520inhibition%2520%2528IC50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29','ref29_2'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':[],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 46 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Alyah F. Chmiel, Oliver P. Williams, Colleen P. Chernowsky, Charles S. Yeung, <span class="NLM_string-name hlFld-ContribAuthor">Zachary K. Wickens</span>. </span><span class="cited-content_cbyCitation_article-title">Non-innocent Radical Ion Intermediates in Photoredox Catalysis: Parallel Reduction Modes Enable Coupling of Diverse Aryl Chlorides. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2021,</strong> <em>143 </em>
                                    (29)
                                     , 10882-10889. <a href="https://doi.org/10.1021/jacs.1c05988" title="DOI URL">https://doi.org/10.1021/jacs.1c05988</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.1c05988&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.1c05988%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DNon-innocent%252BRadical%252BIon%252BIntermediates%252Bin%252BPhotoredox%252BCatalysis%25253A%252BParallel%252BReduction%252BModes%252BEnable%252BCoupling%252Bof%252BDiverse%252BAryl%252BChlorides%26aulast%3DChmiel%26aufirst%3DAlyah%2BF.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D09062021%26date%3D13072021%26volume%3D143%26issue%3D29%26spage%3D10882%26epage%3D10889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Karen R. Winters, <span class="NLM_string-name hlFld-ContribAuthor">Jean-Luc Montchamp</span>. </span><span class="cited-content_cbyCitation_article-title">Evaluation and Development of Methodologies for the Synthesis of Thiophosphinic Acids. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (22)
                                     , 14545-14558. <a href="https://doi.org/10.1021/acs.joc.0c01151" title="DOI URL">https://doi.org/10.1021/acs.joc.0c01151</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c01151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c01151%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DEvaluation%252Band%252BDevelopment%252Bof%252BMethodologies%252Bfor%252Bthe%252BSynthesis%252Bof%252BThiophosphinic%252BAcids%26aulast%3DWinters%26aufirst%3DKaren%2BR.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D14052020%26date%3D11082020%26date%3D28072020%26volume%3D85%26issue%3D22%26spage%3D14545%26epage%3D14558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yuantai Xu, Bing Wang, Julong Jiang, Haizhu Yu, <span class="NLM_string-name hlFld-ContribAuthor">Yao Fu</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanistic Study on Decarbonylative Phosphorylation of Aryl Amides by Nickel Catalysis. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (15)
                                     , 9474-9479. <a href="https://doi.org/10.1021/acs.joc.9b00962" title="DOI URL">https://doi.org/10.1021/acs.joc.9b00962</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b00962&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b00962%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DMechanistic%252BStudy%252Bon%252BDecarbonylative%252BPhosphorylation%252Bof%252BAryl%252BAmides%252Bby%252BNickel%252BCatalysis%26aulast%3DXu%26aufirst%3DYuantai%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D08042019%26date%3D12062019%26date%3D03062019%26volume%3D84%26issue%3D15%26spage%3D9474%26epage%3D9479" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yong Jian, Ming Chen, Binbin Huang, Wei Jia, Chao Yang, <span class="NLM_string-name hlFld-ContribAuthor">Wujiong Xia</span>. </span><span class="cited-content_cbyCitation_article-title">Visible-Light-Induced C(sp2)–P Bond Formation by Denitrogenative Coupling of Benzotriazoles with Phosphites. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (17)
                                     , 5370-5374. <a href="https://doi.org/10.1021/acs.orglett.8b02288" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b02288</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b02288&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b02288%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DVisible-Light-Induced%252BC%252528sp2%252529%2525E2%252580%252593P%252BBond%252BFormation%252Bby%252BDenitrogenative%252BCoupling%252Bof%252BBenzotriazoles%252Bwith%252BPhosphites%26aulast%3DJian%26aufirst%3DYong%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D21072018%26date%3D13082018%26volume%3D20%26issue%3D17%26spage%3D5370%26epage%3D5374" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sandip B.  Bharate</span>, <span class="hlFld-ContribAuthor ">Vikas  Kumar</span>, <span class="hlFld-ContribAuthor ">Shreyans K.  Jain</span>, <span class="hlFld-ContribAuthor ">Mubashir J.  Mintoo</span>, <span class="hlFld-ContribAuthor ">Santosh K.  Guru</span>, <span class="hlFld-ContribAuthor ">Vijay K.  Nuthakki</span>, <span class="hlFld-ContribAuthor ">Mohit  Sharma</span>, <span class="hlFld-ContribAuthor ">Sonali S.  Bharate</span>, <span class="hlFld-ContribAuthor ">Sumit G.  Gandhi</span>, <span class="hlFld-ContribAuthor ">Dilip M.  Mondhe</span>, <span class="hlFld-ContribAuthor ">Shashi  Bhushan</span>, and <span class="hlFld-ContribAuthor ">Ram A.  Vishwakarma</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-Dependent Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (4)
                                     , 1664-1687. <a href="https://doi.org/10.1021/acs.jmedchem.7b01765" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01765</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01765&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01765%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BPreclinical%252BDevelopment%252Bof%252BIIIM-290%25252C%252Ban%252BOrally%252BActive%252BPotent%252BCyclin-Dependent%252BKinase%252BInhibitor%26aulast%3DBharate%26aufirst%3DSandip%2BB.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D30112017%26date%3D06022018%26date%3D22022018%26date%3D25012018%26volume%3D61%26issue%3D4%26spage%3D1664%26epage%3D1687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rebekah R.  Shippy</span>, <span class="hlFld-ContribAuthor ">Xiaochen  Lin</span>, <span class="hlFld-ContribAuthor ">Sherry S.  Agabiti</span>, <span class="hlFld-ContribAuthor ">Jin  Li</span>, <span class="hlFld-ContribAuthor ">Brendan M.  Zangari</span>, <span class="hlFld-ContribAuthor ">Benjamin J.  Foust</span>, <span class="hlFld-ContribAuthor ">Michael M.  Poe</span>, <span class="hlFld-ContribAuthor ">Chia-Hung Christine  Hsiao</span>, <span class="hlFld-ContribAuthor ">Olga  Vinogradova</span>, <span class="hlFld-ContribAuthor ">David F.  Wiemer</span>, and <span class="hlFld-ContribAuthor ">Andrew J.  Wiemer</span>  . </span><span class="cited-content_cbyCitation_article-title">Phosphinophosphonates and Their Tris-pivaloyloxymethyl Prodrugs Reveal a Negatively Cooperative Butyrophilin Activation Mechanism. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (6)
                                     , 2373-2382. <a href="https://doi.org/10.1021/acs.jmedchem.6b00965" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00965</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00965&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00965%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPhosphinophosphonates%252Band%252BTheir%252BTris-pivaloyloxymethyl%252BProdrugs%252BReveal%252Ba%252BNegatively%252BCooperative%252BButyrophilin%252BActivation%252BMechanism%26aulast%3DShippy%26aufirst%3DRebekah%2BR.%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D03112016%26date%3D01032017%26date%3D23032017%26date%3D20022017%26volume%3D60%26issue%3D6%26spage%3D2373%26epage%3D2382" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yogesh A.  Sonawane</span>, <span class="hlFld-ContribAuthor ">Margaret A.  Taylor</span>, <span class="hlFld-ContribAuthor ">John Victor  Napoleon</span>, <span class="hlFld-ContribAuthor ">Sandeep  Rana</span>, <span class="hlFld-ContribAuthor ">Jacob I.  Contreras</span>, and <span class="hlFld-ContribAuthor ">Amarnath  Natarajan</span>  . </span><span class="cited-content_cbyCitation_article-title">Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (19)
                                     , 8667-8684. <a href="https://doi.org/10.1021/acs.jmedchem.6b00150" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00150</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00150%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCyclin%252BDependent%252BKinase%252B9%252BInhibitors%252Bfor%252BCancer%252BTherapy%26aulast%3DSonawane%26aufirst%3DYogesh%2BA.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D29012016%26date%3D03062016%26date%3D13102016%26date%3D12052016%26volume%3D59%26issue%3D19%26spage%3D8667%26epage%3D8684" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chun-Xiao  Li</span>, <span class="hlFld-ContribAuthor ">De-Shuang  Tu</span>, <span class="hlFld-ContribAuthor ">Rui  Yao</span>, <span class="hlFld-ContribAuthor ">Hong  Yan</span>, and <span class="hlFld-ContribAuthor ">Chang-Sheng  Lu</span>  . </span><span class="cited-content_cbyCitation_article-title">Visible-Light-Induced Cascade Reaction of Isocyanides and N-Arylacrylamides with Diphenylphosphine Oxide via Radical C–P and C–C Bond Formation. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2016,</strong> <em>18 </em>
                                    (19)
                                     , 4928-4931. <a href="https://doi.org/10.1021/acs.orglett.6b02413" title="DOI URL">https://doi.org/10.1021/acs.orglett.6b02413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.6b02413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.6b02413%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DVisible-Light-Induced%252BCascade%252BReaction%252Bof%252BIsocyanides%252Band%252BN-Arylacrylamides%252Bwith%252BDiphenylphosphine%252BOxide%252Bvia%252BRadical%252BC%2525E2%252580%252593P%252Band%252BC%2525E2%252580%252593C%252BBond%252BFormation%26aulast%3DLi%26aufirst%3DChun-Xiao%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D12082016%26date%3D28092016%26date%3D07102016%26volume%3D18%26issue%3D19%26spage%3D4928%26epage%3D4931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jia  Yang</span>, <span class="hlFld-ContribAuthor ">Jing  Xiao</span>, <span class="hlFld-ContribAuthor ">Tieqiao  Chen</span>, and <span class="hlFld-ContribAuthor ">Li-Biao  Han</span>  . </span><span class="cited-content_cbyCitation_article-title">Nickel-Catalyzed Phosphorylation of Phenol Derivatives via C–O/P–H Cross-Coupling. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>81 </em>
                                    (9)
                                     , 3911-3916. <a href="https://doi.org/10.1021/acs.joc.6b00289" title="DOI URL">https://doi.org/10.1021/acs.joc.6b00289</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.6b00289&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.6b00289%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DNickel-Catalyzed%252BPhosphorylation%252Bof%252BPhenol%252BDerivatives%252Bvia%252BC%2525E2%252580%252593O%25252FP%2525E2%252580%252593H%252BCross-Coupling%26aulast%3DYang%26aufirst%3DJia%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D08022016%26date%3D14042016%26date%3D06052016%26date%3D07042016%26volume%3D81%26issue%3D9%26spage%3D3911%26epage%3D3916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wai Chung  Fu</span>, <span class="hlFld-ContribAuthor ">Chau Ming  So</span>, and <span class="hlFld-ContribAuthor ">Fuk Yee  Kwong</span>  . </span><span class="cited-content_cbyCitation_article-title">Palladium-Catalyzed Phosphorylation of Aryl Mesylates and Tosylates. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2015,</strong> <em>17 </em>
                                    (23)
                                     , 5906-5909. <a href="https://doi.org/10.1021/acs.orglett.5b03104" title="DOI URL">https://doi.org/10.1021/acs.orglett.5b03104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.5b03104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.5b03104%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DPalladium-Catalyzed%252BPhosphorylation%252Bof%252BAryl%252BMesylates%252Band%252BTosylates%26aulast%3DFu%26aufirst%3DWai%2BChung%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D27102015%26date%3D17112015%26date%3D04122015%26volume%3D17%26issue%3D23%26spage%3D5906%26epage%3D5909" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ahmed  Numan</span>, <span class="hlFld-ContribAuthor ">Matthew  Brichacek</span>. </span><span class="cited-content_cbyCitation_article-title">Asymmetric Synthesis of Stereogenic Phosphorus P(V) Centers Using Chiral Nucleophilic Catalysis. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2021,</strong> <em>26 </em>
                                    (12)
                                     , 3661. <a href="https://doi.org/10.3390/molecules26123661" title="DOI URL">https://doi.org/10.3390/molecules26123661</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules26123661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules26123661%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DAsymmetric%252BSynthesis%252Bof%252BStereogenic%252BPhosphorus%252BP%252528V%252529%252BCenters%252BUsing%252BChiral%252BNucleophilic%252BCatalysis%26aulast%3DNuman%26aufirst%3DAhmed%26date%3D2021%26date%3D2021%26volume%3D26%26issue%3D12%26spage%3D3661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qian  Dou</span>, <span class="hlFld-ContribAuthor ">Li  Geng</span>, <span class="hlFld-ContribAuthor ">Bin  Cheng</span>, <span class="hlFld-ContribAuthor ">Chao-Jun  Li</span>, <span class="hlFld-ContribAuthor ">Huiying  Zeng</span>. </span><span class="cited-content_cbyCitation_article-title">Photoinduced transition-metal and external photosensitizer free cross-coupling of aryl triflates with trialkyl phosphites. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2021,</strong> <em>110 </em><a href="https://doi.org/10.1039/D1CC03496K" title="DOI URL">https://doi.org/10.1039/D1CC03496K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1CC03496K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1CC03496K%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DPhotoinduced%252Btransition-metal%252Band%252Bexternal%252Bphotosensitizer%252Bfree%252Bcross-coupling%252Bof%252Baryl%252Btriflates%252Bwith%252Btrialkyl%252Bphosphites%26aulast%3DDou%26aufirst%3DQian%26date%3D2021%26date%3D2021%26volume%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xunwei  Chen</span>, <span class="hlFld-ContribAuthor ">Wenjun  Luo</span>, <span class="hlFld-ContribAuthor ">Yanlin  Wang</span>, <span class="hlFld-ContribAuthor ">Zikang  Li</span>, <span class="hlFld-ContribAuthor ">Xiaorui  Ma</span>, <span class="hlFld-ContribAuthor ">Ai‐Yun  Peng</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient Synthesis of Phosphonamidates through One‐Pot Sequential Reactions of Phosphonites with Iodine and Amines. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2020,</strong> <em>26 </em>
                                    (63)
                                     , 14474-14480. <a href="https://doi.org/10.1002/chem.202002934" title="DOI URL">https://doi.org/10.1002/chem.202002934</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.202002934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.202002934%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DEfficient%252BSynthesis%252Bof%252BPhosphonamidates%252Bthrough%252BOne%2525E2%252580%252590Pot%252BSequential%252BReactions%252Bof%252BPhosphonites%252Bwith%252BIodine%252Band%252BAmines%26aulast%3DChen%26aufirst%3DXunwei%26date%3D2020%26date%3D2020%26volume%3D26%26issue%3D63%26spage%3D14474%26epage%3D14480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deepa  Rawat</span>, <span class="hlFld-ContribAuthor ">Rahul  Kumar</span>, <span class="hlFld-ContribAuthor ">Adimurthy  Subbarayappa</span>. </span><span class="cited-content_cbyCitation_article-title">Visible-light induced phosphonation of quinoxalines and quinoxalin-2(1
              H
              )-ones under aerobic metal-free conditions. </span><span class="cited-content_cbyCitation_journal-name">Green Chemistry</span><span> <strong>2020,</strong> <em>22 </em>
                                    (18)
                                     , 6170-6175. <a href="https://doi.org/10.1039/D0GC02168G" title="DOI URL">https://doi.org/10.1039/D0GC02168G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0GC02168G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0GC02168G%26sid%3Dliteratum%253Aachs%26jtitle%3DGreen%2520Chemistry%26atitle%3DVisible-light%252Binduced%252Bphosphonation%252Bof%252Bquinoxalines%252Band%252Bquinoxalin-2%2525281%252BH%252B%252529-ones%252Bunder%252Baerobic%252Bmetal-free%252Bconditions%26aulast%3DRawat%26aufirst%3DDeepa%26date%3D2020%26date%3D2020%26volume%3D22%26issue%3D18%26spage%3D6170%26epage%3D6175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saddam  Husen</span>, <span class="hlFld-ContribAuthor ">Anil  Chauhan</span>, <span class="hlFld-ContribAuthor ">Ravindra  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Site-selective 1,3-double functionalization of arenes using
              para
              -quinol, C–N, and C–C/C–P three-component coupling. </span><span class="cited-content_cbyCitation_journal-name">Green Chemistry</span><span> <strong>2020,</strong> <em>22 </em>
                                    (4)
                                     , 1119-1124. <a href="https://doi.org/10.1039/C9GC04103F" title="DOI URL">https://doi.org/10.1039/C9GC04103F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9GC04103F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9GC04103F%26sid%3Dliteratum%253Aachs%26jtitle%3DGreen%2520Chemistry%26atitle%3DSite-selective%252B1%25252C3-double%252Bfunctionalization%252Bof%252Barenes%252Busing%252Bpara%252B-quinol%25252C%252BC%2525E2%252580%252593N%25252C%252Band%252BC%2525E2%252580%252593C%25252FC%2525E2%252580%252593P%252Bthree-component%252Bcoupling%26aulast%3DHusen%26aufirst%3DSaddam%26date%3D2020%26date%3D2020%26volume%3D22%26issue%3D4%26spage%3D1119%26epage%3D1124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen-Yan  Tong</span>, <span class="hlFld-ContribAuthor ">Thu D.  Ly</span>, <span class="hlFld-ContribAuthor ">Tao-Tao  Zhao</span>, <span class="hlFld-ContribAuthor ">Yan-Bo  Wu</span>, <span class="hlFld-ContribAuthor ">Xiaotai  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Mechanism of C–P bond formation
              via
              Pd-catalyzed decarbonylative phosphorylation of amides: insight into the chemistry of the second coordination sphere. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2020,</strong> <em>56 </em>
                                    (1)
                                     , 113-116. <a href="https://doi.org/10.1039/C9CC07923H" title="DOI URL">https://doi.org/10.1039/C9CC07923H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CC07923H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CC07923H%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DMechanism%252Bof%252BC%2525E2%252580%252593P%252Bbond%252Bformation%252Bvia%252BPd-catalyzed%252Bdecarbonylative%252Bphosphorylation%252Bof%252Bamides%25253A%252Binsight%252Binto%252Bthe%252Bchemistry%252Bof%252Bthe%252Bsecond%252Bcoordination%252Bsphere%26aulast%3DTong%26aufirst%3DWen-Yan%26date%3D2020%26date%3D2020%26volume%3D56%26issue%3D1%26spage%3D113%26epage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qianming  Du</span>, <span class="hlFld-ContribAuthor ">Xi  Feng</span>, <span class="hlFld-ContribAuthor ">Yinuo  Wang</span>, <span class="hlFld-ContribAuthor ">Xi  Xu</span>, <span class="hlFld-ContribAuthor ">Yan  Zhang</span>, <span class="hlFld-ContribAuthor ">Xinliang  Qu</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>, <span class="hlFld-ContribAuthor ">Jinlei  Bian</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of phosphonamidate IDO1 inhibitors for the treatment of non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>182 </em>, 111629. <a href="https://doi.org/10.1016/j.ejmech.2019.111629" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111629</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111629%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bphosphonamidate%252BIDO1%252Binhibitors%252Bfor%252Bthe%252Btreatment%252Bof%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DDu%26aufirst%3DQianming%26date%3D2019%26volume%3D182%26spage%3D111629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fátima C.  Teixeira</span>, <span class="hlFld-ContribAuthor ">Ana I.  de Sá</span>, <span class="hlFld-ContribAuthor ">António P.S.  Teixeira</span>, <span class="hlFld-ContribAuthor ">C.M.  Rangel</span>. </span><span class="cited-content_cbyCitation_article-title">Nafion phosphonic acid composite membranes for proton exchange membranes fuel cells. </span><span class="cited-content_cbyCitation_journal-name">Applied Surface Science</span><span> <strong>2019,</strong> <em>487 </em>, 889-897. <a href="https://doi.org/10.1016/j.apsusc.2019.05.078" title="DOI URL">https://doi.org/10.1016/j.apsusc.2019.05.078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsusc.2019.05.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsusc.2019.05.078%26sid%3Dliteratum%253Aachs%26jtitle%3DApplied%2520Surface%2520Science%26atitle%3DNafion%252Bphosphonic%252Bacid%252Bcomposite%252Bmembranes%252Bfor%252Bproton%252Bexchange%252Bmembranes%252Bfuel%252Bcells%26aulast%3DTeixeira%26aufirst%3DF%25C3%25A1tima%2BC.%26date%3D2019%26volume%3D487%26spage%3D889%26epage%3D897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Réka  Henyecz</span>, <span class="hlFld-ContribAuthor ">György  Keglevich</span>. </span><span class="cited-content_cbyCitation_article-title">New Developments on the Hirao Reactions, Especially from “Green” Point of View. </span><span class="cited-content_cbyCitation_journal-name">Current Organic Synthesis</span><span> <strong>2019,</strong> <em>16 </em>
                                    (4)
                                     , 523-545. <a href="https://doi.org/10.2174/1570179416666190415110834" title="DOI URL">https://doi.org/10.2174/1570179416666190415110834</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1570179416666190415110834&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1570179416666190415110834%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Organic%2520Synthesis%26atitle%3DNew%252BDevelopments%252Bon%252Bthe%252BHirao%252BReactions%25252C%252BEspecially%252Bfrom%252B%2525E2%252580%25259CGreen%2525E2%252580%25259D%252BPoint%252Bof%252BView%26aulast%3DHenyecz%26aufirst%3DR%25C3%25A9ka%26date%3D2019%26volume%3D16%26issue%3D4%26spage%3D523%26epage%3D545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin-Chen  Zhan</span>, <span class="hlFld-ContribAuthor ">Yu-Yuan  Hei</span>, <span class="hlFld-ContribAuthor ">Jian-Lan  Song</span>, <span class="hlFld-ContribAuthor ">Peng-Cheng  Qian</span>, <span class="hlFld-ContribAuthor ">Xing-Guo  Zhang</span>, <span class="hlFld-ContribAuthor ">Chen-Liang  Deng</span>. </span><span class="cited-content_cbyCitation_article-title">Copper-catalyzed direct C–H phosphorylation of
              N
              -imino isoquinolinium ylides with H-phosphonates. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2019,</strong> <em>6 </em>
                                    (9)
                                     , 1453-1457. <a href="https://doi.org/10.1039/C9QO00107G" title="DOI URL">https://doi.org/10.1039/C9QO00107G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9QO00107G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9QO00107G%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DCopper-catalyzed%252Bdirect%252BC%2525E2%252580%252593H%252Bphosphorylation%252Bof%252BN%252B-imino%252Bisoquinolinium%252Bylides%252Bwith%252BH-phosphonates%26aulast%3DZhan%26aufirst%3DXin-Chen%26date%3D2019%26date%3D2019%26volume%3D6%26issue%3D9%26spage%3D1453%26epage%3D1457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Moaz M.  Abdou</span>, <span class="hlFld-ContribAuthor ">Paul M.  O’Neill</span>, <span class="hlFld-ContribAuthor ">Eric  Amigues</span>, <span class="hlFld-ContribAuthor ">Magdalini  Matziari</span>. </span><span class="cited-content_cbyCitation_article-title">Phosphinic acids: current status and potential for drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2019,</strong> <em>24 </em>
                                    (3)
                                     , 916-929. <a href="https://doi.org/10.1016/j.drudis.2018.11.016" title="DOI URL">https://doi.org/10.1016/j.drudis.2018.11.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2018.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2018.11.016%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DPhosphinic%252Bacids%25253A%252Bcurrent%252Bstatus%252Band%252Bpotential%252Bfor%252Bdrug%252Bdiscovery%26aulast%3DAbdou%26aufirst%3DMoaz%2BM.%26date%3D2019%26volume%3D24%26issue%3D3%26spage%3D916%26epage%3D929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiu-Li  Wu</span>, <span class="hlFld-ContribAuthor ">Xing-Guo  Chen</span>, <span class="hlFld-ContribAuthor ">Cong-De  Huo</span>, <span class="hlFld-ContribAuthor ">Xi-Cun  Wang</span>, <span class="hlFld-ContribAuthor ">Zheng-Jun  Quan</span>. </span><span class="cited-content_cbyCitation_article-title">Electrochemically driven P–H oxidation and functionalization: synthesis of carbamoylphosphonates from phosphoramides and alcohols. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2019,</strong> <em>43 </em>
                                    (3)
                                     , 1531-1535. <a href="https://doi.org/10.1039/C8NJ05739G" title="DOI URL">https://doi.org/10.1039/C8NJ05739G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8NJ05739G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8NJ05739G%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DElectrochemically%252Bdriven%252BP%2525E2%252580%252593H%252Boxidation%252Band%252Bfunctionalization%25253A%252Bsynthesis%252Bof%252Bcarbamoylphosphonates%252Bfrom%252Bphosphoramides%252Band%252Balcohols%26aulast%3DWu%26aufirst%3DQiu-Li%26date%3D2019%26date%3D2019%26volume%3D43%26issue%3D3%26spage%3D1531%26epage%3D1535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maxime J.  Jean</span>, <span class="hlFld-ContribAuthor ">Guillaume  Fiches</span>, <span class="hlFld-ContribAuthor ">Tsuyoshi  Hayashi</span>, <span class="hlFld-ContribAuthor ">Jian  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors. </span><span class="cited-content_cbyCitation_journal-name">AIDS Research and Human Retroviruses</span><span> <strong>2019,</strong> <em>35 </em>
                                    (1)
                                     , 1-24. <a href="https://doi.org/10.1089/aid.2018.0153" title="DOI URL">https://doi.org/10.1089/aid.2018.0153</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1089/aid.2018.0153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1089%2Faid.2018.0153%26sid%3Dliteratum%253Aachs%26jtitle%3DAIDS%2520Research%2520and%2520Human%2520Retroviruses%26atitle%3DCurrent%252BStrategies%252Bfor%252BElimination%252Bof%252BHIV-1%252BLatent%252BReservoirs%252BUsing%252BChemical%252BCompounds%252BTargeting%252BHost%252Band%252BViral%252BFactors%26aulast%3DJean%26aufirst%3DMaxime%2BJ.%26date%3D2019%26volume%3D35%26issue%3D1%26spage%3D1%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caroline E.  Zetterström</span>, <span class="hlFld-ContribAuthor ">Pia  Uusitalo</span>, <span class="hlFld-ContribAuthor ">Weixing  Qian</span>, <span class="hlFld-ContribAuthor ">Shannon  Hinch</span>, <span class="hlFld-ContribAuthor ">Rémi  Caraballo</span>, <span class="hlFld-ContribAuthor ">Christin  Grundström</span>, <span class="hlFld-ContribAuthor ">Mikael  Elofsson</span>. </span><span class="cited-content_cbyCitation_article-title">Screening for Inhibitors of Acetaldehyde Dehydrogenase (AdhE) from Enterohemorrhagic
              Escherichia coli
              (EHEC). </span><span class="cited-content_cbyCitation_journal-name">SLAS DISCOVERY: Advancing the Science of Drug Discovery</span><span> <strong>2018,</strong> <em>23 </em>
                                    (8)
                                     , 815-822. <a href="https://doi.org/10.1177/2472555218768062" title="DOI URL">https://doi.org/10.1177/2472555218768062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2472555218768062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2472555218768062%26sid%3Dliteratum%253Aachs%26jtitle%3DSLAS%2520DISCOVERY%253A%2520Advancing%2520the%2520Science%2520of%2520Drug%2520Discovery%26atitle%3DScreening%252Bfor%252BInhibitors%252Bof%252BAcetaldehyde%252BDehydrogenase%252B%252528AdhE%252529%252Bfrom%252BEnterohemorrhagic%252BEscherichia%252Bcoli%252B%252528EHEC%252529%26aulast%3DZetterstr%25C3%25B6m%26aufirst%3DCaroline%2BE.%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D8%26spage%3D815%26epage%3D822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zoltán  Nemes</span>, <span class="hlFld-ContribAuthor ">Krisztina  Takács-Novák</span>, <span class="hlFld-ContribAuthor ">Gergely  Völgyi</span>, <span class="hlFld-ContribAuthor ">Klara  Valko</span>, <span class="hlFld-ContribAuthor ">Szabolcs  Béni</span>, <span class="hlFld-ContribAuthor ">Zoltán  Horváth</span>, <span class="hlFld-ContribAuthor ">Bálint  Szokol</span>, <span class="hlFld-ContribAuthor ">Nóra  Breza</span>, <span class="hlFld-ContribAuthor ">Judit  Dobos</span>, <span class="hlFld-ContribAuthor ">Csaba  Szántai-Kis</span>, <span class="hlFld-ContribAuthor ">Eszter  Illyés</span>, <span class="hlFld-ContribAuthor ">Sándor  Boros</span>, <span class="hlFld-ContribAuthor ">Robbert Jan  Kok</span>, <span class="hlFld-ContribAuthor ">László  Őrfi</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and characterization of amino acid substituted sunitinib analogues for the treatment of AML. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (14)
                                     , 2391-2398. <a href="https://doi.org/10.1016/j.bmcl.2018.06.026" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.06.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.06.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.06.026%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bcharacterization%252Bof%252Bamino%252Bacid%252Bsubstituted%252Bsunitinib%252Banalogues%252Bfor%252Bthe%252Btreatment%252Bof%252BAML%26aulast%3DNemes%26aufirst%3DZolt%25C3%25A1n%26date%3D2018%26volume%3D28%26issue%3D14%26spage%3D2391%26epage%3D2398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yong-Hui  Wu</span>, <span class="hlFld-ContribAuthor ">Qiu-Li  Wu</span>, <span class="hlFld-ContribAuthor ">Wen-Peng  Wang</span>, <span class="hlFld-ContribAuthor ">Xi-Cun  Wang</span>, <span class="hlFld-ContribAuthor ">Zheng-Jun  Quan</span>. </span><span class="cited-content_cbyCitation_article-title">Iodine-Promoted Rapid Construction of Carbamoylphosphonates from Phosphinecarboxamides. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2018,</strong> <em>360 </em>
                                    (12)
                                     , 2382-2388. <a href="https://doi.org/10.1002/adsc.201800303" title="DOI URL">https://doi.org/10.1002/adsc.201800303</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201800303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201800303%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DIodine-Promoted%252BRapid%252BConstruction%252Bof%252BCarbamoylphosphonates%252Bfrom%252BPhosphinecarboxamides%26aulast%3DWu%26aufirst%3DYong-Hui%26date%3D2018%26date%3D2018%26volume%3D360%26issue%3D12%26spage%3D2382%26epage%3D2388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amy B  Heptinstall</span>, <span class="hlFld-ContribAuthor ">IWS  Adiyasa</span>, <span class="hlFld-ContribAuthor ">Céline  Cano</span>, <span class="hlFld-ContribAuthor ">Ian R  Hardcastle</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in CDK inhibitors for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2018,</strong> <em>10 </em>
                                    (11)
                                     , 1369-1388. <a href="https://doi.org/10.4155/fmc-2017-0246" title="DOI URL">https://doi.org/10.4155/fmc-2017-0246</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2017-0246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2017-0246%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252BCDK%252Binhibitors%252Bfor%252Bcancer%252Btherapy%26aulast%3DHeptinstall%26aufirst%3DAmy%2BB%26date%3D2018%26volume%3D10%26issue%3D11%26spage%3D1369%26epage%3D1388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zsófia  Czudor</span>, <span class="hlFld-ContribAuthor ">Mária  Balogh</span>, <span class="hlFld-ContribAuthor ">Péter  Bánhegyi</span>, <span class="hlFld-ContribAuthor ">Sándor  Boros</span>, <span class="hlFld-ContribAuthor ">Nóra  Breza</span>, <span class="hlFld-ContribAuthor ">Judit  Dobos</span>, <span class="hlFld-ContribAuthor ">Márk  Fábián</span>, <span class="hlFld-ContribAuthor ">Zoltán  Horváth</span>, <span class="hlFld-ContribAuthor ">Eszter  Illyés</span>, <span class="hlFld-ContribAuthor ">Péter  Markó</span>, <span class="hlFld-ContribAuthor ">Anna  Sipos</span>, <span class="hlFld-ContribAuthor ">Csaba  Szántai-Kis</span>, <span class="hlFld-ContribAuthor ">Bálint  Szokol</span>, <span class="hlFld-ContribAuthor ">László  Őrfi</span>. </span><span class="cited-content_cbyCitation_article-title">Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (4)
                                     , 769-773. <a href="https://doi.org/10.1016/j.bmcl.2018.01.002" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.01.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.01.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.01.002%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNovel%252Bcompounds%252Bwith%252Bpotent%252BCDK9%252Binhibitory%252Bactivity%252Bfor%252Bthe%252Btreatment%252Bof%252Bmyeloma%26aulast%3DCzudor%26aufirst%3DZs%25C3%25B3fia%26date%3D2018%26volume%3D28%26issue%3D4%26spage%3D769%26epage%3D773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Di  Li</span>, <span class="hlFld-ContribAuthor ">Rammohan R. Yadav  Bheemanaboina</span>, <span class="hlFld-ContribAuthor ">Narsaiah  Battini</span>, <span class="hlFld-ContribAuthor ">Vijai Kumar Reddy  Tangadanchu</span>, <span class="hlFld-ContribAuthor ">Xian-Fu  Fang</span>, <span class="hlFld-ContribAuthor ">Cheng-He  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Novel organophosphorus aminopyrimidines as unique structural DNA-targeting membrane active inhibitors towards drug-resistant methicillin-resistant
              Staphylococcus aureus. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2018,</strong> <em>9 </em>
                                    (9)
                                     , 1529-1537. <a href="https://doi.org/10.1039/C8MD00301G" title="DOI URL">https://doi.org/10.1039/C8MD00301G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8MD00301G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8MD00301G%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DNovel%252Borganophosphorus%252Baminopyrimidines%252Bas%252Bunique%252Bstructural%252BDNA-targeting%252Bmembrane%252Bactive%252Binhibitors%252Btowards%252Bdrug-resistant%252Bmethicillin-resistant%252BStaphylococcus%252Baureus%26aulast%3DLi%26aufirst%3DDi%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D9%26spage%3D1529%26epage%3D1537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Victor  Snieckus</span>, <span class="hlFld-ContribAuthor ">Gerald  J. Tanoury</span>, <span class="hlFld-ContribAuthor ">Sahaj  Gupta</span>, <span class="hlFld-ContribAuthor ">Jennifer  A. Melanson</span>, <span class="hlFld-ContribAuthor ">M  Selim Hossain</span>, <span class="hlFld-ContribAuthor ">Louis  Vaillancourt</span>, <span class="hlFld-ContribAuthor ">William  A. Nugent</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 4-Aryl and Unsymmetrical 4,6-Diarylpyrimidines by the Suzuki-Miyaura Cross-Coupling Reaction. </span><span class="cited-content_cbyCitation_journal-name">HETEROCYCLES</span><span> <strong>2018,</strong> <em>96 </em>
                                    (9)
                                     , 1549. <a href="https://doi.org/10.3987/COM-18-13956" title="DOI URL">https://doi.org/10.3987/COM-18-13956</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3987/COM-18-13956&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3987%2FCOM-18-13956%26sid%3Dliteratum%253Aachs%26jtitle%3DHETEROCYCLES%26atitle%3DSynthesis%252Bof%252B4-Aryl%252Band%252BUnsymmetrical%252B4%25252C6-Diarylpyrimidines%252Bby%252Bthe%252BSuzuki-Miyaura%252BCross-Coupling%252BReaction%26aulast%3DSnieckus%26aufirst%3DVictor%26date%3D2018%26volume%3D96%26issue%3D9%26spage%3D1549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chengwei  Liu</span>, <span class="hlFld-ContribAuthor ">Michal  Szostak</span>. </span><span class="cited-content_cbyCitation_article-title">Decarbonylative Phosphorylation of Amides by Palladium and Nickel Catalysis: The Hirao Cross‐Coupling of Amide Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2017,</strong> <em>129 </em>
                                    (41)
                                     , 12892-12896. <a href="https://doi.org/10.1002/ange.201707102" title="DOI URL">https://doi.org/10.1002/ange.201707102</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201707102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201707102%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DDecarbonylative%252BPhosphorylation%252Bof%252BAmides%252Bby%252BPalladium%252Band%252BNickel%252BCatalysis%25253A%252BThe%252BHirao%252BCross%2525E2%252580%252590Coupling%252Bof%252BAmide%252BDerivatives%26aulast%3DLiu%26aufirst%3DChengwei%26date%3D2017%26date%3D2017%26volume%3D129%26issue%3D41%26spage%3D12892%26epage%3D12896" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chengwei  Liu</span>, <span class="hlFld-ContribAuthor ">Michal  Szostak</span>. </span><span class="cited-content_cbyCitation_article-title">Decarbonylative Phosphorylation of Amides by Palladium and Nickel Catalysis: The Hirao Cross‐Coupling of Amide Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2017,</strong> <em>56 </em>
                                    (41)
                                     , 12718-12722. <a href="https://doi.org/10.1002/anie.201707102" title="DOI URL">https://doi.org/10.1002/anie.201707102</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201707102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201707102%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DDecarbonylative%252BPhosphorylation%252Bof%252BAmides%252Bby%252BPalladium%252Band%252BNickel%252BCatalysis%25253A%252BThe%252BHirao%252BCross%2525E2%252580%252590Coupling%252Bof%252BAmide%252BDerivatives%26aulast%3DLiu%26aufirst%3DChengwei%26date%3D2017%26date%3D2017%26volume%3D56%26issue%3D41%26spage%3D12718%26epage%3D12722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Steven R.  Whittaker</span>, <span class="hlFld-ContribAuthor ">Aurélie  Mallinger</span>, <span class="hlFld-ContribAuthor ">Paul  Workman</span>, <span class="hlFld-ContribAuthor ">Paul A.  Clarke</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors of cyclin-dependent kinases as cancer therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2017,</strong> <em>173 </em>, 83-105. <a href="https://doi.org/10.1016/j.pharmthera.2017.02.008" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2017.02.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2017.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2017.02.008%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DInhibitors%252Bof%252Bcyclin-dependent%252Bkinases%252Bas%252Bcancer%252Btherapeutics%26aulast%3DWhittaker%26aufirst%3DSteven%2BR.%26date%3D2017%26volume%3D173%26spage%3D83%26epage%3D105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caroline M.  Robb</span>, <span class="hlFld-ContribAuthor ">Jacob I.  Contreras</span>, <span class="hlFld-ContribAuthor ">Smit  Kour</span>, <span class="hlFld-ContribAuthor ">Margaret A.  Taylor</span>, <span class="hlFld-ContribAuthor ">Mohammad  Abid</span>, <span class="hlFld-ContribAuthor ">Yogesh A.  Sonawane</span>, <span class="hlFld-ContribAuthor ">Muhammad  Zahid</span>, <span class="hlFld-ContribAuthor ">Daryl J.  Murry</span>, <span class="hlFld-ContribAuthor ">Amarnath  Natarajan</span>, <span class="hlFld-ContribAuthor ">Sandeep  Rana</span>. </span><span class="cited-content_cbyCitation_article-title">Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2017,</strong> <em>53 </em>
                                    (54)
                                     , 7577-7580. <a href="https://doi.org/10.1039/C7CC03879H" title="DOI URL">https://doi.org/10.1039/C7CC03879H</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7CC03879H&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7CC03879H%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DChemically%252Binduced%252Bdegradation%252Bof%252BCDK9%252Bby%252Ba%252Bproteolysis%252Btargeting%252Bchimera%252B%252528PROTAC%252529%26aulast%3DRobb%26aufirst%3DCaroline%2BM.%26date%3D2017%26date%3D2017%26volume%3D53%26issue%3D54%26spage%3D7577%26epage%3D7580" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tinghan  Li</span>, <span class="hlFld-ContribAuthor ">Tianwei  Weng</span>, <span class="hlFld-ContribAuthor ">Minzan  Zuo</span>, <span class="hlFld-ContribAuthor ">Zhihui  Wei</span>, <span class="hlFld-ContribAuthor ">Ming  Chen</span>, <span class="hlFld-ContribAuthor ">Zhiyu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2016,</strong> <em>8 </em>
                                    (17)
                                     , 2047-2076. <a href="https://doi.org/10.4155/fmc-2016-0129" title="DOI URL">https://doi.org/10.4155/fmc-2016-0129</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2016-0129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2016-0129%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bof%252Bcyclin-dependent%252Bkinase%252Binhibitors%252Bas%252Bpotential%252Banticancer%252Bagents%26aulast%3DLi%26aufirst%3DTinghan%26date%3D2016%26volume%3D8%26issue%3D17%26spage%3D2047%26epage%3D2076" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jia  Yang</span>, <span class="hlFld-ContribAuthor ">Jing  Xiao</span>, <span class="hlFld-ContribAuthor ">Tieqiao  Chen</span>, <span class="hlFld-ContribAuthor ">Li-Biao  Han</span>. </span><span class="cited-content_cbyCitation_article-title">Nickel-catalyzed phosphorylation of aryl triflates with P(O)H compounds. </span><span class="cited-content_cbyCitation_journal-name">Journal of Organometallic Chemistry</span><span> <strong>2016,</strong> <em>820 </em>, 120-124. <a href="https://doi.org/10.1016/j.jorganchem.2016.07.026" title="DOI URL">https://doi.org/10.1016/j.jorganchem.2016.07.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jorganchem.2016.07.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jorganchem.2016.07.026%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Organometallic%2520Chemistry%26atitle%3DNickel-catalyzed%252Bphosphorylation%252Bof%252Baryl%252Btriflates%252Bwith%252BP%252528O%252529H%252Bcompounds%26aulast%3DYang%26aufirst%3DJia%26date%3D2016%26volume%3D820%26spage%3D120%26epage%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benjamin J.  Foust</span>, <span class="hlFld-ContribAuthor ">Cheryl  Allen</span>, <span class="hlFld-ContribAuthor ">Sarah A.  Holstein</span>, <span class="hlFld-ContribAuthor ">David F.  Wiemer</span>. </span><span class="cited-content_cbyCitation_article-title">A new motif for inhibitors of geranylgeranyl diphosphate synthase. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (16)
                                     , 3734-3741. <a href="https://doi.org/10.1016/j.bmc.2016.06.019" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.06.019</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.06.019%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DA%252Bnew%252Bmotif%252Bfor%252Binhibitors%252Bof%252Bgeranylgeranyl%252Bdiphosphate%252Bsynthase%26aulast%3DFoust%26aufirst%3DBenjamin%2BJ.%26date%3D2016%26volume%3D24%26issue%3D16%26spage%3D3734%26epage%3D3741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kui  Zeng</span>, <span class="hlFld-ContribAuthor ">Lang  Chen</span>, <span class="hlFld-ContribAuthor ">Biquan  Xiong</span>, <span class="hlFld-ContribAuthor ">Yongbo  Zhou</span>, <span class="hlFld-ContribAuthor ">Chak-Tong  Au</span>, <span class="hlFld-ContribAuthor ">Shuang-Feng  Yin</span>. </span><span class="cited-content_cbyCitation_article-title">Base-promoted alkylation of P(O)OH compounds with amines via C–N bond cleavage. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2016,</strong> <em>57 </em>
                                    (21)
                                     , 2222-2226. <a href="https://doi.org/10.1016/j.tetlet.2016.04.009" title="DOI URL">https://doi.org/10.1016/j.tetlet.2016.04.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2016.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2016.04.009%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DBase-promoted%252Balkylation%252Bof%252BP%252528O%252529OH%252Bcompounds%252Bwith%252Bamines%252Bvia%252BC%2525E2%252580%252593N%252Bbond%252Bcleavage%26aulast%3DZeng%26aufirst%3DKui%26date%3D2016%26volume%3D57%26issue%3D21%26spage%3D2222%26epage%3D2226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oriana  Tabarrini</span>, <span class="hlFld-ContribAuthor ">Jenny  Desantis</span>, <span class="hlFld-ContribAuthor ">Serena  Massari</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the identification of Tat-mediated transactivation inhibitors: progressing toward a functional cure of HIV. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2016,</strong> <em>8 </em>
                                    (4)
                                     , 421-442. <a href="https://doi.org/10.4155/fmc.16.3" title="DOI URL">https://doi.org/10.4155/fmc.16.3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.16.3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.16.3%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bidentification%252Bof%252BTat-mediated%252Btransactivation%252Binhibitors%25253A%252Bprogressing%252Btoward%252Ba%252Bfunctional%252Bcure%252Bof%252BHIV%26aulast%3DTabarrini%26aufirst%3DOriana%26date%3D2016%26volume%3D8%26issue%3D4%26spage%3D421%26epage%3D442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kim Alex  Fredriksen</span>, <span class="hlFld-ContribAuthor ">Mohamed  Amedjkouh</span>. </span><span class="cited-content_cbyCitation_article-title">Investigation of Reactive Intermediates and Reaction Pathways in the Coupling Agent Mediated Phos­phonamidation Reaction. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2016,</strong> <em>2016 </em>
                                    (3)
                                     , 474-482. <a href="https://doi.org/10.1002/ejoc.201501244" title="DOI URL">https://doi.org/10.1002/ejoc.201501244</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.201501244&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.201501244%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DInvestigation%252Bof%252BReactive%252BIntermediates%252Band%252BReaction%252BPathways%252Bin%252Bthe%252BCoupling%252BAgent%252BMediated%252BPhos%2525C2%2525ADphonamidation%252BReaction%26aulast%3DFredriksen%26aufirst%3DKim%2BAlex%26date%3D2016%26date%3D2015%26volume%3D2016%26issue%3D3%26spage%3D474%26epage%3D482" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jean-Noël  Volle</span>, <span class="hlFld-ContribAuthor ">Remi  Guillon</span>, <span class="hlFld-ContribAuthor ">Frédéric  Bancel</span>, <span class="hlFld-ContribAuthor ">Yves-Alain  Bekro</span>, <span class="hlFld-ContribAuthor ">Jean-Luc  Pirat</span>, <span class="hlFld-ContribAuthor ">David  Virieux</span>. </span><span class="cited-content_cbyCitation_article-title">Phosphono- and Phosphinolactones in the Life Sciences. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 129-193. <a href="https://doi.org/10.1016/bs.aihch.2015.10.004" title="DOI URL">https://doi.org/10.1016/bs.aihch.2015.10.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2015.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2015.10.004%26sid%3Dliteratum%253Aachs%26atitle%3DPhosphono-%252Band%252BPhosphinolactones%252Bin%252Bthe%252BLife%252BSciences%26aulast%3DVolle%26aufirst%3DJean-No%25C3%25ABl%26date%3D2016%26spage%3D129%26epage%3D193%26pub%3DElsevier%26date%3D2016%26volume%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peipei  Huang</span>, <span class="hlFld-ContribAuthor ">Jiaxi  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of 2-oxophosphorindolines via the copper-catalyzed intramolecular aromatic C–H insertion of diazophosphonamidates. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2016,</strong> <em>6 </em>
                                    (68)
                                     , 63736-63748. <a href="https://doi.org/10.1039/C6RA10555F" title="DOI URL">https://doi.org/10.1039/C6RA10555F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C6RA10555F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC6RA10555F%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DSynthesis%252Bof%252B2-oxophosphorindolines%252Bvia%252Bthe%252Bcopper-catalyzed%252Bintramolecular%252Baromatic%252BC%2525E2%252580%252593H%252Binsertion%252Bof%252Bdiazophosphonamidates%26aulast%3DHuang%26aufirst%3DPeipei%26date%3D2016%26date%3D2016%26volume%3D6%26issue%3D68%26spage%3D63736%26epage%3D63748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Valentina  Gandin</span>, <span class="hlFld-ContribAuthor ">Alessandro  Ferrarese</span>, <span class="hlFld-ContribAuthor ">Martina  Dalla Via</span>, <span class="hlFld-ContribAuthor ">Cristina  Marzano</span>, <span class="hlFld-ContribAuthor ">Adriana  Chilin</span>, <span class="hlFld-ContribAuthor ">Giovanni  Marzaro</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N’-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2015,</strong> <em>5 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/srep16750" title="DOI URL">https://doi.org/10.1038/srep16750</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/srep16750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fsrep16750%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DTargeting%252Bkinases%252Bwith%252Banilinopyrimidines%25253A%252Bdiscovery%252Bof%252BN-phenyl-N%2525E2%252580%252599-%25255B4-%252528pyrimidin-4-ylamino%252529phenyl%25255Durea%252Bderivatives%252Bas%252Bselective%252Binhibitors%252Bof%252Bclass%252BIII%252Breceptor%252Btyrosine%252Bkinase%252Bsubfamily%26aulast%3DGandin%26aufirst%3DValentina%26date%3D2015%26date%3D2015%26volume%3D5%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Louisa J.  Phillipson</span>, <span class="hlFld-ContribAuthor ">David H.  Segal</span>, <span class="hlFld-ContribAuthor ">Tracy L.  Nero</span>, <span class="hlFld-ContribAuthor ">Michael W.  Parker</span>, <span class="hlFld-ContribAuthor ">Soo San  Wan</span>, <span class="hlFld-ContribAuthor ">Melanie  de Silva</span>, <span class="hlFld-ContribAuthor ">Mark A.  Guthridge</span>, <span class="hlFld-ContribAuthor ">Andrew H.  Wei</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Burns</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (19)
                                     , 6280-6296. <a href="https://doi.org/10.1016/j.bmc.2015.08.035" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.08.035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.08.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.08.035%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BSAR%252Bof%252Bnovel%252Bpyrazolo%25255B1%25252C5-a%25255Dpyrimidines%252Bas%252Binhibitors%252Bof%252BCDK9%26aulast%3DPhillipson%26aufirst%3DLouisa%2BJ.%26date%3D2015%26volume%3D23%26issue%3D19%26spage%3D6280%26epage%3D6296" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jiadi  Gao</span>, <span class="hlFld-ContribAuthor ">Cheng  Fang</span>, <span class="hlFld-ContribAuthor ">Zhiyan  Xiao</span>, <span class="hlFld-ContribAuthor ">Li  Huang</span>, <span class="hlFld-ContribAuthor ">Chin-Ho  Chen</span>, <span class="hlFld-ContribAuthor ">Li-Ting  Wang</span>, <span class="hlFld-ContribAuthor ">Kuo-Hsiung  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel 5-fluoro-
              N
              2
              ,
              N
              4
              -diphenylpyrimidine-2,4-diamines as potent inhibitors against CDK2 and CDK9. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2015,</strong> <em>6 </em>
                                    (3)
                                     , 444-454. <a href="https://doi.org/10.1039/C4MD00412D" title="DOI URL">https://doi.org/10.1039/C4MD00412D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4MD00412D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4MD00412D%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DDiscovery%252Bof%252Bnovel%252B5-fluoro-%252BN%252B2%252B%25252C%252BN%252B4%252B-diphenylpyrimidine-2%25252C4-diamines%252Bas%252Bpotent%252Binhibitors%252Bagainst%252BCDK2%252Band%252BCDK9%26aulast%3DGao%26aufirst%3DJiadi%26date%3D2015%26date%3D2015%26volume%3D6%26issue%3D3%26spage%3D444%26epage%3D454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guillaume  Mousseau</span>, <span class="hlFld-ContribAuthor ">Sonia  Mediouni</span>, <span class="hlFld-ContribAuthor ">Susana T.  Valente</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting HIV Transcription: The Quest for a Functional Cure. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 121-145. <a href="https://doi.org/10.1007/82_2015_435" title="DOI URL">https://doi.org/10.1007/82_2015_435</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/82_2015_435&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F82_2015_435%26sid%3Dliteratum%253Aachs%26atitle%3DTargeting%252BHIV%252BTranscription%25253A%252BThe%252BQuest%252Bfor%252Ba%252BFunctional%252BCure%26aulast%3DMousseau%26aufirst%3DGuillaume%26date%3D2015%26date%3D2015%26spage%3D121%26epage%3D145%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DThe%252BFuture%252Bof%252BHIV-1%252BTherapeutics%26aulast%3DTorbett%26aufirst%3DBruce%2BE.%26date%3D2015%26volume%3D389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structure of some representative sulfonamide CDK9 inhibitors (<b>1</b>–<b>5</b>), the flavopiridol <b>6</b>, and general structures of the presented phosphorus moieties. References: <b>1</b> and <b>3</b>,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a><b>2</b> and <b>4</b>,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a><b>5</b>,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a><b>6</b>.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Phosphonic Acid Chlorides, Preparation of Phosphonamidates <b>10</b>–<b>12</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Phenol Derivatives, Phosphorylation, and Hydrolysis<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) IPA, cat. HCl, reflux; (b) <i>t</i>-BuOK, THF, RT; (c) SnCl<sub>2</sub>, EtOH, reflux; (d) Me<sub>3</sub>SiCl, KI, acetone, reflux.</p></p></figure><figure data-id="sch3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <i>meta</i>- and <i>para</i>-Benzylphosphonate Intermediates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) TEA, toluene, RT; (b) HCOOH·NH<sub>3</sub>, Pd/C, MeOH, RT; (c) MeSO<sub>2</sub>Cl, TEA, THF, RT; (d) NH<sub>2</sub>–NH<sub>2</sub>, Pd/C, MeOH, RT; (e) cat. H<sub>2</sub>SO<sub>4</sub>, EtOH, reflux; (f) LiAlH<sub>4</sub>, THF, RT; (g) PBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, RT; (h) P(OEt)<sub>3</sub>, neat, 140 °C; (i) HCOOH·NH<sub>3</sub>, Pd/C, MeOH, RT.</p></p></figure><figure data-id="sch4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <i>meta</i>- and <i>para</i>-Benzylphosphonates and Phosphonic Acids<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) IPA, cat. HCl, reflux; (b) SnCl<sub>2</sub>, EtOH, reflux; (c) (1) HCl (5 M), reflux, (2) propylene oxide, EtOH, 0 °C.</p></p></figure><figure data-id="sch5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <i>meta</i>- and <i>para</i>-Benzylphosphinate Intermediates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) neat, 140 °C; (b) HC(OEt)<sub>3</sub>, RT; (c) SnCl<sub>2</sub>, EtOH, reflux.</p></p></figure><figure data-id="sch6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <i>meta</i>- and <i>para</i>-Benzylphosphinates and Phosphinic Acids<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) IPA, cat. HCl, reflux; (b) SnCl<sub>2</sub>, EtOH, reflux; (c) Me<sub>3</sub>SiCl, KI, CHCl<sub>3</sub>, reflux.</p></p></figure><figure data-id="sch7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0023.jpeg" id="rightTab-GRAPHIC-d1187e1101-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Anilinophosphinates and Phosphonates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, Et<sub>3</sub>N, toluene, reflux; (b) SnCl<sub>2</sub>, EtOH, reflux.</p></p></figure><figure data-id="sch8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0010.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of <i>meta</i>- and <i>para</i>-Arylphosphinates and Arylphosphinates<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) IPA, cat. HCl, reflux; (b) SnCl<sub>2</sub>, EtOH, reflux; (c) (1) HCl (5 M), reflux, (2) propylene oxide, EtOH, 0 °C.</p></p></figure><figure data-id="sch9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0011.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of 6-Phenyl Analogues<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME, H<sub>2</sub>O, RT, reflux; (b) IPA, cat. HCl, reflux.</p></p></figure><figure data-id="sch10" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0012.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of the Compounds with the Optimal Substituent Combination<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) IPA, cat. HCl, reflux; (b) Me<sub>3</sub>SiCl, KI, CHCl<sub>3</sub>, reflux.</p></p></figure><figure data-id="fig2" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Kinase selectivity profiles of flavopiridol (<i>K</i><sub>d</sub> ≤ 1 μM; CDK9 is highlighted with blue)<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> and compound <b>93</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/medium/jm-2013-01742r_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Determination of ATP competition of six inhibitors at 260 nM inhibitor concentration.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-10/jm401742r/production/images/large/jm-2013-01742r_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401742r&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i187">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41225" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41225" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 43 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Cohen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alessi, D. R.</span><span> </span><span class="NLM_article-title">Kinase drug discovery—what’s next in the field?</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">96</span><span class="NLM_x">–</span> <span class="NLM_lpage">104</span></span><div class="citationLinks">[<a href="/doi/10.1021/cb300610s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=96-104&author=P.+Cohenauthor=D.+R.+Alessi&title=Kinase+drug+discovery%E2%80%94what%E2%80%99s+next+in+the+field%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fcb300610s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb300610s%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DP.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26atitle%3DKinase%2520drug%2520discovery%25E2%2580%2594what%25E2%2580%2599s%2520next%2520in%2520the%2520field%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D96%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="2b6f595e4c586b6d6f6a">[email protected]</a>: FDA Approved Drug Products; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>: <span class="NLM_publisher-loc">Silver Spring, MD</span>; <a href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm" class="extLink">http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm</a>, accessed on November 12, 2013.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Drugs%40FDA%3A+FDA+Approved+Drug+Products%3B+U.S.+Food+and+Drug+Administration%3A+Silver+Spring%2C+MD%3B+http%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcder%2Fdrugsatfda%2Findex.cfm%2C+accessed+on+November+12%2C+2013."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%2540FDA%253A%2520FDA%2520Approved%2520Drug%2520Products%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Fisher, R. P.</span><span> </span><span class="NLM_article-title">The CDK Network: Linking Cycles of Cell Division and Gene Expression</span> <span class="citation_source-journal">Genes Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">731</span><span class="NLM_x">–</span> <span class="NLM_lpage">738</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1177%2F1947601912473308" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=23634260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A280%3ADC%252BC3srpvV2itA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=731-738&author=R.+P.+Fisher&title=The+CDK+Network%3A+Linking+Cycles+of+Cell+Division+and+Gene+Expression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">The CDK Network: Linking Cycles of Cell Division and Gene Expression</span></div><div class="casAuthors">Fisher Robert P</div><div class="citationInfo"><span class="NLM_cas:title">Genes & cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11-12</span>),
    <span class="NLM_cas:pages">731-8</span>
        ISSN:<span class="NLM_cas:issn">1947-6019</span>.
    </div><div class="casAbstract">Cyclin-dependent kinases (CDKs) play essential roles in cell proliferation and gene expression.  Although distinct sets of CDKs work in cell division and transcription by RNA polymerase II (Pol II), they share a CDK-activating kinase (CAK), which is itself a CDK-Cdk7-in metazoans.  Thus a unitary CDK network controls and may coordinate cycles of cell division and gene expression.  Recent work reveals decisive roles for Cdk7 in both pathways.  The CAK function of Cdk7 helps determine timing of activation and cyclin-binding preferences of different CDKs during the cell cycle.  In the transcription cycle, Cdk7 is both an effector kinase, which phosphorylates Pol II and other proteins and helps establish promoter-proximal pausing; and a CAK for Cdk9 (P-TEFb), which releases Pol II from the pause.  By governing the transition from initiation to elongation, Cdk7, Cdk9 and their substrates influence expression of genes important for developmental and cell-cycle decisions, and ensure co-transcriptional maturation of Pol II transcripts.  Cdk7 engaged in transcription also appears to be regulated by phosphorylation within its own activation (T) loop.  Here I review recent studies of CDK regulation in cell division and gene expression, and propose a model whereby mitogenic signals trigger a cascade of CDK T-loop phosphorylation that drives cells past the restriction (R) point, when continued cell-cycle progression becomes growth factor-independent.  Because R-point control is frequently deregulated in cancer, the CAK-CDK pathway is an attractive target for chemical inhibition aimed at impeding the inappropriate commitment to cell division.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS_ZrSWKg0eO3y-c-E1v-fmfW6udTcc2eZAzqczA_eCVbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srpvV2itA%253D%253D&md5=24c36366f64a3d308b3453ceeb453243</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1177%2F1947601912473308&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1947601912473308%26sid%3Dliteratum%253Aachs%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DThe%2520CDK%2520Network%253A%2520Linking%2520Cycles%2520of%2520Cell%2520Division%2520and%2520Gene%2520Expression%26jtitle%3DGenes%2520Cancer%26date%3D2012%26volume%3D3%26spage%3D731%26epage%3D738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Cicenas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valius, M.</span><span> </span><span class="NLM_article-title">The CDK inhibitors in cancer research and therapy</span> <span class="citation_source-journal">J. Cancer Res. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">137</span><span class="NLM_x">, </span> <span class="NLM_fpage">1409</span><span class="NLM_x">–</span> <span class="NLM_lpage">1418</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1007%2Fs00432-011-1039-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=21877198" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFynt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2011&pages=1409-1418&author=J.+Cicenasauthor=M.+Valius&title=The+CDK+inhibitors+in+cancer+research+and+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The CDK inhibitors in cancer research and therapy</span></div><div class="casAuthors">Cicenas, Jonas; Valius, Mindaugas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer Research and Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1409-1418</span>CODEN:
                <span class="NLM_cas:coden">JCROD7</span>;
        ISSN:<span class="NLM_cas:issn">0171-5216</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Chem. compds. that interfere with an enzymic function of kinases are useful for gaining insight into the complicated biochem. processes in mammalian cells.  Cyclin-dependent kinases (CDK) play an essential role in the control of the cell cycle and/or proliferation.  These kinases as well as their regulators are frequently deregulated in different human tumors.  Aberrations in CDK activity have also been obsd. in viral infections, Alzheimer's, Parkinson's diseases, ischemia and some proliferative disorders.  This led to an intensive search for small-mol. CDK inhibitors not only for research purposes, but also for therapeutic applications.  Here, we discuss seventeen CDK inhibitors and their use in cancer research or therapy.  This review should help researchers to decide which inhibitor is best suited for the specific purpose of their research.  For this purpose, the targets, com. availability and IC50 values are provided for each inhibitor.  The review will also provide an overview of the clin. studies performed with some of these inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEjNnnzkVahrVg90H21EOLACvtfcHk0ljm01diC-NQ9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFynt7rK&md5=85500301e1d113148cf7854125e542ab</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1007%2Fs00432-011-1039-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00432-011-1039-4%26sid%3Dliteratum%253Aachs%26aulast%3DCicenas%26aufirst%3DJ.%26aulast%3DValius%26aufirst%3DM.%26atitle%3DThe%2520CDK%2520inhibitors%2520in%2520cancer%2520research%2520and%2520therapy%26jtitle%3DJ.%2520Cancer%2520Res.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D137%26spage%3D1409%26epage%3D1418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Németh, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varga, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greff, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bencze, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sipos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szántai-Kis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baska, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gyuris, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelemenics, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szathmáry, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minárovits, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kéri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orfi, L.</span><span> </span><span class="NLM_article-title">Novel, Selective CDK9 Inhibitors for the Treatment of HIV Infection</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">342</span><span class="NLM_x">–</span> <span class="NLM_lpage">358</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.2174%2F092986711794839188" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=21143121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslahtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2011&pages=342-358&author=G.+N%C3%A9methauthor=Z.+Vargaauthor=Z.+Greffauthor=G.+Benczeauthor=A.+Siposauthor=C.+Sz%C3%A1ntai-Kisauthor=F.+Baskaauthor=A.+Gyurisauthor=K.+Kelemenicsauthor=Z.+Szathm%C3%A1ryauthor=J.+Min%C3%A1rovitsauthor=G.+K%C3%A9riauthor=L.+Orfi&title=Novel%2C+Selective+CDK9+Inhibitors+for+the+Treatment+of+HIV+Infection"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Novel, selective CDK9 inhibitors for the treatment of HIV infection</span></div><div class="casAuthors">Nemeth, G.; Varga, Z.; Greff, Z.; Bencze, G.; Sipos, A.; Szantai-Kis, C.; Baska, F.; Gyuris, A.; Kelemenics, K.; Szathmary, Z.; Minarovits, J.; Keri, G.; Orfi, L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">342-358</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Cyclin Dependent Kinases (CDKs) are important regulators of cell cycle and gene expression.  Since an up-to-date review about the pharmacol. inhibitors of CDK family (CDK1-10) is not available; therefore in the present paper we briefly summarize the most relevant inhibitors and point out the low no. of selective inhibitors.  Among CDKs, CDK9 is a validated pathol. target in HIV infection, inflammation and cardiac hypertrophy; however selective CDK9 inhibitors are still not available.  We present a selective inhibitor family of CDK9 based on the 4-phenylamino-6-phenylpyrimidine nucleus.  We show a convenient synthetic method to prep. a useful intermediate and its derivatisation resulting in novel compds.  The CDK9 inhibitory activity of the derivs. was measured in specific kinase assay and the CDK inhibitory profile of the best ones (IC50 < 100nM) was detd.  The most selective compds. had high selectivity over CDK1, 2, 3, 5, 6, 7 and showed at least one order of magnitude higher inhibitory activity over CDK4 inhibition.  The most selective mols. were examd. in cytotoxicity assays and their ability to inhibit HIV-1 replication was detd. in cellular assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-AaopHRq0S7Vg90H21EOLACvtfcHk0lh-1lBaiiexIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslahtr4%253D&md5=2777a90d212ded68b2399beb97d48531</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.2174%2F092986711794839188&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986711794839188%26sid%3Dliteratum%253Aachs%26aulast%3DN%25C3%25A9meth%26aufirst%3DG.%26aulast%3DVarga%26aufirst%3DZ.%26aulast%3DGreff%26aufirst%3DZ.%26aulast%3DBencze%26aufirst%3DG.%26aulast%3DSipos%26aufirst%3DA.%26aulast%3DSz%25C3%25A1ntai-Kis%26aufirst%3DC.%26aulast%3DBaska%26aufirst%3DF.%26aulast%3DGyuris%26aufirst%3DA.%26aulast%3DKelemenics%26aufirst%3DK.%26aulast%3DSzathm%25C3%25A1ry%26aufirst%3DZ.%26aulast%3DMin%25C3%25A1rovits%26aufirst%3DJ.%26aulast%3DK%25C3%25A9ri%26aufirst%3DG.%26aulast%3DOrfi%26aufirst%3DL.%26atitle%3DNovel%252C%2520Selective%2520CDK9%2520Inhibitors%2520for%2520the%2520Treatment%2520of%2520HIV%2520Infection%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2011%26volume%3D18%26spage%3D342%26epage%3D358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Guha, M.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase inhibitors move into Phase III</span> <span class="citation_source-journal">Nature Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">892</span><span class="NLM_x">–</span> <span class="NLM_lpage">894</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=892-894&author=M.+Guha&title=Cyclin-dependent+kinase+inhibitors+move+into+Phase+III"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGuha%26aufirst%3DM.%26atitle%3DCyclin-dependent%2520kinase%2520inhibitors%2520move%2520into%2520Phase%2520III%26jtitle%3DNature%2520Rev.%2520Drug%2520Discovery%26date%3D2012%26volume%3D11%26spage%3D892%26epage%3D894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Canduri, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caceres, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Azevedo, W. F.,  Jr.</span><span> </span><span class="NLM_article-title">CDK9 a potential target for drug development</span> <span class="citation_source-journal">Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">210</span><span class="NLM_x">–</span> <span class="NLM_lpage">218</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.2174%2F157340608784325205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=18473913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmtFamtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=210-218&author=F.+Canduriauthor=P.+C.+Perezauthor=R.+A.+Caceresauthor=W.+F.+de+Azevedo&title=CDK9+a+potential+target+for+drug+development"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">CDK9 a potential target for drug development</span></div><div class="casAuthors">Canduri, Fernanda; Perez, Patricia Cardoso; Caceres, Rafael Andrade; Filgueira de Azevedo, Walter, Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">210-218</span>CODEN:
                <span class="NLM_cas:coden">MCEHAJ</span>;
        ISSN:<span class="NLM_cas:issn">1573-4064</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The family of cyclin-dependent kinases (CDKs) can be subdivided into 2 major functional groups based on their roles in cell cycle and/or transcriptional control.  CDK9 is the catalytic subunit of pos. transcription elongation factor b (P-TEFb).  CDK9 is the kinase of the TAK complex (Tat-assocd. kinase complex), and binds to Tat protein of HIV virus, suggesting a possible role for CDK9 in AIDS progression.  CDK9 complexed with its regulatory partner, cyclin T1, serves as a cellular mediator of the transactivation function of the HIV virus Tat protein.  P-TEFb is responsible for the phosphorylation of the C-terminal domain of RNA polymerase II, resulting in stimulation of transcription.  Furthermore, the complexes contg. CDK9 induce differentiation in distinct tissues.  The CDK9/cyclin T1 complex is expressed at higher levels in more differentiated primary neuroectodermal and neuroblastoma tumors, showing a correlation between kinase expression and tumor differentiation grade.  This may have clin. and therapeutical implications for these tumor types.  Among CDK inhibitors, 2 have been shown to be effective against CDK9; these are rescovitine and flavopiridol.  These 2 inhibitors have prevented the replication of HIV-1 virus by blocking Tat transactivation of the HIV-1 promoter.  These compds. inhibit CDKs by binding to the catalytic domain in place of ATP, preventing transfer of a phosphate group to the substrate.  More sensitive therapeutic agents of CDK9 can be designed, and structural studies can add information for the further understanding of this kinase.  Major features related to CDK9 inhibition are reviewed by the authors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpROfAvp0vSGbVg90H21EOLACvtfcHk0lh-1lBaiiexIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmtFamtro%253D&md5=390603a893aead917c500a56e2367bb1</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.2174%2F157340608784325205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157340608784325205%26sid%3Dliteratum%253Aachs%26aulast%3DCanduri%26aufirst%3DF.%26aulast%3DPerez%26aufirst%3DP.%2BC.%26aulast%3DCaceres%26aufirst%3DR.%2BA.%26aulast%3Dde%2BAzevedo%26aufirst%3DW.%2BF.%26atitle%3DCDK9%2520a%2520potential%2520target%2520for%2520drug%2520development%26jtitle%3DMed.%2520Chem.%26date%3D2008%26volume%3D4%26spage%3D210%26epage%3D218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span> </span><span class="NLM_article-title">Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">302</span><span class="NLM_x">–</span> <span class="NLM_lpage">313</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2008&pages=302-313&author=S.+Wangauthor=P.+M.+Fischer&title=Cyclin-dependent+kinase+9%3A+a+key+transcriptional+regulator+and+potential+drug+target+in+oncology%2C+virology+and+cardiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26atitle%3DCyclin-dependent%2520kinase%25209%253A%2520a%2520key%2520transcriptional%2520regulator%2520and%2520potential%2520drug%2520target%2520in%2520oncology%252C%2520virology%2520and%2520cardiology%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2008%26volume%3D29%26spage%3D302%26epage%3D313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Romano1, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, A.</span><span> </span><span class="NLM_article-title">Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases</span> <span class="citation_source-journal">Cell Cycle</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">3664</span><span class="NLM_x">–</span> <span class="NLM_lpage">3668</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=3664-3668&author=G.+Romano1author=A.+Giordano&title=Role+of+the+cyclin-dependent+kinase+9-related+pathway+in+mammalian+gene+expression+and+human+diseases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRomano1%26aufirst%3DG.%26aulast%3DGiordano%26aufirst%3DA.%26atitle%3DRole%2520of%2520the%2520cyclin-dependent%2520kinase%25209-related%2520pathway%2520in%2520mammalian%2520gene%2520expression%2520and%2520human%2520diseases%26jtitle%3DCell%2520Cycle%26date%3D2008%26volume%3D7%26spage%3D3664%26epage%3D3668" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Price, D. H.</span><span> </span><span class="NLM_article-title">P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2629</span><span class="NLM_x">–</span> <span class="NLM_lpage">2634</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1128%2FMCB.20.8.2629-2634.2000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=10733565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BD3cXit1ymur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=2629-2634&author=D.+H.+Price&title=P-TEFb%2C+a+cyclin-dependent+kinase+controlling+elongation+by+RNA+polymerase+II"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II</span></div><div class="casAuthors">Price, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2629-2634</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A review with 85 refs.  The topics discussed include identification of P-TEFb, cyclin dependence of P-TEFb, involvement of P-TEFb in HIV TAT transactivation, and mechanism of P-TEFb action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ1NqxL4k-67Vg90H21EOLACvtfcHk0liMXCXiLZZMdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXit1ymur0%253D&md5=3a1cfd6f46d2fa10d873497614bc99e3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1128%2FMCB.20.8.2629-2634.2000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.20.8.2629-2634.2000%26sid%3Dliteratum%253Aachs%26aulast%3DPrice%26aufirst%3DD.%2BH.%26atitle%3DP-TEFb%252C%2520a%2520cyclin-dependent%2520kinase%2520controlling%2520elongation%2520by%2520RNA%2520polymerase%2520II%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2000%26volume%3D20%26spage%3D2629%26epage%3D2634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">130</span><span class="NLM_x">, </span> <span class="NLM_fpage">1216</span><span class="NLM_x">–</span> <span class="NLM_lpage">1226</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1002%2Fijc.26127" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=21484792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Cgu7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2012&pages=1216-1226&author=X.+Liuauthor=S.+Shiauthor=F.+Lamauthor=C.+Pepperauthor=P.+M.+Fischerauthor=S.+Wang&title=CDKI-71%2C+a+novel+CDK9+inhibitor%2C+is+preferentially+cytotoxic+to+cancer+cells+compared+to+flavopiridol"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol</span></div><div class="casAuthors">Liu, Xiangrui; Shi, Shenhua; Lam, Frankie; Pepper, Chris; Fischer, Peter M.; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1216-1226</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Cancer cells appear to depend heavily on antiapoptotic proteins for survival and so targeted inhibition of these proteins has therapeutic potential.  One innovative strategy is to inhibit the cyclin-dependent kinases (CDKs) responsible for the regulation of RNA polymerase II (RNAPII).  In our study, we investigated the detailed cellular mechanism of a novel small-mol. CDK inhibitor (CDKI-71) in cancer cell lines, primary leukemia cells, normal B - & T- cells, and embryonic lung fibroblasts and compared the cellular and mol. responses to the clin. CDK inhibitor, flavopiridol.  Like flavopiridol, CDKI-71 displayed potent cytotoxicity and caspase-dependent apoptosis induction that were closely assocd. with the inhibition of RNAPII phosphorylation at serine-2.  This was caused by effective targeting of cyclinT-CDK9 and resulted in the downstream inhibition of Mcl-1.  No correlation between apoptosis and inhibition of cell-cycle CDKs 1 and 2 was obsd.  CDKI-71 showed a 10-fold increase in potency in tumor cell lines when compared to MRC-5 human fibroblast cells.  Significantly, CDKI-71 also demonstrated potent anti-chronic lymphocytic leukemia activity with minimal toxicity in normal B- and T-cells.  In contrast, flavopiridol showed little selectivity between cancer and normal cells.  Here, we provide the first cell-based evidence that flavopiridol induces DNA double-strand breaks: a fact which may explain why flavopiridol has such a narrow therapeutic window in preclin. and clin. settings.  Taken together, our data provide a rationale for the development of selective CDK inhibitors as therapeutic agents and CDKI-71 represents a promising lead in this context.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4fhWaal47LrVg90H21EOLACvtfcHk0liMXCXiLZZMdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Cgu7vP&md5=61b9dd817cb49855a436af69638a28f6</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fijc.26127&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.26127%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DLam%26aufirst%3DF.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DCDKI-71%252C%2520a%2520novel%2520CDK9%2520inhibitor%252C%2520is%2520preferentially%2520cytotoxic%2520to%2520cancer%2520cells%2520compared%2520to%2520flavopiridol%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2012%26volume%3D130%26spage%3D1216%26epage%3D1226" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Hussain, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheney, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grever, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caligiuri, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrd, J. C.</span><span> </span><span class="NLM_article-title">Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2144</span><span class="NLM_x">–</span> <span class="NLM_lpage">2150</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1158%2F1078-0432.CCR-06-2294" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=17404098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjs12rt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2007&pages=2144-2150&author=S.+R.+Hussainauthor=C.+M.+Cheneyauthor=A.+J.+Johnsonauthor=T.+S.+Linauthor=M.+R.+Greverauthor=M.+A.+Caligiuriauthor=D.+M.+Lucasauthor=J.+C.+Byrd&title=Mcl-1+is+a+relevant+therapeutic+target+in+acute+and+chronic+lymphoid+malignancies%3A+down-regulation+enhances+rituximab-mediated+apoptosis+and+complement-dependent+cytotoxicity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Mcl-1 Is a Relevant Therapeutic Target in Acute and Chronic Lymphoid Malignancies: Down-Regulation Enhances Rituximab-Mediated Apoptosis and Complement-Dependent Cytotoxicity</span></div><div class="casAuthors">Hussain, Syed-Rehan A.; Cheney, Carolyn M.; Johnson, Amy J.; Lin, Thomas S.; Grever, Michael R.; Caligiuri, Michael A.; Lucas, David M.; Byrd, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2144-2150</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The antiapoptotic Bcl-2 family member protein Mcl-1 is dynamically regulated in transformed B-cells, has a short mRNA and protein half-life, and is rapidly processed during apoptosis.  Multiple therapies cause down-regulation of Mcl-1 in chronic and acute lymphoid leukemia (CLL and ALL) cells.  Mcl-1 has also been reported to mediate resistance to rituximab in CLL.  We therefore investigated whether direct redn. of Mcl-1 was sufficient to induce apoptosis and increase sensitivity to rituximab.  Exptl. Design: We used Mcl-1-specific small interfering RNA in ALL cell lines and tumor cells from CLL patients to block transcription of Mcl-1.  RESULTS: We show that Mcl-1 down-regulation alone is sufficient to promote mitochondrial membrane depolarization and apoptosis in ALL and CLL cells.  Given the importance of rituximab in B-cell malignancies, we next assessed the influence of Mcl-1 down-regulation on antibody-mediated killing.  Mcl-1 down-regulation by small interfering RNA increased sensitivity to rituximab-mediated killing both by direct apoptosis and complement-dependent cytotoxicity, but did not enhance antibody-dependent cellular cytotoxicity.  CONCLUSIONS: These results show that Mcl-1 is a relevant therapeutic target for ALL and CLL, and its down-regulation has the potential to enhance the therapeutic effect of rituximab in CD20-bearing lymphoid cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqF8amg4BQHg7Vg90H21EOLACvtfcHk0liqsVZcnhcJlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjs12rt7c%253D&md5=23c6d82b7bfb48083888967329fdc1c9</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-06-2294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-06-2294%26sid%3Dliteratum%253Aachs%26aulast%3DHussain%26aufirst%3DS.%2BR.%26aulast%3DCheney%26aufirst%3DC.%2BM.%26aulast%3DJohnson%26aufirst%3DA.%2BJ.%26aulast%3DLin%26aufirst%3DT.%2BS.%26aulast%3DGrever%26aufirst%3DM.%2BR.%26aulast%3DCaligiuri%26aufirst%3DM.%2BA.%26aulast%3DLucas%26aufirst%3DD.%2BM.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26atitle%3DMcl-1%2520is%2520a%2520relevant%2520therapeutic%2520target%2520in%2520acute%2520and%2520chronic%2520lymphoid%2520malignancies%253A%2520down-regulation%2520enhances%2520rituximab-mediated%2520apoptosis%2520and%2520complement-dependent%2520cytotoxicity%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2007%26volume%3D13%26spage%3D2144%26epage%3D2150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Natoni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murillo, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kliszczak, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catherwood, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montagnoli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samali, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santocanale, C.</span><span> </span><span class="NLM_article-title">Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1624</span><span class="NLM_x">–</span> <span class="NLM_lpage">1634</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1158%2F1535-7163.MCT-10-1119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=21768328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFCjurjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=1624-1634&author=A.+Natoniauthor=L.+S.+Murilloauthor=A.+E.+Kliszczakauthor=M.+A.+Catherwoodauthor=A.+Montagnoliauthor=A.+Samaliauthor=M.+O%E2%80%99Dwyerauthor=C.+Santocanale&title=Mechanisms+of+action+of+a+dual+Cdc7%2FCdk9+kinase+inhibitor+against+quiescent+and+proliferating+CLL+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms of Action of a Dual Cdc7/Cdk9 Kinase Inhibitor against Quiescent and Proliferating CLL Cells</span></div><div class="casAuthors">Natoni, Alessandro; Murillo, Laura S.; Kliszczak, Anna E.; Catherwood, Mark A.; Montagnoli, Alessia; Samali, Afshin; O'Dwyer, Michael; Santocanale, Corrado</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1624-1634</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In chronic lymphocytic leukemia (CLL) the proliferation rate and resistance to drug-induced apoptosis are recognized as important factors in the outcome of treatment.  In this study, we assess the activity and the mechanism of action of the prototype cell division cycle kinase 7 (Cdc7) inhibitor, PHA-767491, which inhibits the initiation of DNA replication but also has cyclin-dependent kinase 9 (Cdk9) inhibitory activity.  We have studied the effects of this dual Cdc7/Cdk9 inhibitor in both quiescent CLL cells and CLL cells that have been induced to proliferate using a cellular coculture system that mimics the lymph node microenvironment.  We find that this compd., originally developed as a DNA replication inhibitor, is particularly active in promoting mitochondrial dependent apoptosis in quiescent CLL cells purified from peripheral blood of patients regardless of recognized risk factors.  In this setting, apoptosis is preceded by a decrease in the levels of Mcl-1 protein and transcript possibly due to inhibition of Cdk9.  Following stimulation by CD154 and interleukin-4, CLL cells become highly chemoresistant, reenter into the cell cycle, reexpress Cdc7 kinase, a key mol. switch for the initiation of DNA replication, replicate their DNA, and undergo cell division.  In this context, treatment with PHA-767491 abolished DNA synthesis by inhibiting Cdc7 but is less effective in triggering cell death, although Mcl-1 protein is no longer detectable.  Thus, dual Cdc7/Cdk9 inhibition has the potential to target both the quiescent and actively proliferating CLL populations through two distinct mechanisms and may be a new therapeutic strategy in CLL.  Mol Cancer Ther; 10(9); 1624-34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ3SCRs3F_mbVg90H21EOLACvtfcHk0liqsVZcnhcJlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFCjurjF&md5=a06bf6334282dd3054812e69488c5040</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-1119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-1119%26sid%3Dliteratum%253Aachs%26aulast%3DNatoni%26aufirst%3DA.%26aulast%3DMurillo%26aufirst%3DL.%2BS.%26aulast%3DKliszczak%26aufirst%3DA.%2BE.%26aulast%3DCatherwood%26aufirst%3DM.%2BA.%26aulast%3DMontagnoli%26aufirst%3DA.%26aulast%3DSamali%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DM.%26aulast%3DSantocanale%26aufirst%3DC.%26atitle%3DMechanisms%2520of%2520action%2520of%2520a%2520dual%2520Cdc7%252FCdk9%2520kinase%2520inhibitor%2520against%2520quiescent%2520and%2520proliferating%2520CLL%2520cells%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D1624%26epage%3D1634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Krystof, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chamrád, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jorda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohoutek, J.</span><span> </span><span class="NLM_article-title">Pharmacological targeting of CDK9 in cardiac hypertrophy</span> <span class="citation_source-journal">Med. Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">646</span><span class="NLM_x">–</span> <span class="NLM_lpage">666</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=19757441" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1Snurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=646-666&author=V.+Krystofauthor=I.+Chamr%C3%A1dauthor=R.+Jordaauthor=J.+Kohoutek&title=Pharmacological+targeting+of+CDK9+in+cardiac+hypertrophy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological targeting of CDK9 in cardiac hypertrophy</span></div><div class="casAuthors">Krystof, Vladimir; Chamrad, Ivo; Jorda, Radek; Kohoutek, Jiri</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">646-666</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Cardiac hypertrophy allows the heart to adapt to workload, but persistent or unphysiol. stimulus can result in pump failure.  Cardiac hypertrophy is characterized by an increase in the size of differentiated cardiac myocytes.  At the mol. level, growth of cells is linked to intensive transcription and translation.  Several cyclin-dependent kinases (CDKs) have been identified as principal regulators of transcription, and among these CDK9 is directly assocd. with cardiac hypertrophy.  CDK9 phosphorylates the C-terminal domain of RNA polymerase II and thus stimulates the elongation phase of transcription.  Chronic activation of CDK9 causes not only cardiac myocyte enlargement but also confers predisposition to heart failure.  Due to the long interest of mol. oncologists and medicinal chemists in CDKs as potential targets of anticancer drugs, a portfolio of small-mol. inhibitors of CDK9 is available.  Recent detn. of CDK9's crystal structure now allows the development of selective inhibitors and their further optimization in terms of biochem. potency and selectivity.  CDK9 may therefore constitute a novel target for drugs against cardiac hypertrophy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_kVWpP2zntLVg90H21EOLACvtfcHk0liqsVZcnhcJlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1Snurw%253D&md5=bc8a42d21dbd1653e550e00ddf1f3f91</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKrystof%26aufirst%3DV.%26aulast%3DChamr%25C3%25A1d%26aufirst%3DI.%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DKohoutek%26aufirst%3DJ.%26atitle%3DPharmacological%2520targeting%2520of%2520CDK9%2520in%2520cardiac%2520hypertrophy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2010%26volume%3D30%26spage%3D646%26epage%3D666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Schmerwitz, U. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sass, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khandoga, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joore, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berberich, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Totzke, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krombach, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiegs, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahler, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vollmar, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fürst, R.</span><span> </span><span class="NLM_article-title">Flavopiridol protects against inflammation by attenuating leukocyte–endothelial interaction via inhibition of cyclin-dependent kinase 9</span> <span class="citation_source-journal">Arterioscler. Thromb. Vasc. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">280</span><span class="NLM_x">–</span> <span class="NLM_lpage">288</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1161%2FATVBAHA.110.213934" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=21088252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvVSqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2011&pages=280-288&author=U.+K.+Schmerwitzauthor=G.+Sassauthor=A.+G.+Khandogaauthor=J.+Jooreauthor=B.+A.+Mayerauthor=N.+Berberichauthor=F.+Totzkeauthor=F.+Krombachauthor=G.+Tiegsauthor=S.+Zahlerauthor=A.+M.+Vollmarauthor=R.+F%C3%BCrst&title=Flavopiridol+protects+against+inflammation+by+attenuating+leukocyte%E2%80%93endothelial+interaction+via+inhibition+of+cyclin-dependent+kinase+9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9</span></div><div class="casAuthors">Schmerwitz, Ulrike K.; Sass, Gabriele; Khandoga, Alexander G.; Joore, Jos; Mayer, Bettina A.; Berberich, Nina; Totzke, Frank; Krombach, Fritz; Tiegs, Gisa; Zahler, Stefan; Vollmar, Angelika M.; Fuerst, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Arteriosclerosis, Thrombosis, and Vascular Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">280-288</span>CODEN:
                <span class="NLM_cas:coden">ATVBFA</span>;
        ISSN:<span class="NLM_cas:issn">1079-5642</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">OBJECTIVE-: The cyclin-dependent kinase (CDK) inhibitor flavopiridol is currently being tested in clin. trials as anticancer drug.  Beyond its cell death-inducing action, we hypothesized that flavopiridol affects inflammatory processes.  Therefore, we elucidated the action of flavopiridol on leukocyte-endothelial cell interaction and endothelial activation in vivo and in vitro and studied the underlying mol. mechanisms.  METHODS AND RESULTS-: Flavopiridol suppressed Con A-induced hepatitis and neutrophil infiltration into liver tissue.  Flavopiridol also inhibited tumor necrosis factor-α-induced leukocyte-endothelial cell interaction in the mouse cremaster muscle.  Endothelial cells were found to be the major target of flavopiridol, which blocked the expression of endothelial cell adhesion mols. (intercellular adhesion mol.-1, vascular cell adhesion mol.-1, and E-selectin), as well as NF-κB-dependent transcription.  Flavopiridol did not affect inhibitor of κB (IκB) kinase, the degrdn. and phosphorylation of IκBα, nuclear translocation of p65, or nuclear factor-κB (NF-κB) DNA-binding activity.  By performing a cellular kinome array and a kinase activity panel, we found LIM domain kinase-1 (LIMK1), casein kinase 2, c-Jun N-terminal kinase (JNK), protein kinase Cθ (PKCθ), CDK4, CDK6, CDK8, and CDK9 to be influenced by flavopiridol.  Using specific inhibitors, as well as RNA interference (RNAi), we revealed that only CDK9 is responsible for the action of flavopiridol.  CONCLUSION-: Our study highlights flavopiridol as a promising antiinflammatory compd. and inhibition of CDK9 as a novel approach for the treatment of inflammation-assocd. diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoacqgBRYYzeLVg90H21EOLACvtfcHk0ljmXMHjp9N7Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvVSqtQ%253D%253D&md5=1f502dec3988e3ef290a6a4469f0e50c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1161%2FATVBAHA.110.213934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FATVBAHA.110.213934%26sid%3Dliteratum%253Aachs%26aulast%3DSchmerwitz%26aufirst%3DU.%2BK.%26aulast%3DSass%26aufirst%3DG.%26aulast%3DKhandoga%26aufirst%3DA.%2BG.%26aulast%3DJoore%26aufirst%3DJ.%26aulast%3DMayer%26aufirst%3DB.%2BA.%26aulast%3DBerberich%26aufirst%3DN.%26aulast%3DTotzke%26aufirst%3DF.%26aulast%3DKrombach%26aufirst%3DF.%26aulast%3DTiegs%26aufirst%3DG.%26aulast%3DZahler%26aufirst%3DS.%26aulast%3DVollmar%26aufirst%3DA.%2BM.%26aulast%3DF%25C3%25BCrst%26aufirst%3DR.%26atitle%3DFlavopiridol%2520protects%2520against%2520inflammation%2520by%2520attenuating%2520leukocyte%25E2%2580%2593endothelial%2520interaction%2520via%2520inhibition%2520of%2520cyclin-dependent%2520kinase%25209%26jtitle%3DArterioscler.%2520Thromb.%2520Vasc.%2520Biol.%26date%3D2011%26volume%3D31%26spage%3D280%26epage%3D288" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Tahirov, T. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babayeva, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varzavand, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sedore, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. H.</span><span> </span><span class="NLM_article-title">Crystal structure of HIV-1 Tat complexed with human P-TEFb</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">465</span><span class="NLM_x">, </span> <span class="NLM_fpage">747</span><span class="NLM_x">–</span> <span class="NLM_lpage">751</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=465&publication_year=2010&pages=747-751&author=T.+H.+Tahirovauthor=N.+D.+Babayevaauthor=K.+Varzavandauthor=J.+J.+Cooperauthor=S.+C.+Sedoreauthor=D.+H.+Price&title=Crystal+structure+of+HIV-1+Tat+complexed+with+human+P-TEFb"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTahirov%26aufirst%3DT.%2BH.%26aulast%3DBabayeva%26aufirst%3DN.%2BD.%26aulast%3DVarzavand%26aufirst%3DK.%26aulast%3DCooper%26aufirst%3DJ.%2BJ.%26aulast%3DSedore%26aufirst%3DS.%2BC.%26aulast%3DPrice%26aufirst%3DD.%2BH.%26atitle%3DCrystal%2520structure%2520of%2520HIV-1%2520Tat%2520complexed%2520with%2520human%2520P-TEFb%26jtitle%3DNature%26date%3D2010%26volume%3D465%26spage%3D747%26epage%3D751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Salerno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasham, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garriga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsygankov, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graña, X.</span><span> </span><span class="NLM_article-title">Direct inhibition of CDK9 blocks HIV-1 replication without preventing T-cell activation in primary human peripheral blood lymphocytes</span> <span class="citation_source-journal">Gene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">405</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=405&publication_year=2007&pages=65-78&author=D.+Salernoauthor=M.+G.+Hashamauthor=R.+Marshallauthor=J.+Garrigaauthor=A.+Y.+Tsygankovauthor=X.+Gra%C3%B1a&title=Direct+inhibition+of+CDK9+blocks+HIV-1+replication+without+preventing+T-cell+activation+in+primary+human+peripheral+blood+lymphocytes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSalerno%26aufirst%3DD.%26aulast%3DHasham%26aufirst%3DM.%2BG.%26aulast%3DMarshall%26aufirst%3DR.%26aulast%3DGarriga%26aufirst%3DJ.%26aulast%3DTsygankov%26aufirst%3DA.%2BY.%26aulast%3DGra%25C3%25B1a%26aufirst%3DX.%26atitle%3DDirect%2520inhibition%2520of%2520CDK9%2520blocks%2520HIV-1%2520replication%2520without%2520preventing%2520T-cell%2520activation%2520in%2520primary%2520human%2520peripheral%2520blood%2520lymphocytes%26jtitle%3DGene%26date%3D2007%26volume%3D405%26spage%3D65%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Klebl, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choidas, A.</span><span> </span><span class="NLM_article-title">CDK9/cyclin T1: a host cell target for antiretroviral therapy</span> <span class="citation_source-journal">Future Virol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">317</span><span class="NLM_x">–</span> <span class="NLM_lpage">330</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.2217%2F17460794.1.3.317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvVyhsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=317-330&author=B.+M.+Kleblauthor=A.+Choidas&title=CDK9%2Fcyclin+T1%3A+a+host+cell+target+for+antiretroviral+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">CDK9/cyclin T1: a host cell target for antiretroviral therapy</span></div><div class="casAuthors">Klebl, Bert M.; Choidas, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Future Virology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">317-330</span>CODEN:
                <span class="NLM_cas:coden">FVUIAM</span>;
        ISSN:<span class="NLM_cas:issn">1746-0794</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Hijacking of the host cell's signal transduction machinery has been increasingly regarded as an important strategy for facilitating virus propagation.  The pos.-transcription elongation factor (P-TEFb) complex, cyclin-dependent kinase (CDK)9/cyclin T1, is an example of such an attack by HIV.  Upon infection of cells, the HIV protein transactivator of transcription (Tat) forms a highly specific complex with the two host cell proteins CDK9 and cyclin T1.  This complex ensures phosphorylation of the native CDK9 substrate, RNA polymerase II, leading to productive elongation of viral RNA in the host cell.  Although challenging, inhibition of CDK9 activity with small mols. is a therapeutically valid strategy to inhibit HIV replication.  Other than direct antiviral agents, that inhibit HIV replication through a direct interaction with viral proteins, CDK9 inhibitors might not suffer from the emergence of resistant virus strains.  This review outlines the advantages and prospects of selective CDK9 inhibitors in the management of HIV infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqW77hTG1dJSrVg90H21EOLACvtfcHk0ljmXMHjp9N7Mw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvVyhsbY%253D&md5=b397165e7103194e1cc7b33ce2f8bcbe</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.2217%2F17460794.1.3.317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252F17460794.1.3.317%26sid%3Dliteratum%253Aachs%26aulast%3DKlebl%26aufirst%3DB.%2BM.%26aulast%3DChoidas%26aufirst%3DA.%26atitle%3DCDK9%252Fcyclin%2520T1%253A%2520a%2520host%2520cell%2520target%2520for%2520antiretroviral%2520therapy%26jtitle%3DFuture%2520Virol.%26date%3D2006%26volume%3D1%26spage%3D317%26epage%3D330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Shao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hole, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abbas, A. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumli, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foley, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noble, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Endicott, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pepper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span> </span><span class="NLM_article-title">Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure–activity relationship, and anticancer activities</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">640</span><span class="NLM_x">–</span> <span class="NLM_lpage">659</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm301475f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=640-659&author=H.+Shaoauthor=S.+Shiauthor=S.+Huangauthor=A.+J.+Holeauthor=A.+Y.+Abbasauthor=S.+Baumliauthor=X.+Liuauthor=F.+Lamauthor=D.+W.+Foleyauthor=P.+M.+Fischerauthor=M.+Nobleauthor=J.+A.+Endicottauthor=C.+Pepperauthor=S.+Wang&title=Substituted+4-%28thiazol-5-yl%29-2-%28phenylamino%29pyrimidines+are+highly+active+CDK9+inhibitors%3A+synthesis%2C+X-ray+crystal+structures%2C+structure%E2%80%93activity+relationship%2C+and+anticancer+activities"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm301475f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301475f%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DAbbas%26aufirst%3DA.%2BY.%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLam%26aufirst%3DF.%26aulast%3DFoley%26aufirst%3DD.%2BW.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DNoble%26aufirst%3DM.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DSubstituted%25204-%2528thiazol-5-yl%2529-2-%2528phenylamino%2529pyrimidines%2520are%2520highly%2520active%2520CDK9%2520inhibitors%253A%2520synthesis%252C%2520X-ray%2520crystal%2520structures%252C%2520structure%25E2%2580%2593activity%2520relationship%252C%2520and%2520anticancer%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D640%26epage%3D659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Capranico, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marinello, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baranello, L.</span><span> </span><span class="NLM_article-title">Dissecting the transcriptional functions of human DNA topoisomerase I by selective inhibitors: implications for physiological and therapeutic modulation of enzyme activity</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1806</span><span class="NLM_x">, </span> <span class="NLM_fpage">240</span><span class="NLM_x">–</span> <span class="NLM_lpage">250</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1806&publication_year=2010&pages=240-250&author=G.+Capranicoauthor=J.+Marinelloauthor=L.+Baranello&title=Dissecting+the+transcriptional+functions+of+human+DNA+topoisomerase+I+by+selective+inhibitors%3A+implications+for+physiological+and+therapeutic+modulation+of+enzyme+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCapranico%26aufirst%3DG.%26aulast%3DMarinello%26aufirst%3DJ.%26aulast%3DBaranello%26aufirst%3DL.%26atitle%3DDissecting%2520the%2520transcriptional%2520functions%2520of%2520human%2520DNA%2520topoisomerase%2520I%2520by%2520selective%2520inhibitors%253A%2520implications%2520for%2520physiological%2520and%2520therapeutic%2520modulation%2520of%2520enzyme%2520activity%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2010%26volume%3D1806%26spage%3D240%26epage%3D250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Albert, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rigault, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eickhoff, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgart, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mittler, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meisterernst, M.</span><span> </span><span class="NLM_article-title">Characterisation of molecular and cellular CDK9 functions using a novel specific inhibitor</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">171</span><span class="NLM_x">, </span> <span class="NLM_fpage">55</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1111%2Fbph.12408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=24102143" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2mtLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=171&publication_year=2014&pages=55-68&author=T.+K.+Albertauthor=C.+Rigaultauthor=J.+Eickhoffauthor=K.+Baumgartauthor=C.+Antrechtauthor=B.+Kleblauthor=G.+Mittlerauthor=M.+Meisterernst&title=Characterisation+of+molecular+and+cellular+CDK9+functions+using+a+novel+specific+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor</span></div><div class="casAuthors">Albert, T. K.; Rigault, C.; Eickhoff, J.; Baumgart, K.; Antrecht, C.; Klebl, B.; Mittler, G.; Meisterernst, M.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">171</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">55-68</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background and Purpose : The cyclin-dependent kinase CDK9 is an important therapeutic target but currently available inhibitors exhibit low specificity and/or narrow therapeutic windows.  Here we have used a new highly specific CDK9 inhibitor, LDC000067 to interrogate gene control mechanisms mediated by CDK9.  Exptl. Approach : The selectivity of LDC000067 was established in functional kinase assays.  Functions of CDK9 in gene expression were assessed with in vitro transcription expts., single gene analyses and genome-wide expression profiling.  Cultures of mouse embryonic stem cells, HeLa cells, several cancer cell lines, along with cells from patients with acute myelogenous leukemia were also used to investigate cellular responses to LDC000067.  Key Results : The selectivity of LDC000067 for CDK9 over other CDKs exceeded that of the known inhibitors flavopiridol and DRB.  LDC000067 inhibited in vitro transcription in an ATP-competitive and dose-dependent manner.  Gene expression profiling of cells treated with LDC000067 demonstrated a selective redn. of short-lived mRNAs, including important regulators of proliferation and apoptosis.  Anal. of de novo RNA synthesis suggested a wide ranging pos. role of CDK9.  At the mol. and cellular level, LDC000067 reproduced effects characteristic of CDK9 inhibition such as enhanced pausing of RNA polymerase II on genes and, most importantly, induction of apoptosis in cancer cells.  Conclusions and Implications : Our study provides a framework for the mechanistic understanding of cellular responses to CDK9 inhibition.  LDC000067 represents a promising lead for the development of clin. useful, highly specific CDK9 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphlq2wB8J8BbVg90H21EOLACvtfcHk0lh5QA9KYT6vJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2mtLbF&md5=61dccacb940578e746fb5f3962ccd87e</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1111%2Fbph.12408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.12408%26sid%3Dliteratum%253Aachs%26aulast%3DAlbert%26aufirst%3DT.%2BK.%26aulast%3DRigault%26aufirst%3DC.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DBaumgart%26aufirst%3DK.%26aulast%3DAntrecht%26aufirst%3DC.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DMittler%26aufirst%3DG.%26aulast%3DMeisterernst%26aufirst%3DM.%26atitle%3DCharacterisation%2520of%2520molecular%2520and%2520cellular%2520CDK9%2520functions%2520using%2520a%2520novel%2520specific%2520inhibitor%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2014%26volume%3D171%26spage%3D55%26epage%3D68" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Meanwell, N. A.</span><span> </span><span class="NLM_article-title">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2529</span><span class="NLM_x">–</span> <span class="NLM_lpage">2591</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1013693" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=2529-2591&author=N.+A.+Meanwell&title=Synopsis+of+Some+Recent+Tactical+Application+of+Bioisosteres+in+Drug+Design"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Synopsis of Some Recent Tactical Application of Bioisosteres in Drug Design</span></div><div class="casAuthors">Meanwell, Nicholas A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2529-2591</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The established utility of bioisosteres is broad in nature, extending to improving potency, enhancing selectivity, altering phys. properties, reducing or redirecting metab., eliminating or modifying toxicophores, and acquiring novel intellectual property.  In this Perspective, some contemporary themes exploring the role of isosteres in drug design are sampled, with an emphasis placed on tactical applications designed to solve the kinds of problems that impinge on compd. optimization and the long-term success of drug candidates.  Interesting concepts that may have been poorly effective in the context examd. are captured, since the ideas may have merit in alternative circumstances.  A comprehensive cataloging of bioisosteres is beyond the scope of what will be provided, although a synopsis of relevant isosteres of a particular functionality is summarized in a succinct fashion in several sections.  Isosterism has also found productive application in the design and optimization of organocatalysts, and there are several examples in which functional mimicry established initially in a medicinal chem. setting has been adopted by this community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZ9z_aPcU4ubVg90H21EOLACvtfcHk0lh5QA9KYT6vJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsVCnu7o%253D&md5=0637ab60c379bef535f3f709b26f3582</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm1013693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1013693%26sid%3Dliteratum%253Aachs%26aulast%3DMeanwell%26aufirst%3DN.%2BA.%26atitle%3DSynopsis%2520of%2520Some%2520Recent%2520Tactical%2520Application%2520of%2520Bioisosteres%2520in%2520Drug%2520Design%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D2529%26epage%3D2591" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Moree, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Marel, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Boom, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liskamp, R. M. J.</span><span> </span><span class="NLM_article-title">Peptides containing the novel methylphosphinamide transition-state isostere</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">11055</span><span class="NLM_x">–</span> <span class="NLM_lpage">11064</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1993&pages=11055-11064&author=W.+J.+Moreeauthor=G.+A.+van+der+Marelauthor=J.+H.+van+Boomauthor=R.+M.+J.+Liskamp&title=Peptides+containing+the+novel+methylphosphinamide+transition-state+isostere"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoree%26aufirst%3DW.%2BJ.%26aulast%3Dvan%2Bder%2BMarel%26aufirst%3DG.%2BA.%26aulast%3Dvan%2BBoom%26aufirst%3DJ.%2BH.%26aulast%3DLiskamp%26aufirst%3DR.%2BM.%2BJ.%26atitle%3DPeptides%2520containing%2520the%2520novel%2520methylphosphinamide%2520transition-state%2520isostere%26jtitle%3DTetrahedron%26date%3D1993%26volume%3D49%26spage%3D11055%26epage%3D11064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Elliot, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slowey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conway, S. J.</span><span> </span><span class="NLM_article-title">The use of phosphate bioisosteres in medicinal chemistry and chemical biology</span> <span class="citation_source-journal">Med. Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">735</span><span class="NLM_x">–</span> <span class="NLM_lpage">751</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1039%2Fc2md20079a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=735-751&author=T.+S.+Elliotauthor=A.+Sloweyauthor=Y.+Yeauthor=S.+J.+Conway&title=The+use+of+phosphate+bioisosteres+in+medicinal+chemistry+and+chemical+biology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1039%2Fc2md20079a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20079a%26sid%3Dliteratum%253Aachs%26aulast%3DElliot%26aufirst%3DT.%2BS.%26aulast%3DSlowey%26aufirst%3DA.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DConway%26aufirst%3DS.%2BJ.%26atitle%3DThe%2520use%2520of%2520phosphate%2520bioisosteres%2520in%2520medicinal%2520chemistry%2520and%2520chemical%2520biology%26jtitle%3DMed.%2520Chem.%2520Commun.%26date%3D2012%26volume%3D3%26spage%3D735%26epage%3D751" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Wardle, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigh, S. W. A.</span><span> </span><span class="NLM_article-title"><i>O</i>-Phosphotyrosine Analogues: Synthesis and Therapeutic Role in Modulation of Signal Transduction</span> <span class="citation_source-journal">Curr. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">426</span><span class="NLM_x">–</span> <span class="NLM_lpage">446</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.2174%2F138527210790601189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjsFGjtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2010&pages=426-446&author=N.+J.+Wardleauthor=H.+R.+Hudsonauthor=S.+W.+A.+Bigh&title=O-Phosphotyrosine+Analogues%3A+Synthesis+and+Therapeutic+Role+in+Modulation+of+Signal+Transduction"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">O-phosphotyrosine analogues: synthesis and therapeutic role in modulation of signal transduction</span></div><div class="casAuthors">Wardle, Nick J.; Hudson, Harry R.; Bligh, S. W. Annie</div><div class="citationInfo"><span class="NLM_cas:title">Current Organic Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">426-446</span>CODEN:
                <span class="NLM_cas:coden">CORCFE</span>;
        ISSN:<span class="NLM_cas:issn">1385-2728</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of O-phosphotyrosine (pTyr) analogs is reviewed, along with their application in peptidomimetic ligands to proteins implicated in disease-states arising from dysfunctional intracellular signal transduction pathways.  Salient features of chem. syntheses are critiqued, including those of established mimetics such as 4'-(phosphonomethyl)phenylalanine (Pmp), 4'-(phosphono)phenylalanine (Ppp) and 4'-(phosphonodifluoromethyl)phenylalanine (F2Pmp), their resp. (α-methyl)phenylalanine analogs and "preorganised" side-chain cyclized pTyr mimetics.  Syntheses of 4'-(phosphinomethyl)phenylalanines are also described, as are "bone-directing" residues such as 4'-(diphosphonomethyl)phenylalanine (dpmF), 3',4'-(diphosphono)phenylalanine and 4'-carboxymethyloxy-3'-(phosphono)phenylalanine (CPP), capable of eliciting addnl. interactions with pTyr-binding subsites of specified proteins.  The utility of [(4'-phosphonomethyl)phenyl]propenoic acid in current developments is also discussed as a route to a range of α- and β-substituted pTyr mimetics, and to pTyr mimetics bearing the requisite β-vinyl functionality to facilitate macrocyclization via olefin metathesis of interest in the development of structures exhibiting global conformational constraint.  Finally, developments in prodrug presentation of pTyr mimetics are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoarPHjnlUSArVg90H21EOLACvtfcHk0lhrc6UrvBeVHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjsFGjtLk%253D&md5=d11b3b0b6e728ddda9296a302c46abd4</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.2174%2F138527210790601189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138527210790601189%26sid%3Dliteratum%253Aachs%26aulast%3DWardle%26aufirst%3DN.%2BJ.%26aulast%3DHudson%26aufirst%3DH.%2BR.%26aulast%3DBigh%26aufirst%3DS.%2BW.%2BA.%26atitle%3DO-Phosphotyrosine%2520Analogues%253A%2520Synthesis%2520and%2520Therapeutic%2520Role%2520in%2520Modulation%2520of%2520Signal%2520Transduction%26jtitle%3DCurr.%2520Org.%2520Chem.%26date%3D2010%26volume%3D14%26spage%3D426%26epage%3D446" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Bartlett, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marlowe, C. K.</span><span> </span><span class="NLM_article-title">Phosphonamidates as transition-state analogue inhibitors of thermolysin</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1983</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">4618</span><span class="NLM_x">–</span> <span class="NLM_lpage">4624</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi00289a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1983&pages=4618-4624&author=P.+A.+Bartlettauthor=C.+K.+Marlowe&title=Phosphonamidates+as+transition-state+analogue+inhibitors+of+thermolysin"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fbi00289a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi00289a002%26sid%3Dliteratum%253Aachs%26aulast%3DBartlett%26aufirst%3DP.%2BA.%26aulast%3DMarlowe%26aufirst%3DC.%2BK.%26atitle%3DPhosphonamidates%2520as%2520transition-state%2520analogue%2520inhibitors%2520of%2520thermolysin%26jtitle%3DBiochemistry%26date%3D1983%26volume%3D22%26spage%3D4618%26epage%3D4624" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Wardle, N. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigh, S. W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson, H. R.</span><span> </span><span class="NLM_article-title">Organophosphorus Compounds: Intervention in Mechanisms of Signal Transduction Relevant to Proliferative, Immunological and Circulatory Disorders</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">2230</span><span class="NLM_x">–</span> <span class="NLM_lpage">2257</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.2174%2F092986708785747517" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=18781946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisFCksbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=2230-2257&author=N.+J.+Wardleauthor=S.+W.+A.+Bighauthor=H.+R.+Hudson&title=Organophosphorus+Compounds%3A+Intervention+in+Mechanisms+of+Signal+Transduction+Relevant+to+Proliferative%2C+Immunological+and+Circulatory+Disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Organophosphorus compounds: intervention in mechanisms of signal transduction relevant to proliferative, immunological and circulatory disorders</span></div><div class="casAuthors">Wardle, Nick J.; Bligh, S. W. Annie; Hudson, Harry R.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">2230-2257</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Literature publications reporting the development of organophosphorus compds., targeting aspects of signal transduction to the titled therapeutic ends, are reviewed.  With respect to extracellular targets, the development of ligands to purinergic (P2), and endothelial differentiation-gene receptors (of S1P- and LPA-receptor subtypes) is charted, along with inhibitors of the prodn. and release of tumor necrosis factor-α (TNF-α).  Reported also are inhibitors of the ectoenzymes aminopeptidase N, aminopeptidase A and dipeptidyl peptidase IV, the proteolytic enzyme thrombin, ligands to "apoptosis-receptors" and γδ T-cell activators.  In addn., disruption of intracellular signaling chains mediated through reversible coupling of proteins via phosphorylation of Tyr residues and docking of pTyr residues in SH2-binding domains is covered.  In particular, the development of ligands to SH2-binding domains in tyrosine kinases Src and lck, adaptor protein Grb2, and also ZAP70 protein are reported along with inhibitors to relevant phosphatases.  SAR studies of ligands to Ins(1,4,5)-P3- and ryanodine-type receptors of intracellular Ca2+-storage organelles are described including analogs to secondary messengers cyclic-ADP-ribose (cADPR) and myo-inositol-1,4,5-triphosphate.  Inhibitors of phosphatidyl inositol 3-kinase (PI3K) and sphingomyelinase are also reported, as are inhibitors of farnesyl transferase, the enzyme involved in protein-prenylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozB_--f2IKW7Vg90H21EOLACvtfcHk0lhrc6UrvBeVHA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisFCksbY%253D&md5=5c16a218ec4457ad5c35d0f25d089949</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.2174%2F092986708785747517&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986708785747517%26sid%3Dliteratum%253Aachs%26aulast%3DWardle%26aufirst%3DN.%2BJ.%26aulast%3DBigh%26aufirst%3DS.%2BW.%2BA.%26aulast%3DHudson%26aufirst%3DH.%2BR.%26atitle%3DOrganophosphorus%2520Compounds%253A%2520Intervention%2520in%2520Mechanisms%2520of%2520Signal%2520Transduction%2520Relevant%2520to%2520Proliferative%252C%2520Immunological%2520and%2520Circulatory%2520Disorders%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2008%26volume%3D15%26spage%3D2230%26epage%3D2257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Mucha, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kafarski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berlicki, L.</span><span> </span><span class="NLM_article-title">Remarkable Potential of the α-Aminophosphonate/Phosphinate Structural Motif in Medicinal Chemistry</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">5955</span><span class="NLM_x">–</span> <span class="NLM_lpage">5980</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200587f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvVWlsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5955-5980&author=A.+Muchaauthor=P.+Kafarskiauthor=L.+Berlicki&title=Remarkable+Potential+of+the+%CE%B1-Aminophosphonate%2FPhosphinate+Structural+Motif+in+Medicinal+Chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Remarkable Potential of the α-Aminophosphonate/Phosphinate Structural Motif in Medicinal Chemistry</span></div><div class="casAuthors">Mucha, Artur; Kafarski, Pawel; Berlicki, Lukasz</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5955-5980</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Potential of the α-aminophosphonate/phosphinate structural motif in medicinal chem. is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPPeUBOTalirVg90H21EOLACvtfcHk0ljbp_O_5Zo65w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvVWlsrs%253D&md5=0683f7f9ff6269b7d93ee27e623c21c5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm200587f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200587f%26sid%3Dliteratum%253Aachs%26aulast%3DMucha%26aufirst%3DA.%26aulast%3DKafarski%26aufirst%3DP.%26aulast%3DBerlicki%26aufirst%3DL.%26atitle%3DRemarkable%2520Potential%2520of%2520the%2520%25CE%25B1-Aminophosphonate%252FPhosphinate%2520Structural%2520Motif%2520in%2520Medicinal%2520Chemistry%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D5955%26epage%3D5980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Choidas, A.; Backes, A.; Cotten, M.; Engkvist, O.; Felber, B.; Freisleben, A.; Gold, K.; Greff, Z.; Habenberger, P.; Hafenbradl, D.; Hartung, C.; Herget, T.; Hoppe, E.; Klebl, B.; Missio, A.; Müller, G.; Schwab, W.; Zech, B.; Bravo, J.; Harris, J.; Le, J.; Macritchie, J.</span><span> </span><span class="NLM_article-title">Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases</span>. PCT Int. Appl. WO 2005026129,<span class="NLM_x"> </span><span class="NLM_year">2005</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=A.+Choidas&author=A.+Backes&author=M.+Cotten&author=O.+Engkvist&author=B.+Felber&author=A.+Freisleben&author=K.+Gold&author=Z.+Greff&author=P.+Habenberger&author=D.+Hafenbradl&author=C.+Hartung&author=T.+Herget&author=E.+Hoppe&author=B.+Klebl&author=A.+Missio&author=G.+M%C3%BCller&author=W.+Schwab&author=B.+Zech&author=J.+Bravo&author=J.+Harris&author=J.+Le&author=J.+Macritchie&title=Pharmaceutically+active+4%2C6-disubstituted+aminopyrimidine+derivatives+as+modulators+of+protein+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChoidas%26aufirst%3DA.%26atitle%3DPharmaceutically%2520active%25204%252C6-disubstituted%2520aminopyrimidine%2520derivatives%2520as%2520modulators%2520of%2520protein%2520kinases%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-ref29_2"><span> <span class="citation_source-journal">Chem. Abstr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">142</span><span class="NLM_x">, </span> <span class="NLM_fpage">336376</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Chem.+Abstr.+2005%2C+142%2C+336376"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=ref29_2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26jtitle%3DChem.%2520Abstr.%26date%3D2005%26volume%3D142%26spage%3D336376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Mucha, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grembecka, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cierpicki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kafarski, P.</span><span> </span><span class="NLM_article-title">Hydrolysis of the Phosphonamidate Bond in Phosphono Dipeptide Analogues—The Influence of the Nature of the N-Terminal Functional Group</span> <span class="citation_source-journal">Eur. J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">4797</span><span class="NLM_x">–</span> <span class="NLM_lpage">4803</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2003&pages=4797-4803&author=A.+Muchaauthor=J.+Grembeckaauthor=T.+Cierpickiauthor=P.+Kafarski&title=Hydrolysis+of+the+Phosphonamidate+Bond+in+Phosphono+Dipeptide+Analogues%E2%80%94The+Influence+of+the+Nature+of+the+N-Terminal+Functional+Group"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMucha%26aufirst%3DA.%26aulast%3DGrembecka%26aufirst%3DJ.%26aulast%3DCierpicki%26aufirst%3DT.%26aulast%3DKafarski%26aufirst%3DP.%26atitle%3DHydrolysis%2520of%2520the%2520Phosphonamidate%2520Bond%2520in%2520Phosphono%2520Dipeptide%2520Analogues%25E2%2580%2594The%2520Influence%2520of%2520the%2520Nature%2520of%2520the%2520N-Terminal%2520Functional%2520Group%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2003%26volume%3D24%26spage%3D4797%26epage%3D4803" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Pudovik, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arbuzov, B. A.</span><span> </span><span class="NLM_article-title">Addition of dialkyl phosphites to unsaturated ketones, nitriles and esters</span> <span class="citation_source-journal">Dokl. Akad. Nauk SSSR</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1950</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1950&pages=327&author=A.+N.+Pudovikauthor=B.+A.+Arbuzov&title=Addition+of+dialkyl+phosphites+to+unsaturated+ketones%2C+nitriles+and+esters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPudovik%26aufirst%3DA.%2BN.%26aulast%3DArbuzov%26aufirst%3DB.%2BA.%26atitle%3DAddition%2520of%2520dialkyl%2520phosphites%2520to%2520unsaturated%2520ketones%252C%2520nitriles%2520and%2520esters%26jtitle%3DDokl.%2520Akad.%2520Nauk%2520SSSR%26date%3D1950%26volume%3D73%26spage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Petneházy, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jászay, Z. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabó, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everaert, K.</span><span> </span><span class="NLM_article-title">Convenient One-Pot Synthesis of Phosphonites and H-Phosphinates</span> <span class="citation_source-journal">Synth. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1665</span><span class="NLM_x">–</span> <span class="NLM_lpage">1674</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1081%2FSCC-120018928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktFKhsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2003&pages=1665-1674&author=I.+Petneh%C3%A1zyauthor=Z.+M.+J%C3%A1szayauthor=A.+Szab%C3%B3author=K.+Everaert&title=Convenient+One-Pot+Synthesis+of+Phosphonites+and+H-Phosphinates"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Convenient one pot synthesis of phosphonites and H-phosphinates</span></div><div class="casAuthors">Petnehazy, Imre; Jaszay, Zsuzsa M.; Szabo, Andrea; Everaert, Kinga</div><div class="citationInfo"><span class="NLM_cas:title">Synthetic Communications</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1665-1674</span>CODEN:
                <span class="NLM_cas:coden">SYNCAV</span>;
        ISSN:<span class="NLM_cas:issn">0039-7911</span>.
    
            (<span class="NLM_cas:orgname">Marcel Dekker, Inc.</span>)
        </div><div class="casAbstract">A convenient and simple one-pot method is described for the synthesis of phosphonites [RP(OEt)2] and H-phosphinates [HP(O)R(OEt)] from tri-Et phosphite and appropriate Grignard reagents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ2vCJYXX497Vg90H21EOLACvtfcHk0ljbp_O_5Zo65w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktFKhsLw%253D&md5=895a7d480b73574726aa52ea43892fe4</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1081%2FSCC-120018928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1081%252FSCC-120018928%26sid%3Dliteratum%253Aachs%26aulast%3DPetneh%25C3%25A1zy%26aufirst%3DI.%26aulast%3DJ%25C3%25A1szay%26aufirst%3DZ.%2BM.%26aulast%3DSzab%25C3%25B3%26aufirst%3DA.%26aulast%3DEveraert%26aufirst%3DK.%26atitle%3DConvenient%2520One-Pot%2520Synthesis%2520of%2520Phosphonites%2520and%2520H-Phosphinates%26jtitle%3DSynth.%2520Commun.%26date%3D2003%26volume%3D33%26spage%3D1665%26epage%3D1674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Cristau, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirat, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Virieux, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monbrun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciptadi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bekro, Y. A.</span><span> </span><span class="NLM_article-title">Synthesis, reactivity and stereochemistry of new phosphorus heterocycles with 5- or 6-membered rings</span> <span class="citation_source-journal">J. Organomet. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">690</span><span class="NLM_x">, </span> <span class="NLM_fpage">2472</span><span class="NLM_x">–</span> <span class="NLM_lpage">2481</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1016%2Fj.jorganchem.2004.11.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjvVCru7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=690&publication_year=2005&pages=2472-2481&author=H.+J.+Cristauauthor=J.+L.+Piratauthor=D.+Virieuxauthor=J.+Monbrunauthor=C.+Ciptadiauthor=Y.+A.+Bekro&title=Synthesis%2C+reactivity+and+stereochemistry+of+new+phosphorus+heterocycles+with+5-+or+6-membered+rings"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, reactivity and stereochemistry of new phosphorus heterocycles with 5- or 6-membered rings</span></div><div class="casAuthors">Cristau, Henri-Jean; Pirat, Jean-Luc; Virieux, David; Monbrun, Jerome; Ciptadi, Ciptadi; Bekro, Yves-Alain</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organometallic Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">690</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2472-2481</span>CODEN:
                <span class="NLM_cas:coden">JORCAI</span>;
        ISSN:<span class="NLM_cas:issn">0022-328X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review in conference proceedings.  Syntheses of novel phosphorus heterocycles contg. α-amino or α-hydroxyphosphonic or phosphinic acids motifs are developed.  2,3-Dihydro-1,3-oxaphospholes (1) and 1,4,2-oxazaphosphinanes (2) exhibit a reactive part, resp. the enol ether moiety and the P-H bond, which allows various structural modifications: (i) for 1a, by introduction of amino substituents, (ii) for 2a, by hydroxy- or aminoalkylation, by Michael addn. or by P-arylation.  These reactions present generally a good or even an excellent kinetic diastereoselectivity which can often be predicted by mol. models of the transition states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX7-BQ1tlu1rVg90H21EOLACvtfcHk0lg91-KSqh1LTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjvVCru7s%253D&md5=12adb5db3a09920897c42d32d0a14a52</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.jorganchem.2004.11.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jorganchem.2004.11.035%26sid%3Dliteratum%253Aachs%26aulast%3DCristau%26aufirst%3DH.%2BJ.%26aulast%3DPirat%26aufirst%3DJ.%2BL.%26aulast%3DVirieux%26aufirst%3DD.%26aulast%3DMonbrun%26aufirst%3DJ.%26aulast%3DCiptadi%26aufirst%3DC.%26aulast%3DBekro%26aufirst%3DY.%2BA.%26atitle%3DSynthesis%252C%2520reactivity%2520and%2520stereochemistry%2520of%2520new%2520phosphorus%2520heterocycles%2520with%25205-%2520or%25206-membered%2520rings%26jtitle%3DJ.%2520Organomet.%2520Chem.%26date%3D2005%26volume%3D690%26spage%3D2472%26epage%3D2481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Hartung, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backes, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Missio, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philipp, A.</span><span> </span><span class="NLM_article-title">Efficient microwave-assisted synthesis of highly functionalized pyrimidine derivatives</span> <span class="citation_source-journal">Tetrahedron</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">10055</span><span class="NLM_x">–</span> <span class="NLM_lpage">10064</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=10055-10064&author=C.+G.+Hartungauthor=A.+C.+Backesauthor=B.+Felberauthor=A.+Missioauthor=A.+Philipp&title=Efficient+microwave-assisted+synthesis+of+highly+functionalized+pyrimidine+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHartung%26aufirst%3DC.%2BG.%26aulast%3DBackes%26aufirst%3DA.%2BC.%26aulast%3DFelber%26aufirst%3DB.%26aulast%3DMissio%26aufirst%3DA.%26aulast%3DPhilipp%26aufirst%3DA.%26atitle%3DEfficient%2520microwave-assisted%2520synthesis%2520of%2520highly%2520functionalized%2520pyrimidine%2520derivatives%26jtitle%3DTetrahedron%26date%3D2006%26volume%3D62%26spage%3D10055%26epage%3D10064" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Rees, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Congreve, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, R.</span><span> </span><span class="NLM_article-title">Fragment-based lead discovery</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">660</span><span class="NLM_x">–</span> <span class="NLM_lpage">672</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=660-672&author=D.+C.+Reesauthor=M.+Congreveauthor=C.+W.+Murrayauthor=R.+Carr&title=Fragment-based+lead+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRees%26aufirst%3DD.%2BC.%26aulast%3DCongreve%26aufirst%3DM.%26aulast%3DMurray%26aufirst%3DC.%2BW.%26aulast%3DCarr%26aufirst%3DR.%26atitle%3DFragment-based%2520lead%2520discovery%26jtitle%3DNature%26date%3D2004%26volume%3D3%26spage%3D660%26epage%3D672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nature Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1051</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0lg91-KSqh1LTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNature%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="note"><p class="first last">CDK9 protein was used without its cyclinT1 counterpart.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span>Downloaded from TREEspot Compound Profile Visualization Tool; <span class="NLM_publisher-name">DiscoveRx Corporation</span>: <span class="NLM_publisher-loc">Fremont, CA</span>; <a href="http://treespot.discoverx.com" class="extLink">http://treespot.discoverx.com</a>, accessed on September 3, 2013.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Downloaded+from+TREEspot+Compound+Profile+Visualization+Tool%3B+DiscoveRx+Corporation%3A+Fremont%2C+CA%3B+http%3A%2F%2Ftreespot.discoverx.com%2C+accessed+on+September+3%2C+2013."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26jtitle%3DTREEspot%2520Compound%2520Profile%2520Visualization%2520Tool%26pub%3DDiscoveRx%2520Corporation" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Gyuris, Á.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vajda, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Földes, I.</span><span> </span><span class="NLM_article-title">Establishment of an MT4 cell line persistently producing infective HIV-1 particles</span> <span class="citation_source-journal">Acta Microbiol. Hung.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">279</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A280%3ADyaK2c7mtVKrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1992&pages=271-279&author=%C3%81.+Gyurisauthor=G.+Vajdaauthor=I.+F%C3%B6ldes&title=Establishment+of+an+MT4+cell+line+persistently+producing+infective+HIV-1+particles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Establishment of an MT4 cell line persistently producing infective HIV-1 particles</span></div><div class="casAuthors">Gyuris A; Vajda G; Foldes I</div><div class="citationInfo"><span class="NLM_cas:title">Acta microbiologica Hungarica</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">3-4</span>),
    <span class="NLM_cas:pages">271-9</span>
        ISSN:<span class="NLM_cas:issn">0231-4622</span>.
    </div><div class="casAbstract">Human T cell Lymphotropic Virus-I (HTLV-I) carrying human T cell line MT4 is highly sensitive to Human Immunodeficiency Virus-1 (HIV-1).  After HIV-1 infection cell clusters characteristic of intact MT4 rapidly disintegrate, syncytia appear and the cells die.  Surviving MT4 cells were subcultured following HIV-1 infection of high multiplicity.  We succeeded to establish an MT4 cell line continuously producing infective HIV (MT4/HIV-1).  The original and the HIV-1 infected MT4 cells were morphologically similar.  The MT4/HIV-1 cells proved to be nearly 100% positive in indirect immunofluorescence assay using the serum of an HIV-1 antibody positive individual.  OKT4 surface antigen could not be demonstrated on MT4/HIV-1 cells.  On electron microscopic pictures typical and atypical virus particles could be seen near the surface of the cell membrane.  The persistently produced virus particles were infective for H9 and MT4 cells.  The antigenic structure of the virus produced by MT4 cells was similar to that produced by H9 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRas9ugBpmLmUEgZCMqtRBifW6udTcc2ebZLn-07L2Azbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2c7mtVKrsQ%253D%253D&md5=ec87e45c1d16800d7dd36fce7a9f1e15</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGyuris%26aufirst%3D%25C3%2581.%26aulast%3DVajda%26aufirst%3DG.%26aulast%3DF%25C3%25B6ldes%26aufirst%3DI.%26atitle%3DEstablishment%2520of%2520an%2520MT4%2520cell%2520line%2520persistently%2520producing%2520infective%2520HIV-1%2520particles%26jtitle%3DActa%2520Microbiol.%2520Hung.%26date%3D1992%26volume%3D39%26spage%3D271%26epage%3D279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Gyuris, Á.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szlávik, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minárovits, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molnár, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hohmann, J.</span><span> </span><span class="NLM_article-title">Activities of extracts of <i>Euphorbia hirta</i> L. against HIV-1, HIV-2 and SIV<sub>mac251</sub></span> <span class="citation_source-journal">In Vivo</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">432</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=429-432&author=%C3%81.+Gyurisauthor=L.+Szl%C3%A1vikauthor=J.+Min%C3%A1rovitsauthor=A.+Vasasauthor=J.+Moln%C3%A1rauthor=J.+Hohmann&title=Activities+of+extracts+of+Euphorbia+hirta+L.+against+HIV-1%2C+HIV-2+and+SIVmac251"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGyuris%26aufirst%3D%25C3%2581.%26aulast%3DSzl%25C3%25A1vik%26aufirst%3DL.%26aulast%3DMin%25C3%25A1rovits%26aufirst%3DJ.%26aulast%3DVasas%26aufirst%3DA.%26aulast%3DMoln%25C3%25A1r%26aufirst%3DJ.%26aulast%3DHohmann%26aufirst%3DJ.%26atitle%3DActivities%2520of%2520extracts%2520of%2520Euphorbia%2520hirta%2520L.%2520against%2520HIV-1%252C%2520HIV-2%2520and%2520SIVmac251%26jtitle%3DIn%2520Vivo%26date%3D2009%26volume%3D23%26spage%3D429%26epage%3D432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Teixeira, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomes, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gomes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurel, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbault, F.</span><span> </span><span class="NLM_article-title">Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">979</span><span class="NLM_x">–</span> <span class="NLM_lpage">992</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Fjm401742r&amp;key=10.1016%2Fj.ejmech.2011.01.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Fjm401742r&amp;key=21345545" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Fjm401742r&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjsFWgsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=979-992&author=C.+Teixeiraauthor=J.+R.+Gomesauthor=P.+Gomesauthor=F.+Maurelauthor=F.+Barbault&title=Viral+surface+glycoproteins%2C+gp120+and+gp41%2C+as+potential+drug+targets+against+HIV-1%3A+brief+overview+one+quarter+of+a+century+past+the+approval+of+zidovudine%2C+the+first+anti-retroviral+drug"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: Brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug</span></div><div class="casAuthors">Teixeira, Catia; Gomes, Jose R. B.; Gomes, Paula; Maurel, Francois</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">979-992</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  The first anti-HIV drug, zidovudine (AZT), was approved by the FDA a quarter of a century ago, in 1985.  Currently, anti-HIV drug-combination therapies only target HIV-1 protease and reverse transcriptase.  Unfortunately, most of these mols. present numerous shortcomings such as viral resistances and adverse effects.  In addn., these drugs are involved in later stages of infection.  Thus, it is necessary to develop new drugs that are able to block the first steps of viral life cycle.  Entry of HIV-1 is mediated by its two envelope glycoproteins: gp120 and gp41.  Upon gp120 binding to cellular receptors, gp41 undergoes a series of conformational changes from a non-fusogenic to a fusogenic conformation.  The fusogenic core of gp41 is a trimer-of-hairpins structure in which three C-terminal helixes pack against a central trimeric-coiled coil formed by three N-terminal helixes.  The formation of this fusogenic structure brings the viral and cellular membranes close together, a necessary condition for membrane fusion to occur.  As gp120 and gp41 are attractive targets, the development of entry inhibitors represents an important avenue of anti-HIV drug therapy.  The present review will focus on some general considerations about HIV, the main characteristics of gp120, gp41 and their inhibitors, with special emphasis on the advances of computational approaches employed in the development of bioactive compds. against HIV-1 entry process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodbE31viIEoLVg90H21EOLACvtfcHk0lhBr1_WAp5wDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjsFWgsbk%253D&md5=ee617a973417efe3e4f5c4d7fc4213c3</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.01.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.01.046%26sid%3Dliteratum%253Aachs%26aulast%3DTeixeira%26aufirst%3DC.%26aulast%3DGomes%26aufirst%3DJ.%2BR.%26aulast%3DGomes%26aufirst%3DP.%26aulast%3DMaurel%26aufirst%3DF.%26aulast%3DBarbault%26aufirst%3DF.%26atitle%3DViral%2520surface%2520glycoproteins%252C%2520gp120%2520and%2520gp41%252C%2520as%2520potential%2520drug%2520targets%2520against%2520HIV-1%253A%2520brief%2520overview%2520one%2520quarter%2520of%2520a%2520century%2520past%2520the%2520approval%2520of%2520zidovudine%252C%2520the%2520first%2520anti-retroviral%2520drug%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D979%26epage%3D992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Copeland, R. A.</span> <span class="citation_source-book">Evaluation of Enzyme Inhibitors in Drug Discovery</span>; <span class="NLM_publisher-name">John Wiley & Sons</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2005</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">81</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=48-81&author=R.+A.+Copeland&title=Evaluation+of+Enzyme+Inhibitors+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26btitle%3DEvaluation%2520of%2520Enzyme%2520Inhibitors%2520in%2520Drug%2520Discovery%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%26date%3D2005%26spage%3D48%26epage%3D81" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Cheng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prusoff, W. H.</span><span> </span><span class="NLM_article-title">Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50% inhibition (IC50) of an enzymatic reaction</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1973</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">3099</span><span class="NLM_x">–</span> <span class="NLM_lpage">3108</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=1973&pages=3099-3108&author=Y.+Chengauthor=W.+H.+Prusoff&title=Relationship+between+the+inhibition+constant+%28K1%29+and+the+concentration+of+inhibitor+which+causes+50%25+inhibition+%28IC50%29+of+an+enzymatic+reaction"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DY.%26aulast%3DPrusoff%26aufirst%3DW.%2BH.%26atitle%3DRelationship%2520between%2520the%2520inhibition%2520constant%2520%2528K1%2529%2520and%2520the%2520concentration%2520of%2520inhibitor%2520which%2520causes%252050%2525%2520inhibition%2520%2528IC50%2529%2520of%2520an%2520enzymatic%2520reaction%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1973%26volume%3D22%26spage%3D3099%26epage%3D3108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i183"><a href="/doi/suppl/10.1021/jm401742r">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_03184"></div></div></div></div></div><hr /></hr><p class="last">Predicted and measured ADME-T properties of selected compounds. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm401742r/suppl_file/jm401742r_si_001.pdf">jm401742r_si_001.pdf (150.67 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm401742r&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-10%3Barticle%3Aarticle%3A10.1021%2Fjm401742r" class="show-recommended-placeholder"></div>




        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm401742r" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799e0cecedd3d3c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
